Full length expressed polynucleotides and the polypeptides they encode

ABSTRACT

The present invention provides to polynucleotides and secreted proteins encoded by the polynucleotides. The proteins include a variety of fusion proteins, including fusions comprising a signal peptide selected from the group consisting of signal peptides shown in SEQ ID NO:M, wherein M is an even integer from 2 to 122, operably linked to a second polypeptide. The invention further provides therapeutic and diagnostic methods utilizing the polynucleotides, polypeptides, and antagonists of the polypeptides.

REFERENCE TO RELATED APPLICATIONS

[0001] This application is related to U.S. Provisional Application No. 60/187,221, filed on Mar. 3, 2000, for which claims of benefit are made under 35 U.S.C. § 120 and 35 U.S.C. § 119(e)(1).

BACKGROUND OF THE INVENTION

[0002] Within the field of genetic engineering, polynucleotides encoding proteins of interest have been identified and cloned by methods that require a detailed knowledge of the structure and/or function of the polynucleotide or the encoded protein. These methods include hybridization screening, polymerase chain reaction (PCR), and expression cloning.

[0003] With the more recent advent of large DNA sequence databases and the accompanying data analysis tools, identification of genes of interest is possible through the analysis of raw sequence data. Databases can be “mined” to locate sequences that resemble (are “homologous to”) sequences of known function. Alignment of similar sequences can be used to place novel sequences within families of structurally similar sequences. These analytical tools can be combined with structural information obtained from, for example, X-ray crystallography to predict the higher order structure of a novel polypeptide. These analyses also facilitate prediction of polypeptide function. These recent technological advances have greatly increased the pace of gene discovery.

[0004] Genetic engineering has made available a number of genes and proteins of pharmaceutical or other economic importance. Such proteins include, for example, tissue plasminogen activator (t-PA) (U.S. Pat. No. 4,766,075), coagulation factor VII (U.S. Pat. No. 4,784,950), erythropoietin (U.S. Pat. No. 4,703,008), platelet derived growth factor (U.S. Pat. No. 4,889,919), and various industrial enzymes (e.g., U.S. Pat. Nos. 5,965,384; 5,942,431; and 5,922,586).

[0005] Although estimates vary as to the amount of the human genome that has been identified to date, there remains a need in the art for further characterization of the human genome and the proteins encoded thereby. Previously unknown genes and proteins will be useful in the treatment and/or prevention of many human diseases, included diseases that have heretofore been refractory to treatment.

SUMMARY OF THE INVENTION

[0006] Within one aspect of the invention there is provided an isolated polypeptide comprising fifteen contiguous amino acid residues of a polypeptide as shown in SEQ ID NO:M, wherein M is an even integer from 2 to 122. Within one embodiment, M is 2, 4, 8, 10, 16, 18, 26, 32, 34, 36, 38, 40, 42, 44, 48, 50, 52, 56, 60, 62, 68, 70, 74, 78, 80, 82, 84, 86, 90, 94, 98, 100,102, 104, 106, 108, 110, 112, 114, 116, or 118. Within one embodiment, the isolated polypeptide is from 15 to 514 amino acid residues in length. Within another embodiment, the at least fifteen contiguous amino acid residues of SEQ ID NO:M are operably linked via a peptide bond or polypeptide linker to a second polypeptide selected from the group consisting of maltose binding protein, an immunoglobulin constant region, a polyhistidine tag, and a peptide as shown in SEQ ID NO:123. Within another embodiment, the polypeptide comprises at least 30 contiguous residues of SEQ ID NO:M. Within a further embodiment, the polypeptide comprises at least 47 contiguous residues of SEQ ID NO:M.

[0007] Within a second aspect of the-invention there is provided an isolated, mature protein encoded by a sequence selected from the group consisting of SEQ ID NO:N, wherein N is an odd integer from 1 to 121. Within one embodiment N is 1, 3, 7, 9, 15, 17, 25, 31, 33, 35, 37, 39, 41, 43, 47, 49, 51, 55, 59, 61, 67, 69, 73, 77, 79, 81, 83, 85, 89, 93, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, or 117.

[0008] A third aspect of the invention provides isolated polynucleotides encoding the polypeptides disclosed above. Within certain embodiments of the invention the polynucleotides comprise a sequence of nucleotides as shown in SEQ ID NO:N, wherein N is an odd integer from 1 to 121.

[0009] Within a fourth aspect of the invention there is provided an expression vector comprising the following operably linked elements: a transcription promoter; a DNA segment encoding a polypeptide as shown in SEQ ID NO:M, wherein M is an even integer from 2 to 122; and a transcription terminator.

[0010] A fifth aspect of the invention provides a cultured cell comprising the expression vector disclosed above. The cultured cell can be used, inter alia, within a method of producing a polypeptide, the method comprising (a) culturing the cell under conditions whereby the sequence of nucleotides is expressed, and (b) recovering the polypeptide. The invention also provides a polypeptide produced by this method.

[0011] Within a sixth aspect of the ivention there is provided an isolated polynucleotide encoding a fusion protein, wherein the fusion protein comprises a secretory peptide selected from the group consisting of secretory peptides shown in SEQ ID NO:M, wherein M is an even integer from 2 to 122, operably linked to a second polypeptide.

[0012] Within a seventh aspect of the invention there is provided an expression vector comprising the following operably linked elements: a transcription promoter; a DNA segment encoding a fusion protein as disclosed above; and a transcription terminator. The invention further provides a cultured cell comprising this expression vector, wherein the cell expresses the DNA segment and produces the encoded fusion protein. Also provided is a method of producing a protein comprising culturing the cell under conditions whereby the DNA segment is expressed, and recovering the second polypeptide. Within one embodiment the recovered second polypeptide is joined to a portion of a protein of SEQ ID NO: M, wherein M is an even integer from 2 to 122.

[0013] Within a further aspect of the invention there is provided a computer-readable medium encoded with a data structure comprising SEQ ID NO:X, wherein X is an integer from 1 to 122.

[0014] Within an additional aspect of the invention there is provided an antibody that specifically binds to a protein selected from of the group consisting of SEQ ID NO:M, wherein M is an even integer from 2 to 122.

[0015] Within an additional aspect, the invention provides an isolated polypeptide comprising fourteen contiguous amino acid residues of a polypeptide as shown in SEQ ID NO:M, wherein M is an even integer from 2 to 122. Within an embodiment, said isolated polypeptide comprising said isolated fourteen contiguous amino acid residues is selected from the polypeptides as shown in Table 1. Within another embodiment, said fourteen contiguous amino acid residues can be used in a fusion protein to facilitate the secretion of a second polypeptide of interest outside a cell.

[0016] Within another aspect is provided an isolated immunogenic polypeptide comprising fourteen contiguous amino acid residues of a polypeptide as shown in SEQ ID NO:M, wherein M is an even integer from 2 to 122.

[0017] Within an additional aspect, the invention provides an isolated polypeptide comprising the amino acid sequence as shown in SEQ ID NO:M, wherein M is 4, 34, 40, 44, 48, 52, 56, 60, 62, 82, 84, 98, 100, 102, 104, 110, or 114.

[0018] Within an additional aspect, the invention provides an isolated polypeptide comprising the amino acid sequence as shown in SEQ ID NO:M, wherein M is 16, 68, 100, 106, or 110.

[0019] Within an additional aspect, the invention provides an isolated polypeptide comprising the amino acid sequence as shown in SEQ ID NO:M, wherein M is 52, 78, 80, 106, 114, or 118.

[0020] Within an additional aspect, the invention provides an isolated polypeptide comprising the amino acid sequence as shown in SEQ ID NO:M, wherein M is 2, 4, 8, 10, 16, 26, 32, 34, 38, 40, 44, 50, 52, 56, 62, 68, 74, 82, 86, 94, 98, 100, 110, 112 or 118.

[0021] Within an additional aspect, the invention provides an isolated polypeptide comprising the amino acid sequence as shown in SEQ ID NO:M, wherein M is 2, 4, 8, 10, 16, 26, 32, 34, 38, 40, 44, 50, 52, 56, 62, 68, 74, 82, 86, 94, 98, 100, 104, 110, 112, 116 or 118.

[0022] Within an additional aspect, the invention provides an isolated polypeptide comprising the amino acid sequence as shown in SEQ ID NO:M, wherein M is 18, 36, 42, 50, 60, 70, 90, 102, 108, 114.

[0023] These and other aspects of the invention will become evident upon reference to the following detailed description of the invention.

DETAILED DESCRIPTION OF THE INVENTION

[0024] Prior to setting forth the invention in detail, it may be helpful to the understanding thereof to define the following terms:

[0025] The term “affinity tag” is used herein to denote a polypeptide segment that can be attached to a second polypeptide to provide for purification of the second polypeptide or provide sites for attachment of the second polypeptide to a substrate. In principal, any peptide or protein for which an antibody or other specific binding agent is available can be used as an affinity tag. Affinity tags include a poly-histidine tract, protein A (Nilsson et al., EMBO J. 4:1075, 1985; Nilsson et al., Methods Enzymol. 198:3, 1991), glutathione S transferase (Smith and Johnson, Gene 67:31, 1988), Glu-Glu affinity tag (Grussenmeyer et al., Proc. Natl. Acad. Sci. USA 82:7952-7954, 1985; see SEQ ID NO:123), substance P, Flag™ peptide (Hopp et al., Biotechnology 6:1204-1210, 1988), maltose binding protein (Kellerman and Ferenci, Methods Enzymol. 90:459-463, 1982; Guan et al., Gene 67:21-30, 1987), streptavidin binding peptide, thioredoxin, ubiquitin, cellulose binding protein, T7 polymerase, immunoglobulin constant domain, or other antigenic epitope or binding domain. See, in general, Ford et al., Protein Expression and Purification 2: 95-107, 1991. Affinity tags can be used individually or in combination. DNAs encoding affinity tags and otehr reagents are available from commercial suppliers (e.g., Pharmacia Biotech, Piscataway, N.J.; Eastman Kodak, New Haven, Conn.; New England Biolabs, Beverly, Mass.).

[0026] The term “allelic variant” is used herein to denote any of two or more alternative forms of a gene occupying the same chromosomal locus. Allelic variation arises naturally through mutation, and may result in phenotypic polymorphism within populations. Gene mutations can be silent (no change in the encoded polypeptide) or may encode polypeptides having altered amino acid sequence. The term allelic variant is also used herein to denote a protein encoded by an allelic variant of a gene.

[0027] The terms “amino-terminal” and “carboxyl-terminal” are used herein to denote positions within polypeptides. Where the context allows, these terms are used with reference to a particular sequence or portion of a polypeptide to denote proximity or relative position. For example, a certain sequence positioned carboxyl-terminal to a reference sequence within a polypeptide is located proximal to the carboxyl terminus of the reference sequence, but is not necessarily at the carboxyl terminus of the complete polypeptide.

[0028] A “complement” of a polynucleotide molecule is a polynucleotide molecule having a complementary base sequence and reverse orientation as compared to a reference sequence. For example, the sequence 5′ ATGCACGGG 3′ is complementary to 5′ CCCGTGCAT 3′.

[0029] “Corresponding to”, when used in reference to a nucleotide or amino acid sequence, indicates the position in a second sequence that aligns with the reference position when two sequences are optimally aligned.

[0030] The term “degenerate nucleotide sequence” denotes a sequence of nucleotides that includes one or more degenerate codons (as compared to a reference polynucleotide molecule that encodes a polypeptide). Degenerate codons encompass different triplets of nucleotides, but encode the same amino acid residue (i.e., GAU and GAC triplets each encode Asp).

[0031] The term “expression vector” is used to denote a DNA molecule, linear or circular, that comprises a segment encoding a polypeptide of interest operably linked to additional segments that provide for its transcription, wherein said segments are arranged in a way that does not exist naturally. Such additional segments include promoter and terminator sequences, and may also include one or more origins of replication, one or more selectable markers, an enhancer, a polyadenylation signal, etc.

[0032] Expression vectors are generally derived from plasmid or viral DNA, or may contain elements of both.

[0033] The term “isolated”, when applied to a polynucleotide, denotes that the polynucleotide has been removed from its natural genetic milieu and is thus free of other extraneous or unwanted coding sequences, and is in a form suitable for use within genetically engineered protein production systems. Such isolated molecules are those that are separated from their natural environment and include cDNA and genomic clones. Isolated DNA molecules of the present invention are free of other genes with which they are ordinarily associated, but may include naturally occurring 5′ and 3′ untranslated regions such as promoters and terminators. The identification of associated regions will be evident to one of ordinary skill in the art (see for example, Dynan and Tijan, Nature 316:774-78, 1985).

[0034] An “isolated” polypeptide or protein is a polypeptide or protein that is found in a condition other than its native environment, such as apart from blood and animal tissue. In a preferred form, the isolated polypeptide or protein is substantially free of other polypeptides or proteins, particularly other polypeptides or proteins of animal origin. It is preferred to provide the polypeptides or proteins in a highly purified form, i.e. greater than 95% pure, more preferably greater than 99% pure. When used in this context, the term “isolated” does not exclude the presence of the same polypeptide or protein in alternative physical forms, such as dimers or alternatively glycosylated or derivatized forms.

[0035] A “mature protein” is a protein that is produced by cellular processing of a primary translation product of a DNA sequence. Such processing may include removal of a secretory signal peptide, sometimes in combination with a propeptide. Mature sequences can be predicted from full-length sequences using methods known in the art for predicting cleavage sites. See, for example, von Heijne (Nuc. Acids Res. 14:4683, 1986). The sequence of a mature protein can be determined experimentally by expressing a DNA sequence of interest in a eukaryotic host cell and determining the amino acid sequence of the final product. For proteins lacking secretory peptides, the primary translation product will be the mature protein.

[0036] “Operably linked”, when referring to DNA segments, indicates that the segments are arranged so that they function in concert for their intended purposes, e.g., transcription initiates in the promoter and proceeds through the coding segment to the terminator. When referring to polypeptides, “operably linked” includes both covalently (e.g., by disulfide bonding) and non-covalently (e.g., by hydrogen bonding, hydrophobic interactions, or salt-bridge interactions) linked sequences, wherein the desired function(s) of the sequences are retained.

[0037] The term “ortholog” denotes a polypeptide or protein obtained from one species that is the functional counterpart of a polypeptide or protein from a different species. Sequence differences among orthologs are the result of speciation.

[0038] “Paralogs” are distinct but structurally related proteins made by an organism. Paralogs are believed to arise through gene duplication. For example, α-globin, β-globin, and myoglobin are paralogs of each other.

[0039] A “polynucleotide” is a single- or double-stranded polymer of deoxyribonucleotide or ribonucleotide bases read from the 5′ to the 3′ end.

[0040] Polynucleotides include RNA and DNA, and may be isolated from natural sources, synthesized in vitro, or prepared from a combination of natural and synthetic molecules. Sizes of polynucleotides are expressed as base pairs (abbreviated “bp”), nucleotides (“nt”), or kilobases (“kb”). Where the context allows, the latter two terms may describe polynucleotides that are single-stranded or double-stranded. When the term is applied to double-stranded molecules it is used to denote overall length and will be understood to be equivalent to the term “base pairs”. It will be recognized by those skilled in the art that the two strands of a double-stranded polynucleotide may differ slightly in length and that the ends thereof may be staggered as a result of enzymatic cleavage; thus all nucleotides within a double-stranded polynucleotide molecule may not be paired. Such unpaired ends will in general not exceed 20 nt in length.

[0041] A “polypeptide” is a polymer of amino acid residues joined by peptide bonds, whether produced naturally or synthetically. Polypeptides of less than about 10 amino acid residues are commonly referred to as “peptides”.

[0042] The term “promoter” is used herein for its art-recognized meaning to denote a portion of a gene containing DNA sequences that provide for the binding of RNA polymerase and initiation of transcription. Promoter sequences are commonly, but not always, found in the 5′ non-coding regions of genes.

[0043] A “protein” is a macromolecule comprising one or more polypeptide chains. A protein may also comprise non-peptidic components, such as carbohydrate groups. Carbohydrates and other non-peptidic substituents may be added to a protein by the cell in which the protein is produced, and will vary with the type of cell. Proteins are defined herein in terms of their amino acid backbone structures; substituents such as carbohydrate groups are generally not specified, but may be present nonetheless.

[0044] A “secretory signal sequence” is a DNA sequence that encodes a polypeptide (a “secretory peptide”) that, as a component of a larger polypeptide, directs the larger polypeptide through a secretory pathway of a cell in which it is synthesized. The larger polypeptide is commonly cleaved to remove the secretory peptide during transit through the secretory pathway.

[0045] All references cited herein are incorporated by reference in their entirety.

[0046] The present invention is based in part upon the discovery of a group of novel, protein-enoding DNA molecules, designated “AFP” proteins, polypeptides and polynucleotides. These DNA molecules and the amino acid sequences that they encode are shown in SEQ ID NO:1 through SEQ ID NO:122. Sequence analysis predicts that each of the encoded proteins includes an amino-terminal secretory peptide. These secretory peptides are shown below in Table 1, wherein residue numbers are in reference to the indicated SEQ ID NO. As will be understood by those skilled in the art, the cleavage sites predicted by conventional models of secretory peptide cleavage (e.g., von Heijne, Nuc. Acids Res. 14:4683, 1986) are not always exact and may vary by as much as ±5 residues. In addition, cleavage may occur at multiple sites within 5 residues of the indicated position. The mature form of any given protein may thus consists of a plurality of species differing at their amino termini. TABLE 1 Protein SEQ ID NO: Residues 1 AFP142651 2 28 AFP20937 4 18 AFP417792 6 25 AFP576652 8 22 AFP576853 10 14 AFP583515 12 14 AFP631844 14 28 AFP634707 16 22 AFP635542 18 14 AFP68100 20 24 AFP684692 22 20 AFP632868 24 14 AFP428382 26 22 AFP72084 28 27 AFP639493 30 19 AFP677287 32 17 AFP177404 34 22 AFP277692 36 17 AFP674535 38 22 AFP652829 40 20 AFP321359 42 23 AFP374878 44 19 AFP584218 46 24 AFP39158 48 15 AFP471025 52 16 AFP674834 54 22 AFP669653 56 19 AFP50993 58 14 AFP253034 60 26 AFP490546 62 19 AFP644058 64 16 AFP4581 66 21 AFP301973 68 16 AFP308812 70 19 AFP309995 72 20 AFP141288 74 23 AFP679597 76 19 AFP213641 78 17 AFP241175 80 19 AFP188629 82 23 AFP114314 84 16 AFP548753 86 28 AFP253067 88 14 AFP281501 90 19 AFP513481 92 20 AFP671052 94 24 AFP485790 96 26 AFP616509 98 16 AFP285042 100 15 AFP332354 102 26 AFP162878 104 24 AFP80526 106 19 AFP686580 108 24 AFP677257 110 25 AFP166924 112 29 AFP193083 114 17 AFP355471 116 15 AFP577178 118 18 AFP235412 120 28 AFP669232 122 26

[0047] A secretory peptide of a protein of the present invention can be used to direct the secretion of other proteins of interest from a host cell. Thus, the present invention provides, inter alia, fusions comprising such a secretory peptide of a protein disclosed herein operably linked to another protein of interest. The secretory peptide can be used to direct the secretion of other proteins of interest by joining a polynucleotide sequence encoding it, in the correct reading frame, to the 5′ end of a sequence encoding the other protein of interest. Those skilled in the art will recognize that the resulting fused sequence may encode additional residues of a protein of the present invention at the amino terminus of the protein to be secreted. In the extreme case, the fusion may comprise an entire protein of the present invention fused to the amino terminus of a second protein, whereby secretion of the fusion protein is directed by the secretory peptide of the protein of the present invention. It will often be desirable to include a proteolytic cleavage site between the protein of the present invention (or portion thereof) and the other protein of interest. The joined polynucleotide sequences are then introduced into a host cell, which is cultured according to conventional methods. The protein of interest is then recovered from the culture media. Methods for introducing DNA into host cells, culturing the cells, and isolating recombinant proteins are known in the art. Representative methods are summarized below.

[0048] Higher order structures of the proteins of the present invention can be predicted by computer analysis using available software (e.g., the Insight II® viewer and homology modeling tools available from MSI, San Diego, Calif.; and King and Sternberg, Protein Sci. 5:2298-310, 1996). In addition, analytical algorithms permit the identification of homologies between newly discovered proteins and known proteins. Such homologies are indicative of related biological functions.

[0049] AFP471025 (SEQ ID NO:52) has 29% identity to a glycerophosphoryl diester phosphodiesterase from Bacillus subtilis (Genbank accession number Z26522).

[0050] It may encode a secreted or type II membrane-bound protein with phosphodiesterase activity.

[0051] AFP213641 (SEQ ID NO:78) has 43% identity to tetraspanin protein NET-4 (Genbank accession number AF065389). Tetraspanins contain four hydrophobic membrane spanning domains connected by two extracellular loops. They are implicated in cell proliferation and motility. The four transmembrane domains of AFP213641 are predicted as residue 16 (Ser) of SEQ ID NO:78 to residue 47 (Ala) of SEQ ID NO:78), residue 65 (Ala) of SEQ ID NO:78 to residue 87 (Leu) of SEQ ID NO:78), residue 91 (IIe) of SEQ ID NO:78 to residue 117 (Val) of SEQ ID NO:78, and residue 228 (Leu) of SEQ ID NO:78 to residue 261 (Val) of SEQ ID NO:78.

[0052] AFP80526 (SEQ ID NO:106) has 35% identity to human trypsin, a peptidase that catalyzes hydrolysis of the carboxyl group of either arginine or lysine. AFP80526 contains 2 of the 3 conserved residues found in the catalytic triad of the serine proteases: residue 55 (His) of SEQ ID NO:106 and residue 99 (Asp) of SEQ ID NO:106. These two residues are predicted to be active site catalytic residues essential for enzymatic activity. Interestingly, AFP80526 does not contain the expected active site Ser residue at the expected location (around residue 192 of SEQ ID NO:106). However, rough structural modeling reveals that both residue 92 (Ser) of SEQ ID NO:106 and residue 94 (Ser) of SEQ ID NO:106, while distant in the sequence from residue 192, are close in three dimensional space to the active site pocket. AFP80526 may contain three intra-chain disulfide bonds: residue 40 (Cys) to residue 56 (Cys) of SEQ I) NO:106, residue 131 (Cys) to residue 198 (Cys) of SEQ ID NO:106, and residue 163 (Cys) to residue 177 (Cys) of SEQ ID NO:106.

[0053] AFP193083 (SEQ IID NO:114) has 28% identity to a bacterial lipase (Genbank accession number X67712). Lipases are enzymes that hydrolyze the ester bond of triglycerides. Residues 148 (Ser), 278 (Asp), and 306 (His) of AFP193083 (SEQ ID NO:114) may be active site catalytic residues essential for enzymatic activity. AFP193083 may be a type II membrane-bound protein: residues 6 (Val) through 42 (Trp) of SEQ ID NO: 114 may form an N-terminal transmembrane domain.

[0054] AFP577178 (SEQ ID NO:118) has 28% identity to a Minke whale pancreatic ribonucleases (Medline ID 76277855). The family of secreted pancreatic ribonucleases include bovine seminal vesicle and bovine brain ribonucleases, angiogenin, eosinophil cationic protein, eosinophil derived neurotoxin. The secreted pancreatic ribonucleases have an interesting mechanism of action: e.g., angiogenin; upon binding to endothelial cells, is endocytosed and translocated to the nucleus where it degrades tRNA and abolishes protein synthesis. Residues 82 (His) and 115 (Lys) of AFP577178 (SEQ ID NO: 118) may be active site catalytic residues essential for enzymatic activity. Another active site residue may be residue 187 (His) of SEQ ID NO:118. AFP577178 may be a potent cytotoxin. Alternatively, it may have a role in wound healing and angiogenesis—similar to angiogenin. Finally, it may have antiviral activity—similar to eosinophil cationic protein. AFP577178 has three potential glycosylation sites: at residues 61 (Asn), 89 (Asn), and 1119 (Asn) of SEQ ID NO: 118.

[0055] AFP241175 (SEQ ID NO:80) may be a seven-pass transmembrane receptor. It may be coupled with a guanine nucleotide-binding protein (G protein), and signal on response to an extracellular ligand. The seven transmembrane domains of AFP241175 are predicted as residues 4 (Ala) to 26 (Ala) of SEQ ID NO:80; residues 33 (Ile) to 55 (Met) of SEQ ID NO:80; residues 67 (Thr) to 85 (Met) of SEQ ID NO:80; residues 117 (Ala) to 139 (Asp) of SEQ ID NO:80; residues 154 (Gln) to 176 (Val) of SEQ ID NO:80: residues 187 (Gly) to 209 (Tyr) of SEQ ID NO:80; and residues 213 (Leu) to 235 (Cys) of SEQ ID NO:80.

[0056] Table 2 lists AFP proteins for which regions of identity have been found in the GenBank database. TABLE 2 Locus Accession Number and/or Description AFP20937 AK000732 (Homo sapiens cDNA FLJ20725 clone HEP13903 AEP39158 AK023921 (Homo sapiens cDNA FLJ13859, clone THYRO1001033, similar to Transformation sensitive protein IEF SSP 3521) AEP114314 AK001382 (Homo sapiens cDNA FLJ10520, clone NT2RP2000819 AFP285042 AK001091 (Homo sapiens cDNA FLJ10229, clone HEMBB 1000136) AFP374878 AK001373 (Homo sapiens cDNA FLJ1051, clone NT2RP2000656) AFP332354 AF325707 (Homo sapiens ribosomal protein L2 (RPML2) mRNA; nuclear gene for mitochondrial product AFP490546 AK002204 (Homo sapiens cDNA FLJ1342, clone PLACE1010800) AEP162878 AK023923 (Homo sapiens cDNA FLJ13861, clone THYRO1001100, similar to zinc finger X-linked protein ZXDA.) AFP188629 AB019038 Homo sapiens HMT-1 mRNA for beta- 1,4 mannosyltransferase, AFP193083 AF225418 (Homo sapiens lipase mRNA,) AFP253034 HSA306408 (Homolgoue of yeast MMS 19 nucleotide excision repair) AFP471025 AK026256 (Homo sapiens cDNA: FLJ22603, clone HSI04564 related to phosphodiesterase AFP616509 related to zn finger protein MOBLL AFP652829 ELAC1 ortholog of E. coli elaC AFP669653 AF321613 (Homo sapiens GIBT protein (C3orf5) mRNA,) AFP677257 AF258676 (Homo sapiens MUCDHL-FL (MUCDHL) mRNA complete cds, alternatively spliced,contains mucin and cadherin-like domains)

[0057] Additionally, AFP177404 has been identified as a Beta-Gal 3′-sulfotransferase.

[0058] A protein of the present invention can be prepared as a fusion protein by joining it to a second polypeptide or a plurality of additional polypeptides. Suitable second polypeptides include amino- or carboxyl-terminal extensions, such as linker peptides of up to about 20-25 residues and extensions that facilitate purification (affinity tags) as disclosed above. A protein of interest can be prepared as a fusion to a dimerizing protein as disclosed in U.S. Pat. Nos. 5,155,027 and 5,567,584. Preferred dimerizing proteins in this regard include immunoglobulin constant region domains. Immunoglobulin-polypeptide fusions can be expressed in genetically engineered cells to produce a variety of multimeric analogs of a protein of interest. Fusion proteins can also comprise auxiliary domains that target the protein of interest to specific cells, tissues, or macromolecules (e.g., collagen). For example, a protein of interest can be targeted to a predetermined cell type by fusing it to a ligand that specifically binds to a receptor on the surface of a target cell. In this way, proteins can be targeted for therapeutic or diagnostic purposes. A protein can be fused to two or more moieties, such as an affinity tag for purification and a targeting domain. Protein fusions can also comprise one or more cleavage sites, particularly between domains. See, Tuan et al., Connective Tissue Research 34:1-9, 1996. Proteins of the present invention can also be used as targetting moieties within fusion proteins comprising, for example, cytokines, cytotoxins, or other biologically active polypeptide moieties.

[0059] Protein fusions of the present invention will usually contain not more than about 1,200 amino acid residues joined to the AFP protein. For example, an AFP protein can be fused to E. coli β-galactosidase (1,021 residues; see Casadaban et al., J. Bacteriol 143:971-980, 1980), a 10-residue spacer, and a 4-residue factor Xa cleavage site. Such a protein comprising, for example, AFP68100 (SEQ ID NO:20), contains 514 amino acid residues. In a second example, an AFP protein can be fused to maltose binding protein (approximately 370 residues), a 4-residue cleavage site, and a 6-residue polyhistidine tag.

[0060] As disclosed above, the proteins of the present invention or portions thereof can also be used to direct the secretion of a second protein. When such fusions are designed so that the secreted protein retains a portion of the protein of the present invention, the fusion protein can be purified by means that exploit the properties of the protein of the present invention. Typical of such methods is immunoaffinity chromatography using an antibody directed against a protein of the present invention. When such a fusion is engineered to contain a cleavage site at the fusion point, the fusion can be cleaved and the protein of interest recovered free of extraneous sequence.

[0061] The present invention also provides polynucleotide molecules, including DNA and RNA molecules, that encode the proteins disclosed above. Those skilled in the art will readily recognize that, in view of the degeneracy of the genetic code, considerable sequence variation is possible among these polynucleotide molecules. The amino acid sequence information provided herein can be used by one of ordinary skill in the art to generate degenerate sequences comprising all nucleotide sequences encoding a particular polypeptide. Table 3 sets forth the one-letter codes used to denote degenerate nucleotide positions. “Resolutions” are the nucleotides denoted by a code letter. “Complement” indicates the code for the complementary nucleotide(s). For example, the code Y denotes either C or T, and its complement R denotes A or G, A being complementary to T, and G being complementary to C. TABLE 3 Nucleotide Resolutions Complement Resolutions A A T T C C G G G G C C T T A A R A|G Y C|T Y C|T R A|G M A|C K G|T K G|T M A|C S C|G S C|G W A|T W A|T H A|C|T D A|G|T B C|G|T V A|C|G V A|C|G B C|G|T D A|G|T H A|C|T N A|C|G|T N A|C|G|T

[0062] Degenerate codons encompassing all possible codons for a given amino acid are set forth in Table 4, below. TABLE 4 Amino One-Letter Degenerate Acid Code Codons Codon Cys C TGC TGT TGY Ser S AGC AGT TCA TCC TCG TCT WSN Thr T ACA ACC ACG ACT CAN Pro P CCA CCC CCG CCT CCN Ala A GCA GCC GCG GCT GCN Gly G GGA GGC GGG GGT GGN Asn N AAC AAT AAY Asp D GAC GAT GAY Glu E GAA GAG GAR Gln Q CAA CAG CAR His H CAC CAT CAY Arg R AGA AGG CGA CGC CGG CGT MGN Lys K AAA AAG AAR Met M ATG ATG Ile I ATA ATC ATT ATH Leu L CTA CTC CTG CTT TTA TTG YTN Val V GTA GTC GTG GTT GTN Phe F TTC TTT TTY Tyr Y TAC TAT TAY Trp W TGG TGG Ter TAA TAG TGA TRR Asn|Asp B RAY Glu|Gln Z SAR Any X NNN Gap —

[0063] One of ordinary skill in the art will appreciate that some ambiguity is introduced in determining a degenerate codon, representative of all possible codons encoding each amino acid. For example, the degenerate codon for serine (WSN) can, in some circumstances, encode arginine (AGR), and the degenerate codon for arginine (MGN) can, in some circumstances, encode serine (AGY). A similar relationship exists between codons encoding phenylalanine and leucine. Thus, some polynucleotides encompassed by the degenerate sequences may encode variant amino acid sequences, but one of ordinary skill in the art can easily identify such variant sequences by reference to the amino acid sequences disclosed in the accompanying Sequence Listing.

[0064] Methods for preparing DNA and RNA are well known in the art. Complementary DNA (cDNA) clones are prepared from RNA that is isolated from a tissue or cell that produces large amounts of the cognate mRNA. Such tissues and cells are identified by methods commonly known in the art, such as Northern blotting (Thomas, Proc. Natl. Acad. Sci. USA 77:5201, 1980). Databases of expressed sequence tags (ESTs) can be analyzed to produce an “electronic Northern” wherein sequences are assigned to specific cell or tissue sources on the basis of their abundance within libraries. Table 5, below, shows the results of such an analysis when, as the minimum significant abundance, it was required that at least 10% of all sequences for a given protein were from a single source and at least five individual clones had been identified from that source. Sequences shown in the accompanying Sequence Listing but not listed in Table 5 were widely distributed among various tissues or were represented by few clones. TABLE 5 Protein Tissues AFP634707 fetal lung, testis, or B cell AFP301973 Kidney AFP285042 melanocyte, fetal heart, or pregnant uterus AFP80526 Testis AFP677257 Kidney

[0065] A panel of cDNAs from human tissues was screened for AFP expression using PCR. The panel was made from first strand cDNAs obtained from Clontech laboratories, Inc., Palo Alto, Calif. and contained 20 first-strand cDNA samples from the human tissues shown in Table 6. The panel was set up in a 96-well format that further included a human genomic DNA (obtained from Clontech Laboratories, Inc.) positive control sample and a water-only well as a negative control sample. Each well contained approximately 0.2-100 pg/μl of cDNA, diluted with water to 17.5 μl. The PCR reactions were set up by adding oligonucleotide primers, DNA polymerase (Ex Taq™; TAKARA Shuzo Co. Ltd. Biomedicals Group, Japan or Advantage™ 2 cDNA polymerase mix; Clontech Laboratories, Inc.) with the appropriate supplied buffer, DNTP mix (TAKARA Shuzo Co. Ltd.), and a density increasing agent and tracking dye (RediLoad; Research Genetics, Inc., Huntsville, Ala.) to each sample on the panel. The amplification was carried out as follows: incubation at 94° C. for 2 minutes; 35 cycles of 94° C. for 30 seconds, 60° C. for 20 seconds, and 72° C. for 30 seconds; followed by incubation at 72° C. for 5 minutes. About 10 μl of the PCR reaction product was subjected to standard agarose gel electrophoresis using a 4% agarose gel. TABLE 6 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 AFP141288 y y y y y y y y y y n y y y y y y y y y n y AFP142651 y y y y y y y y y y y y y y y y y y y y n y AFP166924 y y y y y y y y y y y y y y y y y y y y n y APP177404 y y y y y y y y y y y y y y y y n y y y n y AFP188629 y y y y y y y y y y y y y y y y y y y y n y AFP20937 y y y y y y y y y y y y nd y y y y y y y n y AFP285042 y y y y y y y y n y y y y y y y n n y n n n AFP301973 y y y y y y y y y y y y y y y y y y y y n y AFP374878 y y y y y y y y y y y y y y y y y y y y n y AFP428382 y y y n y y y n y y n y y n y n n n n y n y AFP471025 y y y y y y y nd y y y y nd y nd y nd n y y n n AFP490546 y y y y y y y y y y y? y y y y y y y y y n y AFP548753 y y y n y y y n n y y n n n y n n y y y n y AFP576652 n n y y y y n n n n y n n n n n n n y y n y AFP576853 y y y n y y y n n y n y n y y n n n n n n n AFP577178 n n n n n y y n n n n n n n y n n n n n n y AFP616509 n n n y y? y? y n n n n n n n y n n n n n n y AFP634707 y y y y y y y y n y n y n y y n y y y y n y AFP652829 y y y y y y y y y y y y y y y y y y y y n n AFP664311 y y y y y y y y n y n y y y y y n y y y n n AFP669653 y y y y y y y y y y y y y y y y y y y y n n AFP671052 y y y y y y y y n y y y y y y y n y y y n n AFP674535 y n n n n y n n n y n y n n y n n n n n n y AFP677257 n n n n n n n n n n n n n n n n n n n n n y AFP677287 y y y y y y y y y y y y nd y y y y y y y n y

[0066] Total RNA can be prepared using guanidine HCl extraction followed by isolation by centrifugation in a CsCl gradient (Chirgwin et al., Biochemistry 18:52-94, 1979). Poly (A)⁺ RNA is prepared from total RNA using the method of Aviv and Leder (Proc. Natl. Acad. Sci. USA 69:1408-1412, 1972). Complementary DNA (cDNA) is prepared from poly(A)⁺ RNA using known methods. In the alternative, genomic DNA can be isolated. For some applications (e.g., expression in transgenic animals) it may be preferable to use a genomic clone, or to modify a cDNA clone to include at least one genomic intron. Methods for identifying and isolating cDNA and genomic clones are well known and within the level of ordinary skill in the art, and include the use of the sequences disclosed herein, sequences complementary thereto, or parts thereof, for probing or priming a library. Such methods include, for example, hybridization or polymerase chain reaction (“PCR”, Mullis, U.S. Pat. No. 4,683,202). Expression libraries can be probed with antibodies to a protein of interest, receptor fragments, or other specific binding partners.

[0067] The polynucleotides of the present invention can also be prepared by automated synthesis. Synthesis of polynucleotides is within the level of ordinary skill in the art, and suitable equipment and reagents are available from commercial suppliers. See, in general, Glick and Pasternak, Molecular Biotechnology, Principles & Applications of Recombinant DNA, ASM Press, Washington, D.C., 1994; Itakura et al., Ann. Rev. Biochem. 53: 323-56, 1984; and Climie et al., Proc. Natl. Acad. Sci. USA 87:633-7, 1990.

[0068] The present invention further provides antisense polynucleotides that are complementary to a segment of a polynucleotide as set forth in one of SEQ ID NO:N, wherein N is an odd integer from 1 to 121. Such antisense polynucleotides are designed to bind to the corresponding mRNA and inhibit its translation. Antisense polynucleotides are used to inhibit gene expression in cell culture or in a patient, and can be used as probes or primers for research or diagnostic purposes.

[0069] Probes and primers of the present invention comprise a suitable fragment, and may comprise up to the complete sequence, of a polynucleotide as shown in SEQ ID NO:N or the complement thereof, wherein N is an odd integer from 1 to 121. Probes will generally be at least 20 nucleotides in length, although somewhat shorter probes (14-17 nucleotides) can be used. PCR primers are at least 5 nucleotides in length, preferably 15 or more nt, more preferably 20-30 nt. Shorter polynucleotide probes and primers are referred to in the art as “oligonucleotides,” and can be DNA or RNA. Probes will generally comprise an oligonucleotide linked to a label, such as a radionuclide.

[0070] Probes and primers as disclosed herein can be used for cloning allelic, orthologous, and paralogous sequences. Allelic variants of the disclosed sequences can be cloned by probing cDNA or genomic libraries from different individuals according to standard procedures. Orthologous sequences can be cloned using information and compositions provided by the present invention in combination with conventional cloning techniques. For example, a cDNA can be cloned using mRNA obtained from a tissue or cell type that expresses the protein. Suitable sources of mRNA can be identified by probing Northern blots with probes designed from the sequences disclosed herein. A library is then prepared from mRNA of a positive tissue or cell line. A cDNA can then be isolated by a variety of methods, such as by probing with a complete or partial human cDNA or with one or more sets of degenerate probes based on the disclosed sequences. A cDNA can also be cloned by PCR using primers designed from the sequences disclosed herein. Within an additional method, the cDNA library can be used to transform or transfect host cells, and expression of the cDNA of interest can be detected with an antibody to the encoded protein. Similar techniques can also be applied to the isolation of genomic clones. Orthologous and paralogous sequences can be identified from libraries by probing blots at low stringency and washing the blots at successively higher stringency until background is suitably reduced.

[0071] Probes and primers disclosed herein can be used to clone 5′ non-coding regions of a corresponding gene. In view of the tissue-specific expression observed for certain proteins of the invention (Table 4), promoters of these genes are expected to provide tissue-specific expression. Such promoter elements can thus be used to direct the tissue-specific expression of heterologous genes in, for example, transgenic animals or patients treated with gene therapy. Cloning of 5′ flanking sequences also facilitates production of a protein of interest by “gene activation” as disclosed in U.S. Pat. No. 5,641,670. Briefly, expression of an endogenous gene in a cell is altered by introducing into its locus a DNA construct comprising at least a targeting sequence, a regulatory sequence, an exon, and an unpaired splice donor site. The targeting sequence is a 5′ non-coding sequence that permits homologous recombination of the construct with the endogenous locus, whereby the sequences within the construct become operably linked with the endogenous coding sequence. In this way, an endogenous promoter can be replaced or supplemented with other regulatory sequences to provide enhanced, tissue-specific, or otherwise regulated expression.

[0072] The polynucleotides of the present invention further include polynucleotides encoding the fusion proteins, including signal peptide fusions, disclosed above.

[0073] The present invention further provides a computer-readable medium encoded with a data structure that provides at least one of SEQ ID NO: 1 through SEQ ID NO:122. Suitable forms of computer-readable media include magnetic media and optically-readable media. Examples of magnetic media include a hard or fixed drive, a random access memory (RAM) chip, a floppy disk, digital linear tape (DLT), a disk cache, and a ZIP® disk. Optically readable media are exemplified by compact discs (e.g., CD-read only memory (ROM), CD-rewritable (RW), and CD-recordable), and digital versatile/video discs (DVD) (e.g., DVD-ROM, DVD-RAM, and DVD+RW).

[0074] The polypeptides of the present invention, including full-length proteins, biologically active fragments, immunogenic fragments, and fusion proteins, can be produced in genetically engineered host cells according to conventional techniques.

[0075] Suitable host cells are those cell types that can be transformed or transfected with exogenous DNA and grown in culture, and include bacteria, fungal cells, and cultured higher eukaryotic cells. Eukaryotic cells, particularly cultured cells of multicellular organisms, are generally preferred for the production of proteins having higher eukaryotic-type post-translational modifications (e.g., γ-carboxylation) and for making proteins, especially secretory proteins, for pharmaceutical use in humans. Techniques for manipulating cloned DNA molecules and introducing exogenous DNA into a variety of host cells are disclosed by Sarmbrook et al., Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989, and Ausubel et al., eds., Current Protocols in Molecular Biology, Green and Wiley and Sons, NY, 1993.

[0076] In general, a DNA sequence encoding a polypeptide of interest is operably linked to other genetic elements required for its expression, generally including a transcription promoter and terminator, within an expression vector. The vector will also commonly contain one or more selectable markers and one or more origins of replication, although those skilled in the art will recognize that within certain systems selectable markers can be provided on separate vectors, and replication of the exogenous DNA can be achieved through integration into the host cell genome. Selection of promoters, terminators, selectable markers, vectors and other elements is a matter of routine design within the level of ordinary skill in the art. Many such elements are described in the literature and are available through commercial suppliers.

[0077] To direct a polypeptide into the secretory pathway of a host cell, a secretory signal sequence (also known as a leader sequence, prepro sequence or pre sequence) is provided in the expression vector. The secretory signal sequence may be that of the protein of interest, or may be derived from another secreted protein (e.g., t-PA; see U.S. Pat. No. 5,641,655) or synthesized de novo. The secretory signal sequence is operably linked to the DNA sequence encoding the protein of interest, i.e., the two sequences are joined in the correct reading frame and positioned to direct the newly synthesized protein into the secretory pathway of the host cell. Secretory signal sequences are commonly positioned 5′ to the DNA sequence encoding the protein of interest, although certain secretory signal sequences may be positioned elsewhere in the DNA sequence of interest (see, e.g., Welch et al., U.S. Pat. No. 5,037,743; Holland et al., U.S. Pat. No. 5,143,830).

[0078] Cultured mammalian cells are suitable hosts for use within the present invention. Methods for introducing exogenous DNA into mammalian host cells include calcium phosphate-mediated transfection (Wigler et al., Cell 14:725, 1978; Corsaro and Pearson, Somatic Cell Genetics 7:603, 1981: Graham and Van der Eb, Virology 52:456, 1973), electroporation (Neumann et al., EMBO J. 1:841-845, 1982), DEAE-dextran mediated transfection (Ausubel et al., ibid.), and liposome-mediated transfection (Hawley-Nelson et al., Focus 15:73, 1993; Ciccarone et al., Focus 15:80, 1993). The production of recombinant polypeptides in cultured mammalian cells is disclosed by, for example, Levinson et al., U.S. Pat. No. 4,713,339; Hagen et al., U.S. Pat. No. 4,784,950; Palmiter et al., U.S. Pat. No. 4,579,821; and Ringold, U.S. Pat. No. 4,656,134. Suitable cultured mammalian cells include the COS-1 (ATCC No. CRL 1650), COS-7 (ATCC No. CRL 1651), BHK (ATCC No. CRL 1632), BHK 570 (ATCC No. CRL 10314), 293 (ATCC No. CRL 1573; Graham et al., J. Gen. Virol. 36:59-72, 1977) and Chinese hamster ovary (e.g. CHO-K1; ATCC No. CCL 61) cell lines. Additional suitable cell lines are known in the art and available from public depositories such as the American Type Culture Collection, Manasas, Virginia. In general, strong transcription promoters are preferred, such as promoters from SV-40 or cytomegalovirus. See, e.g., U.S. Pat. No. 4,956,288. Other suitable promoters include those from metallothionein genes (U.S. Pat. Nos. 4,579,821 and 4,601,978) and the adenovirus major late promoter. Within an alternative embodiment, adenovirus vectors can be employed. See, for example, Garnier et al., Cytotechnol. 15:145-55, 1994.

[0079] Drug selection is generally used to select for cultured mammalian cells into which foreign DNA has been inserted. Such cells are commonly referred to as “transfectants”. Cells that have been cultured in the presence of the selective agent and are able to pass the gene of interest to their progeny are referred to as “stable transfectants.” An exemplary selectable marker is a gene encoding resistance to the antibiotic neomycin. Selection is carried out in the presence of a neomycin-type drug, such as G-418 or the like. Selection systems can also be used to increase the expression level of the gene of interest, a process referred to as “amplification.” Amplification is carried out by culturing transfectants in the presence of a low level of the selective agent and then increasing the amount of selective agent to select for cells that produce high levels of the products of the introduced genes. An exemplary amplifiable selectable marker is dihydrofolate reductase, which confers resistance to methotrexate. Other drug resistance genes (e.g. hygromycin resistance, multi-drug resistance, puromycin acetyltransferase) can also be used.

[0080] Insect cells can be infected with recombinant baculovirus, commonly derived from Autographa califomica nuclear polyhedrosis virus (AcNPV). See, King and Possee, The Baculovirus Expression System: A Laboratorv Guide, London, Chapman & Hall; O'Reilly et al., Baculovirus Expression Vectors: A Laboratory Manual, New York, Oxford University Press., 1994; and Richardson, Ed., Baculovirus Expression Protocols. Methods in Molecular Biology, Humana Press, Totowa, N.J., 1995. Recombinant baculovirus can also be produced through the use of a transposon-based system described by Luckow et al. (J. Virol. 67:45664579, 1993). This system, which utilizes transfer vectors, is commercially available in kit form (Bac-to-Bac™ kit; Life Technologies, Rockville, Md.). See also, Hill-Perkins and Possee, J. Gen. Virol. 71:971-976, 1990; Bonning et al., J. Gen. Virol. 75:1551-1556, 1994; and Chazenbalk and Rapoport, J. Biol. Chem. 270:1543-1549, 1995.

[0081] For protein production, the recombinant virus is used to infect host cells, typically a cell line derived from the fall armyworm, Spodoptera frugiperda (e.g., Sf9 or Sf21 cells) or Trichoplusia ni (e.g., High Five™ cells; Invitrogen, Carlsbad, Calif.). See, in general, Glick and Pasternak, Molecular Biotechnology: Principles and Applications of Recombinant DNA, ASM Press, Washington, D.C., 1994. See also, U.S. Pat. No. 5,300,435. Serum-free media are used to grow and maintain the cells. Suitable media formulations are known in the art and can be obtained from commercial suppliers. The cells are grown up from an inoculation density of approximately 2-5×10⁵ cells to a density of 1-2×10⁶ cells, at which time a recombinant viral stock is added at a multiplicity of infection (MOI) of 0.1 to 10, more typically near 3. Procedures used are generally described in available laboratory manuals (e.g., King and Possee, ibid.; O'Reilly et al., ibid.; Richardson, ibid.). See also, Guarino et al., U.S. Pat. No. 5,162,222 and WIPO publication WO 94/06463.

[0082] Fungal cells, including yeast cells, can also be used within the present invention. Yeast species of particular interest in this regard include Saccharomyces cerevisiae, Pichia pastoris, and Pichia methanolica. Methods for transforming S. cerevisiae cells with exogenous DNA and producing recombinant polypeptides therefrom are disclosed by, for example, Kawasaki, U.S. Pat. No. 4,599,311; Kawasaki et al., U.S. Pat. No. 4,931,373; Brake, U.S. Pat. No. 4,870,008; Welch et al., U.S. Pat. No. 5,037,743; and Murray et al., U.S. Pat. No. 4,845,075. Transformed cells are selected by phenotype determined by the selectable marker, commonly drug resistance or the ability to grow in the absence of a particular nutrient (e.g., leucine). A preferred vector system for use in Saccharomyces cerevisiae is the POT1 vector system disclosed by Kawasaki et al. (U.S. Pat. No. 4,931,373), which allows transformed cells to be selected by growth in glucose-containing media. Suitable promoters and terminators for use in yeast include those from glycolytic enzyme genes (see, e.g., Kawasaki, U.S. Pat. No. 4,599,311; Kingsman et al., U.S. Pat. No. 4,615,974; and Bitter, U.S. Pat. No. 4,977,092) and alcohol dehydrogenase genes. See also U.S. Pat. Nos. 4,990,446; 5,063,154; 5,139,936 and 4,661,454.

[0083] Transformation systems for other yeasts, including Hansenula polymorpha, Schizosaccharomyces pombe, Kluyveromyces lactis, Kluyveromyces fragilis, Ustilago maydis, Pichia pastoris, Pichia methanolica, Pichia guillermondii and Candida maltosa are known in the art. See, for example, Gleeson et al., J. Gen. Microbiol. 132:3459-3465, 1986 and Cregg, U.S. Pat. No. 4,882,279. Aspergillus cells may be utilized according to the methods of McKnight et al., U.S. Pat. No. 4,935,349. Methods for transforming Acremonium chrysogenum are disclosed by Sumino et al., U.S. Pat. No. 5,162,228. Methods for transforming Neurospora are disclosed by Lambowitz, U.S. Pat. No. 4,486,533. Production of recombinant proteins in Pichia methanolica is disclosed in U.S. Pat. No. 5,716,808, 5,736,383, 5,854,039, and 5,888,768; and WIPO publications WO 99/14347 and WO 99/14320.

[0084] Other higher eukaryotic cells, including plant cells and avian cells, can also be used as hosts according to methods commonly known in the art. For example, the use of Agrobacterium rhizogenes as a vector for expressing genes in plant cells has been reviewed by Sinkar et al., J. Biosci. (Bangalore) 11:47-58, 1987.

[0085] Prokaryotic host cells, including strains of the bacteria Escherichia coli, Bacillus and other genera are also useful host cells within the present invention. Techniques for transforming these hosts and expressing foreign DNA sequences cloned therein are well known in the art (see, e.g., Sambrook et al., ibid.). When expressing a polypeptide in bacteria such as E. coli, the polypeptide may be retained in the cytoplasm, typically as insoluble granules, or may be directed to the periplasmic space by a bacterial secretion sequence. In the former case, the cells are lysed, and the granules are recovered and denatured using, for example, guanidine isothiocyanate or urea. The denatured polypeptide can then be refolded and dimerized by diluting the denaturant, such as by dialysis against a solution of urea and a combination of reduced and oxidized glutathione, followed by dialysis against a buffered saline solution. In the latter case, the polypeptide can be recovered from the periplasmic space in a soluble and functional form by disrupting the cells (by, for example, sonication or osmotic shock) to release the contents of the periplasmic space and recovering the protein, thereby obviating the need for denaturation and refolding.

[0086] Transformed or transfected host cells are cultured according to conventional procedures in a culture medium containing nutrients and other components required for the growth of the chosen host cells. A variety of suitable media, including defined media and complex media, are known in the art and generally include a carbon source, a nitrogen source, essential amino acids, vitamins and minerals. Media may also contain such components as growth factors or serum, as required. The growth medium will generally select for cells containing the exogenously added DNA by, for example, drug selection or deficiency in an essential nutrient which is complemented by the selectable marker carried on the expression vector or co-transfected into the host cell.

[0087] It is preferred to purify the polypeptides and proteins of the present invention to ≧80% purity, more preferably to ≧90% purity, even more preferably ≧95% purity, and particularly preferred is a pharmaceutically pure state, that is greater than 99.9% pure with respect to contaminating macromolecules, particularly other proteins and nucleic acids, and free of infectious and pyrogenic agents. Preferably, a purified polypeptide or protein is substantially free of other polypeptides or proteins, particularly those of animal origin.

[0088] Expressed recombinant proteins (including single polypeptide chains, chimeric polypeptides, and polypeptide multimers) are purified by conventional protein purification methods, typically by a combination of chromatographic techniques. See, in general, Affinity Chromatograph: Principles & Methods, Pharmacia LKB Biotechnology, Uppsala, Sweden, 1988; and Scopes, Protein Purification: Principles and Practice, Springer-Verlag, New York, 1994. Proteins comprising a polyhistidine affinity tag (typically about 6 histidine residues) are purified by affinity chromatography on a nickel chelate resin. See, for example, Houchuli et al., Bio/Technol. 6: 1321-1325, 1988. Proteins comprising a glu-glu tag can be purified by immunoaffinity chromatography essentially as disclosed by Grussenmeyer et al., ibid. Proteins comprising other affinity tags can be purified by appropriate affinity chromatography methods, which are known in the art.

[0089] Proteins of the present invention and fragments thereof can also be prepared through chemical synthesis according to methods known in the art, including exclusive solid phase synthesis, partial solid phase methods, fragment condensation or classical solution synthesis. See, for example, Merrifield, J. Am. Chem. Soc. 85:2149, 1963; Stewart et al., Solid Phase Peptide Synthesis (2nd edition), Pierce Chemical Co., Rockford, Ill., 1984; Bayer and Rapp, Chem. Pept. Prot. 3:3, 1986; and Atherton et al., Solid Phase Peptide Synthesis: A Practical Approach, IRL Press, Oxford, 1989.

[0090] Using methods known in the art, the proteins of the present invention can be prepared in a variety of modified or derivatized forms. For example, the proteins can be prepared glycosylated or non-glycosylated; pegylated or non-pegylated; and may or may not include an initial methionine amino acid residue.

[0091] Biological activities of the proteins of the present invention can be measured in vitro using cultured cells or in vivo by administering molecules of the claimed invention to the appropriate animal model. Many such assays and models are known in the art. Guidance in initial assay selection is provided by structural predictions and sequence alignments. However, even if no functional prediction is made, the activity of a protein can be elucidated by known methods, including, for example, screening a variety of target cells for a biological response, other in vitro assays, expression in a host animal, or through the use of transgenic and/or “knockout” animals. Through the application of robotics, many in vitro assays can be adapted to rapid, high-throughput screeing of a large number of samples. Target cells for use in activity assays include, without limitation, vascular cells (especially endothelial cells and smooth muscle cells), hematopoietic (myeloid and lymphoid) cells, liver cells (including hepatocytes, fenestrated endothelial cells, Kupffer cells, and Ito cells), fibroblasts (including human dermal fibroblasts and lung fibroblasts), neurite cells (including astrocytes, glial cells, dendritic cells, and PC-12 cells), fetal lung cells, articular synoviocytes, pericytes, chondrocytes, osteoblasts, adipocytes, and prostate epithelial cells. Endothelial cells and hematopoietic cells are derived from a common ancestral cell, the hemangioblast (Choi et al., Development 125:725-732, 1998).

[0092] Biological activity can be measured with a silicon-based biosensor microphysiometer that measures the extracellular acidification rate or proton excretion associated with receptor binding and subsequent physiologic cellular responses. An exemplary such device is the Cytosensor™ Microphysiometer manufactured by Molecular Devices, Sunnyvale, Calif. A variety of cellular responses, such as cell proliferation, ion transport, energy production, inflammatory response, regulatory and receptor activation, and the like, can be measured by this method. See, for example, McConnell et al., Science 257:1906-1912, 1992; Pitchford et al., Meth. Enzymol. 228:84-108, 1997; Arimilli et al., J. Immunol. Meth. 212:49-59, 1998; and Van Liefde et al., Eur. J. Pharmacol. 346:87-95, 1998. The microphysiometer can be used for assaying adherent or non-adherent eukaryotic or prokaryotic cells. By measuring extracellular acidification changes in cell media over time, the microphysiometer directly measures cellular responses to various stimuli, including agonistic and antagonistic stimuli. Preferably, the microphysiometer is used to measure responses of a eukaryotic cell known to be responsive to the protein of interest, compared to a control eukaryotic cell that does not respond to the protein of interest. Responsive eukaryotic cells comprise cells into which a receptor for the protein of interest has been transfected, as well as naturally responsive cells. Differences in the response of cells exposed to the protein of interest, relative to a control not so exposed, are a direct measurement of protein-modulated cellular responses. Such responses can be assayed under a variety of stimuli. The present invention thus provides methods of identifying agonists and antagonists of proteins of interest, comprising providing cells responsive to a selected protein, culturing a first portion of the cells in the absence of a test compound, culturing a second portion of the cells in the presence of a test compound, and detecting a change in a cellular response of the second portion of the cells as compared to the first portion of the cells. The change in cellular response is shown as a measurable change in extracellular acidification rate. Culturing a third portion of the cells in the presence of the protein of interest and the absence of a test compound provides a positive control and a control to compare the agonist activity of a test compound with that of the protein of interest. Antagonists can be identified by exposing the cells to the protein of interest in the presence and absence of the test compound, whereby a reduction in protein-stimulated activity is indicative of antagonist activity in the test compound.

[0093] Assays measuring cell proliferation or differentiation are well known in the art. For example, assays measuring proliferation include such assays as chemosensitivity to neutral red dye (Cavanaugh et al., Investigational New Drugs 8:347-354, 1990), incorporation of radiolabelled nucleotides (as disclosed by, e.g., Raines and Ross, Methods Enzymol. 109:749-773, 1985; Wahl et al., Mol. Cell Biol. 8:5016-5025, 1988; and Cook et al., Analytical Biochem. 179: 1-7, 1989), incorporation of 5-bromo-2′-deoxyuridine (BrdU) in the DNA of proliferating cells (Porstmann et al., J. Immunol. Methods 82:169-179, 1985), and use of tetrazolium salts (Mosmann, J. Immunol. Methods 65:55-63, 1983; Alley et al., Cancer Res. 48:589-601, 1988; Marshall et al., Growth Reg. 5:69-84, 1995; and Scudiero et al., Cancer Res. 48:4827-4833, 1988). Differentiation can be assayed using suitable precursor cells that can be induced to differentiate into a more mature phenotype. Assays measuring differentiation include, for example, measuring cell-surface markers associated with stage-specific expression of a tissue, enzymatic activity, functional activity or morphological changes (Watt, FASEB, 5:281-284, 1991; Francis, Differentiation 57:63-75, 1994; Raes, Adv. Anim. Cell Biol. Technol. Bioprocesses, 161-171, 1989). Effects of a protein on tumor cell growth and metastasis can be analyzed using the Lewis lung carcinoma model, for example as described by Cao et al., J. Exp. Med. 182:2069-2077, 1995. Activity of a protein on cells of neural origin can be analyzed using assays that measure effects on neurite growth as disclosed below.

[0094] In vitro assays for pro- and anti-inflammatory activity are known in the art. Exemplary activity assays include mitogenesis assays in which IL-1 responsive cells (e.g., D10.N4.M cells) are incubated in the presence of IL-1 or a test protein for 72 hours at 37° C. in a 5% CO₂ atmosphere. IL-2 (and optionally IL-4) is added to the culture medium to enhance sensitivity and specificity of the assay. ³H-thymidine is then added, and incubation is continued for six hours. The amount of label incorporated is indicative of agonist activity. See, Hopkins and Humphreys, J. Immunol. Methods 120:271-276, 1989; Greenfeder et al., J. Biol. Chem. 270:22460-22466, 1995. Stimulation of cell proliferation can also be measured using thymocytes cultured in a test protein in combination with phytohemagglutinin. IL-1 is used as a control. Proliferation is detected as ³H-thymidine incorporation or metabolic breakdown of (MTT) (Mosman, ibid.).

[0095] Protein activity may also be detected using assays designed to measure induction of one or more growth factors or other macromolecules. Preferred such assays include those for determining the presence of hepatocyte growth factor (HGF), epidermal growth factor (EGF), transforming growth factor alpha (TGFα), interleukin-6 (IL-6), VEGF, acidic fibroblast growth factor (aFGF), angiogenin, and other macromolecules produced by the liver. Suitable assays include mitogenesis assays using target cells responsive to the macromolecule of interest, receptor-binding assays, competition binding assays, immunological assays (e.g., ELISA), and other formats known in the art. Metalloprotease secretion is measured from treated primary human dermal fibroblasts, synoviocytes and chondrocytes. The relative levels of collagenase, gelatinase and stromalysin produced in response to culturing a target cell in the presence of a protein of interest is measured using zymogram gels (Loita and Stetler-Stevenson, Cancer Biology 1:96-106, 1990). Procollagen/collagen synthesis by dermal fibroblasts and chondrocytes in response to a test protein is measured using ³H-proline incorporation into nascent secreted collagen. ³H-labeled collagen is visualized by SDS-PAGE followed by autoradiography (Unemori and Amento, J. Biol. Chem. 265: 10681-10685, 1990). Glycosaminoglycan (GAG) secretion from dermal fibroblasts and chondrocytes is measured using a 1,9-dimethylmethylene blue dye binding assay (Farndale et al., Biochim. Biophys. Acta 883:173-177, 1986). Collagen and GAG assays are also carried out in the presence of IL-1β or TGF-β to examine the ability of a protein to modify the established responses to these cytokines.

[0096] Monocyte activation assays are carried out (1) to look for the ability of a protein of interest to further stimulate monocyte activation, and (2) to examine the ability of a protein of interest to modulate attachment-induced or endotoxin-induced monocyte activation (Fuhlbrigge et al., J. Immunol. 138: 3799-3802, 1987). IL-1β and TNFα levels produced in response to activation are measured by ELISA (Biosource, Inc. Camarillo, Calif.). Monocyte/macrophage cells, by virtue of CD14 (LPS receptor), are exquisitely sensitive to endotoxin, and proteins with moderate levels of endotoxin-like activity will activate these cells.

[0097] Other metabolic effects of proteins can be measured by culturing target cells in the presence and absence of a protein and observing changes in adipogenesis, gluconeogenesis, glycogenolysis, lipogenesis, glucose uptake, or the like. Suitable assays are known in the art.

[0098] Hematopoietic activity of proteins can be assayed on various hematopoietic cells in culture. Preferred assays include primary bone marrow colony assays and later stage lineage-restricted colony assays, which are known in the art (e.g., Holly et al., WIPO Publication WO 95/21920). Marrow cells plated on a suitable semi-solid medium (e.g., 50% methylcellulose containing 15% fetal bovine serum, 10% bovine serum albumin, and 0.6% PSN antibiotic mix) are incubated in the presence of test polypeptide, then examined microscopically for colony formation. Known hematopoietic factors are used as controls. Mitogenic activity of a protein of interest on hematopoietic cell lines can be measured as disclosed above.

[0099] Cell migration is assayed essentially as disclosed by Kahler et al. (Arteriosclerosis, Thrombosis, and Vascular Biology 17:932-939, 1997). A protein is considered to be chemotactic if it induces migration of cells from an area of low protein concentration to an area of high protein concentration. A typical assay is performed using modified Boyden chambers with a polystryrene membrane separating the two chambers (Transwell; Corning Costar Corp.). The test sample, diluted in medium containing 1% BSA, is added to the lower chamber of a 24-well plate containing Transwells. Cells are then placed on the Transwell insert that has been pretreated with 0.2% gelatin. Cell migration is measured after 4 hours of incubation at 37° C. Non-migrating cells are wiped off the top of the Transwell membrane, and cells attached to the lower face of the membrane are fixed and stained with 0.1% crystal violet. Stained cells are then extracted with 10% acetic acid and absorbance is measured at 600 nm.

[0100] Migration is then calculated from a standard calibration curve. Cell migration can also be measured using the matrigel method of Grant et al. (“Angiogenesis as a component of epithelial-mesenchymal interactions” in Goldberg and Rosen, Epithelial-Mesenchymal Interaction in Cancer, Birkhäuser Verlag, 1995, 235-248; Baatout, Anticancer Research 17:451-456, 1997).

[0101] Proteins can be assayed for the ability to modulate axon guidance and growth. Suitable assays that detect changes in neuron growth patterns include, for example, those disclosed in Hastings, WIPO Publication WO 97/29189 and Walter et al., Development 101:685-96, 1987. Assays to measure the effects on neuron growth are well known in the art. For example, the C assay (e.g., Raper and Kapfhammer, Neuron 4:21-9, 1990 and Luo et al., Cell 75:217-27, 1993) can be used to determine collapsing activity of a protein of interest on growing neurons. Other methods that can assess protein-induced inhibition of neurite extension or divert such extension are also known. See, Goodman, Annu. Rev. Neurosci. 19:341-77, 1996. Conditioned media from cells expressing a protein of interest, or aggregates of such cells, can by placed in a gel matrix near suitable neural cells, such as dorsal root ganglia (DRG) or sympathetic ganglia explants, which have been co-cultured with nerve growth factor. Compared to control cells, protein-induced changes in neuron growth can be measured (as disclosed by, for example, Messersmith et al., Neuron 14:949-59, 1995 and Puschel et al., Neuron 14:941-8, 1995). Neurite outgrowth can be measured using neuronal cell suspensions grown in the presence of molecules of the present invention. See, for example, O'Shea et al., Neuron 7:231-7, 199f and DeFreitas et al., Neuron 15:33343, 1995.

[0102] Cell adhesion activity is assayed essentially as disclosed by LaFleur et al. (J. Biol. Chem. 272:32798-32803, 1997). Briefly, microtiter plates are coated with the test protein, non-specific sites are blocked with BSA, and cells (such as smooth muscle cells, leukocytes, or endothelial cells) are plated at a density of approximately 10⁴-10⁵ cells/well. The wells are incubated at 37° C. (typically for about 60 minutes), then non-adherent cells are removed by gentle washing. Adhered cells are quantitated by conventional methods (e.g., by staining with crystal violet, lysing the cells, and determining the optical density of the lysate). Control wells are coated with a known adhesive protein, such as fibronectin or vitronectin.

[0103] Assays for angiogenic activity are also known in the art. For example, the effect of a protein of interest on primordial endothelial cells in angiogenesis can be assayed in the chick chorioallantoic membrane angiogenesis assay (Leung, Science 246:1306-1309, 1989; Ferrara, Ann. NY Acad Sci. 752:246-256, 1995). Briefly, a small window is cut into the shell of an eight-day old fertilized egg, and a test substance is applied to the chorioallantoic membrane. After 72 hours, the membrane is examined for neovascularization. Other suitable assays include microinjection of early stage quail (Coturnix coturnix japonica) embryos as disclosed by Drake et al. (Proc. Natl. Acad. Sci. USA 92:7657-7661, 1995); the rodent model of corneal neovascularization disclosed by Muthukkaruppan and Auerbach (Science 205:1416-1418, 1979), wherein a test substance is inserted into a pocket in the cornea of an inbred mouse; and the hampster cheek pouch assay (Höckel et al., Arch. Surg. 128:423-429, 1993). Induction of vascular permeability, which is indicative of angiogenic activity, is measured in assays designed to detect leakage of protein from the vasculature of a test animal (e.g., mouse or guinea pig) after administration of a test compound (Miles and Miles, J. Physiol. 118:228-257, 1952; Feng et al., J. Exp. Med. 183:1981-1986, 1996). In vitro assays for angiogenic activity include the tridimensional collagen gel matrix model (Pepper et al. Biochem. Biophys. Res. Comm. 189:824-831, 1992 and Ferrara et al., Ann. NY Acad. Sci. 732:246-256, 1995), which measures the formation of tube-like structures by microvascular endothelial cells; and matrigel models (Grant et al., “Angiogenesis as a component of epithelial-mesenchymal interactions” in Goldberg and Rosen, Epithelial-Mesenchymal Interaction in Cancer, Birkhäuser Verlag, 1995, 235-248; Baatout, Anticancer Research 17:451-456, 1997), which are used to determine effects on cell migration and tube formation by endothelial cells seeded in matrigel, a basement membrane extract enriched in laminin. It is preferred to carry out angiogenesis assays in the presence and absence of vascular endothelial growth factor (VEGF) to assess possible combinatorial effects. It is also preferred to use VEGF as a control within in vivo assays.

[0104] Receptor binding can be measured by the competition binding method of Labriola-Tompkins et al., Proc. Natl. Acad. Sci. USA 88:11182-11186, 1991. In an exemplary assay for IL-1 receptor binding, membranes pepared from EL-4 thymoma cells (Paganelli et al., J. Immunol. 138:2249-2253, 1987) are incubated in the presence of the test protein for 30 minutes at 37° C. Labeled IL-1α or IL-1β is then added and the incubation is continued for 60 minutes. The assay is terminated by membrane filtration. The amount of bound label is determined by conventional means (e.g., γ counter). In an alternative assay, the ability of a test protein to compete with labeled IL-1 for binding to cultured human dermal fibroblasts is measured according to the method of Dower et al. (Nature 324:266-268, 1986). Briefly, cells are incubated in a round-bottomed, 96-well plate in a suitable culture medium (e.g., RPMI 1640 containing 1% BSA, 0.1% Na azide, and 20 mM HEPES pH 7.4) at 8° C. on a rocker platform in the presence of labeled IL-1. Various concentrations of test protein are added. After the incubation (typically about two hours), cells are separated from unbound label by centrifuging 60-μl aliquots through 200 μl of phthalate oils in 400-μl polyethylene centrifuge tubes and excising the tips of the tubes with a razor blade as disclosed by Segal and Hurwitz, J. Immunol. 118:1338-1347, 1977. Receptor binding assays for other cell types are known in the art. See, for example, Bowen-Pope and Ross, Methods Enzymol. 109:69-100, 1985.

[0105] Receptor binding can also be measured using immobilized receptors or ligand-binding receptor fragments. For example, an immobilized receptor can be exposed to its labeled ligand and unlabeled test protein, whereby a reduction in labeled ligand binding compared to a control is indicative of receptor-binding activity in the test protein. Within another format, a receptor or ligand-binding receptor fragment is immobilized on a biosensor (e.g., BIACore™, Pharmacia Biosensor, Piscataway, N.J.) and binding is determined. Antagonists of the native ligand will exhibit receptor binding but will exhibit essentially no activity in appropriate activity assays or will reduce the ligand-mediated response when combined with the native ligand. In view of the low level of receptor occupancy required to produce a response to some ligands (e.g., IL-1), a large excess of antagonist (typically a 10- to 1000-fold molar excess) may be necessary to neutralize ligand activity.

[0106] Receptor activation can be detected in target cells by: (1) measurement of adenylate cyclase activity (Salomon et al., Anal. Biochem. 58:541-48, 1974; Alvarez and Daniels, Anal. Biochem. 187:98-103, 1990); (2) measurement of change in intracellular cAMP levels using conventional radioimmunoassay methods (Steiner et al., J. Biol. Chem. 247:1106-13, 1972; Harper and Brooker, J. Cyc. Nucl. Res. 1:207-18, 1975); or (3) through use of a cAMP scintillation proximity assay (SPA) method (such as available from Amersham Corp., Arlington Heights, Ill.).

[0107] Proteins can be tested for serine protease activity or proteinase inhibitory activity using conventional assays. Substrate cleavage is conveniently assayed using a tetrapeptide that mimics the cleavage site of the natural substrate and which is linked, via a peptide bond, to a carboxyl-terminal para-nitro-anilide (pNA) group. The protease hydrolyzes the bond between the fourth amino acid residue and the pNA group, causing the pNA group to undergo a dramatic increase in absorbance at 405 nm. Suitable substrates can be synthesized according to known methods or obtained from commercial suppliers. Inhibitory activity is measured by adding a test sample to a reaction mixture containing enzyme and substrate, and comparing the observed enzyme activity to a control (without the test sample). A variety of such assays are known in the art, including assays measuring inhibition of trypsin, chymotrypsin, plasmin, cathepsin G, and human leukocyte elastase. See, for example, Petersen et al., Eur. J. Biochem. 235:310-316, 1996. In a typical procedure, the inhibitory activity of a test compound is measured by incubating the test compound with the proteinase, then adding an appropriate substrate, typically a chromogenic peptide substrate. See, for example, Norris et al. (Biol. Chem. Hoppe-Seyler 371:37-42, 1990). Various concentrations of the inhibitor are incubated in the presence of trypsin, plasmin, and plasma kallikrein in a low-salt buffer at pH 7.4, 25° C. After 30 minutes, the residual enzymatic activity is measured by the addition of a chromogenic substrate (e.g., S2251 (D-Val-Leu-Lys-Nan) or S2302 (D-Pro-Phe-Arg-Nan), available from Kabi, Stockholm, Sweden) and a 30-minute incubation. Inhibition of enzyme activity is indicated by a decrease in absorbance at 405 nm or fluorescence Em at 460 nm. From the results, the apparent inhibition constant K_(i) is calculated. When a serine protease is prepared as an active precursor (e.g., comprising N-terminal residues 1-109 of SEQ ID NO:2), it is activated by cleavage with a suitable protease (e.g., furin (Steiner et al., J. Biol. Chem. 267:23435-23438, 1992)) prior to assay. Assays of this type are well known in the art. See, for example, Lottenberg et al., Thrombosis Research 28:313-332, 1982; Cho et al., Biochem. 23:644-650, 1984; Foster et al., Biochem. 26:7003-7011, 1987). The inhibition of coagulation factors (e.g., factor VIIa, factor Xa) can be measured using chromogenic substrates or in conventional coagulation assays (e.g., clotting time of normal human plasma; Dennis et al., J. Biol. Chem. 270:25411-25417, 1995).

[0108] Blood coagulation and chromogenic assays, which can be used to detect both procoagulant, anticoagulant, and thrombolytic activities, are known in the art. For example, pro- and anticoagulant activities can be measured in a one-stage clotting assay using platelet-poor or factor-deficient plasma (Levy and Edgington, J. Exp. Med. 151:1232-1243, 1980; Schwartz et al., J. Clin. Invest. 67:1650-1658, 1981). As disclosed by Anderson et al. (Proc. Natl. Acad. Sci. USA 96:11189-11193, 1999), the effect of a test compound on platelet activation can be determined by a change in turbidity, and the procoagulant activity of activated platelets can be determined in a phospholipid-dependent coagulation assay. Activation of thrombin can be determined by hydrolysis of peptide p-nitroanilide substrates as disclosed by Lottenberg et al. (Thrombosis Res. 28:313-332, 1982). Other procoagulant, anticoagulant, and thrombolytic activities can be measured using appropriate chromogenic substrates, a variety of which are available from commercial suppliers. See, for example, Kettner and Shaw, Methods Enzymol. 80:826-842, 1981.

[0109] Anti-microbial activity of proteins is evaluated by techniques that are known in the art. For example, anti-microbial activity can be assayed by evaluating the sensitivity of microbial cell cultures to test agents and by evaluating the protective effect of test agents on infected mice. See, for example, Musiek et al., Antimicrob. Agents Chemothr. 3:40, 1973. Antiviral activity can also be assessed by protection of mammalian cell cultures. Known techniques for evaluating anti-microbial activity include, for example, Barsum et al., Eur. Respir. J. 8:709-714, 1995; Sandovsky-Losica et al., J. Med. Vet. Mycol (England) 28:279-287, 1990; Mehentee et al., J. Gen. Microbiol (England) 135(:2181-2188, 1989; and Segal and Savage, J. Med. Vet. Mycol. 24:477-479, 1986. Assays specific for anti-viral activity include, for example, those described by Daher et al., J. Virol. 60:1068-1074, 1986.

[0110] The assays disclosed above can be modified by those skilled in the art to detect the presence of agonists and antagonists of a selected protein of interest.

[0111] Expression of a polynucleotide encoding a protein of interest in animals provides models for further study of the biological effects of overproduction or inhibition of protein activity in vivo. Polynucleotides and antisense polynucleotides can be introduced into test animals, such as mice, using viral vectors or naked DNA, or transgenic animals can be produced.

[0112] One in vivo approach for assaying proteins of the present invention utilizes viral delivery systems. Exemplary viruses for this purpose include adenovirus, herpesvirus, retroviruses, vaccinia virus, and adeno-associated virus (AAV). Adenovirus, a double-stranded DNA virus, is currently the best studied gene transfer vector for delivery of heterologous nucleic acids. For review, see Becker et al., Meth. Cell Biol. 43:161-89, 1994; and Douglas and Curiel, Science & Medicine 4:44-53, 1997. The adenovirus system offers several advantages. Adenovirus can (i) accommodate relatively large DNA inserts; (ii) be grown to high-titer; (iii) infect a broad range of mammalian cell types; and (iv) be used with many different promoters including ubiquitous, tissue specific, and regulatable promoters. Because adenoviruses are stable in the bloodstream, they can be administered by intravenous injection.

[0113] By deleting portions of the adenovirus genome, larger inserts (up to 7 kb) of heterologous DNA can be accommodated. These inserts can be incorporated into the viral DNA by direct ligation or by homologous recombination with a co-transfected plasmid. In an exemplary system, the essential E1 gene is deleted from the viral vector, and the virus will not replicate unless the E1 gene is provided by the host cell (e.g., the human 293 cell line). When intravenously administered to intact animals, adenovirus primarily targets the liver. If the adenoviral delivery system has an E1 gene deletion, the virus cannot replicate in the host cells. However, the host's tissue (e.g., liver) will express and process (and, if a signal sequence is present, secrete) the heterologous protein. Secreted proteins will enter the circulation in the highly vascularized liver, and effects on the infected animal can be determined.

[0114] An alternative method of gene delivery comprises removing cells from the body and introducing a vector into the cells as a naked DNA plasmid. The transformed cells are then re-implanted in the body. Naked DNA vectors are introduced into host cells by methods known in the art, including transfection, electroporation, microinjection, transduction, cell fusion, DEAE dextran, calcium phosphate precipitation, use of a gene gun, or use of a DNA vector transporter. See, Wu et al., J. Biol. Chem. 263:14621-14624, 1988; Wu et al., J. Biol. Chem. 267:963-967, 1992; and Johnston and Tang, Meth. Cell Biol. 43:353-365, 1994.

[0115] Transgenic mice, engineered to express a gene encoding a protein of interest, and mice that exhibit a complete absence of gene function, referred to as “knockout mice” (Snouwaert et al., Science 257:1083, 1992), can also be generated (Lowell et al., Nature 366:740-742, 1993). These mice can be employed to study the gene of interest and the protein encoded thereby in an in vivo system. Transgenic mice are particularly useful for investigating the role of proteins in early development in that they allow the identification of developmental abnormalities or blocks resulting from the over- or underexpression of a specific factor. See also, Maisonpierre et al., Science 277:55-60, 1997 and Hanahan, Science 277:48-50, 1997. Preferred promoters for transgenic expression include promoters from metallothionein and albumin genes. As disclosed above, the human sequences provided herein can be used to clone orthologous polynucleotides, which may be preferred for use in generating transgenic and knockout animals.

[0116] Antisense methodology can be used to inhibit gene transcription to examine the effects of such inhibition in vivo. Polynucleotides that are complementary to a segment of a protein-encoding polynucleotide are designed to bind to the encoding mRNA and to inhibit translation of such mRNA. Such antisense oligonucleotides can also be used to inhibit expression of protein-encoding genes in cell culture.

[0117] Biological activities of test proteins can also be measured in animal models by administering the test protein, by itself or in combination with other agents, including other proteins. Using such models facilitates the assay of the test protein by itself or as an inhibitor or modulator of another agent, and also facilitates the measurement of combinatorial effects of bioactive compounds.

[0118] Anti-inflammatory activity can be tested in animal models of inflammatory disease. For example, animal models of psoriasis include the analysis of histological alterations in adult mouse tail epidermis (Hofbauer et al, Brit. J. Dennatol. 118:85-89, 1988; Bladon et al., Arch Dermatol. Res. 277:121-125, 1985). In this model, anti-psoriatic activity is indicated by the induction of a granular layer and orthokeratosis in areas of scale between the hinges of the tail epidermis. Typically, a topical ointment comprising a test compound is applied daily for seven consecutive days, then the animal is sacrificed, and tail skin is examined histologically. An additional model is provided by grafting psoriatic human skin to congenitally athymic (nude) mice (Krueger et al., J. Invest. Dermatol. 64:307-312, 1975). Such grafts have been shown to retain the characteristic histology for up to eleven weeks. As in the mouse tail model, the test composition is applied to the skin at predetermined intervals for a period of one to several weeks, at which time the animals are sacrificed and the skin grafts examined histologically. A third model has been disclosed by Fretland et al. (Inflammation 14:727-739, 1990). Briefly, inflammation is induced in guinea pig epidermis by topically applying phorbol ester (phorbol-12-myristate-13-acetate; PMA), typically at ca. 2 g/ml in acetone, to one ear and vehicle to the contralateral ear. Test compounds are applied concurrently with the PMA, or may be given orally. Histological analysis is performed at 96 hours after application of PMA. This model duplicates many symptoms of human psoriasis, including edema, inflammatory cell diapedesis and infiltration, high LTB₄ levels and epidermal proliferation.

[0119] Cerebral ischemia can be studied in a rat model as disclosed by Relton et al. (ibid.) and Loddick et al. (ibid.).

[0120] The effect of a test protein on primordial endothelial cells in angiogenesis can be assayed in the chick chorioallantoic membrane angiogenesis assay (Leung, Science 246:1306-1309, 1989; Ferrara, Ann. NY Acad. Sci. 752:246-256, 1995). Briefly, a small window is cut into the shell of an eight-day old fertilized egg, and a test substance is applied to the chorioallantoic membrane. After 72 hours, the membrane is examined for neovascularization. Embryo microinjection of early stage quail (Coturnix coturnix japonica) embryos can also be used (Drake et al., Proc. Natl. Acad. Sci. USA 92:7657-7661, 1995). Briefly, a solution containing the protein is injected into the interstitial space between the endoderm and the splanchnic mesoderm of early-stage embryos using a micropipette and micromanipulator system. After injection, embryos are placed ventral side down on a nutrient agar medium and incubated for 7 hours at 37° C. in a humidified CO₂/air mixture (10%/90%). Vascular development is assessed by microscopy of fixed, whole-mounted embryos and sections.

[0121] Stimulation of coronary collateral growth can be measured in known animal models, including a rabbit model of peripheral limb ischemia and hind limb ischemia and a pig model of chronic myocardial ischemia (Ferrara et al., Endocrine Reviews 18:4-25, 1997). Test proteins are assayed in the presence and absence of VEGF and basic FGF to test for combinatorial effects. These models can be modified by the use of adenovirus or naked DNA for gene delivery as disclosed in more detail above, resulting in local expression of the test protein(s).

[0122] Angiogenic activity can also be tested in a rodent model of corneal neovascularization as disclosed by Muthukkaruppan and Auerbach, Science 205:1416-1418, 1979, wherein a test substance is inserted into a pocket in the cornea of an inbred mouse. For use in this assay, proteins are combined with a solid or semi-solid, biocompatible carrier, such as a polymer pellet. Angiogenesis is followed microscopically. Vascular growth into the corneal stroma can be detected in about 10 days.

[0123] Angiogenic activity can also be tested in the hampster cheek pouch assay (Hockel et al., Arch. Surg. 128:423-429, 1993). A test substance is injected subcutaneiously into the cheek pouch, and after five days the pouch is examined under low magnification to determine the extent of neovascularization. Tissue sections can also be examined histologically.

[0124] Induction of vascular permeability is measured in assays designed to detect leakage of protein from the vasculature of a test animal (e.g., mouse or guinea pig) after administration of a test compound (Miles and Miles, J. Physiol. 118:228-257, 1952; Feng et al., J. Exp. Med. 183:1981-1986, 1996).

[0125] Wound-healing models include the linear skin incision model of Mustoe et al. (Science 237:1333, 1987). In a typical procedure, a 6-cm incision is made in the dorsal pelt of an adult rat, then closed with wound clips. Test substances and controls (in solution, gel, or powder form) are applied before primary closure. It is preferred to limit administration to a single application, although additional applications can be made on succeeding days by careful injection at several sites under the incision. Wound breaking strength is evaluated between 3 and 21 days post wounding. In a second model, multiple, small, full-thickness excisions are made on the ear of a rabbit. The cartilage in the ear splints the wound, removing the variable of wound contraction from the evaluation of closure. Experimental treatments and controls are applied. The geometry and anatomy of the wound site allow for reliable quantification of cell ingrowth and epithelial migration, as well as quantitative analysis of the biochemistry of the wounds (e.g., collagen content). See, Mustoe et al., J. Clin. Invest. 87:694, 1991. The rabbit ear model can be modified to create an ischemic wound environment, which more closely resembles the clinical situation (Ahn et al., Ann. Plast. Surg. 24:17, 1990). Within a third model, healing of partial-thickness skin wounds in pigs or guinea pigs is evaluated (LeGrand et al., Growth Factors 8:307, 1993). Experimental treatments are applied daily on or under dressings. Seven days after wounding, granulation tissue thickness is determined. This model is preferred for dose-response studies, as it is more quantitative than other in vivo models of wound healing. A full thickness excision model can also be employed. Within this model, the epidermis and dermis are removed down to the panniculus carnosum in rodents or the subcutaneous fat in pigs. Experimental treatments are applied topically on or under a dressing, and can be applied daily if desired. The wound closes by a combination of contraction and cell ingrowth and proliferation. Measurable endpoints include time to wound closure, histologic score, and biochemical parameters of wound tissue. Impaired wound healing models are also known in the art (e.g., Cromack et al., Surgery 113:36, 1993; Pierce et al., Proc. Natl. Acad. Sci. USA 86:2229, 1989; Greenhalgh et al., Amer. J. Pathol. 136:1235, 1990). Delay or prolongation of the wound healing process can be induced pharmacologically by treatment with steroids, irradiation of the wound site, or by concomitant disease states (e.g., diabetes). Linear incisions or full-thickness excisions are most commonly used as the experimental wound. Endpoints are as disclosed above for each type of wound. Subcutaneous implants can be used to assess compounds acting in the early stages of wound healing (Broadley et al., Lab. Invest. 61:571, 1985; 10 Sprugel et al., Amer. J. Pathol. 129: 601, 1987). Implants are prepared in a porous, relatively non-inflammatory container (e.g., polyethylene sponges or expanded polytetrafluoroethylene implants filled with bovine collagen) and placed subcutaneously in mice or rats. The interior of the implant is empty of cells, producing a “wound space” that is well-defined and separable from the preexisting tissue. This arrangement allows the assessment of cell influx and cell type as well as the measurement of vasculogenesis/angiogenesis and extracellular matrix production.

[0126] Inhibition of tumor metastasis can be assessed in mice into which cancerous cells or tumor tissue have been introduced by implantation or injection (e.g., Brown, Advan. Enzyme Regul. 35:293-301, 1995; Conway et al., Clin. Exp. Metastasis 14:115-124, 1996).

[0127] Effects on fibrinolysis can be measured in a rat model wherein the enzyme batroxobin and radiolabeled fibrinogen are administered to test animals.

[0128] Inhibition of fibrinogen activation by a test compound is seen as a reduction in the circulating level of the label as compared to animals not receiving the test compound. See, Lenfors and Gustafsson, Semin. Thromb. Hemost. 22:335-342, 1996.

[0129] The invention further provides polypeptides that comprise an epitope-bearing portion of a protein as shown in SEQ ID NO:M, wherein M is an even integer from 2 to 122. An “epitope” is a region of a protein to which an antibody can bind. See, for example, Geysen et al., Proc. Natl. Acad. Sci. USA 81:3998-4002, 1984. Epitopes can be linear or conformational, the latter being composed of discontinuous regions of the protein that form an epitope upon folding of the protein. Linear epitopes are generally at least 6 amino acid residues in length. Relatively short synthetic peptides that mimic part of a protein sequence are routinely capable of eliciting an antiserum that reacts with the partially mimicked protein. See, for example, Sutcliffe et al., Science 219:660-666, 1983. Antibodies that recognize short, linear epitopes are particularly useful in analytic and diagnostic applications that employ denatured protein, such as Western blotting (Tobin, Proc. Natl. Acad. Sci. USA 76:4350-4356, 1979). Antibodies to short peptides may also recognize proteins in native conformation and will thus be useful for monitoring protein expression and protein isolation, and in detecting proteins in solution, such as by ELISA or in immunoprecipitation studies.

[0130] Antigenic, epitope-bearing polypeptides of the present invention are useful for raising antibodies, including monoclonal antibodies, that specifically bind to the corresponding protein. Antigenic, epitope-bearing polypeptides contain a sequence of at least six, preferably at least nine, more preferably from 15 to about 30 contiguous amino acid residues of a protein. Within certain embodiments of the invention, the polypeptides comprise 40, 50, 100, or more contiguous residues of a protein as shown in SEQ ID NO:M, up to the entire predicted mature protein or the primary translation product. It is preferred that the amino acid sequence of the epitope-bearing polypeptide is selected to provide substantial solubility in aqueous solvents, that is the sequence includes relatively hydrophilic residues, and hydrophobic residues are substantially avoided. Table 7 lists preferred hexapeptides for use as antigens. Within Table 7, each the amino termini of the hexapeptides are specified. Those skilled in the art will recognize that longer polypeptides comprising these hexapeptides can also be used and will often be preferred. TABLE 7 Protein Hexapeptide N-termini AFP142651 112 108 10 9 107 AFP20937 299 42 41 217 227 AFP417792 5 95 59 4 58 AFP576652 23 22 21 39 95 AFP576853 110 108 28 98 27 AFP583515 74 103 73 102 71 AFP631844 66 54 74 121 107 AFP634707 1 109 383 68 124 AFP635542 229 227 28 217 27 AFP68100 450 449 272 474 344 AFP684692 48 65 24 30 47 AFP632868 71 56 94 78 70 AFP428382 44 124 91 121 64 AFP72084 123 121 33 103 53 AFP639493 29 132 143 43 52 AFP677287 49 56 23 78 95 AFP177404 146 96 94 120 144 AFP277692 79 220 219 76 69 AFP674535 223 222 199 196 144 AFP652829 27 26 131 87 128 AFP321359 196 195 194 182 193 AFP374878 118 2 1 146 241 AFP584218 44 43 134 42 133 AFP39158 91 98 90 112 111 AFP664311 340 269 214 339 268 AFP471025 167 152 166 281 265 AFP674834 112 69 102 101 111 AFP669653 187 251 198 186 211 AFP50993 194 222 219 192 129 AFP253034 160 184 182 181 96 AFP490546 275 274 128 69 281 AFP644058 109 210 349 73 72 AFP4581 147 464 157 421 379 AFP301973 84 50 25 65 83 AFP308812 18 142 82 130 24 AFP309995 91 48 81 45 90 AFP141288 55 1 136 110 31 AFP679597 228 223 220 160 189 AFP213641 120 2 1 175 119 AFP241175 179 61 95 252 60 AFP188629 199 23 238 224 223 AFP114314 62 61 80 113 50 AFP548753 68 44 8 6 67 AFP253067 101 31 23 79 78 AFP281501 178 177 150 176 149 AFP513481 38 109 55 140 37 AFP671052 2 49 68 67 47 AFP485790 277 262 276 119 261 AFP616509 18 17 41 120 16 AFP285042 176 119 174 118 31 AFP332354 151 78 51 58 50 AFP162878 48 47 46 102 21 AFP80526 230 229 160 69 145 AFP686580 79 455 399 241 168 AFP677257 113 112 111 154 171 AFP166924 401 414 103 64 189 AFP193083 330 311 310 252 329 AFP355471 142 139 108 127 138 AFP577178 41 91 27 24 65 AFP235412 208 206 119 228 118 AFP669232 252 251 98 97 250

[0131] As used herein, the term “antibodies” includes polyclonal antibodies, monoclonal antibodies, antigen-binding fragments thereof such as F(ab′)₂ and Fab fragments, single chain antibodies, and the like, including genetically engineered antibodies. Non-human antibodies can be humanized by grafting only non-human CDRs onto human framework and constant regions, or by incorporating the entire non-human variable domains (optionally “cloaking” them with a human-like surface by replacement of exposed residues, wherein the result is a “veneered” antibody). In some instances, humanized antibodies may retain non-human residues within the human variable region framework domains to enhance proper binding characteristics. Through humanizing antibodies, biological half-life may be increased, and the potential for adverse immune reactions upon administration to humans is reduced. One skilled in the art can generate humanized antibodies with specific and different constant domains (i.e., different Ig subclasses) to facilitate or inhibit various immune functions associated with particular antibody constant domains.

[0132] Alternative techniques for generating or selecting antibodies useful herein include in vitro exposure of lymphocytes to an immunogenic polypeptide, and selection of antibody display libraries in phage or similar vectors (for instance, through use of an immobilized or labeled polypeptide). Human antibodies can be produced in transgenic, non-human animals that have been engineered to contain human immunoglobulin genes as disclosed in WIPO Publication WO 98/24893. It is preferred that the endogenous immunoglobulin genes in these animals be inactivated or eliminated, such as by homologous recombination.

[0133] Antibodies are defined to be specifically binding if they bind to a target polypeptide with an affinity at least 10-fold greater than the binding affinity to control (non-target) polypeptide. It is preferred that the antibodies exhibit a binding affinity (K_(a)) of 10⁶ M⁻¹ or greater, preferably 10⁷ M⁻¹ or greater, more preferably 10⁸ M⁻¹ or greater, and most preferably 10⁹ M⁻¹ or greater. The affinity of a monoclonal antibody can be readily determined by one of ordinary skill in the art (see, for example, Scatchard, Ann. NY Acad. Sci. 51: 660-672, 1949).

[0134] Methods for preparing polyclonal and monoclonal antibodies are well known in the art (see for example, Hurrell, J. G. R., Ed., Monoclonal Hybridoma Antibodies: Techniques and Applications, CRC Press, Inc., Boca Raton, Fla., 1982). As would be evident to one of ordinary skill in the art, polyclonal antibodies can be generated from a variety of warm-blooded animals such as horses, cows, goats, sheep, dogs, chickens, rabbits, mice, and rats. The immunogenicity of a polypeptide immunogen may be increased through the use of an adjuvant such as alum (aluminum hydroxide) or Freund's complete or incomplete adjuvant. Polypeptides useful for immunization also include fusion polypeptides, such as fusions of a polypeptide of interest or a portion thereof with an immunoglobulin polypeptide or with maltose binding protein. The polypeptide immunogen may be a full-length molecule or a portion thereof. If the polypeptide portion is “hapten-like”, such portion may be advantageously joined or linked to a macromolecular carrier (such as keyhole limpet hemocyanin (KLH), bovine serum albumin (BSA) or tetanus toxoid) for immunization.

[0135] A variety of assays known to those skilled in the art can be utilized to detect antibodies that specifically bind to a polypeptide of interest. Exemplary assays are described in detail in Antibodies: A Laboratory Manual, Harlow and Lane (Eds.), Cold Spring Harbor Laboratory Press, 1988. Representative examples of such assays include concurrent immunoelectrophoresis, radio-immunoassays, radio-immunoprecipitations, enzyme-linked immunosorbent assays (ELISA), dot blot assays, Western blot assays, inhibition or competition assays, and sandwich assays.

[0136] Antibodies can be used, for example, to isolate target polypeptides by affinity purification, for diagnostic assays for determining circulating or localized levels of target polypeptides, for tissue typing, for cell sorting, for screening expression libraries; for generating anti-idiotypic antibodies, and as neutralizing antibodies or as antagonists to block protein activity in vitro and in vivo.

[0137] The present invention also provides reagents for use in diagnostic and therapeutic applications. Such reagents include polynucleotide probes and primers; antibodies, including antibody fragments, single-chain antibodies, and other genetically engineered forms; soluble receptors and other polypeptide binding partners; and the proteins of the invention themselves, including fragments thereof. Those skilled in the art will recognize that diagnostic reagents will commonly be labeled to provide a detectable signal or other second function. Thus, polypeptides, antibodies, receptors, and other binding partners disclosed herein can be directly or indirectly conjugated to drugs, toxins, radionuclides, enzymes, enzyme substrates, cofactors, inhibitors, fluorescent markers, chemiluminescent markers, magnetic particles, and the like, and these conjugates used for in vivo diagnostic or therapeutic applications. Cytotoxic molecules, for example, can be directly or indirectly attached to the binding partner (e.g., by chemical coupling or as a fusion protein), and include bacterial or plant toxins (e.g., diphtheria toxin, Pseudomonas exotoxin, ricin, saporin, abrin, and the like); therapeutic radionuclides (e.g., iodine-131, rhenium-188 or yttrium-90) which can be directly attached to a polypeptide or antibody or indirectly attached through means of a chelating moiety; and cytotoxic drugs (e.g., adriamycin). Methods for preparing labeled reagents are known in the art. Within an alternative embodiment, the detectable signal or other function can be provided by a second member of a complement-anticomplement pair, which second member binds to the diagnostic reagent. For example, a first (unlabeled) antibody can be used to bind to a cell-surface polypeptide, after which a second, labeled antibody which binds to the first antibody is added. Other complement-anticomplement pairs are known in the art and include biotin/streptavidin.

[0138] Diagnostic reagents as disclosed herein can be used in vivo or in vitro. In vitro diagnostic assays include assays of tissue and fluid samples. Assays for protein in serum, for example, may be used to detect metabolic abnormalities characterized by over- or under-production of the protein, such as cancers, immune system abnormalities, infections, organ failure, metabolic imbalances, inborn errors of metabolism and other disease states. Proteins of the present invention can also be used in the detection of circulating autoantibodies, which are indicative of autoimmune disorders. Those skilled in the art will recognize that conditions related to protein underexpression or overexpression may be amenable to treatment by therapeutic manipulation of the relevant protein level(s). Proteins in serum can be quantitated by known methods known in the art, which include the use of antibodies in a variety of formats. Non-antibody binding partners, such as ligand-binding receptor fragments (commonly referred to as “soluble receptors”) can also be used.

[0139] In general, diagnostic methods employing oligonucleotide probes or primers comprise the steps of (a) obtaining a genetic sample from a patient; (b) incubating the genetic sample with an oligonucleotide probe or primer as disclosed above, under conditions wherein the probe or primer will hybridize to a complementary polynucleotide sequence, to produce a first reaction product; and (c) comparing the first reaction product to a control reaction product. A difference between the first reaction product and the control reaction product is indicative of a genetic abnormality in the patient. Genetic samples for use within such methods include genomic DNA, cDNA, and RNA. Suitable assay methods in this regard include molecular genetic techniques known to those in the art, such as restriction fragment length polymorphism (RFLP) analysis, short tandem repeat (STR) analysis employing PCR techniques, ligation chain reaction (Barany, PCR Methods and Applications 1:5-16, 1991), ribonuclease protection assays, and other genetic linkage analysis techniques known in the art (Sambrook et al., ibid.; Ausubel et. al., ibid.; A. J. Marian, Chest 108:255-65, 1995). Ribonuclease protection assays (see, e.g., Ausubel et al., ibid., ch. 4) comprise the hybridization of an RNA probe to a patient RNA sample, after which the reaction product (RNA-RNA hybrid) is exposed to RNase. Hybridized regions of the RNA are protected from digestion. Within PCR assays, a patient genetic sample is incubated with a pair of oligonucleotide primers, and the region between the primers is amplified and recovered. Changes in size, amount, or sequence of recovered product are indicative of mutations in the patient. Another PCR-based technique that can be employed is single strand conformational polymorphism (SSCP) analysis (Hayashi, PCR Methods and Applications 1:34-38, 1991). Chromosomal localization data can be used to correlate AFP gene locations with known genetic disorders using, for example, the OMIM™ Database, Johns Hopkins University, 2000 (http://www.ncbi.nlm.nih.gov/entrez/guerv.fcgi?db=OMIM).

[0140] Relative chromosomal sublocalization shown in Table 8 was determined using the Draft Human Genome Browser (Kent, J., University of California Santa Cruz, http)://genome.ucsc.edu/goldenPath/hgTracks.html) displaying the draft assembly of the Jul. 17, 2000 version of the human genome. Table 8 also correlates AFP sequences with corresponding sequences in public databases by GenBank Accession Number, source clone ID number, and EST accession number. Also see Table 5, above. TABLE 8 AFPID GenbankAcc# CloneID ESTAcc# Chr Band Start Stop AFP141288 AL360089 RP11-298A17 * 9 * 16396850 16656261 AFP142651 AC010998 RP11-95l16 AW959180 10 * 136970451 136971295 AFP162878 * * * * * * * AFP166924 AC025043 RP11-516C1 * 15 15q21.1 28177057 28353179 AFP177404 * * AW961058 7 * 98793392 98794047 AFP188629 AC007011 * 16 * 7299424 7460687 AFP20937 AC067758 RP11-342A16 * 11 * 86760019 86961249 AFP285042 AC018463 RP11-295J19 * 2 * 10748236 10974451 AFP301973 CNS01RHU R-882l14 AL162471 14 * 41476273 41628541 AFP355471 AP002008 RP11-794P6 * 11 11q 119648156 119907393 AFP374878 AC055822 RP11-707M3 * 8 * 75395740 75583383 AFP428382 HS273F20 273F20 * 6 6q16.1-16.3 107800410 107811345 AFP471025 AC012645 RP11-455F5 * 16 * 31496987 32022926 AFP490546 AC015778 RP11-2l11 * 3 * 120742413 120992298 AFP548753 AC018731 RP11-52K24 * 2 * 153134375 153646365 AFP576652 AC073063 RP11-136B3 *AA479429 7 * 97866157 98158059 AFP576853 AP001150 RP11-778O17 * 11 11q23 * * AFP577178 CNS01RIK R-903H12 AL163636 14 * 644847 843898 AFP616509 * * AI819051 X * 148989918 149001745 AFP634707 AC013435 RP11-52C8 * 2 * 239270348 239495054 AFP652829 AP001374 RP11-729G3 * 18 18q21 55228868 55605703 AFP664311 * * Al807759 3 * 61041921 61043252 AFP669653 AC024933 RP11-219D15 AL541985* * * * AFP671052 * * AW976053 2 * 181573356 181578624 AFP674535 AC058819 RP11-620N18 * 12 * 108266276 108436599 AFP677257 AC021663 RP11-496l9 Al691066 1 * 104913091 105104110 AFP677287 CNS01DT4 * Al525611 14 * 19959493 20153358

[0141] Additional chromosomal localizations for AFP sequences is shown in Table 9, below. TABLE 9 AFP Chromosomal Localization AFP664311 3p21.3 AFP308812 3 AFP281501 20p12.2-p13 AFP253034 10q24 AFP635542 11q23 AFP686580 1p32.1-p33 AFP332354 1p32.2-p34.2 AFP277692 8q24.1 AFP321359 11q13 AFP193083 3q AFP39158 11q23

[0142] As a polynucleotide that maps to chromosome 15q21.1, molecules of AFP166924 may find use in treatment and diagnosis of Marfan's Syndrome and associated diseases. In general, see Dietz, H. C. et al.; Hum. Molec. Genet. 4: 1799-1809, 1995. Additional genes which map to this location include Aromatase (also called estrogen synthetase, see Online Mendelian Inheritance of Man (OMIM) entry #107910) and Hereditary Colorectal Cancer (OMIM entry # 604940).

[0143] As polynucleotides that map to chromosome 11q23, AFP635542 and AFP576853, AFP39158, these polynucleotides and polypeptides may be associated with the following disorders: THROMBOCYTOPENIA, PARIS-TROUSSEAU TYPE; TCPT, OMIM#188025; CLEFT LIP/PALATE-ECTODERMAL DYSPLASIA SYNDROME; CLPED1, OMIM#225000; MYELOID/LYMPHOID OR MIXED LINEAGE LEUKEMIA; MLL, OMIM *159555; JACOBSEN SYNDROME; JBS, OMIM#147791; CD3 ANTIGEN, GAMMA SUBUNIT; CD3G, OMIM#186740; PARAGANGLIOMAS, FAMIAL NONCHROMAFFIN, 1; PGL1, OMIM#168000; GLUCOSE-6-PHOSPHATE TRANSPORTER 1; G6PT1, OMIM#*602671; PORPHYRIA, ACUTE INTERMITTENT, OMIM#176000; GLYCOGEN STORAGE DISEASE Ic, OMIM#232240; CELL ADHESION MOLECULE, NEURAL, 1; NCAM1, OMIM#116930; EPSTEIN-BARR VIRUS MODIFICATION SITE 1; EBVM1, OMIM#132860; APOLIPOPROTEIN A-I OF HIGH DENSITY LIPOPROTEIN; APOA1, OMIM#107680; HYPOALPHALIPOPROTEINEMIA, PRIMARY, OMIM605201; HYPOMAGNESEMIA 2, RENAL; HOMG2, OMIM#154020; THY-1 T-CELL ANTIGEN; THY1, OMIM#188230; ERYTHROCYTOSIS, AUTOSOMAL RECESSIVE BENIGN, OMIM#263400; HYDROLETHALUS SYNDROME,OMIM#236680; GLYCOGEN STORAGE DISEASE Ib, OMIM#232220; ECTODERMAL DYSPLASIA, MARGARITA ISLAND TYPE, OMIM#225060; PORPHYRIA, CHESTER TYPE; PORC,OMIM*176010; and GILLES DE LA TOURETTE SYNDROME; GTS, OMIM#137580;

[0144] As polynucleotides that map to chromosome 18q21, molecules polynucleotides and polypeptides of AFP652829 may be associated with the following disorders: SQUAMOUS CELL CARCINOMA ANTIGEN 1; SCCA1, OMIM3600517; B-CELL CLL/LYMPHOMA 2; BCL2, OMIM#151430; POLYPOSIS, JUVENILE INTESTINAL, OMIM#174900; DELETED IN COLORECTAL CARCINOMA; DCC, OMIM#120470; PROTOPORPHYRIA, ERYTHROPOIETIC, OMIM#177000; SQUAMOUS CELL CARCINOMA ANTIGEN 2; SCCA2, MOMI#600518; DIABETES MELLITUS, INSULIN-DEPENDENT, 6; IDDM6, OMIM#601941, CARNOSINEMIA, OMIM#212200; OSTEOGENIC SARCOMA, OMIM#259500; CHOLESTASIS, PROGRESSIVE FAMILIAL INTRAHEPATIC 2; PFIC2,OMIM#601847; MUCOSA-ASSOCIATED LYMPHOID TISSUE LYMPHOMA TRANSLOCATION GENE 1; MALT1, OMIM#604860; DIGEORGE SYNDROME; DGS, OMIM#188400; POLYOSTOTIC OSTEOLYTIC DYSPLASIA, HEREDITARY EXPANSILE; HEPOD, OMIM#174810; GRAVES DISEASE, OMIM#275000; CONE-ROD DYSTROPHY 2; CORD2, OMIM #120970; PAGET DISEASE OF BONE 1; PDB1, OMIM#167250; and CHROMOSOME 18q DELETION SYNDROME, OMIM#601808;

[0145] As polynucleotides that map to chromosome 3p21.3, molecules polynucleotides and polypeptides of AFP664311 may be associated with the following disorders: EPIDERMOLYSIS BULLOSA, PRETIBIAL, OMIM#131850; COLON CANCER, FAMILIAL NONPOLYPOSIS, TYPE 2, OMIM#120436; EPIDERMOLYSIS BULLOSA DYSTROPHICA, PASINI TYPE, OMIM#131750; MUIR-TORRE SYNDROME; MTS, OMIM#158320; EPIDERMOLYSIS BULLOSA DYSTROPHICA, HALLOPEAU-SIEMENS TYPE; EBR1, OMIM #226600; TURCOT SYNDROME, OMIM#276300; and HYALURONIDASE DEFICIENCY, OMIM#*601492;

[0146] As polynucleotides that map to chromosome 10q24, molecules polynucleotides and polypeptides of AFP253034 may be associated with the following disorders: SPLIT-HAND/FOOT MALFORMATION, TYPE 3; SHFM3, OMIM#*600095; DUBIN-JOHNSON SYNDROME; DJS, OMIM#237500; CD39 ANTIGEN; CD39, OMIM#*601752; INFANTILE-ONSET SPINOCEREBELLAR ATAXIA; IOSCA, OMIM#271245; ALZHEIMER DISEASE 6, OMIM#$605526; WOLMAN DISEASE, OMIM#278000; ALZHEIMER DISEASE; AD, OMIM#104300; RENAL-COLOBOMA SYNDROME, OMIM#120330; COUMARIN RESISTANCE, OMIM#122700.

[0147] As polynucleotides that map to chromosome 1p32.1-p33, molecules polynucleotides and polypeptides of AFP686580 and AFP332354 may be associated with the following disorders: EPIPHYSEAL DYSPLASIA, MULTIPLE, 2; EDM2, OMIM#600204; INTERVERTEBRAL DISC DISEASE; IDD, OMIM#603932; ANDT-CELL ACUTE LYMPHOCYTIC LEUKEMIA 1; TAL1,OMIM#187040.

[0148] As a polynucleotide that maps to chromosome 8q24.1, molecules of AFP277692 may find use in treatment and diagnosis of Renal Cell Carcinoma 1 (RCC1) (OMIM#144700), which maps to this location, and a chromosomal translocation with chromosome 3p14, which is associated with features of hereditary renal cell carcinoma (OMIM#603046). See Cohen, A. J. et al., New Eng. J. Med. 301:592-595, 1979, and Li, F. P. et al., Ann. Intern Med 118: 106-111, 1993.

[0149] In addition to transferring carbohydrate molecules to glycoproteins during biosynthesis, members of the glycosyltransferase family have also been detected on the cell surface where they are thought to be involved in varying aspects of cell-cell interactions. This family includes carbohydrate transferring enzymes, such as sialyltransferases and fucosyltransferases, and galactosyltransferases. During the formation of O-linked glycoproteins and the modification of N-linked ones, each sugar transfer is catalyzed by a different type of glycosyltransferase. Thus, as a mannosyltransferase molecules of AFP188629 may be involved in cell-cell recognition and adhesion.

[0150] Polynucleotides of the present invention, including fragments thereof, can also be used for radiation hybrid mapping, a somatic cell genetic technique developed for constructing high-resolution, contiguous maps of mammalian chromosomes (Cox et al., Science 250:245-50, 1990). Partial or full knowledge of a gene's sequence allows the design of PCR primers suitable for use with chromosomal radiation hybrid mapping panels. Commercially available radiation hybrid mapping panels which cover the entire human genome, such as the Stanford G3 RH Panel and the GeneBridge 4 RH Panel (Research Genetics, Inc., Huntsville, Ala.), are available. These panels enable rapid, PCR-based chromosomal localizations and ordering of genes, sequence-tagged sites (STSs), and other nonpolymorphic and polymorphic markers within a region of interest, allowing the establishment of directly proportional physical distances between newly discovered genes of interest and previously mapped markers. The precise knowledge of a gene's position can be useful for a number of purposes, including: 1) determining if a sequence is part of an existing contig and obtaining additional surrounding genetic sequences in various forms, such as YACs, BACs or cDNA clones; 2) providing a possible candidate gene for an inheritable disease which shows linkage to the same chromosomal region; and 3) cross-referencing model organisms, such as mouse, which may aid in determining what function a particular gene might have.

[0151] If a mammal has an insufficiency of a protein of interest (due to, for example, a mutated or absent gene), the corresponding wild-type gene can be introduced into the cells of the mammal. In one embodiment, a gene encoding a protein of interest is introduced into the animal using a viral vector. Such vectors include an attenuated or defective DNA virus, such as, but not limited to, herpes simplex virus (HSV), papillomavirus, Epstein Barr virus (EBV), adenovirus, adeno-associated virus (AAV), and the like. Defective viruses, which entirely or almost entirely lack viral genes, are preferred. A defective virus is not infective after introduction into a cell. Use of defective viral vectors allows for administration to cells in a specific, localized area, without concern that the vector can infect other cells. Examples of particular vectors include, but are not limited to, a defective herpes simplex virus 1 (HSV1) vector (Kaplitt et al., Molec. Cell. Neurosci. 2:320-30, 1991); an attenuated adenovirus vector, such as the vector described by Stratford-Perricaudet et al. (J. Clin. Invest. 90:626-30, 1992); and a defective adeno-associated virus vector (Samulski et al., J. Virol. 61:3096-101, 1987; Samulski et al., J. Virol. 63:3822-28, 1989).

[0152] Within another embodiment, a gene of interest is introducted into an animal by liposome-mediated transfection (“lipofection”) essentially as disclosed above. Lipofection can be used to introduce exogenous genes into specific organs.

[0153] A gene of interest can also be introduced into an animal for gene therapy as a naked DNA plasmid using the methods disclosed above.

[0154] In another embodiment, polypeptide-toxin fusion proteins or antibody/fragment-toxin fusion proteins may be used for targeted cell or tissue inhibition or ablation, such as in cancer therapy. Of particular interest in this regard are conjugates of an AFP protein and a cytotoxin, which can be used to target the cytotoxin to a tumor or other tissue that is undergoing undesired angiogenesis or neovascularization.

[0155] In another embodiment, AFP-cytokine fusion proteins or antibody/fragment-cytokine fusion proteins may be used for enhancing in vitro cytotoxicity (for instance, that mediated by monoclonal antibodies against tumor targets) and for enhancing in vivo killing of target tissues (for example, blood and bone marrow cancers). See, generally, Hornick et al., Blood 89:4437-4447, 1997). In general, cytokines are toxic if administered systemically. The described fusion proteins enable targeting of a cytokine to a desired site of action, such as a cell having binding sites for an AFP protein, thereby providing an elevated local concentration of cytokine.

[0156] Polypeptides, antibodies, or receptors target an undesirable cell or tissue (e.g., a tumor), and the fused cytokine mediates improved target cell lysis by effector cells. Suitable cytokines for this purpose include, for example, interleukin-2 and granulocyte-macrophage colony-stimulating factor (GM-CSF).

[0157] In another embodiment, polypeptide-toxin fusion proteins or other binding partner-linked toxins may be used for targeted cell or tissue inhibition or ablation (for instance, to treat cancer cells or tissues). Target cells (i.e., those displaying a receptor for a polypeptide of interest) bind the polypeptide-toxin conjugate, which is then internalized, killing the cell. The effects of receptor-specific cell killing (target ablation) are revealed by changes in whole animal physiology or through histological examination. Thus, ligand-dependent, receptor-directed cyotoxicity can be used to enhance understanding of the physiological significance of a protein ligand. A preferred such toxin is saporin. Mammalian cells have no receptor for saporin, which is non-toxic when it remains extracellular. Alternatively, if the polypeptide of interest has multiple functional domains (i.e., an activation domain or a ligand binding domain, plus a targeting domain), a fusion protein including only the targeting domain may be suitable for directing a detectable molecule, a cytotoxic molecule or a complementary molecule to a cell or tissue type of interest. In instances where the domain-only fusion protein includes a complementary molecule, the anti-complementary molecule can be conjugated to a detectable or cytotoxic molecule. Such domain-complementary molecule fusion proteins thus represent a generic targeting vehicle for cell- or tissue-specific delivery of generic anti-complementary-detectable/cytotoxic molecule conjugates.

[0158] The bioactive conjugates described herein can be delivered intravenously, intraarterially or intraductally, or may be introduced locally at the intended site of action.

[0159] For pharmaceutical use, the proteins of the present invention are formulated according to conventional methods. Routes of delivery include topical, mucosal, and parenteral, the latter including intravenous and subcutaneous delivery. Intravenous administration will be by bolus injection or infusion over a typical period of one to several hours. In general, pharmaceutical formulations will include a protein of the present invention in combination with a pharmaceutically acceptable vehicle, such as saline, buffered saline, 5% dextrose in water or the like. Formulations may further include one or more excipients, diluents, fillers, emulsifiers, preservatives, solubilizers, buffering agents, wetting agents, stabilizers, colorings, penetration enhancers, albumin to prevent protein loss on vial surfaces, etc. Topical formulations are typically provided as liquids, ointments, salves, gels, emulsions and the like. Methods of formulation are well known in the art and are disclosed, for example, in Remington: The Science and Practice of Pharmacy, Gennaro, ed., Mack Publishing Co., Easton, Pa., 19th ed., 1995. Therapeutic doses will be determined by the clinician according to accepted standards, taking into account the nature and severity of the condition to be treated, patient traits, etc. Proteins of the present invention will generally be formulated to provide a dose of from 0.01 μg to 100 mg per kg patient weight per day, more commonly from 0.1 μg to 10 mg/kg/day, still more commonly from 0.1 μg to 1.0 mg/kg/day. Determination of dose is within the level of ordinary skill in the art. The proteins may be administered for acute treatment, over one week or less, often over a period of one to three days or may be used in chronic treatment, over several months or years. In general, a therapeutically effective amount is an amount sufficient to produce a clinically significant change in the targeted condition.

[0160] Within the laboratory research field, the proteins of the present invention can be used as molecular weight standards, or as standards in the analysis of cell phenotype, and as reagents for the study of cells, receptors, and other binding molecules. Such reagents will generally further comprise a second moiety, such as a label, binding partner, or toxin, that facilitates the detection of the protein when bound to its target. Many such systems are known in the art and are summarized above. Receptors and other cell-surface binding sites for proteins of the present invention can be identified by exposing a population of cells to a labeled protein under physiologic conditions, whereby the protein binds to the surface of the cell. Cells bearing receptors for a protein of interest can also be identified using the protein joined to a toxin, whereby receptor-bearing cells are killed by the toxin.

[0161] AFP proteins and antagonists thereof can be used as standards in assays of protein and protein inhibitors in both clinical and research settings. Such assays can comprise any of a number of standard formats, include radioreceptor assays and ELISAs. Protein standards can be prepared in labeled form using a radioisotope, enzyme, fluorophore, or other compound that produces a detectable signal. The proteins can be packaged in kit form, such kits comprising one or more vials containing the AFP protein and, optionally, a diluent, an antibody, a labeled binding protein, etc. Assay kits can be used in the research laboratory to detect protein and inhibitor activities produced by cultured cells or test animals.

[0162] Proteins of the present invention may also be used as protein and amino acid supplements, including hydrolysates. Specific uses in this regard include use as animal feed supplements and as cell culture components. Proteins rich in a particular amino acid can be used as a source of that amino acid.

[0163] Polynucleotides and polypeptides of the present invention will additionally find use as educational tools as a laboratory practicum kits for courses related to genetics and molecular biology, protein chemistry and antibody production and analysis. Due to their unique polynucleotide and polypeptide sequences, molecules of AFP protein or polynucleotide can be used as standards or as “unknowns” for testing purposes. For example, AFP polynucleotides can be used as aids in teaching students how to prepare expression constructs for bacterial, viral, and/or mammalian expression, including fusion constructs, wherein an AFP polynucleotide is the gene to be expressed; for determining the restriction endonuclease cleavage sites of the polynucleotides (which can be determined from the sequence using conventional computer software, such as MapDraw™ (DNASTAR, Madison, Wis.)); determining mRNA and DNA localization of AFP polynucleotides in tissues (e.g., by Northern and Southern blotting as well as polymerase chain reaction); and for identifying related polynucleotides and polypeptides by nucleic acid hybridization.

[0164] AFP polypeptides can be used educationally as aids to teach preparation of antibodies; identifying proteins by Western blotting; protein purification; determining the weight of expressed AFP polypeptides as a ratio to total protein expressed; identifying peptide cleavage sites; coupling amino and carboxyl terminal tags; amino acid sequence analysis, as well as, but not limited to monitoring biological activities of both the native and tagged protein (i.e., receptor binding, signal transduction, proliferation, and differentiation) in vitro and in vivo. AFP polypeptides can also be used to teach analytical skills such as mass spectrometry, circular dichroism to determine conformation, in particular the locations of the disulfide bonds, x-ray crystallography to determine the three-dimensional structure in atomic detail, nuclear magnetic resonance spectroscopy to reveal the structure of proteins in solution. For example, a kit containing an AFP protein can be given to the student to analyze. Since the amino acid sequence would be known by the professor, the protein can be given to the student as a test to determine the skills or develop the skills of the student, the teacher would then know whether or not the student has correctly analyzed the polypeptide. Since every polypeptide is unique, the educational utility of zcub5 would be unique unto itself.

[0165] Antibodies that bind specifically to an AFP polypeptide can be used as a teaching aid to instruct students how to prepare affinity chromatography columns to purify the cognate polypeptide, cloning and sequencing the polynucleotide that encodes an antibody and thus as a practicum for teaching a student how to design humanized antibodies. The AFP polynucleotide, polypeptide or antibody would then be packaged by reagent companies and sold to universities so that the students gain skill in art of molecular biology. Because each polynucleotide and protein is unique, each polynucleotide and protein creates unique challenges and learning experiences for students in a lab practicum. Such educational kits containing an AFP polynucleotide, polypeptide or antibody are considered within the scope of the present invention.

[0166] The invention is further illustrated by the following non-limiting examples.

EXAMPLES Example 1

[0167] A protein of the present invention (“AFP”) is produced in E. coli using a His₆ tag/maltose binding protein (MBP) double affinity fusion system as generally disclosed by Pryor and Leiting, Prot. Expr. Pur. 10:309-319, 1997. A thrombin cleavage site is placed at the junction between the affinity tag and AFP sequences.

[0168] The fusion construct is assembled in the vector pTAP98, which comprises sequences for replication and selection in E. coli and yeast, the E. coli tac promoter, and a unique SmaI site just downstream of the MBP-His₆-thrombin site coding sequences. The AFP cDNA is amplified by PCR using primers each comprising 40 bp of sequence homologous to vector sequence and 25 bp of sequence that anneals to the cDNA. The reaction is run using Taq DNA polymerase (Boehringer Mannheim, Indianapolis, IN) for 30 cycles of 94° C., 30 seconds; 60° C., 60 seconds; and 72° C., 60 seconds. One microgram of the resulting fragment is mixed with 100 ng of SmaI-cut pTAP98, and the mixture is transformed into yeast to assemble the vector by homologous recombination (Oldenburg et al., Nucl. Acids. Res. 25:451-452, 1997). Ura⁺ transformants are selected.

[0169] Plasmid DNA is prepared from yeast transformants and transformed into E. coli MC1061. Pooled plasmid DNA is then prepared from the MC1061 transformants by the miniprep method after scraping an entire plate. Plasmid DNA is analyzed by restriction digestion.

[0170]E. coli strain BL21 is used for expression of AFP. Cells are transformed by electroporation and grown on minimal glucose plates containing casamino acids and ampicillin.

[0171] Protein expression is analyzed by gel electrophoresis. Cells are grown in liquid glucose media containing casamino acids and ampicillin. After one hour at 37° C., IPTG is added to a final concentration of 1 mM, and the cells are grown for an additional 2-3 hours at 37° C. Cells are disrupted using glass beads, and extracts are prepared.

Example 2

[0172] Larger scale cultures of AFP transformants are prepared by the method of Pryor and Leiting (ibid.). 100-ml cultures in minimal glucose media containing casamino acids and 100 μg/ml ampicillin are grown at 37° C. in 500-ml baffled flasks to OD₆₀₀≈0.5. Cells are harvested by centrifugation and resuspended in 100 ml of the same media at room temperature. After 15 minutes, IPTG is added to 0.5 mM, and cultures are incubated at room temperature (ca. 22.5° C.) for 16 to 20 hours with shaking at 125 rpm. The culture is harvested by centrifugation, and cell pellets are stored at −70° C.

Example 3

[0173] For larger-scale protein preparation, 500-ml cultures of E. coli BL21 expressing the AFP-MBP-HiS₆ fusion protein are prepared essentially as disclosed in Example 2. Cell pellets are resuspended in 100 ml of binding buffer (20 mM Tris, pH 7.58, 100 mM NaCl, 20 mM NaH₂PO₄, 0.4 mM 4-(2-Aminoethyl)-benzenesulfonyl fluoride hydrochloride [Pefabloc® SC; Boehringer-Mannheim], 2 μg/ml Leupeptin, 2 μg/ml Aprotinin). The cells are lysed in a French press at 30,000 psi, and the lysate is centrifuged at 18,000× g for 45 minutes at 4° C. to clarify it. Protein concentration is estimated by gel electrophoresis with a BSA standard.

[0174] Recombinant AFP fusion protein is purified from the lysate by affinity chromatography. Immobilized cobalt resin (Talon® resin; Clontech Laboratories, Inc., Palo Alto, Calif.) is equilibrated in binding buffer. One ml of packed resin per 50 mg protein is combined with the clarified supernatant in a tube, and the tube is capped and sealed, then placed on a rocker overnight at 4° C. The resin is then pelleted by centrifugation at 4° C. and washed three times with binding buffer. Protein is eluted with binding buffer containing 0.2 M imidazole. The resin and elution buffer are mixed for at least one hour at 4° C., the resin is pelleted, and the supernatant is removed. An aliquot is analyzed by gel electrophoresis, and concentration is estimated. Amylose resin is equilibrated in amylose binding buffer (20 mM Tris-HCl, pH 7.0, 100 mM NaCl, 10 mM EDTA) and combined with the supernatant from the Talon resin at a ratio of 2 mg fusion protein per ml of resin. Binding and washing steps are carried out as disclosed above. Protein is eluted with amylose binding buffer containing 10 mM maltose using as small a volume as possible to minimize the need for subsequent concentration. The eluted protein is analyzed by gel electrophoresis and staining with Coomassie blue using a BSA standard, and by Western blotting using an anti-MBP antibody.

Example 4

[0175] An expression plasmid containing all or part of a polynucleotide encoding AFP is constructed via homologous recombination. An AFP coding sequence comprising the ORF with 5′ and 3′ ends corresponding to the vector sequences flanking the insertion point is prepared by PCR. The primers for PCR each include from 5′ to 3′ end: 40 bp of flanking sequence from the vector and 17 bp corresponding to the amino or carboxyl termini from the open reading frame of AFP.

[0176] Ten μl of the 100 μl PCR reaction mixture is run on a 0.8% low-melting-temperature agarose (SeaPlaque GTG®; FMC BioProducts, Rockland, Me.) gel with 1× TBE buffer for analysis. The remaining 90 μl of the reaction mixture is precipitated with the addition of 5 μl 1 M NaCl and 250 μl of absolute ethanol. The plasmid pZMP6, which has been cut with SmaI, is used for recombination with the PCR fragment. Plamid pZMP6 is a mammalian expression vector containing an expression cassette having the cytomegalovirus immediate early promoter, multiple restriction sites for insertion of coding sequences, a stop codon, and a human growth hormone terminator; an E. coli origin of replication; a mammalian selectable marker expression unit comprising an SV40 promoter, enhancer and origin of replication, a DHFR gene, and the SV40 terminator; and URA3 and CEN-ARS sequences required for selection and replication in S. cerevisiae. It was constructed from pZP9 (deposited at the American Type Culture Collection, 10801 University Boulevard, Manassas, Va. 20110-2209, under Accession No. 98668) with the yeast genetic elements taken from pRS316 (available from the American Type Culture Collection, 10801 University Boulevard, Manassas, Va., under Accession No. 77145), an internal ribosome entry site (IRES) element from poliovirus, and the extracellular domain of CD8 truncated at the C-terminal end of the transmembrane domain.

[0177] One hundred microliters of competent yeast (S. cerevisiae) cells are independently combined with 10 μl of the various DNA mixtures from above and transferred to a 0.2-cm electroporation cuvette. The yeast/DNA mixtures are electropulsed using power supply (BioRad Laboratories, Hercules, Calif.) settings of 0.75 kV (5 kV/cm), ∞ohms, 25 μF. To each cuvette is added 600 μl of 1.2 M sorbitol, and the yeast is plated in two 300-μl aliquots onto two URA-D plates (1.8% agar in 2% D-glucose, 0.67% yeast nitrogen base without amino acids, 0.056% -Ura-Trp-Thr powder [made by combining 4.0 g L-adenine, 3.0 g L-arginine, 5.0 g L-aspartic acid, 2.0 g L-histidine, 6.0 g L-isoleucine, 8.0 g L-leucine, 4.0 g L-lysine, 2.0 g L-methionine, 6.0 g L-phenylalanine, 5.0 g L-serine, 5.0 g L-tyrosine, and 6.0 g L-valine], and 0.5% 200× tryptophan, threonine solution [3.0% L-threonine, 0.8% L-tryptophan in H₂O]) and incubated at 30° C. After about 48 hours, the Ura⁺ yeast transformants from a single plate are resuspended in 1 ml H₂O and spun briefly to pellet the yeast cells. The cell pellet is resuspended in 1 ml of lysis buffer (2% Triton X-100, 1% SDS, 100 mM NaCl, 10 mM Tris, pH 8.0, 1 mM EDTA). Five hundred microliters of the lysis mixture is added to an Eppendorf tube containing 300 μl acid-washed glass beads and 200 μl phenol-chloroform, vortexed for 1 minute intervals two or three times, and spun for 5 minutes in an Eppendorf centrifuge at maximum speed. Three hundred microliters of the aqueous phase is transferred to a fresh tube, and the DNA is precipitated with 600 μl ethanol (EtOH), followed by centrifugation for 10 minutes at 4° C. The DNA pellet is resuspended in 10 μl H₂O.

[0178] Transformation of electrocompetent E. coli host cells (Electromax DH10B™ cells; obtained from Life Technologies, Inc., Gaithersburg, Md.) is done with 0.5-2 ml yeast DNA prep and 40 μl of cells. The cells are electropulsed at 1.7 kV, 25 μF., and 400 ohms. Following electroporation, 1 ml SOC (2% Bacto™ Tryptone (Difco, Detroit, Mich.), 0.5% yeast extract (Difco), 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl₂, 10 mM MgSO₄, 20 mM glucose) is plated in 250-μl aliquots on four LB AMP plates (LB broth (Lennox), 1.8% Bacto™ Agar (Difco), 100 mg/L Ampicillin).

[0179] Individual clones harboring the correct expression construct for AFP are identified by restriction digest to verify the presence of the AFP insert and to confirm that the various DNA sequences have been joined correctly to one another. The inserts of positive clones are subjected to sequence analysis. Larger scale plasmid DNA is isolated using a commercially available kit (QIAGEN Plasmid Maxi Kit, Qiagen, Valencia, Calif.) according to manufacturer's instructions. The correct construct is designated pZMP6/AFP.

[0180] Recombinant protein is produced in BHK cells transfected with pZMP6/AFP. BHK 570 cells (ATCC CRL-10314) are plated in 10-cm tissue culture dishes and allowed to grow to approximately 50 to 70% confluence overnight at 37° C., 5% CO₂, in DMEM/FBS media (DMEM, Gibco/BRL High Glucose; Life Technologies), 5% fetal bovine serum (Hyclone, Logan, Utah), 1 mM L-glutamine (JRH Biosciences, Lenexa, Kans.), 1 mM sodium pyruvate (Life Technologies). The cells are then transfected with pZMP6/AFP by liposome-mediated transfection using a 3:1 (w/w) liposome formulation of the polycationic lipid 2,3-dioleyloxy-N-[2(sperminecarboxamido)ethyl]-N,N-dimethyl-1-propaniminium-trifluoroacetate and the neutral lipid dioleoyl phosphatidylethanolamine in membrane-filtered water (Lipofectamine™ Reagent; Life Technologies, Garithersburg, Md.), in serum free (SF) media (DMEM supplemented with 10 mg/nl transferrin, 5 mg/nl insulin, 2 mg/ml fetuin, 1% L-glutamine and 1% sodium pyruvate). The plasmid is diluted into 15-ml tubes to a total final volume of 640 μl with SF media. 35 l of the lipid mixture is mixed with 605 μl of SF medium, and the resulting mixture is allowed to incubate approximately 30 minutes at room temperature. Five milliliters of SF media is then added to the DNA:lipid mixture. The cells are rinsed once with 5 ml of SF media, aspirated, and the DNA:lipid mixture is added. The cells are incubated at 37° C. for five hours, then 6.4 ml of DMEM/10% FBS, 1% PSN media is added to each plate. The plates are incubated at 37° C. overnight, and the DNA:lipid mixture is replaced with fresh 5% FBS/DMEM media the next day. On day 5 post-transfection, the cells are split into T-162 flasks in selection medium (DMEM+5% FBS, 1% L-Gln, 1% NaPyr, 1 μM methotrexate). Approximately 10 days post-transfection, two 150-mm culture dishes of methotrexate-resistant colonies from each transfection are trypsinized, and the cells are pooled and plated into a T-162 flask and transferred to large-scale culture.

[0181] From the foregoing, it will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.

0 SEQUENCE LISTING <160> NUMBER OF SEQ ID NOS: 123 <210> SEQ ID NO 1 <211> LENGTH: 354 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)...(354) <221> NAME/KEY: misc_feature <222> LOCATION: (1)...(354) <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 132 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 1 atg gcc tac tat ggc cgg gaa tca ccc tct gcc cgc gaa aag tct cct 48 Met Ala Tyr Tyr Gly Arg Glu Ser Pro Ser Ala Arg Glu Lys Ser Pro 1 5 10 15 gtg ttc atc ctg tgc tgc ccg ctg tgg aca cca ggt ccc ttc cga gca 96 Val Phe Ile Leu Cys Cys Pro Leu Trp Thr Pro Gly Pro Phe Arg Ala 20 25 30 gcc agc aga gca gac gcg act cac cct tcc tgc ttn tgg gag cct gtg 144 Ala Ser Arg Ala Asp Ala Thr His Pro Ser Cys Xaa Trp Glu Pro Val 35 40 45 aag agt ctc atc aca gcc ctt ttt act ctt ctt ttc ctt aac tat ggt 192 Lys Ser Leu Ile Thr Ala Leu Phe Thr Leu Leu Phe Leu Asn Tyr Gly 50 55 60 tta gag aaa ctc atc act gct ata tat gca gat tat gcc cgg agt ttg 240 Leu Glu Lys Leu Ile Thr Ala Ile Tyr Ala Asp Tyr Ala Arg Ser Leu 65 70 75 80 aag aac ctc ggt ttt aag cag gga gca gtt ctc ttt gct tca aaa gcc 288 Lys Asn Leu Gly Phe Lys Gln Gly Ala Val Leu Phe Ala Ser Lys Ala 85 90 95 gga gca gct ggc aaa gac tta ttg aat gag ctt gag tcc ccc aag gaa 336 Gly Ala Ala Gly Lys Asp Leu Leu Asn Glu Leu Glu Ser Pro Lys Glu 100 105 110 gaa ccc att gaa gag tga 354 Glu Pro Ile Glu Glu * 115 <210> SEQ ID NO 2 <211> LENGTH: 117 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: VARIANT <222> LOCATION: (1)...(117) <223> OTHER INFORMATION: Xaa = Any Amino Acid <221> NAME/KEY: VARIANT <222> LOCATION: 44 <223> OTHER INFORMATION: Xaa = Any Amino Acid <400> SEQUENCE: 2 Met Ala Tyr Tyr Gly Arg Glu Ser Pro Ser Ala Arg Glu Lys Ser Pro 1 5 10 15 Val Phe Ile Leu Cys Cys Pro Leu Trp Thr Pro Gly Pro Phe Arg Ala 20 25 30 Ala Ser Arg Ala Asp Ala Thr His Pro Ser Cys Xaa Trp Glu Pro Val 35 40 45 Lys Ser Leu Ile Thr Ala Leu Phe Thr Leu Leu Phe Leu Asn Tyr Gly 50 55 60 Leu Glu Lys Leu Ile Thr Ala Ile Tyr Ala Asp Tyr Ala Arg Ser Leu 65 70 75 80 Lys Asn Leu Gly Phe Lys Gln Gly Ala Val Leu Phe Ala Ser Lys Ala 85 90 95 Gly Ala Ala Gly Lys Asp Leu Leu Asn Glu Leu Glu Ser Pro Lys Glu 100 105 110 Glu Pro Ile Glu Glu 115 <210> SEQ ID NO 3 <211> LENGTH: 918 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)...(918) <400> SEQUENCE: 3 atg aca gat gaa ctc gtt ggg tta cct ttt tcc tct cat acc tat tcc 48 Met Thr Asp Glu Leu Val Gly Leu Pro Phe Ser Ser His Thr Tyr Ser 1 5 10 15 caa gcc tct gaa ttg ccc aca gat gct gtt gat tgt atg agc aga gag 96 Gln Ala Ser Glu Leu Pro Thr Asp Ala Val Asp Cys Met Ser Arg Glu 20 25 30 ctt gtg tcc ctt act agc cga aat cct gat caa aga aaa gaa tct ttg 144 Leu Val Ser Leu Thr Ser Arg Asn Pro Asp Gln Arg Lys Glu Ser Leu 35 40 45 tgc att agt atc act gtg tcc aag gta gac aaa gac cag cct tcc att 192 Cys Ile Ser Ile Thr Val Ser Lys Val Asp Lys Asp Gln Pro Ser Ile 50 55 60 tta aac tcc tgt gaa gac cca gtt cca ggg atg ttg ttt ttt ttg cca 240 Leu Asn Ser Cys Glu Asp Pro Val Pro Gly Met Leu Phe Phe Leu Pro 65 70 75 80 cct ggt cag cac ttg tca gac tat tcc cag ttg aat gaa agc aca aca 288 Pro Gly Gln His Leu Ser Asp Tyr Ser Gln Leu Asn Glu Ser Thr Thr 85 90 95 aaa gag tct tca gag gcc agc cag ctt gaa gat gct gct ggg ggt gac 336 Lys Glu Ser Ser Glu Ala Ser Gln Leu Glu Asp Ala Ala Gly Gly Asp 100 105 110 agt gca tct gag gaa aaa agt ggg tct gct gag cca ttt gta ccg cca 384 Ser Ala Ser Glu Glu Lys Ser Gly Ser Ala Glu Pro Phe Val Pro Pro 115 120 125 gcc tct tct gtg gaa agt aca tta cca gtg ctt gag gca tcc agt tgg 432 Ala Ser Ser Val Glu Ser Thr Leu Pro Val Leu Glu Ala Ser Ser Trp 130 135 140 aag aag cag gtg tcg cat gac ttc ctg gag acc agg ttt aaa atc cag 480 Lys Lys Gln Val Ser His Asp Phe Leu Glu Thr Arg Phe Lys Ile Gln 145 150 155 160 cag ctt ttg gag cct cag cag tac atg gct ttt ctg ccc cac cac att 528 Gln Leu Leu Glu Pro Gln Gln Tyr Met Ala Phe Leu Pro His His Ile 165 170 175 atg gta aaa atc ttc agg tta ctt ccc acc aag agt tta gtg gcc ctt 576 Met Val Lys Ile Phe Arg Leu Leu Pro Thr Lys Ser Leu Val Ala Leu 180 185 190 aaa tgt acc tgc tgc tat ttc aag ttt atc att gag tac tac aat atc 624 Lys Cys Thr Cys Cys Tyr Phe Lys Phe Ile Ile Glu Tyr Tyr Asn Ile 195 200 205 agg cca gca gat tct cgc tgg gtt cga gat cca cgc tat aga gag gat 672 Arg Pro Ala Asp Ser Arg Trp Val Arg Asp Pro Arg Tyr Arg Glu Asp 210 215 220 cct tgc aaa cag tgc aag aaa aag tat gtg aaa ggg gat gtg tcc ctg 720 Pro Cys Lys Gln Cys Lys Lys Lys Tyr Val Lys Gly Asp Val Ser Leu 225 230 235 240 tgc cga tgg cac ccc aag ccc tat tgc cag gca ttg ccc tat ggg cca 768 Cys Arg Trp His Pro Lys Pro Tyr Cys Gln Ala Leu Pro Tyr Gly Pro 245 250 255 ggg tat tgg atg tgc tgc cac cgg tct cag aaa gga ttc cct ggc tgt 816 Gly Tyr Trp Met Cys Cys His Arg Ser Gln Lys Gly Phe Pro Gly Cys 260 265 270 aag ctg ggg ctt cat gac aat cac tgg gtt cct gcc tgc cac agc ttt 864 Lys Leu Gly Leu His Asp Asn His Trp Val Pro Ala Cys His Ser Phe 275 280 285 aat cgg gca atc cat aag aaa gca aaa ggg act gaa gct gaa gag gaa 912 Asn Arg Ala Ile His Lys Lys Ala Lys Gly Thr Glu Ala Glu Glu Glu 290 295 300 tac taa 918 Tyr * 305 <210> SEQ ID NO 4 <211> LENGTH: 305 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 4 Met Thr Asp Glu Leu Val Gly Leu Pro Phe Ser Ser His Thr Tyr Ser 1 5 10 15 Gln Ala Ser Glu Leu Pro Thr Asp Ala Val Asp Cys Met Ser Arg Glu 20 25 30 Leu Val Ser Leu Thr Ser Arg Asn Pro Asp Gln Arg Lys Glu Ser Leu 35 40 45 Cys Ile Ser Ile Thr Val Ser Lys Val Asp Lys Asp Gln Pro Ser Ile 50 55 60 Leu Asn Ser Cys Glu Asp Pro Val Pro Gly Met Leu Phe Phe Leu Pro 65 70 75 80 Pro Gly Gln His Leu Ser Asp Tyr Ser Gln Leu Asn Glu Ser Thr Thr 85 90 95 Lys Glu Ser Ser Glu Ala Ser Gln Leu Glu Asp Ala Ala Gly Gly Asp 100 105 110 Ser Ala Ser Glu Glu Lys Ser Gly Ser Ala Glu Pro Phe Val Pro Pro 115 120 125 Ala Ser Ser Val Glu Ser Thr Leu Pro Val Leu Glu Ala Ser Ser Trp 130 135 140 Lys Lys Gln Val Ser His Asp Phe Leu Glu Thr Arg Phe Lys Ile Gln 145 150 155 160 Gln Leu Leu Glu Pro Gln Gln Tyr Met Ala Phe Leu Pro His His Ile 165 170 175 Met Val Lys Ile Phe Arg Leu Leu Pro Thr Lys Ser Leu Val Ala Leu 180 185 190 Lys Cys Thr Cys Cys Tyr Phe Lys Phe Ile Ile Glu Tyr Tyr Asn Ile 195 200 205 Arg Pro Ala Asp Ser Arg Trp Val Arg Asp Pro Arg Tyr Arg Glu Asp 210 215 220 Pro Cys Lys Gln Cys Lys Lys Lys Tyr Val Lys Gly Asp Val Ser Leu 225 230 235 240 Cys Arg Trp His Pro Lys Pro Tyr Cys Gln Ala Leu Pro Tyr Gly Pro 245 250 255 Gly Tyr Trp Met Cys Cys His Arg Ser Gln Lys Gly Phe Pro Gly Cys 260 265 270 Lys Leu Gly Leu His Asp Asn His Trp Val Pro Ala Cys His Ser Phe 275 280 285 Asn Arg Ala Ile His Lys Lys Ala Lys Gly Thr Glu Ala Glu Glu Glu 290 295 300 Tyr 305 <210> SEQ ID NO 5 <211> LENGTH: 303 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)...(303) <400> SEQUENCE: 5 atg cga caa gtt ttt ggt gat gag aag aag tac tgg ttg cta ccc att 48 Met Arg Gln Val Phe Gly Asp Glu Lys Lys Tyr Trp Leu Leu Pro Ile 1 5 10 15 ttt tca agt cta ggt gat ggc tgc tcc ttt cca act tgc ctt gtt aac 96 Phe Ser Ser Leu Gly Asp Gly Cys Ser Phe Pro Thr Cys Leu Val Asn 20 25 30 cag gat cct gaa caa gca tct act cct gca ggg ctg aat tcc aca gct 144 Gln Asp Pro Glu Gln Ala Ser Thr Pro Ala Gly Leu Asn Ser Thr Ala 35 40 45 aaa aat ctc gaa aac cat cag ttt cct gca aag cca ttg aga gag tcc 192 Lys Asn Leu Glu Asn His Gln Phe Pro Ala Lys Pro Leu Arg Glu Ser 50 55 60 cag agc cac ctt ctt act gat tct cag tct tgg acg gag agc agc ata 240 Gln Ser His Leu Leu Thr Asp Ser Gln Ser Trp Thr Glu Ser Ser Ile 65 70 75 80 aac cca gga aaa tgc aaa gct ggt atg agc aat cct gca tta acc atg 288 Asn Pro Gly Lys Cys Lys Ala Gly Met Ser Asn Pro Ala Leu Thr Met 85 90 95 gaa aat gag act taa 303 Glu Asn Glu Thr * 100 <210> SEQ ID NO 6 <211> LENGTH: 100 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 6 Met Arg Gln Val Phe Gly Asp Glu Lys Lys Tyr Trp Leu Leu Pro Ile 1 5 10 15 Phe Ser Ser Leu Gly Asp Gly Cys Ser Phe Pro Thr Cys Leu Val Asn 20 25 30 Gln Asp Pro Glu Gln Ala Ser Thr Pro Ala Gly Leu Asn Ser Thr Ala 35 40 45 Lys Asn Leu Glu Asn His Gln Phe Pro Ala Lys Pro Leu Arg Glu Ser 50 55 60 Gln Ser His Leu Leu Thr Asp Ser Gln Ser Trp Thr Glu Ser Ser Ile 65 70 75 80 Asn Pro Gly Lys Cys Lys Ala Gly Met Ser Asn Pro Ala Leu Thr Met 85 90 95 Glu Asn Glu Thr 100 <210> SEQ ID NO 7 <211> LENGTH: 432 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)...(432) <221> NAME/KEY: misc_feature <222> LOCATION: (1)...(432) <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 8, 9, 11, 14, 17 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 7 atg cct gnn cng ang ang ggg ggg ccc tca ttc ggg acc ctg cac tcc 48 Met Pro Xaa Xaa Xaa Xaa Gly Gly Pro Ser Phe Gly Thr Leu His Ser 1 5 10 15 gtc gcc gga agt gcc acc gag aag cgc cgg cct cgg ggc tgt cta cag 96 Val Ala Gly Ser Ala Thr Glu Lys Arg Arg Pro Arg Gly Cys Leu Gln 20 25 30 cgg ccc ggg aga ggc tgt ggt ggc ccc gag cgc gag tgt gta ggt gac 144 Arg Pro Gly Arg Gly Cys Gly Gly Pro Glu Arg Glu Cys Val Gly Asp 35 40 45 agg aca gcg gcc agg ccc gcc cct ccc ctc gtg agt acc cgg aag ccg 192 Arg Thr Ala Ala Arg Pro Ala Pro Pro Leu Val Ser Thr Arg Lys Pro 50 55 60 ttt tgg ggt cgc agc ggg gtg gca gct tgt ttt gcc ttc acg gga gta 240 Phe Trp Gly Arg Ser Gly Val Ala Ala Cys Phe Ala Phe Thr Gly Val 65 70 75 80 gaa gga ggc ggc gtc cgg ccg cgg ccg acg gta gtt cgc ttc ccc gag 288 Glu Gly Gly Gly Val Arg Pro Arg Pro Thr Val Val Arg Phe Pro Glu 85 90 95 agt gcg cgg agg ccc ggg tgc gag gag ggc ctg ttt ctc ttc agc cct 336 Ser Ala Arg Arg Pro Gly Cys Glu Glu Gly Leu Phe Leu Phe Ser Pro 100 105 110 ggt tca ttc acc tcg cgg acc gag ggc ccc gcc gtc agg agc cgg cga 384 Gly Ser Phe Thr Ser Arg Thr Glu Gly Pro Ala Val Arg Ser Arg Arg 115 120 125 ccg tgc cct ggt gcg agc tgt gat ggt cat tgt cct cca gag cag tga 432 Pro Cys Pro Gly Ala Ser Cys Asp Gly His Cys Pro Pro Glu Gln * 130 135 140 <210> SEQ ID NO 8 <211> LENGTH: 143 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: VARIANT <222> LOCATION: (1)...(143) <223> OTHER INFORMATION: Xaa = Any Amino Acid <221> NAME/KEY: VARIANT <222> LOCATION: 3, 4, 5, 6 <223> OTHER INFORMATION: Xaa = Any Amino Acid <400> SEQUENCE: 8 Met Pro Xaa Xaa Xaa Xaa Gly Gly Pro Ser Phe Gly Thr Leu His Ser 1 5 10 15 Val Ala Gly Ser Ala Thr Glu Lys Arg Arg Pro Arg Gly Cys Leu Gln 20 25 30 Arg Pro Gly Arg Gly Cys Gly Gly Pro Glu Arg Glu Cys Val Gly Asp 35 40 45 Arg Thr Ala Ala Arg Pro Ala Pro Pro Leu Val Ser Thr Arg Lys Pro 50 55 60 Phe Trp Gly Arg Ser Gly Val Ala Ala Cys Phe Ala Phe Thr Gly Val 65 70 75 80 Glu Gly Gly Gly Val Arg Pro Arg Pro Thr Val Val Arg Phe Pro Glu 85 90 95 Ser Ala Arg Arg Pro Gly Cys Glu Glu Gly Leu Phe Leu Phe Ser Pro 100 105 110 Gly Ser Phe Thr Ser Arg Thr Glu Gly Pro Ala Val Arg Ser Arg Arg 115 120 125 Pro Cys Pro Gly Ala Ser Cys Asp Gly His Cys Pro Pro Glu Gln 130 135 140 <210> SEQ ID NO 9 <211> LENGTH: 381 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)...(381) <400> SEQUENCE: 9 atg gca tta gct ctg tgt ctg cag gtg ctg tgc agc ctg tgt ggc tgg 48 Met Ala Leu Ala Leu Cys Leu Gln Val Leu Cys Ser Leu Cys Gly Trp 1 5 10 15 ctc tcg ctc tat att tct ttc tgc cac ctg aat aag cac cga agc tat 96 Leu Ser Leu Tyr Ile Ser Phe Cys His Leu Asn Lys His Arg Ser Tyr 20 25 30 gag tgg agc tgc cgc ctg gtc acc ttc acc cat gga gtc ctc tct ata 144 Glu Trp Ser Cys Arg Leu Val Thr Phe Thr His Gly Val Leu Ser Ile 35 40 45 ggc ctc tcc gct tat att ggc ttc att gat ggc cca tgg cct ttt acc 192 Gly Leu Ser Ala Tyr Ile Gly Phe Ile Asp Gly Pro Trp Pro Phe Thr 50 55 60 cac cca ggc tca ccc aat aca cct ctc caa gtt cat gtc ctg tgt ctc 240 His Pro Gly Ser Pro Asn Thr Pro Leu Gln Val His Val Leu Cys Leu 65 70 75 80 acc ttg ggc tac ttc atc ttc gac ttg ggc tgc atc tgg cgc ttt gca 288 Thr Leu Gly Tyr Phe Ile Phe Asp Leu Gly Cys Ile Trp Arg Phe Ala 85 90 95 tgg agg aag agc atc aag aag tac cat gct tgg aga agc agg cgg agt 336 Trp Arg Lys Ser Ile Lys Lys Tyr His Ala Trp Arg Ser Arg Arg Ser 100 105 110 gag gaa cgg cag ctg aaa cac aac gga cat ctc aaa ata cac tag 381 Glu Glu Arg Gln Leu Lys His Asn Gly His Leu Lys Ile His * 115 120 125 <210> SEQ ID NO 10 <211> LENGTH: 126 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 10 Met Ala Leu Ala Leu Cys Leu Gln Val Leu Cys Ser Leu Cys Gly Trp 1 5 10 15 Leu Ser Leu Tyr Ile Ser Phe Cys His Leu Asn Lys His Arg Ser Tyr 20 25 30 Glu Trp Ser Cys Arg Leu Val Thr Phe Thr His Gly Val Leu Ser Ile 35 40 45 Gly Leu Ser Ala Tyr Ile Gly Phe Ile Asp Gly Pro Trp Pro Phe Thr 50 55 60 His Pro Gly Ser Pro Asn Thr Pro Leu Gln Val His Val Leu Cys Leu 65 70 75 80 Thr Leu Gly Tyr Phe Ile Phe Asp Leu Gly Cys Ile Trp Arg Phe Ala 85 90 95 Trp Arg Lys Ser Ile Lys Lys Tyr His Ala Trp Arg Ser Arg Arg Ser 100 105 110 Glu Glu Arg Gln Leu Lys His Asn Gly His Leu Lys Ile His 115 120 125 <210> SEQ ID NO 11 <211> LENGTH: 600 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)...(600) <400> SEQUENCE: 11 atg ggg gca gcc gtg ctg tgc gct agt ttc atg tcc ttt ggc gtg aag 48 Met Gly Ala Ala Val Leu Cys Ala Ser Phe Met Ser Phe Gly Val Lys 1 5 10 15 cgg cgc tgg ttc gcg ctg ggg gcc gca ctc caa ttg gcc att agc acc 96 Arg Arg Trp Phe Ala Leu Gly Ala Ala Leu Gln Leu Ala Ile Ser Thr 20 25 30 tac gcc gcc tac atc ggg ggc tac gtc cac tac ggg gac tgg ctg aag 144 Tyr Ala Ala Tyr Ile Gly Gly Tyr Val His Tyr Gly Asp Trp Leu Lys 35 40 45 gtc cgt atg tac tcg cgc aca gtt gcc atc atc ggc ggc ttt ctt gtg 192 Val Arg Met Tyr Ser Arg Thr Val Ala Ile Ile Gly Gly Phe Leu Val 50 55 60 ttg gcc agc ggt gct ggg gag ctg tac cgc cgg aaa cct cgc agc cgc 240 Leu Ala Ser Gly Ala Gly Glu Leu Tyr Arg Arg Lys Pro Arg Ser Arg 65 70 75 80 tcc ctg cag tcc acc ggc cag gtg ttc ctg ggt atc tac ctc atc tgt 288 Ser Leu Gln Ser Thr Gly Gln Val Phe Leu Gly Ile Tyr Leu Ile Cys 85 90 95 gtg gcc tac tca ctg cag cac agc aag gag gac cgg ctg gcg tat ctg 336 Val Ala Tyr Ser Leu Gln His Ser Lys Glu Asp Arg Leu Ala Tyr Leu 100 105 110 aac cat ctc cca gga ggg gag ctg atg atc cag ctg ttc ttc gtg ctg 384 Asn His Leu Pro Gly Gly Glu Leu Met Ile Gln Leu Phe Phe Val Leu 115 120 125 tat ggc atc ctg gcc ctg gcc ttt ctg tca ggc tac tac gtg acc ctc 432 Tyr Gly Ile Leu Ala Leu Ala Phe Leu Ser Gly Tyr Tyr Val Thr Leu 130 135 140 gct gcc cag atc ctg gct gta ctg ctg ccc cct gtc atg ctg ctc att 480 Ala Ala Gln Ile Leu Ala Val Leu Leu Pro Pro Val Met Leu Leu Ile 145 150 155 160 gat ggc aat gtt gct tac tgg cac aac acg cgg cgt gtt gag ttc tgg 528 Asp Gly Asn Val Ala Tyr Trp His Asn Thr Arg Arg Val Glu Phe Trp 165 170 175 aac cag atg aag ctc ctt gga gag agt gtg ggc atc ttc gga act gct 576 Asn Gln Met Lys Leu Leu Gly Glu Ser Val Gly Ile Phe Gly Thr Ala 180 185 190 gtc atc ctg gcc act gat ggc tga 600 Val Ile Leu Ala Thr Asp Gly * 195 <210> SEQ ID NO 12 <211> LENGTH: 199 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 12 Met Gly Ala Ala Val Leu Cys Ala Ser Phe Met Ser Phe Gly Val Lys 1 5 10 15 Arg Arg Trp Phe Ala Leu Gly Ala Ala Leu Gln Leu Ala Ile Ser Thr 20 25 30 Tyr Ala Ala Tyr Ile Gly Gly Tyr Val His Tyr Gly Asp Trp Leu Lys 35 40 45 Val Arg Met Tyr Ser Arg Thr Val Ala Ile Ile Gly Gly Phe Leu Val 50 55 60 Leu Ala Ser Gly Ala Gly Glu Leu Tyr Arg Arg Lys Pro Arg Ser Arg 65 70 75 80 Ser Leu Gln Ser Thr Gly Gln Val Phe Leu Gly Ile Tyr Leu Ile Cys 85 90 95 Val Ala Tyr Ser Leu Gln His Ser Lys Glu Asp Arg Leu Ala Tyr Leu 100 105 110 Asn His Leu Pro Gly Gly Glu Leu Met Ile Gln Leu Phe Phe Val Leu 115 120 125 Tyr Gly Ile Leu Ala Leu Ala Phe Leu Ser Gly Tyr Tyr Val Thr Leu 130 135 140 Ala Ala Gln Ile Leu Ala Val Leu Leu Pro Pro Val Met Leu Leu Ile 145 150 155 160 Asp Gly Asn Val Ala Tyr Trp His Asn Thr Arg Arg Val Glu Phe Trp 165 170 175 Asn Gln Met Lys Leu Leu Gly Glu Ser Val Gly Ile Phe Gly Thr Ala 180 185 190 Val Ile Leu Ala Thr Asp Gly 195 <210> SEQ ID NO 13 <211> LENGTH: 447 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)...(447) <400> SEQUENCE: 13 atg gct gcc tcc ccc gcg cgg cct gct gtc ctg gcc ctg acc ggg ctg 48 Met Ala Ala Ser Pro Ala Arg Pro Ala Val Leu Ala Leu Thr Gly Leu 1 5 10 15 gcg ctg ctc ctg ctc ctg tgc tgg ggc cca ggt ggc ata agt gga aat 96 Ala Leu Leu Leu Leu Leu Cys Trp Gly Pro Gly Gly Ile Ser Gly Asn 20 25 30 aaa ctc aag ctg atg ctt caa aaa cga gaa gca cct gtt cca act aag 144 Lys Leu Lys Leu Met Leu Gln Lys Arg Glu Ala Pro Val Pro Thr Lys 35 40 45 act aaa gtg gcc gtt gat gag aat aaa gcc aaa gaa ttc ctt ggc agc 192 Thr Lys Val Ala Val Asp Glu Asn Lys Ala Lys Glu Phe Leu Gly Ser 50 55 60 ctg aag cgc cag aag cgg cag ctg tgg gac cgg act cgg ccc gag gtg 240 Leu Lys Arg Gln Lys Arg Gln Leu Trp Asp Arg Thr Arg Pro Glu Val 65 70 75 80 cag cag tgg tac cag cag ttt ctc tac atg ggc ttt gac gaa gcg aaa 288 Gln Gln Trp Tyr Gln Gln Phe Leu Tyr Met Gly Phe Asp Glu Ala Lys 85 90 95 ttt gaa gat gac atc acc tat tgg ctt aac aga gat cga aat gga cat 336 Phe Glu Asp Asp Ile Thr Tyr Trp Leu Asn Arg Asp Arg Asn Gly His 100 105 110 gaa tac tat ggc gat tac tac caa cgt cac tat gat gaa gac tct gca 384 Glu Tyr Tyr Gly Asp Tyr Tyr Gln Arg His Tyr Asp Glu Asp Ser Ala 115 120 125 att ggt ccc cgg agc ccc tac ggc ttt agg cat gga gcc agc gtc aac 432 Ile Gly Pro Arg Ser Pro Tyr Gly Phe Arg His Gly Ala Ser Val Asn 130 135 140 tac gat gac tac taa 447 Tyr Asp Asp Tyr * 145 <210> SEQ ID NO 14 <211> LENGTH: 148 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 14 Met Ala Ala Ser Pro Ala Arg Pro Ala Val Leu Ala Leu Thr Gly Leu 1 5 10 15 Ala Leu Leu Leu Leu Leu Cys Trp Gly Pro Gly Gly Ile Ser Gly Asn 20 25 30 Lys Leu Lys Leu Met Leu Gln Lys Arg Glu Ala Pro Val Pro Thr Lys 35 40 45 Thr Lys Val Ala Val Asp Glu Asn Lys Ala Lys Glu Phe Leu Gly Ser 50 55 60 Leu Lys Arg Gln Lys Arg Gln Leu Trp Asp Arg Thr Arg Pro Glu Val 65 70 75 80 Gln Gln Trp Tyr Gln Gln Phe Leu Tyr Met Gly Phe Asp Glu Ala Lys 85 90 95 Phe Glu Asp Asp Ile Thr Tyr Trp Leu Asn Arg Asp Arg Asn Gly His 100 105 110 Glu Tyr Tyr Gly Asp Tyr Tyr Gln Arg His Tyr Asp Glu Asp Ser Ala 115 120 125 Ile Gly Pro Arg Ser Pro Tyr Gly Phe Arg His Gly Ala Ser Val Asn 130 135 140 Tyr Asp Asp Tyr 145 <210> SEQ ID NO 15 <211> LENGTH: 1296 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)...(1296) <221> NAME/KEY: misc_feature <222> LOCATION: (1)...(1296) <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 56 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 15 atg cgg cgg ctg cgg cgc ctg gcg cac ctg gtg ctc ttc tgc ccc ttc 48 Met Arg Arg Leu Arg Arg Leu Ala His Leu Val Leu Phe Cys Pro Phe 1 5 10 15 tcc aag cnc ctg cag ggc cgg ctc cca ggc ctc agg gtc cgc tgc atc 96 Ser Lys Xaa Leu Gln Gly Arg Leu Pro Gly Leu Arg Val Arg Cys Ile 20 25 30 ttc ctg gcc tgg ctg ggc gtc ttt gca ggc agc tgg ctg gtg tac gtg 144 Phe Leu Ala Trp Leu Gly Val Phe Ala Gly Ser Trp Leu Val Tyr Val 35 40 45 cac tac tcg tcc tac tcg gag cgc tgt cgc ggc cat gtc tgc cag gtg 192 His Tyr Ser Ser Tyr Ser Glu Arg Cys Arg Gly His Val Cys Gln Val 50 55 60 gtc att tgt gac cag tac cgc aag ggg atc atc tcg ggc tcc gtc tgc 240 Val Ile Cys Asp Gln Tyr Arg Lys Gly Ile Ile Ser Gly Ser Val Cys 65 70 75 80 cag gac ctg tgt gag ctg cat atg gtg gag tgg agg acc tgc ctc tcg 288 Gln Asp Leu Cys Glu Leu His Met Val Glu Trp Arg Thr Cys Leu Ser 85 90 95 gtg gcc ccg ggc cag cag gtg tac agc ggg ctc tgg cgg gac aag gat 336 Val Ala Pro Gly Gln Gln Val Tyr Ser Gly Leu Trp Arg Asp Lys Asp 100 105 110 gta acc atc aag tgt ggc att gag gag acc ctc gac tcc aag gcc cgg 384 Val Thr Ile Lys Cys Gly Ile Glu Glu Thr Leu Asp Ser Lys Ala Arg 115 120 125 tcg gat gcg gcc ccc cgg cgg gag ctg gta ctg ttt gac aag ccc acc 432 Ser Asp Ala Ala Pro Arg Arg Glu Leu Val Leu Phe Asp Lys Pro Thr 130 135 140 cgg ggc acc tcc atc aag gaa ttc cgg gag atg acc ctc ggc ttc ctc 480 Arg Gly Thr Ser Ile Lys Glu Phe Arg Glu Met Thr Leu Gly Phe Leu 145 150 155 160 aag gcg aac ctg gga gac ctg cct tcc ctg ccg gcg ctg gtt ggc cag 528 Lys Ala Asn Leu Gly Asp Leu Pro Ser Leu Pro Ala Leu Val Gly Gln 165 170 175 gtc ctg ctc atg gct gac ttc aac aag gac aac cgg gtg tcc ctg gcg 576 Val Leu Leu Met Ala Asp Phe Asn Lys Asp Asn Arg Val Ser Leu Ala 180 185 190 gaa gcc aag tcc gtg tgg gcc ctg ctg cag cgt aac gag ttc ctg ctg 624 Glu Ala Lys Ser Val Trp Ala Leu Leu Gln Arg Asn Glu Phe Leu Leu 195 200 205 ctg ctg tcc ctg cag gag aag gag cac gcc tcc aga ctg ctg ggc tac 672 Leu Leu Ser Leu Gln Glu Lys Glu His Ala Ser Arg Leu Leu Gly Tyr 210 215 220 tgt ggg gac ctc tac ctc acc gag ggc gtg ccg cat ggc gcc tgg cac 720 Cys Gly Asp Leu Tyr Leu Thr Glu Gly Val Pro His Gly Ala Trp His 225 230 235 240 gcg gcc gcc ctc cca ccc ctg ttg cgc cca ctg ctg ccg cct gcc ctg 768 Ala Ala Ala Leu Pro Pro Leu Leu Arg Pro Leu Leu Pro Pro Ala Leu 245 250 255 cag ggt gct ctc cag cag tgg ctg ggg cct gcg tgg cct tgg cgg gcc 816 Gln Gly Ala Leu Gln Gln Trp Leu Gly Pro Ala Trp Pro Trp Arg Ala 260 265 270 aag atc gcc atc ggc ctg ctg gag ttc gtg gag gag ctc ttc cac ggc 864 Lys Ile Ala Ile Gly Leu Leu Glu Phe Val Glu Glu Leu Phe His Gly 275 280 285 tct tac ggg act ttc tac atg tgt gag acc aca ctg gcc aac gtg ggc 912 Ser Tyr Gly Thr Phe Tyr Met Cys Glu Thr Thr Leu Ala Asn Val Gly 290 295 300 tac aca gcc acc tac gac ttc aag atg gcc gac ctg cag cag gtg gca 960 Tyr Thr Ala Thr Tyr Asp Phe Lys Met Ala Asp Leu Gln Gln Val Ala 305 310 315 320 ccc gag gcc acc gtg cgc cgc ttc ctg cag ggc cgc cgc tgc gag cac 1008 Pro Glu Ala Thr Val Arg Arg Phe Leu Gln Gly Arg Arg Cys Glu His 325 330 335 agc acc gac tgc acc tac ggg cgc gac tgc agg gcc ccg tgt gac agg 1056 Ser Thr Asp Cys Thr Tyr Gly Arg Asp Cys Arg Ala Pro Cys Asp Arg 340 345 350 ctc atg agg cag tgc aag ggc gac ctc atc cag ccc aac ctg gcc aag 1104 Leu Met Arg Gln Cys Lys Gly Asp Leu Ile Gln Pro Asn Leu Ala Lys 355 360 365 gtg tgc gca ctg cta cgg ggc tac ctg ctg cct ggc gcg ccc gcc gac 1152 Val Cys Ala Leu Leu Arg Gly Tyr Leu Leu Pro Gly Ala Pro Ala Asp 370 375 380 ctc cgc gag gag ctg ggc aca cag ctg cgc acc tgt acc acg ctg agc 1200 Leu Arg Glu Glu Leu Gly Thr Gln Leu Arg Thr Cys Thr Thr Leu Ser 385 390 395 400 ggg ctg gcc agc cag gtg gag gcc cat cac tcg ctg gtg ctc agc cac 1248 Gly Leu Ala Ser Gln Val Glu Ala His His Ser Leu Val Leu Ser His 405 410 415 ctc aag act ctg ctc tgg aag aag atc tcc aac acc aag tac tct tga 1296 Leu Lys Thr Leu Leu Trp Lys Lys Ile Ser Asn Thr Lys Tyr Ser * 420 425 430 <210> SEQ ID NO 16 <211> LENGTH: 431 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: VARIANT <222> LOCATION: (1)...(431) <223> OTHER INFORMATION: Xaa = Any Amino Acid <221> NAME/KEY: VARIANT <222> LOCATION: 19 <223> OTHER INFORMATION: Xaa = Any Amino Acid <400> SEQUENCE: 16 Met Arg Arg Leu Arg Arg Leu Ala His Leu Val Leu Phe Cys Pro Phe 1 5 10 15 Ser Lys Xaa Leu Gln Gly Arg Leu Pro Gly Leu Arg Val Arg Cys Ile 20 25 30 Phe Leu Ala Trp Leu Gly Val Phe Ala Gly Ser Trp Leu Val Tyr Val 35 40 45 His Tyr Ser Ser Tyr Ser Glu Arg Cys Arg Gly His Val Cys Gln Val 50 55 60 Val Ile Cys Asp Gln Tyr Arg Lys Gly Ile Ile Ser Gly Ser Val Cys 65 70 75 80 Gln Asp Leu Cys Glu Leu His Met Val Glu Trp Arg Thr Cys Leu Ser 85 90 95 Val Ala Pro Gly Gln Gln Val Tyr Ser Gly Leu Trp Arg Asp Lys Asp 100 105 110 Val Thr Ile Lys Cys Gly Ile Glu Glu Thr Leu Asp Ser Lys Ala Arg 115 120 125 Ser Asp Ala Ala Pro Arg Arg Glu Leu Val Leu Phe Asp Lys Pro Thr 130 135 140 Arg Gly Thr Ser Ile Lys Glu Phe Arg Glu Met Thr Leu Gly Phe Leu 145 150 155 160 Lys Ala Asn Leu Gly Asp Leu Pro Ser Leu Pro Ala Leu Val Gly Gln 165 170 175 Val Leu Leu Met Ala Asp Phe Asn Lys Asp Asn Arg Val Ser Leu Ala 180 185 190 Glu Ala Lys Ser Val Trp Ala Leu Leu Gln Arg Asn Glu Phe Leu Leu 195 200 205 Leu Leu Ser Leu Gln Glu Lys Glu His Ala Ser Arg Leu Leu Gly Tyr 210 215 220 Cys Gly Asp Leu Tyr Leu Thr Glu Gly Val Pro His Gly Ala Trp His 225 230 235 240 Ala Ala Ala Leu Pro Pro Leu Leu Arg Pro Leu Leu Pro Pro Ala Leu 245 250 255 Gln Gly Ala Leu Gln Gln Trp Leu Gly Pro Ala Trp Pro Trp Arg Ala 260 265 270 Lys Ile Ala Ile Gly Leu Leu Glu Phe Val Glu Glu Leu Phe His Gly 275 280 285 Ser Tyr Gly Thr Phe Tyr Met Cys Glu Thr Thr Leu Ala Asn Val Gly 290 295 300 Tyr Thr Ala Thr Tyr Asp Phe Lys Met Ala Asp Leu Gln Gln Val Ala 305 310 315 320 Pro Glu Ala Thr Val Arg Arg Phe Leu Gln Gly Arg Arg Cys Glu His 325 330 335 Ser Thr Asp Cys Thr Tyr Gly Arg Asp Cys Arg Ala Pro Cys Asp Arg 340 345 350 Leu Met Arg Gln Cys Lys Gly Asp Leu Ile Gln Pro Asn Leu Ala Lys 355 360 365 Val Cys Ala Leu Leu Arg Gly Tyr Leu Leu Pro Gly Ala Pro Ala Asp 370 375 380 Leu Arg Glu Glu Leu Gly Thr Gln Leu Arg Thr Cys Thr Thr Leu Ser 385 390 395 400 Gly Leu Ala Ser Gln Val Glu Ala His His Ser Leu Val Leu Ser His 405 410 415 Leu Lys Thr Leu Leu Trp Lys Lys Ile Ser Asn Thr Lys Tyr Ser 420 425 430 <210> SEQ ID NO 17 <211> LENGTH: 738 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)...(738) <221> NAME/KEY: misc_feature <222> LOCATION: (1)...(738) <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 343 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 17 atg gca tta gct ctg tgt ctg cag gtg ctg tgc agc ctg tgt ggc tgg 48 Met Ala Leu Ala Leu Cys Leu Gln Val Leu Cys Ser Leu Cys Gly Trp 1 5 10 15 ctc tcg ctc tat att tct ttc tgc cac ctg aat aag cac cga agc tat 96 Leu Ser Leu Tyr Ile Ser Phe Cys His Leu Asn Lys His Arg Ser Tyr 20 25 30 gag tgg agc tgc cgc ctg gtc acc ttc acc cat gga gtc ctc tct ata 144 Glu Trp Ser Cys Arg Leu Val Thr Phe Thr His Gly Val Leu Ser Ile 35 40 45 ggc ctc tcc gct tat att ggc ttc att gat ggc cca tgg cct ttt acc 192 Gly Leu Ser Ala Tyr Ile Gly Phe Ile Asp Gly Pro Trp Pro Phe Thr 50 55 60 cac cca ggc tca ccc aat aca cct ctc caa gtt cat gtc ctg tgt ctc 240 His Pro Gly Ser Pro Asn Thr Pro Leu Gln Val His Val Leu Cys Leu 65 70 75 80 acc ttg ggc tac ttc atc ttc gac ttg ggc tgg tgc gtc tac ttt cag 288 Thr Leu Gly Tyr Phe Ile Phe Asp Leu Gly Trp Cys Val Tyr Phe Gln 85 90 95 tct gag ggt gcc ttg atg ctg gct cat cac aca ttg agt atc ttg ggc 336 Ser Glu Gly Ala Leu Met Leu Ala His His Thr Leu Ser Ile Leu Gly 100 105 110 att atc ntg gcc ctt gtg ctt ggg gag tct ggc aca gag gtc aat gca 384 Ile Ile Xaa Ala Leu Val Leu Gly Glu Ser Gly Thr Glu Val Asn Ala 115 120 125 gtc ctc ttt gga agt gag ctt acc aac ccc ttg cta cag atg cgc tgg 432 Val Leu Phe Gly Ser Glu Leu Thr Asn Pro Leu Leu Gln Met Arg Trp 130 135 140 ttt ctc cgg gaa aca ggg cac tat cac agt ttc act gga gat gta gtg 480 Phe Leu Arg Glu Thr Gly His Tyr His Ser Phe Thr Gly Asp Val Val 145 150 155 160 gac ttc ctc ttt gtg gct ctg ttc aca gga gtg agg att ggt gtg gga 528 Asp Phe Leu Phe Val Ala Leu Phe Thr Gly Val Arg Ile Gly Val Gly 165 170 175 gct tgc ctc ctt ttc tgt gaa atg gtc tcc ccc acg cct aag tgg ttt 576 Ala Cys Leu Leu Phe Cys Glu Met Val Ser Pro Thr Pro Lys Trp Phe 180 185 190 gtg aag gct ggg gga gta gcg atg tat gct gtg tct tgg tgt ttc atg 624 Val Lys Ala Gly Gly Val Ala Met Tyr Ala Val Ser Trp Cys Phe Met 195 200 205 ttt agc atc tgg cgc ttt gca tgg agg aag agc atc aag aag tac cat 672 Phe Ser Ile Trp Arg Phe Ala Trp Arg Lys Ser Ile Lys Lys Tyr His 210 215 220 gct tgg aga agc agg cgg agt gag gaa cgg cag ctg aaa cac aac gga 720 Ala Trp Arg Ser Arg Arg Ser Glu Glu Arg Gln Leu Lys His Asn Gly 225 230 235 240 cat ctc aaa ata cac tag 738 His Leu Lys Ile His * 245 <210> SEQ ID NO 18 <211> LENGTH: 245 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: VARIANT <222> LOCATION: (1)...(245) <223> OTHER INFORMATION: Xaa = Any Amino Acid <221> NAME/KEY: VARIANT <222> LOCATION: 115 <223> OTHER INFORMATION: Xaa = Any Amino Acid <400> SEQUENCE: 18 Met Ala Leu Ala Leu Cys Leu Gln Val Leu Cys Ser Leu Cys Gly Trp 1 5 10 15 Leu Ser Leu Tyr Ile Ser Phe Cys His Leu Asn Lys His Arg Ser Tyr 20 25 30 Glu Trp Ser Cys Arg Leu Val Thr Phe Thr His Gly Val Leu Ser Ile 35 40 45 Gly Leu Ser Ala Tyr Ile Gly Phe Ile Asp Gly Pro Trp Pro Phe Thr 50 55 60 His Pro Gly Ser Pro Asn Thr Pro Leu Gln Val His Val Leu Cys Leu 65 70 75 80 Thr Leu Gly Tyr Phe Ile Phe Asp Leu Gly Trp Cys Val Tyr Phe Gln 85 90 95 Ser Glu Gly Ala Leu Met Leu Ala His His Thr Leu Ser Ile Leu Gly 100 105 110 Ile Ile Xaa Ala Leu Val Leu Gly Glu Ser Gly Thr Glu Val Asn Ala 115 120 125 Val Leu Phe Gly Ser Glu Leu Thr Asn Pro Leu Leu Gln Met Arg Trp 130 135 140 Phe Leu Arg Glu Thr Gly His Tyr His Ser Phe Thr Gly Asp Val Val 145 150 155 160 Asp Phe Leu Phe Val Ala Leu Phe Thr Gly Val Arg Ile Gly Val Gly 165 170 175 Ala Cys Leu Leu Phe Cys Glu Met Val Ser Pro Thr Pro Lys Trp Phe 180 185 190 Val Lys Ala Gly Gly Val Ala Met Tyr Ala Val Ser Trp Cys Phe Met 195 200 205 Phe Ser Ile Trp Arg Phe Ala Trp Arg Lys Ser Ile Lys Lys Tyr His 210 215 220 Ala Trp Arg Ser Arg Arg Ser Glu Glu Arg Gln Leu Lys His Asn Gly 225 230 235 240 His Leu Lys Ile His 245 <210> SEQ ID NO 19 <211> LENGTH: 1545 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)...(1545) <221> NAME/KEY: misc_feature <222> LOCATION: (1)...(1545) <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 16 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 19 atg tcc tgg ccg cgc ngc ctc ctg ctc aga tac ctg ttc ccg gcc ctc 48 Met Ser Trp Pro Arg Xaa Leu Leu Leu Arg Tyr Leu Phe Pro Ala Leu 1 5 10 15 ctg ctt cac ggg ctg gga gag ggt tct gcc ctc ctt cat cca gac agc 96 Leu Leu His Gly Leu Gly Glu Gly Ser Ala Leu Leu His Pro Asp Ser 20 25 30 agg tct cat cct agg tcc tta gag aaa agt gcc tgg agg gct ttt aag 144 Arg Ser His Pro Arg Ser Leu Glu Lys Ser Ala Trp Arg Ala Phe Lys 35 40 45 gag tca cag tgc cat cac atg ctc aaa cat ctc cac aat ggt gca agg 192 Glu Ser Gln Cys His His Met Leu Lys His Leu His Asn Gly Ala Arg 50 55 60 atc aca gtg cag atg cca cct aca atc gag ggc cac tgg gtc tcc aca 240 Ile Thr Val Gln Met Pro Pro Thr Ile Glu Gly His Trp Val Ser Thr 65 70 75 80 ggc tgt gaa gta agg tca ggc cca gag ttc atc aca agg tcc tac aga 288 Gly Cys Glu Val Arg Ser Gly Pro Glu Phe Ile Thr Arg Ser Tyr Arg 85 90 95 ttc tac cac aat aac acc ttc aag gcc tac caa ttt tat tat ggc agc 336 Phe Tyr His Asn Asn Thr Phe Lys Ala Tyr Gln Phe Tyr Tyr Gly Ser 100 105 110 aac cgg tgc aca aat ccc act tat act ctc atc atc cgg ggc aag atc 384 Asn Arg Cys Thr Asn Pro Thr Tyr Thr Leu Ile Ile Arg Gly Lys Ile 115 120 125 cgc ctc cgc cag gcc tcc tgg atc atc cga ggg ggc acg gaa gcc gac 432 Arg Leu Arg Gln Ala Ser Trp Ile Ile Arg Gly Gly Thr Glu Ala Asp 130 135 140 tac cag ctg cac aac gtc cag gtg atc tgc cac aca gag gcg gtg gcc 480 Tyr Gln Leu His Asn Val Gln Val Ile Cys His Thr Glu Ala Val Ala 145 150 155 160 gag aag ctc ggc cag cag gtg aac cgc aca tgc ccg ggc ttc ctc gca 528 Glu Lys Leu Gly Gln Gln Val Asn Arg Thr Cys Pro Gly Phe Leu Ala 165 170 175 gac ggg ggt ccc tgg gtg cag gac gtg gcc tat gac ctc tgg cga gag 576 Asp Gly Gly Pro Trp Val Gln Asp Val Ala Tyr Asp Leu Trp Arg Glu 180 185 190 gag aac ggc tgt gag tgc acc aag gcc gtg aac ttt gcc atg cat gaa 624 Glu Asn Gly Cys Glu Cys Thr Lys Ala Val Asn Phe Ala Met His Glu 195 200 205 ctt cag ctc atc cgg gtg gag aag cag tac ctt cac cac aac ctc gac 672 Leu Gln Leu Ile Arg Val Glu Lys Gln Tyr Leu His His Asn Leu Asp 210 215 220 cac ctg gtc gag gag ctc ttc ctt ggt gac att cac act gat gcc acc 720 His Leu Val Glu Glu Leu Phe Leu Gly Asp Ile His Thr Asp Ala Thr 225 230 235 240 cag agg atg ttc tac cgg ccc tcc agt tac cag ccc cct ctg cag aat 768 Gln Arg Met Phe Tyr Arg Pro Ser Ser Tyr Gln Pro Pro Leu Gln Asn 245 250 255 gcc aag aac cac gac cat gcc tgc atc gcc tgt cgg atc atc tat cgg 816 Ala Lys Asn His Asp His Ala Cys Ile Ala Cys Arg Ile Ile Tyr Arg 260 265 270 tca gac gag cac cac cct ccc atc ctg ccc cca aag gca gac ctg acc 864 Ser Asp Glu His His Pro Pro Ile Leu Pro Pro Lys Ala Asp Leu Thr 275 280 285 atc ggc ctg cac ggg gag tgg gtg agc cag cgc tgt gag gtg cgc ccc 912 Ile Gly Leu His Gly Glu Trp Val Ser Gln Arg Cys Glu Val Arg Pro 290 295 300 gaa gtc ctc ttc ctc acc cgc cac ttc atc ttc cat gac aac aac aac 960 Glu Val Leu Phe Leu Thr Arg His Phe Ile Phe His Asp Asn Asn Asn 305 310 315 320 acc tgg gag ggc cac tac tac cac tac tca gac ccg gtg tgc aag cac 1008 Thr Trp Glu Gly His Tyr Tyr His Tyr Ser Asp Pro Val Cys Lys His 325 330 335 ccc acc ttc tcc atc tac gcc cgg ggc cgc tac agc cgc ggc gtc ctc 1056 Pro Thr Phe Ser Ile Tyr Ala Arg Gly Arg Tyr Ser Arg Gly Val Leu 340 345 350 tcg tcc agg gtc atg gga ggc acc gag ttc gtg ttc aaa gtg aat cac 1104 Ser Ser Arg Val Met Gly Gly Thr Glu Phe Val Phe Lys Val Asn His 355 360 365 atg aag gtc acc ccc atg gat gcg gcc aca gcc tca ctg ctc aac gtc 1152 Met Lys Val Thr Pro Met Asp Ala Ala Thr Ala Ser Leu Leu Asn Val 370 375 380 ttc aac ggg aat gag tgc ggg gcc gag ggc tcc tgg cag gtg ggc atc 1200 Phe Asn Gly Asn Glu Cys Gly Ala Glu Gly Ser Trp Gln Val Gly Ile 385 390 395 400 cag cag gat gtg acc cac acc aat ggc tgc gtg gcc ctg ggc atc aaa 1248 Gln Gln Asp Val Thr His Thr Asn Gly Cys Val Ala Leu Gly Ile Lys 405 410 415 cta cct cac acg gag tac gag atc ttc aaa atg gaa cag gat gcc cgg 1296 Leu Pro His Thr Glu Tyr Glu Ile Phe Lys Met Glu Gln Asp Ala Arg 420 425 430 ggg cgc tat ctg ctg ttc aac ggt cag agg ccc agc gac ggg tcc agc 1344 Gly Arg Tyr Leu Leu Phe Asn Gly Gln Arg Pro Ser Asp Gly Ser Ser 435 440 445 cca gac agg cca gag aag aga gcc acg tcc tac cag atg ccc ttg gtc 1392 Pro Asp Arg Pro Glu Lys Arg Ala Thr Ser Tyr Gln Met Pro Leu Val 450 455 460 cag tgt gcc tcc tct tcg ccg agg gca gag gac ctc gca gaa gac agt 1440 Gln Cys Ala Ser Ser Ser Pro Arg Ala Glu Asp Leu Ala Glu Asp Ser 465 470 475 480 gga agc agc ctg tat ggc cgg gcc cct ggg agg cac acc tgg tcc ctg 1488 Gly Ser Ser Leu Tyr Gly Arg Ala Pro Gly Arg His Thr Trp Ser Leu 485 490 495 ctg ctg gct gca ctt gcc tgc ctt gtc cct ctg ctg cat tgg aac atc 1536 Leu Leu Ala Ala Leu Ala Cys Leu Val Pro Leu Leu His Trp Asn Ile 500 505 510 cgc aga tag 1545 Arg Arg * <210> SEQ ID NO 20 <211> LENGTH: 514 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: VARIANT <222> LOCATION: (1)...(514) <223> OTHER INFORMATION: Xaa = Any Amino Acid <221> NAME/KEY: VARIANT <222> LOCATION: 6 <223> OTHER INFORMATION: Xaa = Any Amino Acid <400> SEQUENCE: 20 Met Ser Trp Pro Arg Xaa Leu Leu Leu Arg Tyr Leu Phe Pro Ala Leu 1 5 10 15 Leu Leu His Gly Leu Gly Glu Gly Ser Ala Leu Leu His Pro Asp Ser 20 25 30 Arg Ser His Pro Arg Ser Leu Glu Lys Ser Ala Trp Arg Ala Phe Lys 35 40 45 Glu Ser Gln Cys His His Met Leu Lys His Leu His Asn Gly Ala Arg 50 55 60 Ile Thr Val Gln Met Pro Pro Thr Ile Glu Gly His Trp Val Ser Thr 65 70 75 80 Gly Cys Glu Val Arg Ser Gly Pro Glu Phe Ile Thr Arg Ser Tyr Arg 85 90 95 Phe Tyr His Asn Asn Thr Phe Lys Ala Tyr Gln Phe Tyr Tyr Gly Ser 100 105 110 Asn Arg Cys Thr Asn Pro Thr Tyr Thr Leu Ile Ile Arg Gly Lys Ile 115 120 125 Arg Leu Arg Gln Ala Ser Trp Ile Ile Arg Gly Gly Thr Glu Ala Asp 130 135 140 Tyr Gln Leu His Asn Val Gln Val Ile Cys His Thr Glu Ala Val Ala 145 150 155 160 Glu Lys Leu Gly Gln Gln Val Asn Arg Thr Cys Pro Gly Phe Leu Ala 165 170 175 Asp Gly Gly Pro Trp Val Gln Asp Val Ala Tyr Asp Leu Trp Arg Glu 180 185 190 Glu Asn Gly Cys Glu Cys Thr Lys Ala Val Asn Phe Ala Met His Glu 195 200 205 Leu Gln Leu Ile Arg Val Glu Lys Gln Tyr Leu His His Asn Leu Asp 210 215 220 His Leu Val Glu Glu Leu Phe Leu Gly Asp Ile His Thr Asp Ala Thr 225 230 235 240 Gln Arg Met Phe Tyr Arg Pro Ser Ser Tyr Gln Pro Pro Leu Gln Asn 245 250 255 Ala Lys Asn His Asp His Ala Cys Ile Ala Cys Arg Ile Ile Tyr Arg 260 265 270 Ser Asp Glu His His Pro Pro Ile Leu Pro Pro Lys Ala Asp Leu Thr 275 280 285 Ile Gly Leu His Gly Glu Trp Val Ser Gln Arg Cys Glu Val Arg Pro 290 295 300 Glu Val Leu Phe Leu Thr Arg His Phe Ile Phe His Asp Asn Asn Asn 305 310 315 320 Thr Trp Glu Gly His Tyr Tyr His Tyr Ser Asp Pro Val Cys Lys His 325 330 335 Pro Thr Phe Ser Ile Tyr Ala Arg Gly Arg Tyr Ser Arg Gly Val Leu 340 345 350 Ser Ser Arg Val Met Gly Gly Thr Glu Phe Val Phe Lys Val Asn His 355 360 365 Met Lys Val Thr Pro Met Asp Ala Ala Thr Ala Ser Leu Leu Asn Val 370 375 380 Phe Asn Gly Asn Glu Cys Gly Ala Glu Gly Ser Trp Gln Val Gly Ile 385 390 395 400 Gln Gln Asp Val Thr His Thr Asn Gly Cys Val Ala Leu Gly Ile Lys 405 410 415 Leu Pro His Thr Glu Tyr Glu Ile Phe Lys Met Glu Gln Asp Ala Arg 420 425 430 Gly Arg Tyr Leu Leu Phe Asn Gly Gln Arg Pro Ser Asp Gly Ser Ser 435 440 445 Pro Asp Arg Pro Glu Lys Arg Ala Thr Ser Tyr Gln Met Pro Leu Val 450 455 460 Gln Cys Ala Ser Ser Ser Pro Arg Ala Glu Asp Leu Ala Glu Asp Ser 465 470 475 480 Gly Ser Ser Leu Tyr Gly Arg Ala Pro Gly Arg His Thr Trp Ser Leu 485 490 495 Leu Leu Ala Ala Leu Ala Cys Leu Val Pro Leu Leu His Trp Asn Ile 500 505 510 Arg Arg <210> SEQ ID NO 21 <211> LENGTH: 381 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)...(381) <400> SEQUENCE: 21 atg aag aaa atc cgc cat ctc tct ctg att gaa ttg act gcc ttt ttt 48 Met Lys Lys Ile Arg His Leu Ser Leu Ile Glu Leu Thr Ala Phe Phe 1 5 10 15 gat gcc ttt gga att caa ctg aaa agg aac aaa aca gag aaa gta aaa 96 Asp Ala Phe Gly Ile Gln Leu Lys Arg Asn Lys Thr Glu Lys Val Lys 20 25 30 gga cga gac aat ggg att ttt gga gtt cca ctt aca gtc ctc ctg gac 144 Gly Arg Asp Asn Gly Ile Phe Gly Val Pro Leu Thr Val Leu Leu Asp 35 40 45 ggt gac cga aag aaa gac cct gga gtg aaa gtt ccc ctg gta tta caa 192 Gly Asp Arg Lys Lys Asp Pro Gly Val Lys Val Pro Leu Val Leu Gln 50 55 60 aaa caa tac cgt gaa gaa ctt gat gcc aag ttt aat gct gat aaa ttt 240 Lys Gln Tyr Arg Glu Glu Leu Asp Ala Lys Phe Asn Ala Asp Lys Phe 65 70 75 80 aaa tgg gac aaa atg tgc cat aga gaa gct gca gta atg ttg aaa gcg 288 Lys Trp Asp Lys Met Cys His Arg Glu Ala Ala Val Met Leu Lys Ala 85 90 95 ttt ttc aga gaa cta ccc acc tct ctc ttc cct gtg gaa tat ata cct 336 Phe Phe Arg Glu Leu Pro Thr Ser Leu Phe Pro Val Glu Tyr Ile Pro 100 105 110 gcc ttc atc agt cta atg gaa aga ggg cct cac gtc aaa gta tag 381 Ala Phe Ile Ser Leu Met Glu Arg Gly Pro His Val Lys Val * 115 120 125 <210> SEQ ID NO 22 <211> LENGTH: 126 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 22 Met Lys Lys Ile Arg His Leu Ser Leu Ile Glu Leu Thr Ala Phe Phe 1 5 10 15 Asp Ala Phe Gly Ile Gln Leu Lys Arg Asn Lys Thr Glu Lys Val Lys 20 25 30 Gly Arg Asp Asn Gly Ile Phe Gly Val Pro Leu Thr Val Leu Leu Asp 35 40 45 Gly Asp Arg Lys Lys Asp Pro Gly Val Lys Val Pro Leu Val Leu Gln 50 55 60 Lys Gln Tyr Arg Glu Glu Leu Asp Ala Lys Phe Asn Ala Asp Lys Phe 65 70 75 80 Lys Trp Asp Lys Met Cys His Arg Glu Ala Ala Val Met Leu Lys Ala 85 90 95 Phe Phe Arg Glu Leu Pro Thr Ser Leu Phe Pro Val Glu Tyr Ile Pro 100 105 110 Ala Phe Ile Ser Leu Met Glu Arg Gly Pro His Val Lys Val 115 120 125 <210> SEQ ID NO 23 <211> LENGTH: 303 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)...(303) <400> SEQUENCE: 23 atg gcg tgg ctc ccc ggc tcc tgc gcc cgc gtg gct ttc gcg gcg ggc 48 Met Ala Trp Leu Pro Gly Ser Cys Ala Arg Val Ala Phe Ala Ala Gly 1 5 10 15 gct gcg gcc cgg tat tgg aca gcc tgg cag ggc agc gcg ggg ccg aat 96 Ala Ala Ala Arg Tyr Trp Thr Ala Trp Gln Gly Ser Ala Gly Pro Asn 20 25 30 ccg gct gcc gtg gct gag gct cat gga tcc cgt tgt tat gga ggg cca 144 Pro Ala Ala Val Ala Glu Ala His Gly Ser Arg Cys Tyr Gly Gly Pro 35 40 45 cat ctg cca gag cct gga gtc tgc gaa ggc cgg gac ccg gtt ccc cgg 192 His Leu Pro Glu Pro Gly Val Cys Glu Gly Arg Asp Pro Val Pro Arg 50 55 60 ccc aca gtg ggg gtg tgc aaa ccc gag aga act ggg ttg caa att cgt 240 Pro Thr Val Gly Val Cys Lys Pro Glu Arg Thr Gly Leu Gln Ile Arg 65 70 75 80 gaa gaa tca gca tca tgt ttg gca gct gag tat tgg agc cag gag cct 288 Glu Glu Ser Ala Ser Cys Leu Ala Ala Glu Tyr Trp Ser Gln Glu Pro 85 90 95 gcc atg agg ttt tga 303 Ala Met Arg Phe * 100 <210> SEQ ID NO 24 <211> LENGTH: 100 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 24 Met Ala Trp Leu Pro Gly Ser Cys Ala Arg Val Ala Phe Ala Ala Gly 1 5 10 15 Ala Ala Ala Arg Tyr Trp Thr Ala Trp Gln Gly Ser Ala Gly Pro Asn 20 25 30 Pro Ala Ala Val Ala Glu Ala His Gly Ser Arg Cys Tyr Gly Gly Pro 35 40 45 His Leu Pro Glu Pro Gly Val Cys Glu Gly Arg Asp Pro Val Pro Arg 50 55 60 Pro Thr Val Gly Val Cys Lys Pro Glu Arg Thr Gly Leu Gln Ile Arg 65 70 75 80 Glu Glu Ser Ala Ser Cys Leu Ala Ala Glu Tyr Trp Ser Gln Glu Pro 85 90 95 Ala Met Arg Phe 100 <210> SEQ ID NO 25 <211> LENGTH: 390 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)...(390) <400> SEQUENCE: 25 atg ggg ccc aag ctt tcc act ctt gac gcc act gtc ttt gga cac ttg 48 Met Gly Pro Lys Leu Ser Thr Leu Asp Ala Thr Val Phe Gly His Leu 1 5 10 15 gca cag gca atg tgg acc tta cca ggg aca aga ccc gaa cgg ctg atc 96 Ala Gln Ala Met Trp Thr Leu Pro Gly Thr Arg Pro Glu Arg Leu Ile 20 25 30 aaa ggt gag ctg atc aac ctt gcc atg tac tgt gag agg ata agg agg 144 Lys Gly Glu Leu Ile Asn Leu Ala Met Tyr Cys Glu Arg Ile Arg Arg 35 40 45 aaa ttt tgg cca gag tgg cac cac gat gat gac aat acc atc tat gag 192 Lys Phe Trp Pro Glu Trp His His Asp Asp Asp Asn Thr Ile Tyr Glu 50 55 60 tct gag gag agc agc gaa ggc agc aaa acc cac acc ccg ctg ctg gat 240 Ser Glu Glu Ser Ser Glu Gly Ser Lys Thr His Thr Pro Leu Leu Asp 65 70 75 80 ttt agc ttt tac tca agg aca gag acc ttt gaa gat gag gga gca gaa 288 Phe Ser Phe Tyr Ser Arg Thr Glu Thr Phe Glu Asp Glu Gly Ala Glu 85 90 95 aac agt ttt tcc aga acc cca gac aca gat ttt act gga cac tca ctc 336 Asn Ser Phe Ser Arg Thr Pro Asp Thr Asp Phe Thr Gly His Ser Leu 100 105 110 ttt gat tcg gat gtg gac atg gat gac tat aca gac cac gaa cag tgc 384 Phe Asp Ser Asp Val Asp Met Asp Asp Tyr Thr Asp His Glu Gln Cys 115 120 125 aag tga 390 Lys * <210> SEQ ID NO 26 <211> LENGTH: 129 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 26 Met Gly Pro Lys Leu Ser Thr Leu Asp Ala Thr Val Phe Gly His Leu 1 5 10 15 Ala Gln Ala Met Trp Thr Leu Pro Gly Thr Arg Pro Glu Arg Leu Ile 20 25 30 Lys Gly Glu Leu Ile Asn Leu Ala Met Tyr Cys Glu Arg Ile Arg Arg 35 40 45 Lys Phe Trp Pro Glu Trp His His Asp Asp Asp Asn Thr Ile Tyr Glu 50 55 60 Ser Glu Glu Ser Ser Glu Gly Ser Lys Thr His Thr Pro Leu Leu Asp 65 70 75 80 Phe Ser Phe Tyr Ser Arg Thr Glu Thr Phe Glu Asp Glu Gly Ala Glu 85 90 95 Asn Ser Phe Ser Arg Thr Pro Asp Thr Asp Phe Thr Gly His Ser Leu 100 105 110 Phe Asp Ser Asp Val Asp Met Asp Asp Tyr Thr Asp His Glu Gln Cys 115 120 125 Lys <210> SEQ ID NO 27 <211> LENGTH: 414 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)...(414) <400> SEQUENCE: 27 atg gag tac ata cag cag ttg aag gac ttt act acc gat gac ctg ttg 48 Met Glu Tyr Ile Gln Gln Leu Lys Asp Phe Thr Thr Asp Asp Leu Leu 1 5 10 15 cag cta tta atg tca tgt ccc caa gtt gaa tta att cag tgt ctc act 96 Gln Leu Leu Met Ser Cys Pro Gln Val Glu Leu Ile Gln Cys Leu Thr 20 25 30 aaa gag ttg aat gag aaa caa cca tct tta tct ttt ggt ctt gct ata 144 Lys Glu Leu Asn Glu Lys Gln Pro Ser Leu Ser Phe Gly Leu Ala Ile 35 40 45 ctt cat ctg ttc tct gca gac atg aaa aaa gtt ggc att aag cta ctt 192 Leu His Leu Phe Ser Ala Asp Met Lys Lys Val Gly Ile Lys Leu Leu 50 55 60 caa gaa atc aat aaa ggt ggg ata gat gca gta gaa agt ctt atg ata 240 Gln Glu Ile Asn Lys Gly Gly Ile Asp Ala Val Glu Ser Leu Met Ile 65 70 75 80 aat gat tcc ttt tgc tcc ata gaa aag tgg caa gaa gtg gca aat ata 288 Asn Asp Ser Phe Cys Ser Ile Glu Lys Trp Gln Glu Val Ala Asn Ile 85 90 95 tgt tca cag aat ggc ttt gac aaa tta tct aat gac atc acg tct att 336 Cys Ser Gln Asn Gly Phe Asp Lys Leu Ser Asn Asp Ile Thr Ser Ile 100 105 110 ctt cga tct cag gct gca gtt aca gaa att tct gaa gag gat gac gca 384 Leu Arg Ser Gln Ala Ala Val Thr Glu Ile Ser Glu Glu Asp Asp Ala 115 120 125 gtc aac cta atg gaa cat gtg ttt tgg tag 414 Val Asn Leu Met Glu His Val Phe Trp * 130 135 <210> SEQ ID NO 28 <211> LENGTH: 137 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 28 Met Glu Tyr Ile Gln Gln Leu Lys Asp Phe Thr Thr Asp Asp Leu Leu 1 5 10 15 Gln Leu Leu Met Ser Cys Pro Gln Val Glu Leu Ile Gln Cys Leu Thr 20 25 30 Lys Glu Leu Asn Glu Lys Gln Pro Ser Leu Ser Phe Gly Leu Ala Ile 35 40 45 Leu His Leu Phe Ser Ala Asp Met Lys Lys Val Gly Ile Lys Leu Leu 50 55 60 Gln Glu Ile Asn Lys Gly Gly Ile Asp Ala Val Glu Ser Leu Met Ile 65 70 75 80 Asn Asp Ser Phe Cys Ser Ile Glu Lys Trp Gln Glu Val Ala Asn Ile 85 90 95 Cys Ser Gln Asn Gly Phe Asp Lys Leu Ser Asn Asp Ile Thr Ser Ile 100 105 110 Leu Arg Ser Gln Ala Ala Val Thr Glu Ile Ser Glu Glu Asp Asp Ala 115 120 125 Val Asn Leu Met Glu His Val Phe Trp 130 135 <210> SEQ ID NO 29 <211> LENGTH: 456 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)...(456) <400> SEQUENCE: 29 atg ccc gtg ctg aag agc agc ctg gcc ttg ggc ctg gag ctg cgg gcc 48 Met Pro Val Leu Lys Ser Ser Leu Ala Leu Gly Leu Glu Leu Arg Ala 1 5 10 15 gca gcc ggg agc cac ttt gat gct gcg aag gcc gtg gag gaa cag ctg 96 Ala Ala Gly Ser His Phe Asp Ala Ala Lys Ala Val Glu Glu Gln Leu 20 25 30 aga aag tcg ttc cag atc cgc tgc ggc ctg gag gag agc gtg tcc gag 144 Arg Lys Ser Phe Gln Ile Arg Cys Gly Leu Glu Glu Ser Val Ser Glu 35 40 45 ggg ctg aac gtg ccg cgc tcc aag cgg ctc ttc cgg gac ctg gtg agc 192 Gly Leu Asn Val Pro Arg Ser Lys Arg Leu Phe Arg Asp Leu Val Ser 50 55 60 ctg cag gtg ccg gag gaa cag gtt ctg aat gcc gcg ctc agg gag aaa 240 Leu Gln Val Pro Glu Glu Gln Val Leu Asn Ala Ala Leu Arg Glu Lys 65 70 75 80 ttg gct ctc ctg ccg cca cag gct cga gcc ccg cac cca aag gag cca 288 Leu Ala Leu Leu Pro Pro Gln Ala Arg Ala Pro His Pro Lys Glu Pro 85 90 95 cct ggg cct ggg cca gac atg acc atc ttg tgt gac cca gaa acg cta 336 Pro Gly Pro Gly Pro Asp Met Thr Ile Leu Cys Asp Pro Glu Thr Leu 100 105 110 ttt tat gaa tct cca cac ctg acc ctg gac ggt ctg ccc cct ctc cga 384 Phe Tyr Glu Ser Pro His Leu Thr Leu Asp Gly Leu Pro Pro Leu Arg 115 120 125 ctt caa ctc cgg ccc cgc cct tca gag gac acc ttc ctc atg cac cgg 432 Leu Gln Leu Arg Pro Arg Pro Ser Glu Asp Thr Phe Leu Met His Arg 130 135 140 aca ctg agg cga tgg gaa gcg tag 456 Thr Leu Arg Arg Trp Glu Ala * 145 150 <210> SEQ ID NO 30 <211> LENGTH: 151 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 30 Met Pro Val Leu Lys Ser Ser Leu Ala Leu Gly Leu Glu Leu Arg Ala 1 5 10 15 Ala Ala Gly Ser His Phe Asp Ala Ala Lys Ala Val Glu Glu Gln Leu 20 25 30 Arg Lys Ser Phe Gln Ile Arg Cys Gly Leu Glu Glu Ser Val Ser Glu 35 40 45 Gly Leu Asn Val Pro Arg Ser Lys Arg Leu Phe Arg Asp Leu Val Ser 50 55 60 Leu Gln Val Pro Glu Glu Gln Val Leu Asn Ala Ala Leu Arg Glu Lys 65 70 75 80 Leu Ala Leu Leu Pro Pro Gln Ala Arg Ala Pro His Pro Lys Glu Pro 85 90 95 Pro Gly Pro Gly Pro Asp Met Thr Ile Leu Cys Asp Pro Glu Thr Leu 100 105 110 Phe Tyr Glu Ser Pro His Leu Thr Leu Asp Gly Leu Pro Pro Leu Arg 115 120 125 Leu Gln Leu Arg Pro Arg Pro Ser Glu Asp Thr Phe Leu Met His Arg 130 135 140 Thr Leu Arg Arg Trp Glu Ala 145 150 <210> SEQ ID NO 31 <211> LENGTH: 351 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)...(351) <221> NAME/KEY: misc_feature <222> LOCATION: (1)...(351) <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 347 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 31 atg gcg gat gag gcg ttg ttt ttg ctt ctc cat aac gag atg gtg tct 48 Met Ala Asp Glu Ala Leu Phe Leu Leu Leu His Asn Glu Met Val Ser 1 5 10 15 gga gtg tac aag tcc gcg gag cag ggg gag gtg gaa aac gga cga tgt 96 Gly Val Tyr Lys Ser Ala Glu Gln Gly Glu Val Glu Asn Gly Arg Cys 20 25 30 att act aag ctg gaa aac atg ggg ttt cga gtg gga caa gga ttg ata 144 Ile Thr Lys Leu Glu Asn Met Gly Phe Arg Val Gly Gln Gly Leu Ile 35 40 45 gaa agg ttt aca aaa gat act gca agg ttc aag gat gag tta gat atc 192 Glu Arg Phe Thr Lys Asp Thr Ala Arg Phe Lys Asp Glu Leu Asp Ile 50 55 60 atg aag ttc att tgt aaa gat ttt tgg act acg gta ttc aag aaa caa 240 Met Lys Phe Ile Cys Lys Asp Phe Trp Thr Thr Val Phe Lys Lys Gln 65 70 75 80 atc gac aat cta agg aca aat cat cag ggc atc tat gta ctt cag gac 288 Ile Asp Asn Leu Arg Thr Asn His Gln Gly Ile Tyr Val Leu Gln Asp 85 90 95 aac aaa ttt cgc ctg ctt act cag atg tct gca gga aaa cag tat tta 336 Asn Lys Phe Arg Leu Leu Thr Gln Met Ser Ala Gly Lys Gln Tyr Leu 100 105 110 gaa cat gca tnc taa 351 Glu His Ala Xaa * 115 <210> SEQ ID NO 32 <211> LENGTH: 116 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: VARIANT <222> LOCATION: 116 <223> OTHER INFORMATION: Xaa = Any Amino Acid <400> SEQUENCE: 32 Met Ala Asp Glu Ala Leu Phe Leu Leu Leu His Asn Glu Met Val Ser 1 5 10 15 Gly Val Tyr Lys Ser Ala Glu Gln Gly Glu Val Glu Asn Gly Arg Cys 20 25 30 Ile Thr Lys Leu Glu Asn Met Gly Phe Arg Val Gly Gln Gly Leu Ile 35 40 45 Glu Arg Phe Thr Lys Asp Thr Ala Arg Phe Lys Asp Glu Leu Asp Ile 50 55 60 Met Lys Phe Ile Cys Lys Asp Phe Trp Thr Thr Val Phe Lys Lys Gln 65 70 75 80 Ile Asp Asn Leu Arg Thr Asn His Gln Gly Ile Tyr Val Leu Gln Asp 85 90 95 Asn Lys Phe Arg Leu Leu Thr Gln Met Ser Ala Gly Lys Gln Tyr Leu 100 105 110 Glu His Ala Xaa 115 <210> SEQ ID NO 33 <211> LENGTH: 558 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)...(558) <400> SEQUENCE: 33 atg gtg gct gag tac ttc gat gag tca ttg gtt ctg ctg gca gat gcc 48 Met Val Ala Glu Tyr Phe Asp Glu Ser Leu Val Leu Leu Ala Asp Ala 1 5 10 15 ctg tgc tgg ggt cta gat gac gtg gtg ggc ttc atg cac aat gcc cag 96 Leu Cys Trp Gly Leu Asp Asp Val Val Gly Phe Met His Asn Ala Gln 20 25 30 gct gga cat aag cag ggc ctc agc act gtc agc aac agt gga ctg act 144 Ala Gly His Lys Gln Gly Leu Ser Thr Val Ser Asn Ser Gly Leu Thr 35 40 45 gcg gag gac cgg cag ctg act gca cgg gcc cga gcc tgg aac aac ctg 192 Ala Glu Asp Arg Gln Leu Thr Ala Arg Ala Arg Ala Trp Asn Asn Leu 50 55 60 gac tgg gct ctc tat gtc cac ttc aac cgc agt ctc tgg gca cgg ata 240 Asp Trp Ala Leu Tyr Val His Phe Asn Arg Ser Leu Trp Ala Arg Ile 65 70 75 80 gag aaa tac ggc cag ggc cgg ctg cag aca gct gtg gcc gag ctc cgg 288 Glu Lys Tyr Gly Gln Gly Arg Leu Gln Thr Ala Val Ala Glu Leu Arg 85 90 95 gct cgc cga gag gcc cta gcg aaa cat tgt ctg gta ggg ggt gag gct 336 Ala Arg Arg Glu Ala Leu Ala Lys His Cys Leu Val Gly Gly Glu Ala 100 105 110 tct gac ccc aaa tac atc act gat cgc cgg ttc cgc ccc ttc cag ttt 384 Ser Asp Pro Lys Tyr Ile Thr Asp Arg Arg Phe Arg Pro Phe Gln Phe 115 120 125 ggg tca gct aag gtt ttg ggc tat ata ctt cgg agt gga ttg agc ccc 432 Gly Ser Ala Lys Val Leu Gly Tyr Ile Leu Arg Ser Gly Leu Ser Pro 130 135 140 caa gac caa gag gaa tgt gag cgc cta gct acc cct gag ctc cag tac 480 Gln Asp Gln Glu Glu Cys Glu Arg Leu Ala Thr Pro Glu Leu Gln Tyr 145 150 155 160 aag gac aag ctg gat gtc aag cag ttc ccc cct acc gtc tca ctg ccc 528 Lys Asp Lys Leu Asp Val Lys Gln Phe Pro Pro Thr Val Ser Leu Pro 165 170 175 ctc aag act tca agg cca ctc tcc cca taa 558 Leu Lys Thr Ser Arg Pro Leu Ser Pro * 180 185 <210> SEQ ID NO 34 <211> LENGTH: 185 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 34 Met Val Ala Glu Tyr Phe Asp Glu Ser Leu Val Leu Leu Ala Asp Ala 1 5 10 15 Leu Cys Trp Gly Leu Asp Asp Val Val Gly Phe Met His Asn Ala Gln 20 25 30 Ala Gly His Lys Gln Gly Leu Ser Thr Val Ser Asn Ser Gly Leu Thr 35 40 45 Ala Glu Asp Arg Gln Leu Thr Ala Arg Ala Arg Ala Trp Asn Asn Leu 50 55 60 Asp Trp Ala Leu Tyr Val His Phe Asn Arg Ser Leu Trp Ala Arg Ile 65 70 75 80 Glu Lys Tyr Gly Gln Gly Arg Leu Gln Thr Ala Val Ala Glu Leu Arg 85 90 95 Ala Arg Arg Glu Ala Leu Ala Lys His Cys Leu Val Gly Gly Glu Ala 100 105 110 Ser Asp Pro Lys Tyr Ile Thr Asp Arg Arg Phe Arg Pro Phe Gln Phe 115 120 125 Gly Ser Ala Lys Val Leu Gly Tyr Ile Leu Arg Ser Gly Leu Ser Pro 130 135 140 Gln Asp Gln Glu Glu Cys Glu Arg Leu Ala Thr Pro Glu Leu Gln Tyr 145 150 155 160 Lys Asp Lys Leu Asp Val Lys Gln Phe Pro Pro Thr Val Ser Leu Pro 165 170 175 Leu Lys Thr Ser Arg Pro Leu Ser Pro 180 185 <210> SEQ ID NO 35 <211> LENGTH: 678 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)...(678) <221> NAME/KEY: misc_feature <222> LOCATION: (1)...(678) <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 47, 48 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 35 atg ggc ttc cct cca gga ctg gca aca gct gcc acc gcc gga ggg ann 48 Met Gly Phe Pro Pro Gly Leu Ala Thr Ala Ala Thr Ala Gly Gly Xaa 1 5 10 15 gcg aag aac cct gct gct gtg ctg ccc ctg atg ctg cca gga atg gcg 96 Ala Lys Asn Pro Ala Ala Val Leu Pro Leu Met Leu Pro Gly Met Ala 20 25 30 ggc ctg ccc aac gtg ttt ggc ttg ggc ggg ctg ttg aat aac cct ctg 144 Gly Leu Pro Asn Val Phe Gly Leu Gly Gly Leu Leu Asn Asn Pro Leu 35 40 45 tca gct gct act gga aac acc act act gct tct agt caa gga gaa ccg 192 Ser Ala Ala Thr Gly Asn Thr Thr Thr Ala Ser Ser Gln Gly Glu Pro 50 55 60 gaa gac agc act tca aaa gga gag gag aaa gga aat gag aat gaa gac 240 Glu Asp Ser Thr Ser Lys Gly Glu Glu Lys Gly Asn Glu Asn Glu Asp 65 70 75 80 gag aac aaa gac tct gag aaa agc aca gat gct gtt tcg gct gct gac 288 Glu Asn Lys Asp Ser Glu Lys Ser Thr Asp Ala Val Ser Ala Ala Asp 85 90 95 tct gcg aat gga tct gtt ggt gct gct act gcc ccg gct gga ttg ccc 336 Ser Ala Asn Gly Ser Val Gly Ala Ala Thr Ala Pro Ala Gly Leu Pro 100 105 110 tca aac ccg cta gcc ttc aac cct ttc ctc ctg tcc aca atg gcc ccg 384 Ser Asn Pro Leu Ala Phe Asn Pro Phe Leu Leu Ser Thr Met Ala Pro 115 120 125 ggc ctc ttc tac cca tcc atg ttt cta cct cca gga ctg ggg gga ttg 432 Gly Leu Phe Tyr Pro Ser Met Phe Leu Pro Pro Gly Leu Gly Gly Leu 130 135 140 acg ctg cct ggg ttc cca gca ttg gca gga ctt cag aat gcc gtg ggc 480 Thr Leu Pro Gly Phe Pro Ala Leu Ala Gly Leu Gln Asn Ala Val Gly 145 150 155 160 tcc agc gaa gaa aag gct gct gac aag gct gag gga gga ccc ttt aaa 528 Ser Ser Glu Glu Lys Ala Ala Asp Lys Ala Glu Gly Gly Pro Phe Lys 165 170 175 gat gga gag acc ctt gaa ggc agc gat gcc gag gag agc ctg gat aag 576 Asp Gly Glu Thr Leu Glu Gly Ser Asp Ala Glu Glu Ser Leu Asp Lys 180 185 190 act gca gag tcc tcc ctc tta gaa gac gaa ata gca cag ggt gaa gag 624 Thr Ala Glu Ser Ser Leu Leu Glu Asp Glu Ile Ala Gln Gly Glu Glu 195 200 205 cta gac tca ctt gat ggg ggg gat gaa ata gaa aac aat gaa aat gat 672 Leu Asp Ser Leu Asp Gly Gly Asp Glu Ile Glu Asn Asn Glu Asn Asp 210 215 220 gaa taa 678 Glu * 225 <210> SEQ ID NO 36 <211> LENGTH: 225 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: VARIANT <222> LOCATION: 16 <223> OTHER INFORMATION: Xaa = Any Amino Acid <400> SEQUENCE: 36 Met Gly Phe Pro Pro Gly Leu Ala Thr Ala Ala Thr Ala Gly Gly Xaa 1 5 10 15 Ala Lys Asn Pro Ala Ala Val Leu Pro Leu Met Leu Pro Gly Met Ala 20 25 30 Gly Leu Pro Asn Val Phe Gly Leu Gly Gly Leu Leu Asn Asn Pro Leu 35 40 45 Ser Ala Ala Thr Gly Asn Thr Thr Thr Ala Ser Ser Gln Gly Glu Pro 50 55 60 Glu Asp Ser Thr Ser Lys Gly Glu Glu Lys Gly Asn Glu Asn Glu Asp 65 70 75 80 Glu Asn Lys Asp Ser Glu Lys Ser Thr Asp Ala Val Ser Ala Ala Asp 85 90 95 Ser Ala Asn Gly Ser Val Gly Ala Ala Thr Ala Pro Ala Gly Leu Pro 100 105 110 Ser Asn Pro Leu Ala Phe Asn Pro Phe Leu Leu Ser Thr Met Ala Pro 115 120 125 Gly Leu Phe Tyr Pro Ser Met Phe Leu Pro Pro Gly Leu Gly Gly Leu 130 135 140 Thr Leu Pro Gly Phe Pro Ala Leu Ala Gly Leu Gln Asn Ala Val Gly 145 150 155 160 Ser Ser Glu Glu Lys Ala Ala Asp Lys Ala Glu Gly Gly Pro Phe Lys 165 170 175 Asp Gly Glu Thr Leu Glu Gly Ser Asp Ala Glu Glu Ser Leu Asp Lys 180 185 190 Thr Ala Glu Ser Ser Leu Leu Glu Asp Glu Ile Ala Gln Gly Glu Glu 195 200 205 Leu Asp Ser Leu Asp Gly Gly Asp Glu Ile Glu Asn Asn Glu Asn Asp 210 215 220 Glu 225 <210> SEQ ID NO 37 <211> LENGTH: 723 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)...(723) <221> NAME/KEY: misc_feature <222> LOCATION: (1)...(723) <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 359 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 37 atg att ctt cag ttt gga ttc aca act atc ttt gtg gca gct ttt ccc 48 Met Ile Leu Gln Phe Gly Phe Thr Thr Ile Phe Val Ala Ala Phe Pro 1 5 10 15 cta gca cca ctt ctg gcc tta ctg aat aac ata att gaa att cga ctt 96 Leu Ala Pro Leu Leu Ala Leu Leu Asn Asn Ile Ile Glu Ile Arg Leu 20 25 30 gat gct tac aaa ttt gtc aca cag tgg agg aga cct tta gct tca agg 144 Asp Ala Tyr Lys Phe Val Thr Gln Trp Arg Arg Pro Leu Ala Ser Arg 35 40 45 gcc aaa gac ata gga att tgg tat gga att ctt gaa ggc att gga att 192 Ala Lys Asp Ile Gly Ile Trp Tyr Gly Ile Leu Glu Gly Ile Gly Ile 50 55 60 ctc tct gtt atc aca aat gca ttt gtc ata gcg ata aca tct gac ttt 240 Leu Ser Val Ile Thr Asn Ala Phe Val Ile Ala Ile Thr Ser Asp Phe 65 70 75 80 atc cct cgc ttg gtg tat gct tat aag tat gga cct tgt gca ggc caa 288 Ile Pro Arg Leu Val Tyr Ala Tyr Lys Tyr Gly Pro Cys Ala Gly Gln 85 90 95 gga gaa gct ggg caa aag tgc atg gtt ggc tat gtg aat gcc agc ttg 336 Gly Glu Ala Gly Gln Lys Cys Met Val Gly Tyr Val Asn Ala Ser Leu 100 105 110 tct gta ttt cga att tct gac tnt gag aac cga tct gag cct gaa tct 384 Ser Val Phe Arg Ile Ser Asp Xaa Glu Asn Arg Ser Glu Pro Glu Ser 115 120 125 gat ggc agt gag ttc tcg ggg act cct ctt aag tac tgc aga tac cgg 432 Asp Gly Ser Glu Phe Ser Gly Thr Pro Leu Lys Tyr Cys Arg Tyr Arg 130 135 140 gac tac cgt gac ccg cct cat tca ctg gtg ccc tat ggc tac aca ctg 480 Asp Tyr Arg Asp Pro Pro His Ser Leu Val Pro Tyr Gly Tyr Thr Leu 145 150 155 160 cag ttt tgg cat gtc cta gct gct cga tta gct ttt atc att gtc ttt 528 Gln Phe Trp His Val Leu Ala Ala Arg Leu Ala Phe Ile Ile Val Phe 165 170 175 gag cac ctc gtg ttt tgt ata aag cac ctc att tca tat ctg atc cca 576 Glu His Leu Val Phe Cys Ile Lys His Leu Ile Ser Tyr Leu Ile Pro 180 185 190 gac ctc cca aaa gac cta agg gat cga atg aga aga gag aag tac ttg 624 Asp Leu Pro Lys Asp Leu Arg Asp Arg Met Arg Arg Glu Lys Tyr Leu 195 200 205 att cag gag atg atg tat gaa gca gaa ctg gaa cgt ctc cag aag gaa 672 Ile Gln Glu Met Met Tyr Glu Ala Glu Leu Glu Arg Leu Gln Lys Glu 210 215 220 cga aag gag agg aag aag aat gga aaa gca cac cac aac gag tgg ccg 720 Arg Lys Glu Arg Lys Lys Asn Gly Lys Ala His His Asn Glu Trp Pro 225 230 235 240 tga 723 * <210> SEQ ID NO 38 <211> LENGTH: 240 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: VARIANT <222> LOCATION: (1)...(240) <223> OTHER INFORMATION: Xaa = Any Amino Acid <221> NAME/KEY: VARIANT <222> LOCATION: 120 <223> OTHER INFORMATION: Xaa = Any Amino Acid <400> SEQUENCE: 38 Met Ile Leu Gln Phe Gly Phe Thr Thr Ile Phe Val Ala Ala Phe Pro 1 5 10 15 Leu Ala Pro Leu Leu Ala Leu Leu Asn Asn Ile Ile Glu Ile Arg Leu 20 25 30 Asp Ala Tyr Lys Phe Val Thr Gln Trp Arg Arg Pro Leu Ala Ser Arg 35 40 45 Ala Lys Asp Ile Gly Ile Trp Tyr Gly Ile Leu Glu Gly Ile Gly Ile 50 55 60 Leu Ser Val Ile Thr Asn Ala Phe Val Ile Ala Ile Thr Ser Asp Phe 65 70 75 80 Ile Pro Arg Leu Val Tyr Ala Tyr Lys Tyr Gly Pro Cys Ala Gly Gln 85 90 95 Gly Glu Ala Gly Gln Lys Cys Met Val Gly Tyr Val Asn Ala Ser Leu 100 105 110 Ser Val Phe Arg Ile Ser Asp Xaa Glu Asn Arg Ser Glu Pro Glu Ser 115 120 125 Asp Gly Ser Glu Phe Ser Gly Thr Pro Leu Lys Tyr Cys Arg Tyr Arg 130 135 140 Asp Tyr Arg Asp Pro Pro His Ser Leu Val Pro Tyr Gly Tyr Thr Leu 145 150 155 160 Gln Phe Trp His Val Leu Ala Ala Arg Leu Ala Phe Ile Ile Val Phe 165 170 175 Glu His Leu Val Phe Cys Ile Lys His Leu Ile Ser Tyr Leu Ile Pro 180 185 190 Asp Leu Pro Lys Asp Leu Arg Asp Arg Met Arg Arg Glu Lys Tyr Leu 195 200 205 Ile Gln Glu Met Met Tyr Glu Ala Glu Leu Glu Arg Leu Gln Lys Glu 210 215 220 Arg Lys Glu Arg Lys Lys Asn Gly Lys Ala His His Asn Glu Trp Pro 225 230 235 240 <210> SEQ ID NO 39 <211> LENGTH: 450 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)...(450) <400> SEQUENCE: 39 atg tct atg gat gtg aca ttc ctg ggg acg ggt gca gca tac cca tct 48 Met Ser Met Asp Val Thr Phe Leu Gly Thr Gly Ala Ala Tyr Pro Ser 1 5 10 15 cca acc cgg ggt gcc tct gct gtg gtc ctt cgg tgt gaa ggc gag tgc 96 Pro Thr Arg Gly Ala Ser Ala Val Val Leu Arg Cys Glu Gly Glu Cys 20 25 30 tgg ctc ttt gac tgt ggg gag gga aca cag aca cag ctt atg aaa agc 144 Trp Leu Phe Asp Cys Gly Glu Gly Thr Gln Thr Gln Leu Met Lys Ser 35 40 45 caa ctt aaa gca ggg aga att acc aag atc ttc atc aca cac ctt cat 192 Gln Leu Lys Ala Gly Arg Ile Thr Lys Ile Phe Ile Thr His Leu His 50 55 60 gga gac cat ttc ttt ggc ctt cct ggg ctc ctc tgc aca atc agc ctg 240 Gly Asp His Phe Phe Gly Leu Pro Gly Leu Leu Cys Thr Ile Ser Leu 65 70 75 80 cag agt ggc tcc atg gtg tcc aaa cag cct att gaa atc tat ggc cct 288 Gln Ser Gly Ser Met Val Ser Lys Gln Pro Ile Glu Ile Tyr Gly Pro 85 90 95 gta ggg ctt cgg gac ttt atc tgg cga acc atg gaa ctc tct cac acg 336 Val Gly Leu Arg Asp Phe Ile Trp Arg Thr Met Glu Leu Ser His Thr 100 105 110 gag ctg gtc ttc cat tat gtg gtt cat gaa ctg gtt cct aca gca gat 384 Glu Leu Val Phe His Tyr Val Val His Glu Leu Val Pro Thr Ala Asp 115 120 125 caa tgt cct gca gaa gaa tgt tca att tcc tct ggg ttc tgg ggc ttc 432 Gln Cys Pro Ala Glu Glu Cys Ser Ile Ser Ser Gly Phe Trp Gly Phe 130 135 140 tct ggc caa att ttt tga 450 Ser Gly Gln Ile Phe * 145 <210> SEQ ID NO 40 <211> LENGTH: 149 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 40 Met Ser Met Asp Val Thr Phe Leu Gly Thr Gly Ala Ala Tyr Pro Ser 1 5 10 15 Pro Thr Arg Gly Ala Ser Ala Val Val Leu Arg Cys Glu Gly Glu Cys 20 25 30 Trp Leu Phe Asp Cys Gly Glu Gly Thr Gln Thr Gln Leu Met Lys Ser 35 40 45 Gln Leu Lys Ala Gly Arg Ile Thr Lys Ile Phe Ile Thr His Leu His 50 55 60 Gly Asp His Phe Phe Gly Leu Pro Gly Leu Leu Cys Thr Ile Ser Leu 65 70 75 80 Gln Ser Gly Ser Met Val Ser Lys Gln Pro Ile Glu Ile Tyr Gly Pro 85 90 95 Val Gly Leu Arg Asp Phe Ile Trp Arg Thr Met Glu Leu Ser His Thr 100 105 110 Glu Leu Val Phe His Tyr Val Val His Glu Leu Val Pro Thr Ala Asp 115 120 125 Gln Cys Pro Ala Glu Glu Cys Ser Ile Ser Ser Gly Phe Trp Gly Phe 130 135 140 Ser Gly Gln Ile Phe 145 <210> SEQ ID NO 41 <211> LENGTH: 615 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)...(615) <400> SEQUENCE: 41 atg gga gct gat ggc ttc gtg ccc ctg ggc acc ctc ctg cag ttg ccc 48 Met Gly Ala Asp Gly Phe Val Pro Leu Gly Thr Leu Leu Gln Leu Pro 1 5 10 15 cag ttc cgc ggc ttc tct gct gaa gat gtg cag cgc gtg gtg gac acc 96 Gln Phe Arg Gly Phe Ser Ala Glu Asp Val Gln Arg Val Val Asp Thr 20 25 30 aat agg aag cag cgg ttc gcc ctg cag ctg ggg gat ccc agc act ggc 144 Asn Arg Lys Gln Arg Phe Ala Leu Gln Leu Gly Asp Pro Ser Thr Gly 35 40 45 ctt ctc atc cgg gcc aac cag ggc cat tcc ctg cag gta cct aag ttg 192 Leu Leu Ile Arg Ala Asn Gln Gly His Ser Leu Gln Val Pro Lys Leu 50 55 60 gag ctg atg ccc ctg gag aca ccg cag gcc ctg ccc ccg atg cta gtc 240 Glu Leu Met Pro Leu Glu Thr Pro Gln Ala Leu Pro Pro Met Leu Val 65 70 75 80 cat ggt aca ttc tgg aag cac tgg cca tcc atc cta ctc aaa ggc ctg 288 His Gly Thr Phe Trp Lys His Trp Pro Ser Ile Leu Leu Lys Gly Leu 85 90 95 tcc tgc cag gga agg acg cac att cac ctg gcc cca gga ctg cct gga 336 Ser Cys Gln Gly Arg Thr His Ile His Leu Ala Pro Gly Leu Pro Gly 100 105 110 gac ccc ggt atc atc agt ggc atg cgg tcc cat tgt gaa ata gct gtg 384 Asp Pro Gly Ile Ile Ser Gly Met Arg Ser His Cys Glu Ile Ala Val 115 120 125 ttc atc gat gga ccc ctg gct ctg gca gat gga ata ccc ttc ttc cgc 432 Phe Ile Asp Gly Pro Leu Ala Leu Ala Asp Gly Ile Pro Phe Phe Arg 130 135 140 tct gcc aat ggg gtg att ctg act cca ggg aat act gat ggc ttc ctc 480 Ser Ala Asn Gly Val Ile Leu Thr Pro Gly Asn Thr Asp Gly Phe Leu 145 150 155 160 ctt ccc aag tac ttc aag gag gcc ctg cag cta cgc cct acc cga aag 528 Leu Pro Lys Tyr Phe Lys Glu Ala Leu Gln Leu Arg Pro Thr Arg Lys 165 170 175 ccc ctt tcc ttg gct ggt gat gaa gag aca gag tgt cag agt agc ccc 576 Pro Leu Ser Leu Ala Gly Asp Glu Glu Thr Glu Cys Gln Ser Ser Pro 180 185 190 aag cac agc tcc aga gaa agg agg agg atc caa caa taa 615 Lys His Ser Ser Arg Glu Arg Arg Arg Ile Gln Gln * 195 200 <210> SEQ ID NO 42 <211> LENGTH: 204 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 42 Met Gly Ala Asp Gly Phe Val Pro Leu Gly Thr Leu Leu Gln Leu Pro 1 5 10 15 Gln Phe Arg Gly Phe Ser Ala Glu Asp Val Gln Arg Val Val Asp Thr 20 25 30 Asn Arg Lys Gln Arg Phe Ala Leu Gln Leu Gly Asp Pro Ser Thr Gly 35 40 45 Leu Leu Ile Arg Ala Asn Gln Gly His Ser Leu Gln Val Pro Lys Leu 50 55 60 Glu Leu Met Pro Leu Glu Thr Pro Gln Ala Leu Pro Pro Met Leu Val 65 70 75 80 His Gly Thr Phe Trp Lys His Trp Pro Ser Ile Leu Leu Lys Gly Leu 85 90 95 Ser Cys Gln Gly Arg Thr His Ile His Leu Ala Pro Gly Leu Pro Gly 100 105 110 Asp Pro Gly Ile Ile Ser Gly Met Arg Ser His Cys Glu Ile Ala Val 115 120 125 Phe Ile Asp Gly Pro Leu Ala Leu Ala Asp Gly Ile Pro Phe Phe Arg 130 135 140 Ser Ala Asn Gly Val Ile Leu Thr Pro Gly Asn Thr Asp Gly Phe Leu 145 150 155 160 Leu Pro Lys Tyr Phe Lys Glu Ala Leu Gln Leu Arg Pro Thr Arg Lys 165 170 175 Pro Leu Ser Leu Ala Gly Asp Glu Glu Thr Glu Cys Gln Ser Ser Pro 180 185 190 Lys His Ser Ser Arg Glu Arg Arg Arg Ile Gln Gln 195 200 <210> SEQ ID NO 43 <211> LENGTH: 828 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)...(828) <400> SEQUENCE: 43 atg agt gaa gag cct gac gct cta tcg gta gtt aac cag tta cgg gat 48 Met Ser Glu Glu Pro Asp Ala Leu Ser Val Val Asn Gln Leu Arg Asp 1 5 10 15 cta gca gca gat ccg tta aac aga aga gcc atc gtc cag gat cag gga 96 Leu Ala Ala Asp Pro Leu Asn Arg Arg Ala Ile Val Gln Asp Gln Gly 20 25 30 tgt ctg cct ggc ctt att tta ttt atg gac cat ccc aac cct cca gtc 144 Cys Leu Pro Gly Leu Ile Leu Phe Met Asp His Pro Asn Pro Pro Val 35 40 45 gtc cac tcc gct ttg ctt gct ctt cga tac ttg gca gaa tgc cgt gca 192 Val His Ser Ala Leu Leu Ala Leu Arg Tyr Leu Ala Glu Cys Arg Ala 50 55 60 aac aga gaa aag atg aaa gga gaa ctg ggt atg atg ttg agc tta caa 240 Asn Arg Glu Lys Met Lys Gly Glu Leu Gly Met Met Leu Ser Leu Gln 65 70 75 80 aat gtt ata cag aaa act aca act cca gga gaa aca aaa ctt ctg gcc 288 Asn Val Ile Gln Lys Thr Thr Thr Pro Gly Glu Thr Lys Leu Leu Ala 85 90 95 tct gaa atc tat gac att ctt cag tcc tcc aat atg gca gat ggt gat 336 Ser Glu Ile Tyr Asp Ile Leu Gln Ser Ser Asn Met Ala Asp Gly Asp 100 105 110 agt ttt aat gag atg aat tca cgt cga agg aaa gct caa ttt ttt ctg 384 Ser Phe Asn Glu Met Asn Ser Arg Arg Arg Lys Ala Gln Phe Phe Leu 115 120 125 gga act aca aac aaa cgt gcc aaa aca gtg gtt ttg cat ata gat ggc 432 Gly Thr Thr Asn Lys Arg Ala Lys Thr Val Val Leu His Ile Asp Gly 130 135 140 ctt gat gat acg tct cgg aga aat cta tgt gaa gag gct ttg tta aaa 480 Leu Asp Asp Thr Ser Arg Arg Asn Leu Cys Glu Glu Ala Leu Leu Lys 145 150 155 160 att aaa ggt gtt att agc ttt act ttt caa atg gct gtt caa agg tgt 528 Ile Lys Gly Val Ile Ser Phe Thr Phe Gln Met Ala Val Gln Arg Cys 165 170 175 gtg gtg cga atc cgt tca gat ttg aaa gct gag gct ttg gca tca gca 576 Val Val Arg Ile Arg Ser Asp Leu Lys Ala Glu Ala Leu Ala Ser Ala 180 185 190 ata gca tca acc aag gtt atg aaa gct cag caa gtt gtg aaa agt gaa 624 Ile Ala Ser Thr Lys Val Met Lys Ala Gln Gln Val Val Lys Ser Glu 195 200 205 agt gga gaa gag atg ttg gtc cca ttc caa gat act cct gtg gaa gtt 672 Ser Gly Glu Glu Met Leu Val Pro Phe Gln Asp Thr Pro Val Glu Val 210 215 220 gaa cag aac aca gag cta cct gac tac ctg cct gag gat gag agt ccc 720 Glu Gln Asn Thr Glu Leu Pro Asp Tyr Leu Pro Glu Asp Glu Ser Pro 225 230 235 240 aca aag gaa cag gac aaa gcg gtg tcc cgg gtc ggc tca cac cca gaa 768 Thr Lys Glu Gln Asp Lys Ala Val Ser Arg Val Gly Ser His Pro Glu 245 250 255 ggt gga gct agc tgg ctt agc aca gct gca aac ttt tta tcc aga tca 816 Gly Gly Ala Ser Trp Leu Ser Thr Ala Ala Asn Phe Leu Ser Arg Ser 260 265 270 ttt tat tgg tga 828 Phe Tyr Trp * 275 <210> SEQ ID NO 44 <211> LENGTH: 275 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 44 Met Ser Glu Glu Pro Asp Ala Leu Ser Val Val Asn Gln Leu Arg Asp 1 5 10 15 Leu Ala Ala Asp Pro Leu Asn Arg Arg Ala Ile Val Gln Asp Gln Gly 20 25 30 Cys Leu Pro Gly Leu Ile Leu Phe Met Asp His Pro Asn Pro Pro Val 35 40 45 Val His Ser Ala Leu Leu Ala Leu Arg Tyr Leu Ala Glu Cys Arg Ala 50 55 60 Asn Arg Glu Lys Met Lys Gly Glu Leu Gly Met Met Leu Ser Leu Gln 65 70 75 80 Asn Val Ile Gln Lys Thr Thr Thr Pro Gly Glu Thr Lys Leu Leu Ala 85 90 95 Ser Glu Ile Tyr Asp Ile Leu Gln Ser Ser Asn Met Ala Asp Gly Asp 100 105 110 Ser Phe Asn Glu Met Asn Ser Arg Arg Arg Lys Ala Gln Phe Phe Leu 115 120 125 Gly Thr Thr Asn Lys Arg Ala Lys Thr Val Val Leu His Ile Asp Gly 130 135 140 Leu Asp Asp Thr Ser Arg Arg Asn Leu Cys Glu Glu Ala Leu Leu Lys 145 150 155 160 Ile Lys Gly Val Ile Ser Phe Thr Phe Gln Met Ala Val Gln Arg Cys 165 170 175 Val Val Arg Ile Arg Ser Asp Leu Lys Ala Glu Ala Leu Ala Ser Ala 180 185 190 Ile Ala Ser Thr Lys Val Met Lys Ala Gln Gln Val Val Lys Ser Glu 195 200 205 Ser Gly Glu Glu Met Leu Val Pro Phe Gln Asp Thr Pro Val Glu Val 210 215 220 Glu Gln Asn Thr Glu Leu Pro Asp Tyr Leu Pro Glu Asp Glu Ser Pro 225 230 235 240 Thr Lys Glu Gln Asp Lys Ala Val Ser Arg Val Gly Ser His Pro Glu 245 250 255 Gly Gly Ala Ser Trp Leu Ser Thr Ala Ala Asn Phe Leu Ser Arg Ser 260 265 270 Phe Tyr Trp 275 <210> SEQ ID NO 45 <211> LENGTH: 423 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)...(423) <221> NAME/KEY: misc_feature <222> LOCATION: (1)...(423) <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 214 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 45 atg ggc cgg gtc tca ggg ctt gtg ccc tct cgc ttc ctg acg ctc ctg 48 Met Gly Arg Val Ser Gly Leu Val Pro Ser Arg Phe Leu Thr Leu Leu 1 5 10 15 gcg cat ctg gtg gtc gtc atc acc tta ttc tgg tcc cgg gac agc aac 96 Ala His Leu Val Val Val Ile Thr Leu Phe Trp Ser Arg Asp Ser Asn 20 25 30 ata cag gcc tgc ctg cct ctc acg ttc acc ccc gag gag tat gac aag 144 Ile Gln Ala Cys Leu Pro Leu Thr Phe Thr Pro Glu Glu Tyr Asp Lys 35 40 45 cag gac att cag ctg gtg gcc gcg ctc tct gtc acc ctg ggc ctc ttt 192 Gln Asp Ile Gln Leu Val Ala Ala Leu Ser Val Thr Leu Gly Leu Phe 50 55 60 gca gtg gag ctg gcc ggt ttc ntc tca gga gtc tcc atg ttc aac agc 240 Ala Val Glu Leu Ala Gly Phe Xaa Ser Gly Val Ser Met Phe Asn Ser 65 70 75 80 acc cag agc ctc atc tcc att ggg gct cac tgt agt gca tcc gtg gcc 288 Thr Gln Ser Leu Ile Ser Ile Gly Ala His Cys Ser Ala Ser Val Ala 85 90 95 ctg tcc ttc ttc ata ttc gag cgt tgg gag tgc act acg tat tgg tac 336 Leu Ser Phe Phe Ile Phe Glu Arg Trp Glu Cys Thr Thr Tyr Trp Tyr 100 105 110 att ttt gtc ttc tgc agt gcc ctt cca gct gtc act gaa atg gct tta 384 Ile Phe Val Phe Cys Ser Ala Leu Pro Ala Val Thr Glu Met Ala Leu 115 120 125 ttc gtc acc gtc ttt ggg ctg aaa aag aaa ccc ttc tga 423 Phe Val Thr Val Phe Gly Leu Lys Lys Lys Pro Phe * 130 135 140 <210> SEQ ID NO 46 <211> LENGTH: 140 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: VARIANT <222> LOCATION: (1)...(140) <223> OTHER INFORMATION: Xaa = Any Amino Acid <221> NAME/KEY: VARIANT <222> LOCATION: 72 <223> OTHER INFORMATION: Xaa = Any Amino Acid <400> SEQUENCE: 46 Met Gly Arg Val Ser Gly Leu Val Pro Ser Arg Phe Leu Thr Leu Leu 1 5 10 15 Ala His Leu Val Val Val Ile Thr Leu Phe Trp Ser Arg Asp Ser Asn 20 25 30 Ile Gln Ala Cys Leu Pro Leu Thr Phe Thr Pro Glu Glu Tyr Asp Lys 35 40 45 Gln Asp Ile Gln Leu Val Ala Ala Leu Ser Val Thr Leu Gly Leu Phe 50 55 60 Ala Val Glu Leu Ala Gly Phe Xaa Ser Gly Val Ser Met Phe Asn Ser 65 70 75 80 Thr Gln Ser Leu Ile Ser Ile Gly Ala His Cys Ser Ala Ser Val Ala 85 90 95 Leu Ser Phe Phe Ile Phe Glu Arg Trp Glu Cys Thr Thr Tyr Trp Tyr 100 105 110 Ile Phe Val Phe Cys Ser Ala Leu Pro Ala Val Thr Glu Met Ala Leu 115 120 125 Phe Val Thr Val Phe Gly Leu Lys Lys Lys Pro Phe 130 135 140 <210> SEQ ID NO 47 <211> LENGTH: 609 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)...(609) <400> SEQUENCE: 47 atg aac ctg tgt ctt cag gct ccc ttt gtc tct gag gtt tgg gct gtg 48 Met Asn Leu Cys Leu Gln Ala Pro Phe Val Ser Glu Val Trp Ala Val 1 5 10 15 gag gtg agc aga agg tgc ctg tct tta cta aac agc cag gat gga gga 96 Glu Val Ser Arg Arg Cys Leu Ser Leu Leu Asn Ser Gln Asp Gly Gly 20 25 30 atc ctg aca aga gct gct ggt gtt ctg agc cgg acc ctt tct tcc tct 144 Ile Leu Thr Arg Ala Ala Gly Val Leu Ser Arg Thr Leu Ser Ser Ser 35 40 45 ctg aaa att gtt gag gag gcc ttg cga gca gga gtg gta aag aaa atg 192 Leu Lys Ile Val Glu Glu Ala Leu Arg Ala Gly Val Val Lys Lys Met 50 55 60 atg aaa ttc ctg aag aca gga ggt gag act gca tca cgt tat gct ata 240 Met Lys Phe Leu Lys Thr Gly Gly Glu Thr Ala Ser Arg Tyr Ala Ile 65 70 75 80 aag ata cta gct atc tgc acg aat agt tat cat gaa gct cgg gaa gaa 288 Lys Ile Leu Ala Ile Cys Thr Asn Ser Tyr His Glu Ala Arg Glu Glu 85 90 95 gta ata aga ctg gat aaa aag ttg agc gtt atg atg aag ctg ctc agc 336 Val Ile Arg Leu Asp Lys Lys Leu Ser Val Met Met Lys Leu Leu Ser 100 105 110 tcg gag gat gag gtt ctg gtg ggc aac gct gcc ctc tgc ctt ggt aac 384 Ser Glu Asp Glu Val Leu Val Gly Asn Ala Ala Leu Cys Leu Gly Asn 115 120 125 tgc atg gag gtg ccc aac gtt gcg tct tcc ctg cta aag acg gac ctt 432 Cys Met Glu Val Pro Asn Val Ala Ser Ser Leu Leu Lys Thr Asp Leu 130 135 140 ttg cag gtc ttg tta aag ctt gca ggc agt gac aca cag aag acg gcc 480 Leu Gln Val Leu Leu Lys Leu Ala Gly Ser Asp Thr Gln Lys Thr Ala 145 150 155 160 gtg cag gtg aac gca ggc att gct ctg ggg aag ctg tgc aca gct gag 528 Val Gln Val Asn Ala Gly Ile Ala Leu Gly Lys Leu Cys Thr Ala Glu 165 170 175 ccc aga ttt gct gct caa ctg aga aag ctt cat ggc cta gaa att ctc 576 Pro Arg Phe Ala Ala Gln Leu Arg Lys Leu His Gly Leu Glu Ile Leu 180 185 190 aac tct acg atg aaa tac atc agt gat tct tga 609 Asn Ser Thr Met Lys Tyr Ile Ser Asp Ser * 195 200 <210> SEQ ID NO 48 <211> LENGTH: 202 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 48 Met Asn Leu Cys Leu Gln Ala Pro Phe Val Ser Glu Val Trp Ala Val 1 5 10 15 Glu Val Ser Arg Arg Cys Leu Ser Leu Leu Asn Ser Gln Asp Gly Gly 20 25 30 Ile Leu Thr Arg Ala Ala Gly Val Leu Ser Arg Thr Leu Ser Ser Ser 35 40 45 Leu Lys Ile Val Glu Glu Ala Leu Arg Ala Gly Val Val Lys Lys Met 50 55 60 Met Lys Phe Leu Lys Thr Gly Gly Glu Thr Ala Ser Arg Tyr Ala Ile 65 70 75 80 Lys Ile Leu Ala Ile Cys Thr Asn Ser Tyr His Glu Ala Arg Glu Glu 85 90 95 Val Ile Arg Leu Asp Lys Lys Leu Ser Val Met Met Lys Leu Leu Ser 100 105 110 Ser Glu Asp Glu Val Leu Val Gly Asn Ala Ala Leu Cys Leu Gly Asn 115 120 125 Cys Met Glu Val Pro Asn Val Ala Ser Ser Leu Leu Lys Thr Asp Leu 130 135 140 Leu Gln Val Leu Leu Lys Leu Ala Gly Ser Asp Thr Gln Lys Thr Ala 145 150 155 160 Val Gln Val Asn Ala Gly Ile Ala Leu Gly Lys Leu Cys Thr Ala Glu 165 170 175 Pro Arg Phe Ala Ala Gln Leu Arg Lys Leu His Gly Leu Glu Ile Leu 180 185 190 Asn Ser Thr Met Lys Tyr Ile Ser Asp Ser 195 200 <210> SEQ ID NO 49 <211> LENGTH: 1065 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)...(1065) <221> NAME/KEY: misc_feature <222> LOCATION: (1)...(1065) <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 153 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 49 atg gag cca gat ggc tac aag gta gta ttc gtg cgc cgg agc ccg ctg 48 Met Glu Pro Asp Gly Tyr Lys Val Val Phe Val Arg Arg Ser Pro Leu 1 5 10 15 gtg cta gtg gcg gtg gct cgt acg cgg cag tcg gca caa gag ctg gcg 96 Val Leu Val Ala Val Ala Arg Thr Arg Gln Ser Ala Gln Glu Leu Ala 20 25 30 cag gag ctg ctc tac atc tac tac cag atc cta agc ctt ctt acc ggt 144 Gln Glu Leu Leu Tyr Ile Tyr Tyr Gln Ile Leu Ser Leu Leu Thr Gly 35 40 45 gcg caa tgn agc cac atc ttc cag cag aag cag aac tat gat ttg cgg 192 Ala Gln Xaa Ser His Ile Phe Gln Gln Lys Gln Asn Tyr Asp Leu Arg 50 55 60 cgc cta ctc tcg ggc tca gag cgc atc acc gac aac ctg ctg cag ctc 240 Arg Leu Leu Ser Gly Ser Glu Arg Ile Thr Asp Asn Leu Leu Gln Leu 65 70 75 80 atg gca cga gac ccc agc ttc ctg atg ggg gcg gca cgg tgc ctg ccc 288 Met Ala Arg Asp Pro Ser Phe Leu Met Gly Ala Ala Arg Cys Leu Pro 85 90 95 ctg gcg gcg gcc gtg cgc gac act gtg agc gcc acc ctg cag cag gcg 336 Leu Ala Ala Ala Val Arg Asp Thr Val Ser Ala Thr Leu Gln Gln Ala 100 105 110 cgt gcg cgc agc ctg gtc ttc tcc atc ctg ctg gcc cgc aac cag ctc 384 Arg Ala Arg Ser Leu Val Phe Ser Ile Leu Leu Ala Arg Asn Gln Leu 115 120 125 gtg gca ctc gtg cgc cga aag gac caa ttt ctg cac ccc atc gac ctg 432 Val Ala Leu Val Arg Arg Lys Asp Gln Phe Leu His Pro Ile Asp Leu 130 135 140 cac ctg ctc ttc aac ctc att agt tcc tcc tcg tcc ttt cgc gag ggc 480 His Leu Leu Phe Asn Leu Ile Ser Ser Ser Ser Ser Phe Arg Glu Gly 145 150 155 160 gag gcc tgg acg ccc gtg tgc ctg ccc aaa ttc aac gca gcc ggc ttc 528 Glu Ala Trp Thr Pro Val Cys Leu Pro Lys Phe Asn Ala Ala Gly Phe 165 170 175 ttc cac gca cac atc tct tac cta gag cct gac act gac ctc tgc ctg 576 Phe His Ala His Ile Ser Tyr Leu Glu Pro Asp Thr Asp Leu Cys Leu 180 185 190 ctg ctt gtc tcc act gac cgt gag gac ttc ttt gca gtc tct gac tgc 624 Leu Leu Val Ser Thr Asp Arg Glu Asp Phe Phe Ala Val Ser Asp Cys 195 200 205 cgc cgc cgc ttc cag gag cgc ctt cgc aag cgc gga gcc cac ctg gcc 672 Arg Arg Arg Phe Gln Glu Arg Leu Arg Lys Arg Gly Ala His Leu Ala 210 215 220 ctg cga gag gca ctg cgc aca ccc tac tac agc gtt gcc caa gtg ggc 720 Leu Arg Glu Ala Leu Arg Thr Pro Tyr Tyr Ser Val Ala Gln Val Gly 225 230 235 240 atc cct gac ctg cgt cac ttc ctc tat aag tca aag agc tcg gga ctc 768 Ile Pro Asp Leu Arg His Phe Leu Tyr Lys Ser Lys Ser Ser Gly Leu 245 250 255 ttc acc agc cct gag att gag gcc cca tac acc agt gaa gag gag cag 816 Phe Thr Ser Pro Glu Ile Glu Ala Pro Tyr Thr Ser Glu Glu Glu Gln 260 265 270 gag cgg ctg ctg ggc ctc tac cag tac ttg cac agt cgt gcc cac aat 864 Glu Arg Leu Leu Gly Leu Tyr Gln Tyr Leu His Ser Arg Ala His Asn 275 280 285 gcc tct cgc cca ctc aag acc att tac tac acg ggc ccc aac gag aac 912 Ala Ser Arg Pro Leu Lys Thr Ile Tyr Tyr Thr Gly Pro Asn Glu Asn 290 295 300 ctc ctg gcc tgg gtg aca ggc gcc ttt gag ctc tac atg tgt tac agc 960 Leu Leu Ala Trp Val Thr Gly Ala Phe Glu Leu Tyr Met Cys Tyr Ser 305 310 315 320 ccc ctg ggg acc aag gcg tca gcc gtc agt gcc atc cat aag ctg atg 1008 Pro Leu Gly Thr Lys Ala Ser Ala Val Ser Ala Ile His Lys Leu Met 325 330 335 cgc tgg atc cgc aaa gag gaa gac cgc ctc ttc att ctc acg ccc ctc 1056 Arg Trp Ile Arg Lys Glu Glu Asp Arg Leu Phe Ile Leu Thr Pro Leu 340 345 350 acc tat tga 1065 Thr Tyr * <210> SEQ ID NO 50 <211> LENGTH: 354 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: VARIANT <222> LOCATION: (1)...(354) <223> OTHER INFORMATION: Xaa = Any Amino Acid <221> NAME/KEY: VARIANT <222> LOCATION: 51 <223> OTHER INFORMATION: Xaa = Any Amino Acid <400> SEQUENCE: 50 Met Glu Pro Asp Gly Tyr Lys Val Val Phe Val Arg Arg Ser Pro Leu 1 5 10 15 Val Leu Val Ala Val Ala Arg Thr Arg Gln Ser Ala Gln Glu Leu Ala 20 25 30 Gln Glu Leu Leu Tyr Ile Tyr Tyr Gln Ile Leu Ser Leu Leu Thr Gly 35 40 45 Ala Gln Xaa Ser His Ile Phe Gln Gln Lys Gln Asn Tyr Asp Leu Arg 50 55 60 Arg Leu Leu Ser Gly Ser Glu Arg Ile Thr Asp Asn Leu Leu Gln Leu 65 70 75 80 Met Ala Arg Asp Pro Ser Phe Leu Met Gly Ala Ala Arg Cys Leu Pro 85 90 95 Leu Ala Ala Ala Val Arg Asp Thr Val Ser Ala Thr Leu Gln Gln Ala 100 105 110 Arg Ala Arg Ser Leu Val Phe Ser Ile Leu Leu Ala Arg Asn Gln Leu 115 120 125 Val Ala Leu Val Arg Arg Lys Asp Gln Phe Leu His Pro Ile Asp Leu 130 135 140 His Leu Leu Phe Asn Leu Ile Ser Ser Ser Ser Ser Phe Arg Glu Gly 145 150 155 160 Glu Ala Trp Thr Pro Val Cys Leu Pro Lys Phe Asn Ala Ala Gly Phe 165 170 175 Phe His Ala His Ile Ser Tyr Leu Glu Pro Asp Thr Asp Leu Cys Leu 180 185 190 Leu Leu Val Ser Thr Asp Arg Glu Asp Phe Phe Ala Val Ser Asp Cys 195 200 205 Arg Arg Arg Phe Gln Glu Arg Leu Arg Lys Arg Gly Ala His Leu Ala 210 215 220 Leu Arg Glu Ala Leu Arg Thr Pro Tyr Tyr Ser Val Ala Gln Val Gly 225 230 235 240 Ile Pro Asp Leu Arg His Phe Leu Tyr Lys Ser Lys Ser Ser Gly Leu 245 250 255 Phe Thr Ser Pro Glu Ile Glu Ala Pro Tyr Thr Ser Glu Glu Glu Gln 260 265 270 Glu Arg Leu Leu Gly Leu Tyr Gln Tyr Leu His Ser Arg Ala His Asn 275 280 285 Ala Ser Arg Pro Leu Lys Thr Ile Tyr Tyr Thr Gly Pro Asn Glu Asn 290 295 300 Leu Leu Ala Trp Val Thr Gly Ala Phe Glu Leu Tyr Met Cys Tyr Ser 305 310 315 320 Pro Leu Gly Thr Lys Ala Ser Ala Val Ser Ala Ile His Lys Leu Met 325 330 335 Arg Trp Ile Arg Lys Glu Glu Asp Arg Leu Phe Ile Leu Thr Pro Leu 340 345 350 Thr Tyr <210> SEQ ID NO 51 <211> LENGTH: 993 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)...(993) <400> SEQUENCE: 51 atg agc ctt ttg ctg tac tat gcc ctc cct gcc ctg ggc agc tat gcc 48 Met Ser Leu Leu Leu Tyr Tyr Ala Leu Pro Ala Leu Gly Ser Tyr Ala 1 5 10 15 atg ctc tcc atc ttc ttc ctg cgc cgg cct cat ctg ctg cac acg ccc 96 Met Leu Ser Ile Phe Phe Leu Arg Arg Pro His Leu Leu His Thr Pro 20 25 30 agg gct ccc acc ttc cgc atc cgc ctg ggg gcc cac cga gga gga tct 144 Arg Ala Pro Thr Phe Arg Ile Arg Leu Gly Ala His Arg Gly Gly Ser 35 40 45 gga gag ctg ctg gag aac acc atg gag gcc atg gag aac tcc atg gcc 192 Gly Glu Leu Leu Glu Asn Thr Met Glu Ala Met Glu Asn Ser Met Ala 50 55 60 cag cgc tcg gac ctc ctg gag ctc gac tgt cag ctg aca cgg gac aga 240 Gln Arg Ser Asp Leu Leu Glu Leu Asp Cys Gln Leu Thr Arg Asp Arg 65 70 75 80 gtg gtg gtg gtg tca cat gat gag aac ctg tgc cgc cag tcg ggc cta 288 Val Val Val Val Ser His Asp Glu Asn Leu Cys Arg Gln Ser Gly Leu 85 90 95 aac agg gat gtg ggc agc ctg gac ttc gag gac ctg ccc ctc tac aag 336 Asn Arg Asp Val Gly Ser Leu Asp Phe Glu Asp Leu Pro Leu Tyr Lys 100 105 110 gag aag ctg gag gtt tac ttc tct cca ggc cac ttt gct cac ggg tca 384 Glu Lys Leu Glu Val Tyr Phe Ser Pro Gly His Phe Ala His Gly Ser 115 120 125 gac cgg cgc atg gtt cgt ctg gag gac ctg ttc cag agg ttt cca agg 432 Asp Arg Arg Met Val Arg Leu Glu Asp Leu Phe Gln Arg Phe Pro Arg 130 135 140 aca ccc atg agc gta gag atc aaa ggg aag aac gaa gag ctc atc cgt 480 Thr Pro Met Ser Val Glu Ile Lys Gly Lys Asn Glu Glu Leu Ile Arg 145 150 155 160 gag ata gca ggc ttg gtg aga cgc tat gac cgt aat gaa atc acc atc 528 Glu Ile Ala Gly Leu Val Arg Arg Tyr Asp Arg Asn Glu Ile Thr Ile 165 170 175 tgg gcc tcg gag aag agc tcg gtc atg aag aaa tgc aag gct gcc aac 576 Trp Ala Ser Glu Lys Ser Ser Val Met Lys Lys Cys Lys Ala Ala Asn 180 185 190 ccc gag atg ccc ctg tcc ttc aca ata agc cga gga ttc tgg gtg ctg 624 Pro Glu Met Pro Leu Ser Phe Thr Ile Ser Arg Gly Phe Trp Val Leu 195 200 205 ctt tcc tac tac ctg ggg ctg ctg ccc ttc atc cca atc cct gag aag 672 Leu Ser Tyr Tyr Leu Gly Leu Leu Pro Phe Ile Pro Ile Pro Glu Lys 210 215 220 ttc ttc ttc tgc ttc ctg ccc aac atc atc aac agg acc tat ttc cca 720 Phe Phe Phe Cys Phe Leu Pro Asn Ile Ile Asn Arg Thr Tyr Phe Pro 225 230 235 240 ttt tcc tgc tct tgc ctg aac cag tta ttg gct gtg gtt tcg aaa tgg 768 Phe Ser Cys Ser Cys Leu Asn Gln Leu Leu Ala Val Val Ser Lys Trp 245 250 255 ctg atc atg agg aag agt ctg atc cga cac ttg gag gag cga ggg gtg 816 Leu Ile Met Arg Lys Ser Leu Ile Arg His Leu Glu Glu Arg Gly Val 260 265 270 cag gtg gtc ttt tgg tgc ctt aat gaa gag tcg gat ttt gaa gca gcc 864 Gln Val Val Phe Trp Cys Leu Asn Glu Glu Ser Asp Phe Glu Ala Ala 275 280 285 ttc agc gtg gga gcc act ggc gtc ata acg gat tat ccc aca gcc tgc 912 Phe Ser Val Gly Ala Thr Gly Val Ile Thr Asp Tyr Pro Thr Ala Cys 290 295 300 ggc act acc tgg aca acc atg gac cag ctg ccc gga cct cct aag tcc 960 Gly Thr Thr Trp Thr Thr Met Asp Gln Leu Pro Gly Pro Pro Lys Ser 305 310 315 320 aga agc ctc gag gtc tcc tgt ttc tct tcc tga 993 Arg Ser Leu Glu Val Ser Cys Phe Ser Ser * 325 330 <210> SEQ ID NO 52 <211> LENGTH: 330 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 52 Met Ser Leu Leu Leu Tyr Tyr Ala Leu Pro Ala Leu Gly Ser Tyr Ala 1 5 10 15 Met Leu Ser Ile Phe Phe Leu Arg Arg Pro His Leu Leu His Thr Pro 20 25 30 Arg Ala Pro Thr Phe Arg Ile Arg Leu Gly Ala His Arg Gly Gly Ser 35 40 45 Gly Glu Leu Leu Glu Asn Thr Met Glu Ala Met Glu Asn Ser Met Ala 50 55 60 Gln Arg Ser Asp Leu Leu Glu Leu Asp Cys Gln Leu Thr Arg Asp Arg 65 70 75 80 Val Val Val Val Ser His Asp Glu Asn Leu Cys Arg Gln Ser Gly Leu 85 90 95 Asn Arg Asp Val Gly Ser Leu Asp Phe Glu Asp Leu Pro Leu Tyr Lys 100 105 110 Glu Lys Leu Glu Val Tyr Phe Ser Pro Gly His Phe Ala His Gly Ser 115 120 125 Asp Arg Arg Met Val Arg Leu Glu Asp Leu Phe Gln Arg Phe Pro Arg 130 135 140 Thr Pro Met Ser Val Glu Ile Lys Gly Lys Asn Glu Glu Leu Ile Arg 145 150 155 160 Glu Ile Ala Gly Leu Val Arg Arg Tyr Asp Arg Asn Glu Ile Thr Ile 165 170 175 Trp Ala Ser Glu Lys Ser Ser Val Met Lys Lys Cys Lys Ala Ala Asn 180 185 190 Pro Glu Met Pro Leu Ser Phe Thr Ile Ser Arg Gly Phe Trp Val Leu 195 200 205 Leu Ser Tyr Tyr Leu Gly Leu Leu Pro Phe Ile Pro Ile Pro Glu Lys 210 215 220 Phe Phe Phe Cys Phe Leu Pro Asn Ile Ile Asn Arg Thr Tyr Phe Pro 225 230 235 240 Phe Ser Cys Ser Cys Leu Asn Gln Leu Leu Ala Val Val Ser Lys Trp 245 250 255 Leu Ile Met Arg Lys Ser Leu Ile Arg His Leu Glu Glu Arg Gly Val 260 265 270 Gln Val Val Phe Trp Cys Leu Asn Glu Glu Ser Asp Phe Glu Ala Ala 275 280 285 Phe Ser Val Gly Ala Thr Gly Val Ile Thr Asp Tyr Pro Thr Ala Cys 290 295 300 Gly Thr Thr Trp Thr Thr Met Asp Gln Leu Pro Gly Pro Pro Lys Ser 305 310 315 320 Arg Ser Leu Glu Val Ser Cys Phe Ser Ser 325 330 <210> SEQ ID NO 53 <211> LENGTH: 714 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)...(714) <400> SEQUENCE: 53 atg gcg ctg tgg cgc ggc tcc gcg tac gcg ggc ttc ctg gcg ctg gcc 48 Met Ala Leu Trp Arg Gly Ser Ala Tyr Ala Gly Phe Leu Ala Leu Ala 1 5 10 15 gtg ggc tgc gtc ttc ctg ctg gag cca gag ctg cca ggc tcg gcg ctg 96 Val Gly Cys Val Phe Leu Leu Glu Pro Glu Leu Pro Gly Ser Ala Leu 20 25 30 cgc tct ctc tgg agc tcg ctg tgt ctg ggg ccc gcg cct gcg ccc ccg 144 Arg Ser Leu Trp Ser Ser Leu Cys Leu Gly Pro Ala Pro Ala Pro Pro 35 40 45 gga ccc gtc tcc ccc gag ggc cgg ttg gcg gca gcc tgg gac gcg ctt 192 Gly Pro Val Ser Pro Glu Gly Arg Leu Ala Ala Ala Trp Asp Ala Leu 50 55 60 atc gtg cgg cca gtc cgg cgc tgg cgc cgc gtg gca gtg gga gtc aat 240 Ile Val Arg Pro Val Arg Arg Trp Arg Arg Val Ala Val Gly Val Asn 65 70 75 80 gca tgt gtt gat gtg gtg ctc tca ggg gtg aag ctc ttg cag gca ctt 288 Ala Cys Val Asp Val Val Leu Ser Gly Val Lys Leu Leu Gln Ala Leu 85 90 95 ggc ctt agt cct ggg aat ggg aaa gat cac agc att ctg cat tca agg 336 Gly Leu Ser Pro Gly Asn Gly Lys Asp His Ser Ile Leu His Ser Arg 100 105 110 aat gat ctg gaa gaa gcc ttc att cac ttc atg ggg aag gga gca gct 384 Asn Asp Leu Glu Glu Ala Phe Ile His Phe Met Gly Lys Gly Ala Ala 115 120 125 gct gag cgc ttc ttc agt gat aag gaa act ttt cac gac att gcc cag 432 Ala Glu Arg Phe Phe Ser Asp Lys Glu Thr Phe His Asp Ile Ala Gln 130 135 140 gtt gcg tca gag ttc cca gga gcc cag cac tat gta gga gga aat gca 480 Val Ala Ser Glu Phe Pro Gly Ala Gln His Tyr Val Gly Gly Asn Ala 145 150 155 160 gct tta att gga cag aaa ttt gca gcc aac tca gat tta aag gtt ctt 528 Ala Leu Ile Gly Gln Lys Phe Ala Ala Asn Ser Asp Leu Lys Val Leu 165 170 175 ctt tgc ggt cca gtt ggt cca aag cta cat gag ctt ctt gat gac aat 576 Leu Cys Gly Pro Val Gly Pro Lys Leu His Glu Leu Leu Asp Asp Asn 180 185 190 gtc ttt gtt cca cca gag tca ttg cag gaa gtg gat gag ttc cac ctc 624 Val Phe Val Pro Pro Glu Ser Leu Gln Glu Val Asp Glu Phe His Leu 195 200 205 att tta gag tat caa gca ggg gct ggg gag cct ctg agg gac tct ttc 672 Ile Leu Glu Tyr Gln Ala Gly Ala Gly Glu Pro Leu Arg Asp Ser Phe 210 215 220 att ctg cag ttg tct gga agc ctg ggt ggc gtc atg agc tga 714 Ile Leu Gln Leu Ser Gly Ser Leu Gly Gly Val Met Ser * 225 230 235 <210> SEQ ID NO 54 <211> LENGTH: 237 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 54 Met Ala Leu Trp Arg Gly Ser Ala Tyr Ala Gly Phe Leu Ala Leu Ala 1 5 10 15 Val Gly Cys Val Phe Leu Leu Glu Pro Glu Leu Pro Gly Ser Ala Leu 20 25 30 Arg Ser Leu Trp Ser Ser Leu Cys Leu Gly Pro Ala Pro Ala Pro Pro 35 40 45 Gly Pro Val Ser Pro Glu Gly Arg Leu Ala Ala Ala Trp Asp Ala Leu 50 55 60 Ile Val Arg Pro Val Arg Arg Trp Arg Arg Val Ala Val Gly Val Asn 65 70 75 80 Ala Cys Val Asp Val Val Leu Ser Gly Val Lys Leu Leu Gln Ala Leu 85 90 95 Gly Leu Ser Pro Gly Asn Gly Lys Asp His Ser Ile Leu His Ser Arg 100 105 110 Asn Asp Leu Glu Glu Ala Phe Ile His Phe Met Gly Lys Gly Ala Ala 115 120 125 Ala Glu Arg Phe Phe Ser Asp Lys Glu Thr Phe His Asp Ile Ala Gln 130 135 140 Val Ala Ser Glu Phe Pro Gly Ala Gln His Tyr Val Gly Gly Asn Ala 145 150 155 160 Ala Leu Ile Gly Gln Lys Phe Ala Ala Asn Ser Asp Leu Lys Val Leu 165 170 175 Leu Cys Gly Pro Val Gly Pro Lys Leu His Glu Leu Leu Asp Asp Asn 180 185 190 Val Phe Val Pro Pro Glu Ser Leu Gln Glu Val Asp Glu Phe His Leu 195 200 205 Ile Leu Glu Tyr Gln Ala Gly Ala Gly Glu Pro Leu Arg Asp Ser Phe 210 215 220 Ile Leu Gln Leu Ser Gly Ser Leu Gly Gly Val Met Ser 225 230 235 <210> SEQ ID NO 55 <211> LENGTH: 1083 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)...(1083) <400> SEQUENCE: 55 atg gcg ccc ctc gga aca act gta ttg ctg tgg agc ctc ttg agg agt 48 Met Ala Pro Leu Gly Thr Thr Val Leu Leu Trp Ser Leu Leu Arg Ser 1 5 10 15 tct ccg ggc gtg gaa cgg gtc tgt ttc cgg gct cga atc cag ccc tgg 96 Ser Pro Gly Val Glu Arg Val Cys Phe Arg Ala Arg Ile Gln Pro Trp 20 25 30 cac ggt ggc ctg ctc caa ccg cta cct tgc tct ttc gag atg ggg ctg 144 His Gly Gly Leu Leu Gln Pro Leu Pro Cys Ser Phe Glu Met Gly Leu 35 40 45 cca cgc cgc cgg ttc agc tcc gag gcc gca gaa tct ggt agc cca gag 192 Pro Arg Arg Arg Phe Ser Ser Glu Ala Ala Glu Ser Gly Ser Pro Glu 50 55 60 acc aag aaa cct aca ttt atg gat gag gaa gtt caa agc ata ctc acg 240 Thr Lys Lys Pro Thr Phe Met Asp Glu Glu Val Gln Ser Ile Leu Thr 65 70 75 80 aaa atg aca ggc ttg aac ttg cag aag act ttt aag cca gct ata caa 288 Lys Met Thr Gly Leu Asn Leu Gln Lys Thr Phe Lys Pro Ala Ile Gln 85 90 95 gaa ctg aag cca cca acc tat aag cta atg act cag gca cag ttg gaa 336 Glu Leu Lys Pro Pro Thr Tyr Lys Leu Met Thr Gln Ala Gln Leu Glu 100 105 110 gag gct aca aga cag gca gtt gag gca gct aaa gta cga tta aaa atg 384 Glu Ala Thr Arg Gln Ala Val Glu Ala Ala Lys Val Arg Leu Lys Met 115 120 125 cca cca gtt ctg gaa gag cga gta cca ata aat gat gtg tta gct gaa 432 Pro Pro Val Leu Glu Glu Arg Val Pro Ile Asn Asp Val Leu Ala Glu 130 135 140 gat aag att ttg gaa gga aca gaa aca acc aaa tat gtg ttt act gat 480 Asp Lys Ile Leu Glu Gly Thr Glu Thr Thr Lys Tyr Val Phe Thr Asp 145 150 155 160 ata tca tat agc ata cca cac cgg gag cgt ttt att gtc gtc aga gaa 528 Ile Ser Tyr Ser Ile Pro His Arg Glu Arg Phe Ile Val Val Arg Glu 165 170 175 cca agt ggc aca cta cgc aaa gcc tct tgg gaa gaa cgg gac cga atg 576 Pro Ser Gly Thr Leu Arg Lys Ala Ser Trp Glu Glu Arg Asp Arg Met 180 185 190 ata caa gtt tat ttc cca aaa gaa ggt cgt aaa att ttg aca cca ata 624 Ile Gln Val Tyr Phe Pro Lys Glu Gly Arg Lys Ile Leu Thr Pro Ile 195 200 205 att ttc aag gaa gaa aat ctt agg act atg tat agc cag gac agg cat 672 Ile Phe Lys Glu Glu Asn Leu Arg Thr Met Tyr Ser Gln Asp Arg His 210 215 220 gtt gat gtc ctc aat ctc tgc ttt gcc cag ttt gag cca gat tcc aca 720 Val Asp Val Leu Asn Leu Cys Phe Ala Gln Phe Glu Pro Asp Ser Thr 225 230 235 240 gag tat atc aag gtt cat cac aag acc tat gaa gat ata gat aaa cgt 768 Glu Tyr Ile Lys Val His His Lys Thr Tyr Glu Asp Ile Asp Lys Arg 245 250 255 gga aaa tat gac ctt tta cgt tca aca aga tac ttt ggt gga atg gtg 816 Gly Lys Tyr Asp Leu Leu Arg Ser Thr Arg Tyr Phe Gly Gly Met Val 260 265 270 tgg tat ttt gta aat aat aaa aag att gat ggt ttg ctg att gac cag 864 Trp Tyr Phe Val Asn Asn Lys Lys Ile Asp Gly Leu Leu Ile Asp Gln 275 280 285 att cag aga gat tta atc gat gat gca acc aac ttg gtc cag ctg tat 912 Ile Gln Arg Asp Leu Ile Asp Asp Ala Thr Asn Leu Val Gln Leu Tyr 290 295 300 cac gtg ctc cat cca gat ggc cag tcg gct caa ggg gcc aag gat cag 960 His Val Leu His Pro Asp Gly Gln Ser Ala Gln Gly Ala Lys Asp Gln 305 310 315 320 gct gct gag gga ata aat tta atc aag gtc ttt gca aaa aca gaa gca 1008 Ala Ala Glu Gly Ile Asn Leu Ile Lys Val Phe Ala Lys Thr Glu Ala 325 330 335 cag aag gga gcc tat ata gaa cta aca ctg cag act tat caa gaa gca 1056 Gln Lys Gly Ala Tyr Ile Glu Leu Thr Leu Gln Thr Tyr Gln Glu Ala 340 345 350 ctc agt cgc cat tct gca gct tcc taa 1083 Leu Ser Arg His Ser Ala Ala Ser * 355 360 <210> SEQ ID NO 56 <211> LENGTH: 360 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 56 Met Ala Pro Leu Gly Thr Thr Val Leu Leu Trp Ser Leu Leu Arg Ser 1 5 10 15 Ser Pro Gly Val Glu Arg Val Cys Phe Arg Ala Arg Ile Gln Pro Trp 20 25 30 His Gly Gly Leu Leu Gln Pro Leu Pro Cys Ser Phe Glu Met Gly Leu 35 40 45 Pro Arg Arg Arg Phe Ser Ser Glu Ala Ala Glu Ser Gly Ser Pro Glu 50 55 60 Thr Lys Lys Pro Thr Phe Met Asp Glu Glu Val Gln Ser Ile Leu Thr 65 70 75 80 Lys Met Thr Gly Leu Asn Leu Gln Lys Thr Phe Lys Pro Ala Ile Gln 85 90 95 Glu Leu Lys Pro Pro Thr Tyr Lys Leu Met Thr Gln Ala Gln Leu Glu 100 105 110 Glu Ala Thr Arg Gln Ala Val Glu Ala Ala Lys Val Arg Leu Lys Met 115 120 125 Pro Pro Val Leu Glu Glu Arg Val Pro Ile Asn Asp Val Leu Ala Glu 130 135 140 Asp Lys Ile Leu Glu Gly Thr Glu Thr Thr Lys Tyr Val Phe Thr Asp 145 150 155 160 Ile Ser Tyr Ser Ile Pro His Arg Glu Arg Phe Ile Val Val Arg Glu 165 170 175 Pro Ser Gly Thr Leu Arg Lys Ala Ser Trp Glu Glu Arg Asp Arg Met 180 185 190 Ile Gln Val Tyr Phe Pro Lys Glu Gly Arg Lys Ile Leu Thr Pro Ile 195 200 205 Ile Phe Lys Glu Glu Asn Leu Arg Thr Met Tyr Ser Gln Asp Arg His 210 215 220 Val Asp Val Leu Asn Leu Cys Phe Ala Gln Phe Glu Pro Asp Ser Thr 225 230 235 240 Glu Tyr Ile Lys Val His His Lys Thr Tyr Glu Asp Ile Asp Lys Arg 245 250 255 Gly Lys Tyr Asp Leu Leu Arg Ser Thr Arg Tyr Phe Gly Gly Met Val 260 265 270 Trp Tyr Phe Val Asn Asn Lys Lys Ile Asp Gly Leu Leu Ile Asp Gln 275 280 285 Ile Gln Arg Asp Leu Ile Asp Asp Ala Thr Asn Leu Val Gln Leu Tyr 290 295 300 His Val Leu His Pro Asp Gly Gln Ser Ala Gln Gly Ala Lys Asp Gln 305 310 315 320 Ala Ala Glu Gly Ile Asn Leu Ile Lys Val Phe Ala Lys Thr Glu Ala 325 330 335 Gln Lys Gly Ala Tyr Ile Glu Leu Thr Leu Gln Thr Tyr Gln Glu Ala 340 345 350 Leu Ser Arg His Ser Ala Ala Ser 355 360 <210> SEQ ID NO 57 <211> LENGTH: 894 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)...(894) <400> SEQUENCE: 57 atg tcg gct tgg gct gct gcc agc cta agc agg gcc gct gcc cga tgc 48 Met Ser Ala Trp Ala Ala Ala Ser Leu Ser Arg Ala Ala Ala Arg Cys 1 5 10 15 ttg ctg gca cga ggc ccc ggg gtc agg gcg gct cct ccg cgc gac ccc 96 Leu Leu Ala Arg Gly Pro Gly Val Arg Ala Ala Pro Pro Arg Asp Pro 20 25 30 cgg ccc tcc cac ccc gag ccc cgg ggc tgc ggt gcc gct ccg ggc agg 144 Arg Pro Ser His Pro Glu Pro Arg Gly Cys Gly Ala Ala Pro Gly Arg 35 40 45 acg ctg cac ttt acc gcg gct gtc ccc gcc ggg cac aac aag tgg tcc 192 Thr Leu His Phe Thr Ala Ala Val Pro Ala Gly His Asn Lys Trp Ser 50 55 60 aaa gtc agg cac atc aag ggt ccg aag gac gtc gaa agg agt cgc atc 240 Lys Val Arg His Ile Lys Gly Pro Lys Asp Val Glu Arg Ser Arg Ile 65 70 75 80 ttc tcc aaa ctc tgt ttg aac atc cgc ctg gca gtg aaa gaa gga ggc 288 Phe Ser Lys Leu Cys Leu Asn Ile Arg Leu Ala Val Lys Glu Gly Gly 85 90 95 ccc aac cct gag cac aac agc aac ctg gcc aat atc tta gag gtg tgt 336 Pro Asn Pro Glu His Asn Ser Asn Leu Ala Asn Ile Leu Glu Val Cys 100 105 110 cgc agc aaa cat atg ccc aag tca acg att gag aca gca ctg aaa atg 384 Arg Ser Lys His Met Pro Lys Ser Thr Ile Glu Thr Ala Leu Lys Met 115 120 125 gag aaa tcc aag gac act tat ttg ctg tat gag ggt cga ggc cct ggt 432 Glu Lys Ser Lys Asp Thr Tyr Leu Leu Tyr Glu Gly Arg Gly Pro Gly 130 135 140 ggc tct tct ctg ctc atc gag gca tta tct aac agt agc cac aag tgc 480 Gly Ser Ser Leu Leu Ile Glu Ala Leu Ser Asn Ser Ser His Lys Cys 145 150 155 160 caa gca gac att aga cat atc ctg aat aag aat gga gga gtg atg gct 528 Gln Ala Asp Ile Arg His Ile Leu Asn Lys Asn Gly Gly Val Met Ala 165 170 175 gta gga gct cgt cac tct ttt gac aaa aag ggg gtg att gtg gtt gaa 576 Val Gly Ala Arg His Ser Phe Asp Lys Lys Gly Val Ile Val Val Glu 180 185 190 gtg gag gac aga gag aag aag gct gtg aac cta gag cgt gcc ctg gag 624 Val Glu Asp Arg Glu Lys Lys Ala Val Asn Leu Glu Arg Ala Leu Glu 195 200 205 atg gca atc gaa gca gga gct gag gat gtc aag gaa act gaa gat gaa 672 Met Ala Ile Glu Ala Gly Ala Glu Asp Val Lys Glu Thr Glu Asp Glu 210 215 220 gaa gaa agg aac gtt ttt aaa ttt att tgt gat gcc tct tca ctg cac 720 Glu Glu Arg Asn Val Phe Lys Phe Ile Cys Asp Ala Ser Ser Leu His 225 230 235 240 caa gtg agg aag aag ctg gac tcc ctg ggc ctg tgt tct gtg tcc tgt 768 Gln Val Arg Lys Lys Leu Asp Ser Leu Gly Leu Cys Ser Val Ser Cys 245 250 255 gca cta gag ttc atc ccc aac tca aag gtg cag ctg gct gag ccc gac 816 Ala Leu Glu Phe Ile Pro Asn Ser Lys Val Gln Leu Ala Glu Pro Asp 260 265 270 ctg gaa cag gcc gca cat ctc att cag gct ctc agc aac cac gag gat 864 Leu Glu Gln Ala Ala His Leu Ile Gln Ala Leu Ser Asn His Glu Asp 275 280 285 gtg att cac gtc tat gat aac att gaa taa 894 Val Ile His Val Tyr Asp Asn Ile Glu * 290 295 <210> SEQ ID NO 58 <211> LENGTH: 297 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 58 Met Ser Ala Trp Ala Ala Ala Ser Leu Ser Arg Ala Ala Ala Arg Cys 1 5 10 15 Leu Leu Ala Arg Gly Pro Gly Val Arg Ala Ala Pro Pro Arg Asp Pro 20 25 30 Arg Pro Ser His Pro Glu Pro Arg Gly Cys Gly Ala Ala Pro Gly Arg 35 40 45 Thr Leu His Phe Thr Ala Ala Val Pro Ala Gly His Asn Lys Trp Ser 50 55 60 Lys Val Arg His Ile Lys Gly Pro Lys Asp Val Glu Arg Ser Arg Ile 65 70 75 80 Phe Ser Lys Leu Cys Leu Asn Ile Arg Leu Ala Val Lys Glu Gly Gly 85 90 95 Pro Asn Pro Glu His Asn Ser Asn Leu Ala Asn Ile Leu Glu Val Cys 100 105 110 Arg Ser Lys His Met Pro Lys Ser Thr Ile Glu Thr Ala Leu Lys Met 115 120 125 Glu Lys Ser Lys Asp Thr Tyr Leu Leu Tyr Glu Gly Arg Gly Pro Gly 130 135 140 Gly Ser Ser Leu Leu Ile Glu Ala Leu Ser Asn Ser Ser His Lys Cys 145 150 155 160 Gln Ala Asp Ile Arg His Ile Leu Asn Lys Asn Gly Gly Val Met Ala 165 170 175 Val Gly Ala Arg His Ser Phe Asp Lys Lys Gly Val Ile Val Val Glu 180 185 190 Val Glu Asp Arg Glu Lys Lys Ala Val Asn Leu Glu Arg Ala Leu Glu 195 200 205 Met Ala Ile Glu Ala Gly Ala Glu Asp Val Lys Glu Thr Glu Asp Glu 210 215 220 Glu Glu Arg Asn Val Phe Lys Phe Ile Cys Asp Ala Ser Ser Leu His 225 230 235 240 Gln Val Arg Lys Lys Leu Asp Ser Leu Gly Leu Cys Ser Val Ser Cys 245 250 255 Ala Leu Glu Phe Ile Pro Asn Ser Lys Val Gln Leu Ala Glu Pro Asp 260 265 270 Leu Glu Gln Ala Ala His Leu Ile Gln Ala Leu Ser Asn His Glu Asp 275 280 285 Val Ile His Val Tyr Asp Asn Ile Glu 290 295 <210> SEQ ID NO 59 <211> LENGTH: 789 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)...(789) <400> SEQUENCE: 59 atg gcc gct gcc gcg gct gtg gag gcg gcg gcg cct atg ggt gcc cta 48 Met Ala Ala Ala Ala Ala Val Glu Ala Ala Ala Pro Met Gly Ala Leu 1 5 10 15 tgg ggc ctc gtg cac gac ttc gtc gtg ggt cag caa gag ggc ccc gct 96 Trp Gly Leu Val His Asp Phe Val Val Gly Gln Gln Glu Gly Pro Ala 20 25 30 gac cag gtg gct gca gat gtg aaa tct ggc aac tat aca gtg tta caa 144 Asp Gln Val Ala Ala Asp Val Lys Ser Gly Asn Tyr Thr Val Leu Gln 35 40 45 gtt gtg gaa gcc ctt ggg tcc tct cta gag aat cca gaa ccc cga act 192 Val Val Glu Ala Leu Gly Ser Ser Leu Glu Asn Pro Glu Pro Arg Thr 50 55 60 cgg gca cga gga atc cag ctt ttg tca cag gtg cta ctc cac tgt cac 240 Arg Ala Arg Gly Ile Gln Leu Leu Ser Gln Val Leu Leu His Cys His 65 70 75 80 acc ttg ctc ctg gag aag gaa gtg gta cac ctg ata ctg ttc tat gag 288 Thr Leu Leu Leu Glu Lys Glu Val Val His Leu Ile Leu Phe Tyr Glu 85 90 95 aac cgg ctg aag gac cat cat ctt gtg atc cca tct gtc ctg cag ggt 336 Asn Arg Leu Lys Asp His His Leu Val Ile Pro Ser Val Leu Gln Gly 100 105 110 ttg aag gca ctt agc ctg tgt gtg gcc ctg ccc cca ggg ctg gct gtt 384 Leu Lys Ala Leu Ser Leu Cys Val Ala Leu Pro Pro Gly Leu Ala Val 115 120 125 tct gtg ctt aaa gcc atc ttc cag gaa gtg cat gta cag tcc ctg cca 432 Ser Val Leu Lys Ala Ile Phe Gln Glu Val His Val Gln Ser Leu Pro 130 135 140 cag gtg gac cga cac aca gtc tac aat atc atc acc aat ttt atg cga 480 Gln Val Asp Arg His Thr Val Tyr Asn Ile Ile Thr Asn Phe Met Arg 145 150 155 160 acc cgg gaa gaa gag cta aag agc cta gga gct gac ttc acc ttt ggc 528 Thr Arg Glu Glu Glu Leu Lys Ser Leu Gly Ala Asp Phe Thr Phe Gly 165 170 175 ttc atc cag gtg atg gat ggg gaa aag gat ccc cgt aat ctt ctg gtg 576 Phe Ile Gln Val Met Asp Gly Glu Lys Asp Pro Arg Asn Leu Leu Val 180 185 190 gcc ttc cgc atc gtc cat gac ctc atc tcc agg gac tat agc ctg gga 624 Ala Phe Arg Ile Val His Asp Leu Ile Ser Arg Asp Tyr Ser Leu Gly 195 200 205 ccc ttt gtg gag gag ttg ttt gaa gtg aca tcc tgt tat ttc cct atc 672 Pro Phe Val Glu Glu Leu Phe Glu Val Thr Ser Cys Tyr Phe Pro Ile 210 215 220 gat ttt acc cct cca cct aat gat ccc cat ggt atc cag aga gaa gac 720 Asp Phe Thr Pro Pro Pro Asn Asp Pro His Gly Ile Gln Arg Glu Asp 225 230 235 240 ctc atc ctg agt ctt cgc gct gtg ctg gct tct aca cca cga ttt gct 768 Leu Ile Leu Ser Leu Arg Ala Val Leu Ala Ser Thr Pro Arg Phe Ala 245 250 255 gag ttt ctg ctg ccc tgt tga 789 Glu Phe Leu Leu Pro Cys * 260 <210> SEQ ID NO 60 <211> LENGTH: 262 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 60 Met Ala Ala Ala Ala Ala Val Glu Ala Ala Ala Pro Met Gly Ala Leu 1 5 10 15 Trp Gly Leu Val His Asp Phe Val Val Gly Gln Gln Glu Gly Pro Ala 20 25 30 Asp Gln Val Ala Ala Asp Val Lys Ser Gly Asn Tyr Thr Val Leu Gln 35 40 45 Val Val Glu Ala Leu Gly Ser Ser Leu Glu Asn Pro Glu Pro Arg Thr 50 55 60 Arg Ala Arg Gly Ile Gln Leu Leu Ser Gln Val Leu Leu His Cys His 65 70 75 80 Thr Leu Leu Leu Glu Lys Glu Val Val His Leu Ile Leu Phe Tyr Glu 85 90 95 Asn Arg Leu Lys Asp His His Leu Val Ile Pro Ser Val Leu Gln Gly 100 105 110 Leu Lys Ala Leu Ser Leu Cys Val Ala Leu Pro Pro Gly Leu Ala Val 115 120 125 Ser Val Leu Lys Ala Ile Phe Gln Glu Val His Val Gln Ser Leu Pro 130 135 140 Gln Val Asp Arg His Thr Val Tyr Asn Ile Ile Thr Asn Phe Met Arg 145 150 155 160 Thr Arg Glu Glu Glu Leu Lys Ser Leu Gly Ala Asp Phe Thr Phe Gly 165 170 175 Phe Ile Gln Val Met Asp Gly Glu Lys Asp Pro Arg Asn Leu Leu Val 180 185 190 Ala Phe Arg Ile Val His Asp Leu Ile Ser Arg Asp Tyr Ser Leu Gly 195 200 205 Pro Phe Val Glu Glu Leu Phe Glu Val Thr Ser Cys Tyr Phe Pro Ile 210 215 220 Asp Phe Thr Pro Pro Pro Asn Asp Pro His Gly Ile Gln Arg Glu Asp 225 230 235 240 Leu Ile Leu Ser Leu Arg Ala Val Leu Ala Ser Thr Pro Arg Phe Ala 245 250 255 Glu Phe Leu Leu Pro Cys 260 <210> SEQ ID NO 61 <211> LENGTH: 921 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)...(921) <400> SEQUENCE: 61 atg gcg gtt gcg cgc ttg gca gct gtg gcg gcc tgg gta cct tgt cgg 48 Met Ala Val Ala Arg Leu Ala Ala Val Ala Ala Trp Val Pro Cys Arg 1 5 10 15 agc tgg ggc tgg gca gcc gtc ccc ttc ggt ccc cac cgt ggc ctc agc 96 Ser Trp Gly Trp Ala Ala Val Pro Phe Gly Pro His Arg Gly Leu Ser 20 25 30 gtg ctg ctt gca cgg ata cct cag cgg gcg cca cgg tgg ctc cca gct 144 Val Leu Leu Ala Arg Ile Pro Gln Arg Ala Pro Arg Trp Leu Pro Ala 35 40 45 tgt aga caa aag acg tca ctc tca ttc ctt aat cga cca gac ctt cca 192 Cys Arg Gln Lys Thr Ser Leu Ser Phe Leu Asn Arg Pro Asp Leu Pro 50 55 60 aac ctg gct tat aag aag cta aaa ggc aaa agt cca gga att atc ttc 240 Asn Leu Ala Tyr Lys Lys Leu Lys Gly Lys Ser Pro Gly Ile Ile Phe 65 70 75 80 atc cct ggc tat ctt tct tat atg aat ggt aca aaa gcg ttg gcg att 288 Ile Pro Gly Tyr Leu Ser Tyr Met Asn Gly Thr Lys Ala Leu Ala Ile 85 90 95 gag gag ttt tgc aaa tct cta ggt cac gcc tgc ata agg ttt gat tac 336 Glu Glu Phe Cys Lys Ser Leu Gly His Ala Cys Ile Arg Phe Asp Tyr 100 105 110 tca gga gtt gga agt tca gat ggt aac tca gag gaa agc aca ctg ggg 384 Ser Gly Val Gly Ser Ser Asp Gly Asn Ser Glu Glu Ser Thr Leu Gly 115 120 125 aaa tgg aga aaa gat gtt ctt tct ata att gat gac tta gct gat ggg 432 Lys Trp Arg Lys Asp Val Leu Ser Ile Ile Asp Asp Leu Ala Asp Gly 130 135 140 cca cag att ctt gtt gga tct agc ctt gga ggg tgg ctt atg ctt cat 480 Pro Gln Ile Leu Val Gly Ser Ser Leu Gly Gly Trp Leu Met Leu His 145 150 155 160 gct gca att gca cga cca gag aag gtc gtg gct ctt att ggt gta gct 528 Ala Ala Ile Ala Arg Pro Glu Lys Val Val Ala Leu Ile Gly Val Ala 165 170 175 aca gct gca gat acc tta gtg aca aag ttt aat cag ctt cct gtt gag 576 Thr Ala Ala Asp Thr Leu Val Thr Lys Phe Asn Gln Leu Pro Val Glu 180 185 190 cta aaa aag gaa gta gag atg aaa ggt gtg tgg agc atg cca tca aaa 624 Leu Lys Lys Glu Val Glu Met Lys Gly Val Trp Ser Met Pro Ser Lys 195 200 205 tac tct gaa gaa gga gtt tat aac gtt cag tac agt ttc att aaa gaa 672 Tyr Ser Glu Glu Gly Val Tyr Asn Val Gln Tyr Ser Phe Ile Lys Glu 210 215 220 gct gaa cat cac tgc ttg tta cat agc cca att cct gtg aac tgc ccc 720 Ala Glu His His Cys Leu Leu His Ser Pro Ile Pro Val Asn Cys Pro 225 230 235 240 ata aga ttg ctc cat ggc atg aag gat gac att gta cct tgg cat aca 768 Ile Arg Leu Leu His Gly Met Lys Asp Asp Ile Val Pro Trp His Thr 245 250 255 tca atg cag gtt gcc gat cga gta ctc agc aca gat gtg gat gtc atc 816 Ser Met Gln Val Ala Asp Arg Val Leu Ser Thr Asp Val Asp Val Ile 260 265 270 ctc cga aaa cac agt gat cac cga atg agg gaa aaa gca gac att caa 864 Leu Arg Lys His Ser Asp His Arg Met Arg Glu Lys Ala Asp Ile Gln 275 280 285 ctt ctt gtt tac act att gat gac tta att gat aag ctc tca act ata 912 Leu Leu Val Tyr Thr Ile Asp Asp Leu Ile Asp Lys Leu Ser Thr Ile 290 295 300 gtt aac tag 921 Val Asn * 305 <210> SEQ ID NO 62 <211> LENGTH: 306 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 62 Met Ala Val Ala Arg Leu Ala Ala Val Ala Ala Trp Val Pro Cys Arg 1 5 10 15 Ser Trp Gly Trp Ala Ala Val Pro Phe Gly Pro His Arg Gly Leu Ser 20 25 30 Val Leu Leu Ala Arg Ile Pro Gln Arg Ala Pro Arg Trp Leu Pro Ala 35 40 45 Cys Arg Gln Lys Thr Ser Leu Ser Phe Leu Asn Arg Pro Asp Leu Pro 50 55 60 Asn Leu Ala Tyr Lys Lys Leu Lys Gly Lys Ser Pro Gly Ile Ile Phe 65 70 75 80 Ile Pro Gly Tyr Leu Ser Tyr Met Asn Gly Thr Lys Ala Leu Ala Ile 85 90 95 Glu Glu Phe Cys Lys Ser Leu Gly His Ala Cys Ile Arg Phe Asp Tyr 100 105 110 Ser Gly Val Gly Ser Ser Asp Gly Asn Ser Glu Glu Ser Thr Leu Gly 115 120 125 Lys Trp Arg Lys Asp Val Leu Ser Ile Ile Asp Asp Leu Ala Asp Gly 130 135 140 Pro Gln Ile Leu Val Gly Ser Ser Leu Gly Gly Trp Leu Met Leu His 145 150 155 160 Ala Ala Ile Ala Arg Pro Glu Lys Val Val Ala Leu Ile Gly Val Ala 165 170 175 Thr Ala Ala Asp Thr Leu Val Thr Lys Phe Asn Gln Leu Pro Val Glu 180 185 190 Leu Lys Lys Glu Val Glu Met Lys Gly Val Trp Ser Met Pro Ser Lys 195 200 205 Tyr Ser Glu Glu Gly Val Tyr Asn Val Gln Tyr Ser Phe Ile Lys Glu 210 215 220 Ala Glu His His Cys Leu Leu His Ser Pro Ile Pro Val Asn Cys Pro 225 230 235 240 Ile Arg Leu Leu His Gly Met Lys Asp Asp Ile Val Pro Trp His Thr 245 250 255 Ser Met Gln Val Ala Asp Arg Val Leu Ser Thr Asp Val Asp Val Ile 260 265 270 Leu Arg Lys His Ser Asp His Arg Met Arg Glu Lys Ala Asp Ile Gln 275 280 285 Leu Leu Val Tyr Thr Ile Asp Asp Leu Ile Asp Lys Leu Ser Thr Ile 290 295 300 Val Asn 305 <210> SEQ ID NO 63 <211> LENGTH: 1143 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)...(1143) <400> SEQUENCE: 63 atg ttc cgg ctc ctg agc tgg agc ctg ggc cga ggc ttc ctg cgg gcc 48 Met Phe Arg Leu Leu Ser Trp Ser Leu Gly Arg Gly Phe Leu Arg Ala 1 5 10 15 gcg ggg cgg cgg tgc cgg ggc tgc tcc gcg cgc ctg ctc ccg ggg ctg 96 Ala Gly Arg Arg Cys Arg Gly Cys Ser Ala Arg Leu Leu Pro Gly Leu 20 25 30 gca gga ggt ccg ggg ccc gag gtg cag gtg ccg cca tcc cga gtc gcg 144 Ala Gly Gly Pro Gly Pro Glu Val Gln Val Pro Pro Ser Arg Val Ala 35 40 45 ccg cac ggc cgg ggc cca ggc ctg ctg ccg ctg ctg gca gcg ctc gcc 192 Pro His Gly Arg Gly Pro Gly Leu Leu Pro Leu Leu Ala Ala Leu Ala 50 55 60 tgg ttc tcg agg ccc gct gcg gca gag gag gag gag cag cag gga gcc 240 Trp Phe Ser Arg Pro Ala Ala Ala Glu Glu Glu Glu Gln Gln Gly Ala 65 70 75 80 gac ggg gcc gct gcc gag gac ggg gcg gac gag gcc gag gca gag atc 288 Asp Gly Ala Ala Ala Glu Asp Gly Ala Asp Glu Ala Glu Ala Glu Ile 85 90 95 atc cag ctg ctg aag cga gcc aag ttg agc att atg aaa gat gag cca 336 Ile Gln Leu Leu Lys Arg Ala Lys Leu Ser Ile Met Lys Asp Glu Pro 100 105 110 gaa gag gct gag tta att ttg cat gac gct ctt cgt ctc gcc tat cag 384 Glu Glu Ala Glu Leu Ile Leu His Asp Ala Leu Arg Leu Ala Tyr Gln 115 120 125 act gat aac aag aag gcc atc act tac act tat gat ttg atg gcc aac 432 Thr Asp Asn Lys Lys Ala Ile Thr Tyr Thr Tyr Asp Leu Met Ala Asn 130 135 140 tta gca ttt ata cgg ggt cag ctt gaa aat gct gaa caa ctt ttt aaa 480 Leu Ala Phe Ile Arg Gly Gln Leu Glu Asn Ala Glu Gln Leu Phe Lys 145 150 155 160 gca aca atg agt tac ctc ctt gga ggg ggc atg aag cag gag gac aat 528 Ala Thr Met Ser Tyr Leu Leu Gly Gly Gly Met Lys Gln Glu Asp Asn 165 170 175 gca ata att gaa att tcc cta aag ctg gcc agt atc tat gct gcg cag 576 Ala Ile Ile Glu Ile Ser Leu Lys Leu Ala Ser Ile Tyr Ala Ala Gln 180 185 190 aac aga cag gaa ttt gct gtt gct ggc tat gaa ttc tgc att tca act 624 Asn Arg Gln Glu Phe Ala Val Ala Gly Tyr Glu Phe Cys Ile Ser Thr 195 200 205 cta gag gaa aaa att gaa aga gaa aag gaa tta gca gaa gac att atg 672 Leu Glu Glu Lys Ile Glu Arg Glu Lys Glu Leu Ala Glu Asp Ile Met 210 215 220 tca gtg gaa gag aaa gcc aat acc cac ctc ctc ttg ggc atg tgc tta 720 Ser Val Glu Glu Lys Ala Asn Thr His Leu Leu Leu Gly Met Cys Leu 225 230 235 240 gac gcc tgt gct cgc tac ctt ctg ttc tcc aag cag ccg tca cag gca 768 Asp Ala Cys Ala Arg Tyr Leu Leu Phe Ser Lys Gln Pro Ser Gln Ala 245 250 255 caa agg atg tat gaa aaa gct ctg cag att tct gaa gaa ata caa gga 816 Gln Arg Met Tyr Glu Lys Ala Leu Gln Ile Ser Glu Glu Ile Gln Gly 260 265 270 gaa aga cac cca cag acc att gtg ctg atg agt gac ctg gct act acc 864 Glu Arg His Pro Gln Thr Ile Val Leu Met Ser Asp Leu Ala Thr Thr 275 280 285 ctg gat gca cag ggc cgc ttt gat gag gcc tat att tat atg caa agg 912 Leu Asp Ala Gln Gly Arg Phe Asp Glu Ala Tyr Ile Tyr Met Gln Arg 290 295 300 gca tca gat ctg gca aga cag ata aat cat cct gag cta cac atg gta 960 Ala Ser Asp Leu Ala Arg Gln Ile Asn His Pro Glu Leu His Met Val 305 310 315 320 ctc agt aat cta gct gca gtt ttg atg cac aga gaa cga tat aca caa 1008 Leu Ser Asn Leu Ala Ala Val Leu Met His Arg Glu Arg Tyr Thr Gln 325 330 335 gca aaa gag atc tac cag gaa gca ctg aag caa gca aag ctg aaa aaa 1056 Ala Lys Glu Ile Tyr Gln Glu Ala Leu Lys Gln Ala Lys Leu Lys Lys 340 345 350 gat gaa att tct gta caa cac atc agg gaa gag ttg gct gag ctg tca 1104 Asp Glu Ile Ser Val Gln His Ile Arg Glu Glu Leu Ala Glu Leu Ser 355 360 365 aag aaa agt aga cct ttg aca aat tct gtc aag ctc taa 1143 Lys Lys Ser Arg Pro Leu Thr Asn Ser Val Lys Leu * 370 375 380 <210> SEQ ID NO 64 <211> LENGTH: 380 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 64 Met Phe Arg Leu Leu Ser Trp Ser Leu Gly Arg Gly Phe Leu Arg Ala 1 5 10 15 Ala Gly Arg Arg Cys Arg Gly Cys Ser Ala Arg Leu Leu Pro Gly Leu 20 25 30 Ala Gly Gly Pro Gly Pro Glu Val Gln Val Pro Pro Ser Arg Val Ala 35 40 45 Pro His Gly Arg Gly Pro Gly Leu Leu Pro Leu Leu Ala Ala Leu Ala 50 55 60 Trp Phe Ser Arg Pro Ala Ala Ala Glu Glu Glu Glu Gln Gln Gly Ala 65 70 75 80 Asp Gly Ala Ala Ala Glu Asp Gly Ala Asp Glu Ala Glu Ala Glu Ile 85 90 95 Ile Gln Leu Leu Lys Arg Ala Lys Leu Ser Ile Met Lys Asp Glu Pro 100 105 110 Glu Glu Ala Glu Leu Ile Leu His Asp Ala Leu Arg Leu Ala Tyr Gln 115 120 125 Thr Asp Asn Lys Lys Ala Ile Thr Tyr Thr Tyr Asp Leu Met Ala Asn 130 135 140 Leu Ala Phe Ile Arg Gly Gln Leu Glu Asn Ala Glu Gln Leu Phe Lys 145 150 155 160 Ala Thr Met Ser Tyr Leu Leu Gly Gly Gly Met Lys Gln Glu Asp Asn 165 170 175 Ala Ile Ile Glu Ile Ser Leu Lys Leu Ala Ser Ile Tyr Ala Ala Gln 180 185 190 Asn Arg Gln Glu Phe Ala Val Ala Gly Tyr Glu Phe Cys Ile Ser Thr 195 200 205 Leu Glu Glu Lys Ile Glu Arg Glu Lys Glu Leu Ala Glu Asp Ile Met 210 215 220 Ser Val Glu Glu Lys Ala Asn Thr His Leu Leu Leu Gly Met Cys Leu 225 230 235 240 Asp Ala Cys Ala Arg Tyr Leu Leu Phe Ser Lys Gln Pro Ser Gln Ala 245 250 255 Gln Arg Met Tyr Glu Lys Ala Leu Gln Ile Ser Glu Glu Ile Gln Gly 260 265 270 Glu Arg His Pro Gln Thr Ile Val Leu Met Ser Asp Leu Ala Thr Thr 275 280 285 Leu Asp Ala Gln Gly Arg Phe Asp Glu Ala Tyr Ile Tyr Met Gln Arg 290 295 300 Ala Ser Asp Leu Ala Arg Gln Ile Asn His Pro Glu Leu His Met Val 305 310 315 320 Leu Ser Asn Leu Ala Ala Val Leu Met His Arg Glu Arg Tyr Thr Gln 325 330 335 Ala Lys Glu Ile Tyr Gln Glu Ala Leu Lys Gln Ala Lys Leu Lys Lys 340 345 350 Asp Glu Ile Ser Val Gln His Ile Arg Glu Glu Leu Ala Glu Leu Ser 355 360 365 Lys Lys Ser Arg Pro Leu Thr Asn Ser Val Lys Leu 370 375 380 <210> SEQ ID NO 65 <211> LENGTH: 1410 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)...(1410) <400> SEQUENCE: 65 atg ctt gtg aac ttg tgc ttt cat att ttc cta acc tgt gtg gtc ttt 48 Met Leu Val Asn Leu Cys Phe His Ile Phe Leu Thr Cys Val Val Phe 1 5 10 15 gtg gga gga ata acc cag act agg aat gcc agc atc tgc caa gca gtt 96 Val Gly Gly Ile Thr Gln Thr Arg Asn Ala Ser Ile Cys Gln Ala Val 20 25 30 ggg ata att ctt cac tat tcc acc ctt gcc aca gta cta tgg gta gga 144 Gly Ile Ile Leu His Tyr Ser Thr Leu Ala Thr Val Leu Trp Val Gly 35 40 45 gtg aca gct cga aat atc tac aaa caa gtc act aaa aaa gct aaa aga 192 Val Thr Ala Arg Asn Ile Tyr Lys Gln Val Thr Lys Lys Ala Lys Arg 50 55 60 tgc cag gat cct gat gaa cca cca cct cca cca aga cca atg ctc aga 240 Cys Gln Asp Pro Asp Glu Pro Pro Pro Pro Pro Arg Pro Met Leu Arg 65 70 75 80 ttt tac ctg att ggt ggt ggt atc ccc atc att gtt tgc ggc ata act 288 Phe Tyr Leu Ile Gly Gly Gly Ile Pro Ile Ile Val Cys Gly Ile Thr 85 90 95 gca gca gcg aac att aag aat tac ggc agt cgg cca aac gca ccc tat 336 Ala Ala Ala Asn Ile Lys Asn Tyr Gly Ser Arg Pro Asn Ala Pro Tyr 100 105 110 tgc tgg atg gca tgg gaa ccc tcc ttg gga gcc ttc tat ggg cca gcc 384 Cys Trp Met Ala Trp Glu Pro Ser Leu Gly Ala Phe Tyr Gly Pro Ala 115 120 125 agc ttc atc act ttt gta aac tgc atg tac ttt ctg agc ata ttt att 432 Ser Phe Ile Thr Phe Val Asn Cys Met Tyr Phe Leu Ser Ile Phe Ile 130 135 140 cag ttg aaa aga cac cct gag cgc aaa tat gag ctt aag gag ccc acg 480 Gln Leu Lys Arg His Pro Glu Arg Lys Tyr Glu Leu Lys Glu Pro Thr 145 150 155 160 gag gag caa cag aga ttg gca gcc aat gaa aat ggc gaa ata aat cat 528 Glu Glu Gln Gln Arg Leu Ala Ala Asn Glu Asn Gly Glu Ile Asn His 165 170 175 cag gat tca atg tct ttg tct ctg att tct aca tca gcc ttg gaa aat 576 Gln Asp Ser Met Ser Leu Ser Leu Ile Ser Thr Ser Ala Leu Glu Asn 180 185 190 gag cac act ttt cat tct cag ctc ttg ggg gcc agc ctt act ttg ctc 624 Glu His Thr Phe His Ser Gln Leu Leu Gly Ala Ser Leu Thr Leu Leu 195 200 205 tta tat gtt gca ctg tgg atg ttt ggg gct ttg gct gtt tct ttg tat 672 Leu Tyr Val Ala Leu Trp Met Phe Gly Ala Leu Ala Val Ser Leu Tyr 210 215 220 tac cct ttg gac ttg gtt ttt agc ttc gtt ttt gga gcc aca agt tta 720 Tyr Pro Leu Asp Leu Val Phe Ser Phe Val Phe Gly Ala Thr Ser Leu 225 230 235 240 agc ttc agt gcg ttc ttc gtg gtc cac cat tgt gtt aat agg gag gat 768 Ser Phe Ser Ala Phe Phe Val Val His His Cys Val Asn Arg Glu Asp 245 250 255 gtt aga ctt gcg tgg atc atg act tgc tgc cca gga cgg agc tcg tat 816 Val Arg Leu Ala Trp Ile Met Thr Cys Cys Pro Gly Arg Ser Ser Tyr 260 265 270 tca gtg caa gtc aac gtc cag ccc ccc aac tct aat ggg acg aat gga 864 Ser Val Gln Val Asn Val Gln Pro Pro Asn Ser Asn Gly Thr Asn Gly 275 280 285 gag gca ccc aaa tgc ccc aat agc agt gcg gag tct tca tgc aca aac 912 Glu Ala Pro Lys Cys Pro Asn Ser Ser Ala Glu Ser Ser Cys Thr Asn 290 295 300 aaa agt gct tca agc ttc aaa aat tcc tcc cag ggc tgc aaa tta aca 960 Lys Ser Ala Ser Ser Phe Lys Asn Ser Ser Gln Gly Cys Lys Leu Thr 305 310 315 320 aac ttg cag gcg gct gca gct cag tgc cat gcc aat tct tta cct ttg 1008 Asn Leu Gln Ala Ala Ala Ala Gln Cys His Ala Asn Ser Leu Pro Leu 325 330 335 aac tcc acc cct cag ctt gat aat agt ctg aca gaa cat tca atg gac 1056 Asn Ser Thr Pro Gln Leu Asp Asn Ser Leu Thr Glu His Ser Met Asp 340 345 350 aat gat att aaa atg cac gtg gcg cct tta gaa gtt cag ttt cga aca 1104 Asn Asp Ile Lys Met His Val Ala Pro Leu Glu Val Gln Phe Arg Thr 355 360 365 aat gtg cac tca agc cgc cac cat aaa aac aga agt aaa gga cac cgg 1152 Asn Val His Ser Ser Arg His His Lys Asn Arg Ser Lys Gly His Arg 370 375 380 gca agc cga ctc aca gtc ctg aga gaa tat gcc tac gat gtc cca acg 1200 Ala Ser Arg Leu Thr Val Leu Arg Glu Tyr Ala Tyr Asp Val Pro Thr 385 390 395 400 agc gtg gaa gga agc gtg cag aac ggc tta cct aaa agc cgg ctg ggc 1248 Ser Val Glu Gly Ser Val Gln Asn Gly Leu Pro Lys Ser Arg Leu Gly 405 410 415 aat aac gaa gga cac tcg agg agc cga aga gct tat tta gcc tac aga 1296 Asn Asn Glu Gly His Ser Arg Ser Arg Arg Ala Tyr Leu Ala Tyr Arg 420 425 430 gag aga cag tac aac cca ccc cag caa gac agc agc gat gct tgt agc 1344 Glu Arg Gln Tyr Asn Pro Pro Gln Gln Asp Ser Ser Asp Ala Cys Ser 435 440 445 aca ctt ccc aaa agt agc aga aat ttt gaa aag cca gtt tca acc act 1392 Thr Leu Pro Lys Ser Ser Arg Asn Phe Glu Lys Pro Val Ser Thr Thr 450 455 460 agt aaa aag atg cgt taa 1410 Ser Lys Lys Met Arg * 465 <210> SEQ ID NO 66 <211> LENGTH: 469 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 66 Met Leu Val Asn Leu Cys Phe His Ile Phe Leu Thr Cys Val Val Phe 1 5 10 15 Val Gly Gly Ile Thr Gln Thr Arg Asn Ala Ser Ile Cys Gln Ala Val 20 25 30 Gly Ile Ile Leu His Tyr Ser Thr Leu Ala Thr Val Leu Trp Val Gly 35 40 45 Val Thr Ala Arg Asn Ile Tyr Lys Gln Val Thr Lys Lys Ala Lys Arg 50 55 60 Cys Gln Asp Pro Asp Glu Pro Pro Pro Pro Pro Arg Pro Met Leu Arg 65 70 75 80 Phe Tyr Leu Ile Gly Gly Gly Ile Pro Ile Ile Val Cys Gly Ile Thr 85 90 95 Ala Ala Ala Asn Ile Lys Asn Tyr Gly Ser Arg Pro Asn Ala Pro Tyr 100 105 110 Cys Trp Met Ala Trp Glu Pro Ser Leu Gly Ala Phe Tyr Gly Pro Ala 115 120 125 Ser Phe Ile Thr Phe Val Asn Cys Met Tyr Phe Leu Ser Ile Phe Ile 130 135 140 Gln Leu Lys Arg His Pro Glu Arg Lys Tyr Glu Leu Lys Glu Pro Thr 145 150 155 160 Glu Glu Gln Gln Arg Leu Ala Ala Asn Glu Asn Gly Glu Ile Asn His 165 170 175 Gln Asp Ser Met Ser Leu Ser Leu Ile Ser Thr Ser Ala Leu Glu Asn 180 185 190 Glu His Thr Phe His Ser Gln Leu Leu Gly Ala Ser Leu Thr Leu Leu 195 200 205 Leu Tyr Val Ala Leu Trp Met Phe Gly Ala Leu Ala Val Ser Leu Tyr 210 215 220 Tyr Pro Leu Asp Leu Val Phe Ser Phe Val Phe Gly Ala Thr Ser Leu 225 230 235 240 Ser Phe Ser Ala Phe Phe Val Val His His Cys Val Asn Arg Glu Asp 245 250 255 Val Arg Leu Ala Trp Ile Met Thr Cys Cys Pro Gly Arg Ser Ser Tyr 260 265 270 Ser Val Gln Val Asn Val Gln Pro Pro Asn Ser Asn Gly Thr Asn Gly 275 280 285 Glu Ala Pro Lys Cys Pro Asn Ser Ser Ala Glu Ser Ser Cys Thr Asn 290 295 300 Lys Ser Ala Ser Ser Phe Lys Asn Ser Ser Gln Gly Cys Lys Leu Thr 305 310 315 320 Asn Leu Gln Ala Ala Ala Ala Gln Cys His Ala Asn Ser Leu Pro Leu 325 330 335 Asn Ser Thr Pro Gln Leu Asp Asn Ser Leu Thr Glu His Ser Met Asp 340 345 350 Asn Asp Ile Lys Met His Val Ala Pro Leu Glu Val Gln Phe Arg Thr 355 360 365 Asn Val His Ser Ser Arg His His Lys Asn Arg Ser Lys Gly His Arg 370 375 380 Ala Ser Arg Leu Thr Val Leu Arg Glu Tyr Ala Tyr Asp Val Pro Thr 385 390 395 400 Ser Val Glu Gly Ser Val Gln Asn Gly Leu Pro Lys Ser Arg Leu Gly 405 410 415 Asn Asn Glu Gly His Ser Arg Ser Arg Arg Ala Tyr Leu Ala Tyr Arg 420 425 430 Glu Arg Gln Tyr Asn Pro Pro Gln Gln Asp Ser Ser Asp Ala Cys Ser 435 440 445 Thr Leu Pro Lys Ser Ser Arg Asn Phe Glu Lys Pro Val Ser Thr Thr 450 455 460 Ser Lys Lys Met Arg 465 <210> SEQ ID NO 67 <211> LENGTH: 426 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)...(426) <400> SEQUENCE: 67 atg gtg gac att gca tat ggc ggt gca ttt tat gca ttt gtt act gct 48 Met Val Asp Ile Ala Tyr Gly Gly Ala Phe Tyr Ala Phe Val Thr Ala 1 5 10 15 gaa aag tta gga cta gac att tgt tct gca aag acc agg gac ctt gtg 96 Glu Lys Leu Gly Leu Asp Ile Cys Ser Ala Lys Thr Arg Asp Leu Val 20 25 30 gat gca gcg agt gca gtg aca gag gca gtg aaa gct cag ttt aaa att 144 Asp Ala Ala Ser Ala Val Thr Glu Ala Val Lys Ala Gln Phe Lys Ile 35 40 45 aat cat cct gat agt gaa gac ctt gcc ttt tta tat gga act ata tta 192 Asn His Pro Asp Ser Glu Asp Leu Ala Phe Leu Tyr Gly Thr Ile Leu 50 55 60 aca gat gga aaa gat gct tat acc aag gaa cca acc acc aac att tgt 240 Thr Asp Gly Lys Asp Ala Tyr Thr Lys Glu Pro Thr Thr Asn Ile Cys 65 70 75 80 gtt ttt gca gat gaa cag gtt gac aga agt ccc act ggc tca gga gtg 288 Val Phe Ala Asp Glu Gln Val Asp Arg Ser Pro Thr Gly Ser Gly Val 85 90 95 aca gcc cga att gcc tta cag tat cac aaa ggg ctt ctg gaa ctg aac 336 Thr Ala Arg Ile Ala Leu Gln Tyr His Lys Gly Leu Leu Glu Leu Asn 100 105 110 cag atg aga gcc ttc aaa agc agt gca act ggc tca gta ttc aca ggg 384 Gln Met Arg Ala Phe Lys Ser Ser Ala Thr Gly Ser Val Phe Thr Gly 115 120 125 aaa gct gtg agg gaa gcg gca ccc tta gct tct tat tta taa 426 Lys Ala Val Arg Glu Ala Ala Pro Leu Ala Ser Tyr Leu * 130 135 140 <210> SEQ ID NO 68 <211> LENGTH: 141 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 68 Met Val Asp Ile Ala Tyr Gly Gly Ala Phe Tyr Ala Phe Val Thr Ala 1 5 10 15 Glu Lys Leu Gly Leu Asp Ile Cys Ser Ala Lys Thr Arg Asp Leu Val 20 25 30 Asp Ala Ala Ser Ala Val Thr Glu Ala Val Lys Ala Gln Phe Lys Ile 35 40 45 Asn His Pro Asp Ser Glu Asp Leu Ala Phe Leu Tyr Gly Thr Ile Leu 50 55 60 Thr Asp Gly Lys Asp Ala Tyr Thr Lys Glu Pro Thr Thr Asn Ile Cys 65 70 75 80 Val Phe Ala Asp Glu Gln Val Asp Arg Ser Pro Thr Gly Ser Gly Val 85 90 95 Thr Ala Arg Ile Ala Leu Gln Tyr His Lys Gly Leu Leu Glu Leu Asn 100 105 110 Gln Met Arg Ala Phe Lys Ser Ser Ala Thr Gly Ser Val Phe Thr Gly 115 120 125 Lys Ala Val Arg Glu Ala Ala Pro Leu Ala Ser Tyr Leu 130 135 140 <210> SEQ ID NO 69 <211> LENGTH: 480 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)...(480) <400> SEQUENCE: 69 atg gtg ctg cgg cgg ctg ctg gcc gcc ctg ctg cac agc ccg cag ctg 48 Met Val Leu Arg Arg Leu Leu Ala Ala Leu Leu His Ser Pro Gln Leu 1 5 10 15 gtg gaa cgt ctg tca gag tcg cgg cct atc cga cgt gcg gcg cac tca 96 Val Glu Arg Leu Ser Glu Ser Arg Pro Ile Arg Arg Ala Ala His Ser 20 25 30 cgg cct tcg cac tgc tgc agg ccc agc tgc ggg gcc agg acg cgg ccc 144 Arg Pro Ser His Cys Cys Arg Pro Ser Cys Gly Ala Arg Thr Arg Pro 35 40 45 gcc gcc tgc agg acc tcg cgg ctg ggc ccg tgg gct ccc tgt gcc gcc 192 Ala Ala Cys Arg Thr Ser Arg Leu Gly Pro Trp Ala Pro Cys Ala Ala 50 55 60 gcg ctg agc gat tta gag acg cct tca ccc agg agc tac gcc gcg gcc 240 Ala Leu Ser Asp Leu Glu Thr Pro Ser Pro Arg Ser Tyr Ala Ala Ala 65 70 75 80 tcc gag gcc gct cgg ggc cac cac cag gta gcc aga ggg gcc ctg gcg 288 Ser Glu Ala Ala Arg Gly His His Gln Val Ala Arg Gly Ala Leu Ala 85 90 95 caa aca ttt aat cct ggg ctg tgc ggg gcc gag gcc gct tgc ttt tcc 336 Gln Thr Phe Asn Pro Gly Leu Cys Gly Ala Glu Ala Ala Cys Phe Ser 100 105 110 ttc cgg gct cta cag tgg cat caa tgt gga ggg gtc att ccg ggc act 384 Phe Arg Ala Leu Gln Trp His Gln Cys Gly Gly Val Ile Pro Gly Thr 115 120 125 gcg cgc ggc ttc gaa tcc cga ctg gga ttg ttg gcc tgc aga cat ccc 432 Ala Arg Gly Phe Glu Ser Arg Leu Gly Leu Leu Ala Cys Arg His Pro 130 135 140 acg cat aag agc cta ggc cag acc gcc cgc tcc gtt gaa gtc ttg tga 480 Thr His Lys Ser Leu Gly Gln Thr Ala Arg Ser Val Glu Val Leu * 145 150 155 <210> SEQ ID NO 70 <211> LENGTH: 159 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 70 Met Val Leu Arg Arg Leu Leu Ala Ala Leu Leu His Ser Pro Gln Leu 1 5 10 15 Val Glu Arg Leu Ser Glu Ser Arg Pro Ile Arg Arg Ala Ala His Ser 20 25 30 Arg Pro Ser His Cys Cys Arg Pro Ser Cys Gly Ala Arg Thr Arg Pro 35 40 45 Ala Ala Cys Arg Thr Ser Arg Leu Gly Pro Trp Ala Pro Cys Ala Ala 50 55 60 Ala Leu Ser Asp Leu Glu Thr Pro Ser Pro Arg Ser Tyr Ala Ala Ala 65 70 75 80 Ser Glu Ala Ala Arg Gly His His Gln Val Ala Arg Gly Ala Leu Ala 85 90 95 Gln Thr Phe Asn Pro Gly Leu Cys Gly Ala Glu Ala Ala Cys Phe Ser 100 105 110 Phe Arg Ala Leu Gln Trp His Gln Cys Gly Gly Val Ile Pro Gly Thr 115 120 125 Ala Arg Gly Phe Glu Ser Arg Leu Gly Leu Leu Ala Cys Arg His Pro 130 135 140 Thr His Lys Ser Leu Gly Gln Thr Ala Arg Ser Val Glu Val Leu 145 150 155 <210> SEQ ID NO 71 <211> LENGTH: 345 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)...(345) <400> SEQUENCE: 71 atg tgg aca gct ctt gtg ctc att tgg att ttc tcc ttg tcc tta tct 48 Met Trp Thr Ala Leu Val Leu Ile Trp Ile Phe Ser Leu Ser Leu Ser 1 5 10 15 gaa agc cat gcg gca tcc aac gat cca cgc aac ttt gtc cct aac aaa 96 Glu Ser His Ala Ala Ser Asn Asp Pro Arg Asn Phe Val Pro Asn Lys 20 25 30 atg tgg aag gga tta gtc aag agg aat gca tct gtg gaa aca gtt gat 144 Met Trp Lys Gly Leu Val Lys Arg Asn Ala Ser Val Glu Thr Val Asp 35 40 45 aat aaa acg tct gag gat gta acc atg gca gca gct tct cct gtc aca 192 Asn Lys Thr Ser Glu Asp Val Thr Met Ala Ala Ala Ser Pro Val Thr 50 55 60 ttg acc aaa ggg act tcg gca gcc cac ctc aac tct atg gaa gtc aca 240 Leu Thr Lys Gly Thr Ser Ala Ala His Leu Asn Ser Met Glu Val Thr 65 70 75 80 aca gag gac aca agc agg aca gag gcc tat gag agc tac aag aag aag 288 Thr Glu Asp Thr Ser Arg Thr Glu Ala Tyr Glu Ser Tyr Lys Lys Lys 85 90 95 gac tac acc cag gtg gac tac tta atc aac ggg atg tat gcg gac tca 336 Asp Tyr Thr Gln Val Asp Tyr Leu Ile Asn Gly Met Tyr Ala Asp Ser 100 105 110 gaa atg tga 345 Glu Met * <210> SEQ ID NO 72 <211> LENGTH: 114 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 72 Met Trp Thr Ala Leu Val Leu Ile Trp Ile Phe Ser Leu Ser Leu Ser 1 5 10 15 Glu Ser His Ala Ala Ser Asn Asp Pro Arg Asn Phe Val Pro Asn Lys 20 25 30 Met Trp Lys Gly Leu Val Lys Arg Asn Ala Ser Val Glu Thr Val Asp 35 40 45 Asn Lys Thr Ser Glu Asp Val Thr Met Ala Ala Ala Ser Pro Val Thr 50 55 60 Leu Thr Lys Gly Thr Ser Ala Ala His Leu Asn Ser Met Glu Val Thr 65 70 75 80 Thr Glu Asp Thr Ser Arg Thr Glu Ala Tyr Glu Ser Tyr Lys Lys Lys 85 90 95 Asp Tyr Thr Gln Val Asp Tyr Leu Ile Asn Gly Met Tyr Ala Asp Ser 100 105 110 Glu Met <210> SEQ ID NO 73 <211> LENGTH: 465 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)...(465) <400> SEQUENCE: 73 atg ggc cga gct gag gcc atg gcc gcc tac ctg gcc ctg gcg gcg cag 48 Met Gly Arg Ala Glu Ala Met Ala Ala Tyr Leu Ala Leu Ala Ala Gln 1 5 10 15 tgt ccg ggg ttc ggc gct gct cgg tat gac gtt ctg gag ctg agc acg 96 Cys Pro Gly Phe Gly Ala Ala Arg Tyr Asp Val Leu Glu Leu Ser Thr 20 25 30 gag cct ggt cgg ggt gct cca cag aag ctg tgc ctg ggc ttg gga gcc 144 Glu Pro Gly Arg Gly Ala Pro Gln Lys Leu Cys Leu Gly Leu Gly Ala 35 40 45 aag gcc atg tcc ctc tcc cgg cca ggg gag acg gag ccc atc cac agt 192 Lys Ala Met Ser Leu Ser Arg Pro Gly Glu Thr Glu Pro Ile His Ser 50 55 60 gtc agc tat ggc cat gtg gcc gcc tgc cag cta atg ggc ccc cac acc 240 Val Ser Tyr Gly His Val Ala Ala Cys Gln Leu Met Gly Pro His Thr 65 70 75 80 ctg gcc ttg agg gtg gga gag agc cag ctc ctc ctg cag agc ccc cag 288 Leu Ala Leu Arg Val Gly Glu Ser Gln Leu Leu Leu Gln Ser Pro Gln 85 90 95 gtg gaa gag atc atg cag ctg gtg aat gcc tac ttg gcc aac ccc tcc 336 Val Glu Glu Ile Met Gln Leu Val Asn Ala Tyr Leu Ala Asn Pro Ser 100 105 110 ccc gag agg ccc tgc agc agc tct tct cct cca tgc caa gac ctg cca 384 Pro Glu Arg Pro Cys Ser Ser Ser Ser Pro Pro Cys Gln Asp Leu Pro 115 120 125 gac acc tcc cct ccc agc cag cgc ccg ggc ctg gac gag ccc cag gga 432 Asp Thr Ser Pro Pro Ser Gln Arg Pro Gly Leu Asp Glu Pro Gln Gly 130 135 140 cag tct ggc tgc ttg ggg cag ctg cag gac tga 465 Gln Ser Gly Cys Leu Gly Gln Leu Gln Asp * 145 150 <210> SEQ ID NO 74 <211> LENGTH: 154 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 74 Met Gly Arg Ala Glu Ala Met Ala Ala Tyr Leu Ala Leu Ala Ala Gln 1 5 10 15 Cys Pro Gly Phe Gly Ala Ala Arg Tyr Asp Val Leu Glu Leu Ser Thr 20 25 30 Glu Pro Gly Arg Gly Ala Pro Gln Lys Leu Cys Leu Gly Leu Gly Ala 35 40 45 Lys Ala Met Ser Leu Ser Arg Pro Gly Glu Thr Glu Pro Ile His Ser 50 55 60 Val Ser Tyr Gly His Val Ala Ala Cys Gln Leu Met Gly Pro His Thr 65 70 75 80 Leu Ala Leu Arg Val Gly Glu Ser Gln Leu Leu Leu Gln Ser Pro Gln 85 90 95 Val Glu Glu Ile Met Gln Leu Val Asn Ala Tyr Leu Ala Asn Pro Ser 100 105 110 Pro Glu Arg Pro Cys Ser Ser Ser Ser Pro Pro Cys Gln Asp Leu Pro 115 120 125 Asp Thr Ser Pro Pro Ser Gln Arg Pro Gly Leu Asp Glu Pro Gln Gly 130 135 140 Gln Ser Gly Cys Leu Gly Gln Leu Gln Asp 145 150 <210> SEQ ID NO 75 <211> LENGTH: 708 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)...(708) <400> SEQUENCE: 75 atg aag ctt ttg cgc cag agc ttg gcc act ctc cta att acc tcc cag 48 Met Lys Leu Leu Arg Gln Ser Leu Ala Thr Leu Leu Ile Thr Ser Gln 1 5 10 15 atc ctc aac caa att atg gaa tct ttt ctt cct tat tgg ctc caa agg 96 Ile Leu Asn Gln Ile Met Glu Ser Phe Leu Pro Tyr Trp Leu Gln Arg 20 25 30 aag cat ggt gtg cag gtg aag agg aag gtg cag gct tta aag gca gac 144 Lys His Gly Val Gln Val Lys Arg Lys Val Gln Ala Leu Lys Ala Asp 35 40 45 att gat gct aca tta tat gaa caa gtc atc ctg gaa aaa gaa atg gga 192 Ile Asp Ala Thr Leu Tyr Glu Gln Val Ile Leu Glu Lys Glu Met Gly 50 55 60 act tat ttg ggc acc ttt gat gat tac ttg gag tta ttc ctg cag ttt 240 Thr Tyr Leu Gly Thr Phe Asp Asp Tyr Leu Glu Leu Phe Leu Gln Phe 65 70 75 80 ggt tat gtg agc ctt ttc tcc tgt gtt tac cca tta gca gct gcc ttt 288 Gly Tyr Val Ser Leu Phe Ser Cys Val Tyr Pro Leu Ala Ala Ala Phe 85 90 95 gct gtg tta aat aac ttc act gaa gta aat tca gat gcc tta aaa atg 336 Ala Val Leu Asn Asn Phe Thr Glu Val Asn Ser Asp Ala Leu Lys Met 100 105 110 tgc agg gtc ttc aaa cgt cca ttc tca gaa cct tca gcc aat att ggt 384 Cys Arg Val Phe Lys Arg Pro Phe Ser Glu Pro Ser Ala Asn Ile Gly 115 120 125 gtg tgg cag ttg gct ttt gaa acg atg agt gtt ata tct gtg gtc act 432 Val Trp Gln Leu Ala Phe Glu Thr Met Ser Val Ile Ser Val Val Thr 130 135 140 aac tgt gcg ctg att gga atg tca cca caa gtg aat gca gtc ttt cca 480 Asn Cys Ala Leu Ile Gly Met Ser Pro Gln Val Asn Ala Val Phe Pro 145 150 155 160 gaa tca aaa gca gac ctc att ttg att gta gta gca gtg gag cac gca 528 Glu Ser Lys Ala Asp Leu Ile Leu Ile Val Val Ala Val Glu His Ala 165 170 175 ctc ctg gct tta aag ttt ata ctt gca ttt gcc ata cct gat aag cca 576 Leu Leu Ala Leu Lys Phe Ile Leu Ala Phe Ala Ile Pro Asp Lys Pro 180 185 190 cgg cat atc cag atg aaa cta gcc aga ctg gaa ttt gag tct ttg gag 624 Arg His Ile Gln Met Lys Leu Ala Arg Leu Glu Phe Glu Ser Leu Glu 195 200 205 gca ctc aag cag cag caa atg aag ctc gtg acc gag aac ctg aag gag 672 Ala Leu Lys Gln Gln Gln Met Lys Leu Val Thr Glu Asn Leu Lys Glu 210 215 220 gaa cca atg gaa agc ggg aag gag aag gca acc tga 708 Glu Pro Met Glu Ser Gly Lys Glu Lys Ala Thr * 225 230 235 <210> SEQ ID NO 76 <211> LENGTH: 235 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 76 Met Lys Leu Leu Arg Gln Ser Leu Ala Thr Leu Leu Ile Thr Ser Gln 1 5 10 15 Ile Leu Asn Gln Ile Met Glu Ser Phe Leu Pro Tyr Trp Leu Gln Arg 20 25 30 Lys His Gly Val Gln Val Lys Arg Lys Val Gln Ala Leu Lys Ala Asp 35 40 45 Ile Asp Ala Thr Leu Tyr Glu Gln Val Ile Leu Glu Lys Glu Met Gly 50 55 60 Thr Tyr Leu Gly Thr Phe Asp Asp Tyr Leu Glu Leu Phe Leu Gln Phe 65 70 75 80 Gly Tyr Val Ser Leu Phe Ser Cys Val Tyr Pro Leu Ala Ala Ala Phe 85 90 95 Ala Val Leu Asn Asn Phe Thr Glu Val Asn Ser Asp Ala Leu Lys Met 100 105 110 Cys Arg Val Phe Lys Arg Pro Phe Ser Glu Pro Ser Ala Asn Ile Gly 115 120 125 Val Trp Gln Leu Ala Phe Glu Thr Met Ser Val Ile Ser Val Val Thr 130 135 140 Asn Cys Ala Leu Ile Gly Met Ser Pro Gln Val Asn Ala Val Phe Pro 145 150 155 160 Glu Ser Lys Ala Asp Leu Ile Leu Ile Val Val Ala Val Glu His Ala 165 170 175 Leu Leu Ala Leu Lys Phe Ile Leu Ala Phe Ala Ile Pro Asp Lys Pro 180 185 190 Arg His Ile Gln Met Lys Leu Ala Arg Leu Glu Phe Glu Ser Leu Glu 195 200 205 Ala Leu Lys Gln Gln Gln Met Lys Leu Val Thr Glu Asn Leu Lys Glu 210 215 220 Glu Pro Met Glu Ser Gly Lys Glu Lys Ala Thr 225 230 235 <210> SEQ ID NO 77 <211> LENGTH: 852 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)...(852) <400> SEQUENCE: 77 atg gcg cgg aga ccc cgg gcg ccg gcc gcc tcc ggg gag gag ttc tcc 48 Met Ala Arg Arg Pro Arg Ala Pro Ala Ala Ser Gly Glu Glu Phe Ser 1 5 10 15 ttc gtc agc ccg ctg gtg aaa tac ctg ctc ttc ttc ttc aac atg ctc 96 Phe Val Ser Pro Leu Val Lys Tyr Leu Leu Phe Phe Phe Asn Met Leu 20 25 30 ttc tgg gtg att tcc atg gtg atg gtg gct gtg ggt gtc tac gct cgg 144 Phe Trp Val Ile Ser Met Val Met Val Ala Val Gly Val Tyr Ala Arg 35 40 45 cta atg aag cat gca gaa gca gcc cta gcc tgc ctg gca gtg gac cct 192 Leu Met Lys His Ala Glu Ala Ala Leu Ala Cys Leu Ala Val Asp Pro 50 55 60 gcc atc ctg ctg atc gtg gtg ggt gtc ctc atg ttc ctg ctc acc ttc 240 Ala Ile Leu Leu Ile Val Val Gly Val Leu Met Phe Leu Leu Thr Phe 65 70 75 80 tgt ggc tgc att ggg tcc ctc cgc gag aac atc tgc ctc ctg cag acg 288 Cys Gly Cys Ile Gly Ser Leu Arg Glu Asn Ile Cys Leu Leu Gln Thr 85 90 95 ttc tcc ctc tgc ctc acc gct gtg ttc ctg ctg cag ctg gcc gct ggg 336 Phe Ser Leu Cys Leu Thr Ala Val Phe Leu Leu Gln Leu Ala Ala Gly 100 105 110 atc ctg ggc ttc gtc ttc tca gac aag gct cga ggg aaa gtg agt gag 384 Ile Leu Gly Phe Val Phe Ser Asp Lys Ala Arg Gly Lys Val Ser Glu 115 120 125 atc atc aac aat gcc att gtg cac tac cga gat gac ttg gat ctg cag 432 Ile Ile Asn Asn Ala Ile Val His Tyr Arg Asp Asp Leu Asp Leu Gln 130 135 140 aac ctc att gat ttt ggc cag aaa aag ttt agc tgc tgt gga ggg att 480 Asn Leu Ile Asp Phe Gly Gln Lys Lys Phe Ser Cys Cys Gly Gly Ile 145 150 155 160 tcc tac aag gac tgg tct cag aac atg tat ttc aac tgc tca gaa gac 528 Ser Tyr Lys Asp Trp Ser Gln Asn Met Tyr Phe Asn Cys Ser Glu Asp 165 170 175 aac ccc agt cga gag cgc tgc tct gtg cct tac tcc tgt tgc ttg cct 576 Asn Pro Ser Arg Glu Arg Cys Ser Val Pro Tyr Ser Cys Cys Leu Pro 180 185 190 act cct gac cag gca gtg atc aac act atg tgt ggc caa ggt atg cag 624 Thr Pro Asp Gln Ala Val Ile Asn Thr Met Cys Gly Gln Gly Met Gln 195 200 205 gcc ttt gac tac ttg gaa gct agc aaa gtc atc tac acc aat ggc tgt 672 Ala Phe Asp Tyr Leu Glu Ala Ser Lys Val Ile Tyr Thr Asn Gly Cys 210 215 220 att gac aag ttg gtc aac tgg ata cac agc aac cta ttc tta ctt ggt 720 Ile Asp Lys Leu Val Asn Trp Ile His Ser Asn Leu Phe Leu Leu Gly 225 230 235 240 ggt gtg gct cta ggc ctg gcc atc ccc cag ctg gtg gga att ctg ctg 768 Gly Val Ala Leu Gly Leu Ala Ile Pro Gln Leu Val Gly Ile Leu Leu 245 250 255 tcc cag atc cta gtg aat cag atc aaa gat cag atc aag cta cag ctc 816 Ser Gln Ile Leu Val Asn Gln Ile Lys Asp Gln Ile Lys Leu Gln Leu 260 265 270 tac aac cag cag cac cgg gct gac cca tgg tac tga 852 Tyr Asn Gln Gln His Arg Ala Asp Pro Trp Tyr * 275 280 <210> SEQ ID NO 78 <211> LENGTH: 283 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 78 Met Ala Arg Arg Pro Arg Ala Pro Ala Ala Ser Gly Glu Glu Phe Ser 1 5 10 15 Phe Val Ser Pro Leu Val Lys Tyr Leu Leu Phe Phe Phe Asn Met Leu 20 25 30 Phe Trp Val Ile Ser Met Val Met Val Ala Val Gly Val Tyr Ala Arg 35 40 45 Leu Met Lys His Ala Glu Ala Ala Leu Ala Cys Leu Ala Val Asp Pro 50 55 60 Ala Ile Leu Leu Ile Val Val Gly Val Leu Met Phe Leu Leu Thr Phe 65 70 75 80 Cys Gly Cys Ile Gly Ser Leu Arg Glu Asn Ile Cys Leu Leu Gln Thr 85 90 95 Phe Ser Leu Cys Leu Thr Ala Val Phe Leu Leu Gln Leu Ala Ala Gly 100 105 110 Ile Leu Gly Phe Val Phe Ser Asp Lys Ala Arg Gly Lys Val Ser Glu 115 120 125 Ile Ile Asn Asn Ala Ile Val His Tyr Arg Asp Asp Leu Asp Leu Gln 130 135 140 Asn Leu Ile Asp Phe Gly Gln Lys Lys Phe Ser Cys Cys Gly Gly Ile 145 150 155 160 Ser Tyr Lys Asp Trp Ser Gln Asn Met Tyr Phe Asn Cys Ser Glu Asp 165 170 175 Asn Pro Ser Arg Glu Arg Cys Ser Val Pro Tyr Ser Cys Cys Leu Pro 180 185 190 Thr Pro Asp Gln Ala Val Ile Asn Thr Met Cys Gly Gln Gly Met Gln 195 200 205 Ala Phe Asp Tyr Leu Glu Ala Ser Lys Val Ile Tyr Thr Asn Gly Cys 210 215 220 Ile Asp Lys Leu Val Asn Trp Ile His Ser Asn Leu Phe Leu Leu Gly 225 230 235 240 Gly Val Ala Leu Gly Leu Ala Ile Pro Gln Leu Val Gly Ile Leu Leu 245 250 255 Ser Gln Ile Leu Val Asn Gln Ile Lys Asp Gln Ile Lys Leu Gln Leu 260 265 270 Tyr Asn Gln Gln His Arg Ala Asp Pro Trp Tyr 275 280 <210> SEQ ID NO 79 <211> LENGTH: 774 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)...(774) <400> SEQUENCE: 79 atg act gcg gcc gtg ttc ttc ggc tgc gcc ttc att gcc ttc ggg cct 48 Met Thr Ala Ala Val Phe Phe Gly Cys Ala Phe Ile Ala Phe Gly Pro 1 5 10 15 gcg ctc gcc ctt tat gtc ttc acc atc gcc acc gag ccg ttg cgt atc 96 Ala Leu Ala Leu Tyr Val Phe Thr Ile Ala Thr Glu Pro Leu Arg Ile 20 25 30 atc ttc ctc atc gcc gga gct ttc ttc tgg ttg gtg tct cta ctg att 144 Ile Phe Leu Ile Ala Gly Ala Phe Phe Trp Leu Val Ser Leu Leu Ile 35 40 45 tcg tcc ctt gtt tgg ttc atg gca aga gtc att att gac aac aaa gat 192 Ser Ser Leu Val Trp Phe Met Ala Arg Val Ile Ile Asp Asn Lys Asp 50 55 60 gga cca aca cag aaa tat ctg ctg atc ttt gga gcg ttt gtc tct gtc 240 Gly Pro Thr Gln Lys Tyr Leu Leu Ile Phe Gly Ala Phe Val Ser Val 65 70 75 80 tat atc caa gaa atg ttc cga ttt gca tat tat aaa ctc tta aaa aaa 288 Tyr Ile Gln Glu Met Phe Arg Phe Ala Tyr Tyr Lys Leu Leu Lys Lys 85 90 95 gcc agt gaa ggt ttg aag agt ata aac cca ggt gag aca gca ccc tct 336 Ala Ser Glu Gly Leu Lys Ser Ile Asn Pro Gly Glu Thr Ala Pro Ser 100 105 110 atg cga ctg ctg gcc tat gtt tct ggc ttg ggc ttt gga atc atg agt 384 Met Arg Leu Leu Ala Tyr Val Ser Gly Leu Gly Phe Gly Ile Met Ser 115 120 125 gga gta ttt tcc ttt gtg aat acc cta tct gac tcc ttg ggg cca ggc 432 Gly Val Phe Ser Phe Val Asn Thr Leu Ser Asp Ser Leu Gly Pro Gly 130 135 140 aca gtg ggc att cat gga gat tct cct caa ttc ttc ctt tat tca gct 480 Thr Val Gly Ile His Gly Asp Ser Pro Gln Phe Phe Leu Tyr Ser Ala 145 150 155 160 ttc atg acg ctg gtc att atc ttg ctg cat gta ttc tgg ggc att gta 528 Phe Met Thr Leu Val Ile Ile Leu Leu His Val Phe Trp Gly Ile Val 165 170 175 ttt ttt gat ggc tgt gag aag aaa aag tgg ggc atc ctc ctt atc gtt 576 Phe Phe Asp Gly Cys Glu Lys Lys Lys Trp Gly Ile Leu Leu Ile Val 180 185 190 ctc ctg acc cac ctg ctg gtg tca gcc cag acc ttc ata agt tct tat 624 Leu Leu Thr His Leu Leu Val Ser Ala Gln Thr Phe Ile Ser Ser Tyr 195 200 205 tat gga ata aac ctg gcg tca gca ttt ata atc ctg gtg ctc atg ggc 672 Tyr Gly Ile Asn Leu Ala Ser Ala Phe Ile Ile Leu Val Leu Met Gly 210 215 220 acc tgg gca ttc tta gct gcg gga ggc agc tgc cga agc ctg aaa ctc 720 Thr Trp Ala Phe Leu Ala Ala Gly Gly Ser Cys Arg Ser Leu Lys Leu 225 230 235 240 tgc ctg ctc tgc caa gac aag aac ttt ctt ctt tac aac cag cgc tcc 768 Cys Leu Leu Cys Gln Asp Lys Asn Phe Leu Leu Tyr Asn Gln Arg Ser 245 250 255 aga taa 774 Arg * <210> SEQ ID NO 80 <211> LENGTH: 257 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 80 Met Thr Ala Ala Val Phe Phe Gly Cys Ala Phe Ile Ala Phe Gly Pro 1 5 10 15 Ala Leu Ala Leu Tyr Val Phe Thr Ile Ala Thr Glu Pro Leu Arg Ile 20 25 30 Ile Phe Leu Ile Ala Gly Ala Phe Phe Trp Leu Val Ser Leu Leu Ile 35 40 45 Ser Ser Leu Val Trp Phe Met Ala Arg Val Ile Ile Asp Asn Lys Asp 50 55 60 Gly Pro Thr Gln Lys Tyr Leu Leu Ile Phe Gly Ala Phe Val Ser Val 65 70 75 80 Tyr Ile Gln Glu Met Phe Arg Phe Ala Tyr Tyr Lys Leu Leu Lys Lys 85 90 95 Ala Ser Glu Gly Leu Lys Ser Ile Asn Pro Gly Glu Thr Ala Pro Ser 100 105 110 Met Arg Leu Leu Ala Tyr Val Ser Gly Leu Gly Phe Gly Ile Met Ser 115 120 125 Gly Val Phe Ser Phe Val Asn Thr Leu Ser Asp Ser Leu Gly Pro Gly 130 135 140 Thr Val Gly Ile His Gly Asp Ser Pro Gln Phe Phe Leu Tyr Ser Ala 145 150 155 160 Phe Met Thr Leu Val Ile Ile Leu Leu His Val Phe Trp Gly Ile Val 165 170 175 Phe Phe Asp Gly Cys Glu Lys Lys Lys Trp Gly Ile Leu Leu Ile Val 180 185 190 Leu Leu Thr His Leu Leu Val Ser Ala Gln Thr Phe Ile Ser Ser Tyr 195 200 205 Tyr Gly Ile Asn Leu Ala Ser Ala Phe Ile Ile Leu Val Leu Met Gly 210 215 220 Thr Trp Ala Phe Leu Ala Ala Gly Gly Ser Cys Arg Ser Leu Lys Leu 225 230 235 240 Cys Leu Leu Cys Gln Asp Lys Asn Phe Leu Leu Tyr Asn Gln Arg Ser 245 250 255 Arg <210> SEQ ID NO 81 <211> LENGTH: 861 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)...(861) <400> SEQUENCE: 81 atg cag tac cac gcg ctg tcg ttg gcc atg cac ggc ttc tcg gtg acc 48 Met Gln Tyr His Ala Leu Ser Leu Ala Met His Gly Phe Ser Val Thr 1 5 10 15 ctc ctg ggg ttc tgc aac tcc aaa ccc cat gat gag ctc ttg cag aac 96 Leu Leu Gly Phe Cys Asn Ser Lys Pro His Asp Glu Leu Leu Gln Asn 20 25 30 aac aga att cag att gtg ggg ttg aca gaa ctt cag agt ctt gca gtt 144 Asn Arg Ile Gln Ile Val Gly Leu Thr Glu Leu Gln Ser Leu Ala Val 35 40 45 ggg ccc cga gtt ttc cag tac gga gtc aaa gtt gta ctt cag gct atg 192 Gly Pro Arg Val Phe Gln Tyr Gly Val Lys Val Val Leu Gln Ala Met 50 55 60 tac ttg ctg tgg aag ttg atg tgg agg gag cca ggt gcc tat atc ttt 240 Tyr Leu Leu Trp Lys Leu Met Trp Arg Glu Pro Gly Ala Tyr Ile Phe 65 70 75 80 ctc cag aac ccc cca ggt ctg cct agc att gct gtc tgc tgg ttc gtg 288 Leu Gln Asn Pro Pro Gly Leu Pro Ser Ile Ala Val Cys Trp Phe Val 85 90 95 ggc tgc ctt tgt gga agc aag ctc gtc att gac tgg cac aac tat ggc 336 Gly Cys Leu Cys Gly Ser Lys Leu Val Ile Asp Trp His Asn Tyr Gly 100 105 110 tac tcc atc atg ggt ctg gtg cat ggc ccc aac cat ccc ctc gtt ctg 384 Tyr Ser Ile Met Gly Leu Val His Gly Pro Asn His Pro Leu Val Leu 115 120 125 ctg gcc aag tgg tac gag aag ttc ttt ggg cgc ctg tcc cac ctg aac 432 Leu Ala Lys Trp Tyr Glu Lys Phe Phe Gly Arg Leu Ser His Leu Asn 130 135 140 ctg tgt gtt acc aat gct atg cga gaa gac ctg gcg gat aac tgg cac 480 Leu Cys Val Thr Asn Ala Met Arg Glu Asp Leu Ala Asp Asn Trp His 145 150 155 160 atc agg gct gtg acc gtc tac gac aag ccc gca tct ttc ttt aaa gag 528 Ile Arg Ala Val Thr Val Tyr Asp Lys Pro Ala Ser Phe Phe Lys Glu 165 170 175 aca cct ctg gac ctg cag cac cgg ctc ttc atg aag ctg ggc agc atg 576 Thr Pro Leu Asp Leu Gln His Arg Leu Phe Met Lys Leu Gly Ser Met 180 185 190 cac tct ccg ttc agg gcc cgc tca gaa cct gag gac cca gtc acg gag 624 His Ser Pro Phe Arg Ala Arg Ser Glu Pro Glu Asp Pro Val Thr Glu 195 200 205 cgg tcg gcc ttc acg gag cgg gat gct ggg agc ggg ctg gtg acg cgt 672 Arg Ser Ala Phe Thr Glu Arg Asp Ala Gly Ser Gly Leu Val Thr Arg 210 215 220 ctc cgt gag cgg cca gcc ctg ctg gtc agc agc acg agc tgg aca gag 720 Leu Arg Glu Arg Pro Ala Leu Leu Val Ser Ser Thr Ser Trp Thr Glu 225 230 235 240 gac gaa gac ttc tcc atc ctg cgg gaa gct ttg gtt ggc ctt gat ttc 768 Asp Glu Asp Phe Ser Ile Leu Arg Glu Ala Leu Val Gly Leu Asp Phe 245 250 255 ttc tct gga ggc ttg gaa acg ctt cct ctc ttc ttc tgt tct tca cgc 816 Phe Ser Gly Gly Leu Glu Thr Leu Pro Leu Phe Phe Cys Ser Ser Arg 260 265 270 ccc atg ccc ctg cta gcg tat tac tgt tct gtg act tcc ctg tga 861 Pro Met Pro Leu Leu Ala Tyr Tyr Cys Ser Val Thr Ser Leu * 275 280 285 <210> SEQ ID NO 82 <211> LENGTH: 286 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 82 Met Gln Tyr His Ala Leu Ser Leu Ala Met His Gly Phe Ser Val Thr 1 5 10 15 Leu Leu Gly Phe Cys Asn Ser Lys Pro His Asp Glu Leu Leu Gln Asn 20 25 30 Asn Arg Ile Gln Ile Val Gly Leu Thr Glu Leu Gln Ser Leu Ala Val 35 40 45 Gly Pro Arg Val Phe Gln Tyr Gly Val Lys Val Val Leu Gln Ala Met 50 55 60 Tyr Leu Leu Trp Lys Leu Met Trp Arg Glu Pro Gly Ala Tyr Ile Phe 65 70 75 80 Leu Gln Asn Pro Pro Gly Leu Pro Ser Ile Ala Val Cys Trp Phe Val 85 90 95 Gly Cys Leu Cys Gly Ser Lys Leu Val Ile Asp Trp His Asn Tyr Gly 100 105 110 Tyr Ser Ile Met Gly Leu Val His Gly Pro Asn His Pro Leu Val Leu 115 120 125 Leu Ala Lys Trp Tyr Glu Lys Phe Phe Gly Arg Leu Ser His Leu Asn 130 135 140 Leu Cys Val Thr Asn Ala Met Arg Glu Asp Leu Ala Asp Asn Trp His 145 150 155 160 Ile Arg Ala Val Thr Val Tyr Asp Lys Pro Ala Ser Phe Phe Lys Glu 165 170 175 Thr Pro Leu Asp Leu Gln His Arg Leu Phe Met Lys Leu Gly Ser Met 180 185 190 His Ser Pro Phe Arg Ala Arg Ser Glu Pro Glu Asp Pro Val Thr Glu 195 200 205 Arg Ser Ala Phe Thr Glu Arg Asp Ala Gly Ser Gly Leu Val Thr Arg 210 215 220 Leu Arg Glu Arg Pro Ala Leu Leu Val Ser Ser Thr Ser Trp Thr Glu 225 230 235 240 Asp Glu Asp Phe Ser Ile Leu Arg Glu Ala Leu Val Gly Leu Asp Phe 245 250 255 Phe Ser Gly Gly Leu Glu Thr Leu Pro Leu Phe Phe Cys Ser Ser Arg 260 265 270 Pro Met Pro Leu Leu Ala Tyr Tyr Cys Ser Val Thr Ser Leu 275 280 285 <210> SEQ ID NO 83 <211> LENGTH: 546 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)...(546) <400> SEQUENCE: 83 atg ccc aga gct gcc tca gct gca ttt cca tat ggt ggg gtg ctg gct 48 Met Pro Arg Ala Ala Ser Ala Ala Phe Pro Tyr Gly Gly Val Leu Ala 1 5 10 15 gga acc ttg gag gat gct tca ttc tgg gaa cag aaa atg gac ttt tct 96 Gly Thr Leu Glu Asp Ala Ser Phe Trp Glu Gln Lys Met Asp Phe Ser 20 25 30 cat tgg cct cat gtg ctg ccc ttg gag cca ggg ggc tgc ata gac ttt 144 His Trp Pro His Val Leu Pro Leu Glu Pro Gly Gly Cys Ile Asp Phe 35 40 45 cag aca gag aac agc tcc cgg cac tgt ctt gtg acc tac agg cct gat 192 Gln Thr Glu Asn Ser Ser Arg His Cys Leu Val Thr Tyr Arg Pro Asp 50 55 60 aaa aat cac acc acc ata cga agt gtg ctg atg gaa atg tcc tac cga 240 Lys Asn His Thr Thr Ile Arg Ser Val Leu Met Glu Met Ser Tyr Arg 65 70 75 80 ctg gat gac act gga aat cca atc tgc tcc tgc cag cct gta cat aca 288 Leu Asp Asp Thr Gly Asn Pro Ile Cys Ser Cys Gln Pro Val His Thr 85 90 95 ttt ttt gga gga cct act tgc aaa cta ttg acc aaa aat gcc att ttc 336 Phe Phe Gly Gly Pro Thr Cys Lys Leu Leu Thr Lys Asn Ala Ile Phe 100 105 110 caa agc cca gag aat gat ggc aac atc ctg gtg tgt act ggg gat gaa 384 Gln Ser Pro Glu Asn Asp Gly Asn Ile Leu Val Cys Thr Gly Asp Glu 115 120 125 gca gca aat tct gcc ctg ctg tgg gat gct gcc agt ggc tcg ttg ctc 432 Ala Ala Asn Ser Ala Leu Leu Trp Asp Ala Ala Ser Gly Ser Leu Leu 130 135 140 cag gac cta cag acc gat cag cct gtg ttg gac atc tgc cca ttt gag 480 Gln Asp Leu Gln Thr Asp Gln Pro Val Leu Asp Ile Cys Pro Phe Glu 145 150 155 160 gtg aac cgt aac agc tac ttg gct acc tta aca gag aag atg gtc cac 528 Val Asn Arg Asn Ser Tyr Leu Ala Thr Leu Thr Glu Lys Met Val His 165 170 175 atc tat aag tgg gag tga 546 Ile Tyr Lys Trp Glu * 180 <210> SEQ ID NO 84 <211> LENGTH: 181 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 84 Met Pro Arg Ala Ala Ser Ala Ala Phe Pro Tyr Gly Gly Val Leu Ala 1 5 10 15 Gly Thr Leu Glu Asp Ala Ser Phe Trp Glu Gln Lys Met Asp Phe Ser 20 25 30 His Trp Pro His Val Leu Pro Leu Glu Pro Gly Gly Cys Ile Asp Phe 35 40 45 Gln Thr Glu Asn Ser Ser Arg His Cys Leu Val Thr Tyr Arg Pro Asp 50 55 60 Lys Asn His Thr Thr Ile Arg Ser Val Leu Met Glu Met Ser Tyr Arg 65 70 75 80 Leu Asp Asp Thr Gly Asn Pro Ile Cys Ser Cys Gln Pro Val His Thr 85 90 95 Phe Phe Gly Gly Pro Thr Cys Lys Leu Leu Thr Lys Asn Ala Ile Phe 100 105 110 Gln Ser Pro Glu Asn Asp Gly Asn Ile Leu Val Cys Thr Gly Asp Glu 115 120 125 Ala Ala Asn Ser Ala Leu Leu Trp Asp Ala Ala Ser Gly Ser Leu Leu 130 135 140 Gln Asp Leu Gln Thr Asp Gln Pro Val Leu Asp Ile Cys Pro Phe Glu 145 150 155 160 Val Asn Arg Asn Ser Tyr Leu Ala Thr Leu Thr Glu Lys Met Val His 165 170 175 Ile Tyr Lys Trp Glu 180 <210> SEQ ID NO 85 <211> LENGTH: 327 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)...(327) <400> SEQUENCE: 85 atg gca tca gtt ttg aat gtc aag gaa tcc aaa gct cct gaa aga acg 48 Met Ala Ser Val Leu Asn Val Lys Glu Ser Lys Ala Pro Glu Arg Thr 1 5 10 15 gtt gta gtt gct ggt ctt cca gtt gac ctt ttt agt gat caa tta ttg 96 Val Val Val Ala Gly Leu Pro Val Asp Leu Phe Ser Asp Gln Leu Leu 20 25 30 gcc gta tta gtg aag agc cac ttc caa gac att aag aat gag ggc gga 144 Ala Val Leu Val Lys Ser His Phe Gln Asp Ile Lys Asn Glu Gly Gly 35 40 45 gat gtt gaa gat gtg ata tat ccg aca aga acc aag gga gtt gca tat 192 Asp Val Glu Asp Val Ile Tyr Pro Thr Arg Thr Lys Gly Val Ala Tyr 50 55 60 gta ata ttc aaa gaa aaa aaa gtt gca gag aat gtc atc aga caa aag 240 Val Ile Phe Lys Glu Lys Lys Val Ala Glu Asn Val Ile Arg Gln Lys 65 70 75 80 aaa cac tgg cta gca agg aag act aga cat gct gaa ctc aca gtc tct 288 Lys His Trp Leu Ala Arg Lys Thr Arg His Ala Glu Leu Thr Val Ser 85 90 95 ctc aga gtc tct cat ttt ggt gac aag gtc ttc gga taa 327 Leu Arg Val Ser His Phe Gly Asp Lys Val Phe Gly * 100 105 <210> SEQ ID NO 86 <211> LENGTH: 108 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 86 Met Ala Ser Val Leu Asn Val Lys Glu Ser Lys Ala Pro Glu Arg Thr 1 5 10 15 Val Val Val Ala Gly Leu Pro Val Asp Leu Phe Ser Asp Gln Leu Leu 20 25 30 Ala Val Leu Val Lys Ser His Phe Gln Asp Ile Lys Asn Glu Gly Gly 35 40 45 Asp Val Glu Asp Val Ile Tyr Pro Thr Arg Thr Lys Gly Val Ala Tyr 50 55 60 Val Ile Phe Lys Glu Lys Lys Val Ala Glu Asn Val Ile Arg Gln Lys 65 70 75 80 Lys His Trp Leu Ala Arg Lys Thr Arg His Ala Glu Leu Thr Val Ser 85 90 95 Leu Arg Val Ser His Phe Gly Asp Lys Val Phe Gly 100 105 <210> SEQ ID NO 87 <211> LENGTH: 414 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)...(414) <400> SEQUENCE: 87 atg ggc gtc ctg gcc gca gcg gcg cgc tgc ctg gtc cgg ggt gcg gac 48 Met Gly Val Leu Ala Ala Ala Ala Arg Cys Leu Val Arg Gly Ala Asp 1 5 10 15 cga atg agc aag tgg acg agc aag cgg ggc ccg cgc agc ttc agg ggc 96 Arg Met Ser Lys Trp Thr Ser Lys Arg Gly Pro Arg Ser Phe Arg Gly 20 25 30 cgc aag ggc cgg ggc gcc aag ggc atc ggc ttc ctc acc tcg ggc tgg 144 Arg Lys Gly Arg Gly Ala Lys Gly Ile Gly Phe Leu Thr Ser Gly Trp 35 40 45 agg ttc gtg cag atc aag gag atg gtc ccg gag ttc gtc gtc ccg gat 192 Arg Phe Val Gln Ile Lys Glu Met Val Pro Glu Phe Val Val Pro Asp 50 55 60 ctg acc ggc ttc aag ctc aag ccc tac gtg agc tac ctc gcc cct gag 240 Leu Thr Gly Phe Lys Leu Lys Pro Tyr Val Ser Tyr Leu Ala Pro Glu 65 70 75 80 agc gag gag acg ccc ctg acg gcc gcg cag ctc ttc agc gaa gcc gtg 288 Ser Glu Glu Thr Pro Leu Thr Ala Ala Gln Leu Phe Ser Glu Ala Val 85 90 95 gcg cct gcc atc gaa aag gac ttc aag gac ggt acc ttc gac cct gac 336 Ala Pro Ala Ile Glu Lys Asp Phe Lys Asp Gly Thr Phe Asp Pro Asp 100 105 110 aac ctg gaa aag tac ggc ttc gag ccc aca cag aag gga aag ctc ttc 384 Asn Leu Glu Lys Tyr Gly Phe Glu Pro Thr Gln Lys Gly Lys Leu Phe 115 120 125 cag ctc tac ccc agg aac ttc ctg cgc tag 414 Gln Leu Tyr Pro Arg Asn Phe Leu Arg * 130 135 <210> SEQ ID NO 88 <211> LENGTH: 137 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 88 Met Gly Val Leu Ala Ala Ala Ala Arg Cys Leu Val Arg Gly Ala Asp 1 5 10 15 Arg Met Ser Lys Trp Thr Ser Lys Arg Gly Pro Arg Ser Phe Arg Gly 20 25 30 Arg Lys Gly Arg Gly Ala Lys Gly Ile Gly Phe Leu Thr Ser Gly Trp 35 40 45 Arg Phe Val Gln Ile Lys Glu Met Val Pro Glu Phe Val Val Pro Asp 50 55 60 Leu Thr Gly Phe Lys Leu Lys Pro Tyr Val Ser Tyr Leu Ala Pro Glu 65 70 75 80 Ser Glu Glu Thr Pro Leu Thr Ala Ala Gln Leu Phe Ser Glu Ala Val 85 90 95 Ala Pro Ala Ile Glu Lys Asp Phe Lys Asp Gly Thr Phe Asp Pro Asp 100 105 110 Asn Leu Glu Lys Tyr Gly Phe Glu Pro Thr Gln Lys Gly Lys Leu Phe 115 120 125 Gln Leu Tyr Pro Arg Asn Phe Leu Arg 130 135 <210> SEQ ID NO 89 <211> LENGTH: 552 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)...(552) <400> SEQUENCE: 89 atg aag ctc ctt ttt cct atc ttt gcc agc ctc atg cta cag tac cag 48 Met Lys Leu Leu Phe Pro Ile Phe Ala Ser Leu Met Leu Gln Tyr Gln 1 5 10 15 gtg aac aca gaa ttt att ggc ttg aga cgc tgt tta atg ggt ttg ggg 96 Val Asn Thr Glu Phe Ile Gly Leu Arg Arg Cys Leu Met Gly Leu Gly 20 25 30 aga tgc agg gat cac tgc aat gtg gat gaa aaa gag ata cag aaa tgc 144 Arg Cys Arg Asp His Cys Asn Val Asp Glu Lys Glu Ile Gln Lys Cys 35 40 45 aag atg aaa aaa tgt tgt gtt gga cca aaa gtg gtt aaa ttg att aaa 192 Lys Met Lys Lys Cys Cys Val Gly Pro Lys Val Val Lys Leu Ile Lys 50 55 60 aac tac cta caa tat gga aca cca aat gta ctt aat gaa gac gtc caa 240 Asn Tyr Leu Gln Tyr Gly Thr Pro Asn Val Leu Asn Glu Asp Val Gln 65 70 75 80 gaa atg cta aaa cct gcc aag aat tct agt gct gtg ata caa aga aaa 288 Glu Met Leu Lys Pro Ala Lys Asn Ser Ser Ala Val Ile Gln Arg Lys 85 90 95 cat att tta tct gtt ctc ccc caa atc aaa agc act agc ttt ttt gct 336 His Ile Leu Ser Val Leu Pro Gln Ile Lys Ser Thr Ser Phe Phe Ala 100 105 110 aat acc aac ttt gtc atc att cca aat gcc acc cct atg aac tct gcc 384 Asn Thr Asn Phe Val Ile Ile Pro Asn Ala Thr Pro Met Asn Ser Ala 115 120 125 acc atc agc act atg acc cca gga cag atc aca tac act gct act tct 432 Thr Ile Ser Thr Met Thr Pro Gly Gln Ile Thr Tyr Thr Ala Thr Ser 130 135 140 acc aag agt aac acc aaa gaa agc aga gat tct gcc act gcc tcg cca 480 Thr Lys Ser Asn Thr Lys Glu Ser Arg Asp Ser Ala Thr Ala Ser Pro 145 150 155 160 cca cca gca cca cct cca cca aac ata ctg cca aca cca tca ctg gag 528 Pro Pro Ala Pro Pro Pro Pro Asn Ile Leu Pro Thr Pro Ser Leu Glu 165 170 175 cta gag gaa gca gaa gag cag taa 552 Leu Glu Glu Ala Glu Glu Gln * 180 <210> SEQ ID NO 90 <211> LENGTH: 183 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 90 Met Lys Leu Leu Phe Pro Ile Phe Ala Ser Leu Met Leu Gln Tyr Gln 1 5 10 15 Val Asn Thr Glu Phe Ile Gly Leu Arg Arg Cys Leu Met Gly Leu Gly 20 25 30 Arg Cys Arg Asp His Cys Asn Val Asp Glu Lys Glu Ile Gln Lys Cys 35 40 45 Lys Met Lys Lys Cys Cys Val Gly Pro Lys Val Val Lys Leu Ile Lys 50 55 60 Asn Tyr Leu Gln Tyr Gly Thr Pro Asn Val Leu Asn Glu Asp Val Gln 65 70 75 80 Glu Met Leu Lys Pro Ala Lys Asn Ser Ser Ala Val Ile Gln Arg Lys 85 90 95 His Ile Leu Ser Val Leu Pro Gln Ile Lys Ser Thr Ser Phe Phe Ala 100 105 110 Asn Thr Asn Phe Val Ile Ile Pro Asn Ala Thr Pro Met Asn Ser Ala 115 120 125 Thr Ile Ser Thr Met Thr Pro Gly Gln Ile Thr Tyr Thr Ala Thr Ser 130 135 140 Thr Lys Ser Asn Thr Lys Glu Ser Arg Asp Ser Ala Thr Ala Ser Pro 145 150 155 160 Pro Pro Ala Pro Pro Pro Pro Asn Ile Leu Pro Thr Pro Ser Leu Glu 165 170 175 Leu Glu Glu Ala Glu Glu Gln 180 <210> SEQ ID NO 91 <211> LENGTH: 438 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)...(438) <400> SEQUENCE: 91 atg cag ctc ggc act ggg ctc ctg ctg gcc gcc gtc ctg agc ctg cag 48 Met Gln Leu Gly Thr Gly Leu Leu Leu Ala Ala Val Leu Ser Leu Gln 1 5 10 15 ctg gct gca gcc gaa gcc ata tgg tgt cac cag tgc acg ggc ttc gga 96 Leu Ala Ala Ala Glu Ala Ile Trp Cys His Gln Cys Thr Gly Phe Gly 20 25 30 ggg tgc tcc cat gga tcc aga tgc ctg agg gac tcc acc cac tgt gtc 144 Gly Cys Ser His Gly Ser Arg Cys Leu Arg Asp Ser Thr His Cys Val 35 40 45 acc act gcc acc cgg gtc ctc agc aac acc gag gat ttg cct ctg gtc 192 Thr Thr Ala Thr Arg Val Leu Ser Asn Thr Glu Asp Leu Pro Leu Val 50 55 60 acc aag atg tgc cac ata ggc tgc ccc gat atc ccc agc ctg ggc ctg 240 Thr Lys Met Cys His Ile Gly Cys Pro Asp Ile Pro Ser Leu Gly Leu 65 70 75 80 ggc cct acg tat cca tcg ctt gct gcc aga cca gcc tct gca acc atg 288 Gly Pro Thr Tyr Pro Ser Leu Ala Ala Arg Pro Ala Ser Ala Thr Met 85 90 95 act gac ggc tgc cct cct cca ggc ccc cgg acg ctc agc ccc cac agc 336 Thr Asp Gly Cys Pro Pro Pro Gly Pro Arg Thr Leu Ser Pro His Ser 100 105 110 ccc cac agc ctg gcg cca ggg ctc acg gcc gcc cct ccc tcg aga ctg 384 Pro His Ser Leu Ala Pro Gly Leu Thr Ala Ala Pro Pro Ser Arg Leu 115 120 125 gcc agc cca cct ctc ccg gcc tct gca gcc acc gtc cag cac cgc ttg 432 Ala Ser Pro Pro Leu Pro Ala Ser Ala Ala Thr Val Gln His Arg Leu 130 135 140 tcc tag 438 Ser * 145 <210> SEQ ID NO 92 <211> LENGTH: 145 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 92 Met Gln Leu Gly Thr Gly Leu Leu Leu Ala Ala Val Leu Ser Leu Gln 1 5 10 15 Leu Ala Ala Ala Glu Ala Ile Trp Cys His Gln Cys Thr Gly Phe Gly 20 25 30 Gly Cys Ser His Gly Ser Arg Cys Leu Arg Asp Ser Thr His Cys Val 35 40 45 Thr Thr Ala Thr Arg Val Leu Ser Asn Thr Glu Asp Leu Pro Leu Val 50 55 60 Thr Lys Met Cys His Ile Gly Cys Pro Asp Ile Pro Ser Leu Gly Leu 65 70 75 80 Gly Pro Thr Tyr Pro Ser Leu Ala Ala Arg Pro Ala Ser Ala Thr Met 85 90 95 Thr Asp Gly Cys Pro Pro Pro Gly Pro Arg Thr Leu Ser Pro His Ser 100 105 110 Pro His Ser Leu Ala Pro Gly Leu Thr Ala Ala Pro Pro Ser Arg Leu 115 120 125 Ala Ser Pro Pro Leu Pro Ala Ser Ala Ala Thr Val Gln His Arg Leu 130 135 140 Ser 145 <210> SEQ ID NO 93 <211> LENGTH: 501 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)...(501) <400> SEQUENCE: 93 atg gat gaa cag aat ccc aag gga agg gac aaa gct att gtt ttc cca 48 Met Asp Glu Gln Asn Pro Lys Gly Arg Asp Lys Ala Ile Val Phe Pro 1 5 10 15 gca cat aca acc ata gct ttc agt gtt ttt gaa ctc ttc ata tac ctg 96 Ala His Thr Thr Ile Ala Phe Ser Val Phe Glu Leu Phe Ile Tyr Leu 20 25 30 gat ggt gcc ttt gac ctt tgt gtc act tca gtg tca aaa gga gga ttt 144 Asp Gly Ala Phe Asp Leu Cys Val Thr Ser Val Ser Lys Gly Gly Phe 35 40 45 gaa agg gaa gaa acg gca aca ttt gca ctg ctg tac agg ttg aga aat 192 Glu Arg Glu Glu Thr Ala Thr Phe Ala Leu Leu Tyr Arg Leu Arg Asn 50 55 60 atc cta ttt gaa aga aat aga aga gtg atg gat gtc att tct cgt tca 240 Ile Leu Phe Glu Arg Asn Arg Arg Val Met Asp Val Ile Ser Arg Ser 65 70 75 80 cag ctt tac ttg gat gat ctt ttt tct gac tac tat gac aaa cct ctc 288 Gln Leu Tyr Leu Asp Asp Leu Phe Ser Asp Tyr Tyr Asp Lys Pro Leu 85 90 95 agc atg act gat att tca ctc aaa gaa ggg acc cat atc cga gtt aac 336 Ser Met Thr Asp Ile Ser Leu Lys Glu Gly Thr His Ile Arg Val Asn 100 105 110 tta ctt aat cac aac att ccc aaa ggg cct tgc ata ctc tgt gga atg 384 Leu Leu Asn His Asn Ile Pro Lys Gly Pro Cys Ile Leu Cys Gly Met 115 120 125 ggg aac ttc aaa agg gag aca gtt tat ggg tgc ttt cag tgt tct gtt 432 Gly Asn Phe Lys Arg Glu Thr Val Tyr Gly Cys Phe Gln Cys Ser Val 130 135 140 gat ggt cag aag tat gtg aga ctt cat gca gtt cct tgt ttt gat att 480 Asp Gly Gln Lys Tyr Val Arg Leu His Ala Val Pro Cys Phe Asp Ile 145 150 155 160 tgg cac aag agg atg aaa taa 501 Trp His Lys Arg Met Lys * 165 <210> SEQ ID NO 94 <211> LENGTH: 166 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 94 Met Asp Glu Gln Asn Pro Lys Gly Arg Asp Lys Ala Ile Val Phe Pro 1 5 10 15 Ala His Thr Thr Ile Ala Phe Ser Val Phe Glu Leu Phe Ile Tyr Leu 20 25 30 Asp Gly Ala Phe Asp Leu Cys Val Thr Ser Val Ser Lys Gly Gly Phe 35 40 45 Glu Arg Glu Glu Thr Ala Thr Phe Ala Leu Leu Tyr Arg Leu Arg Asn 50 55 60 Ile Leu Phe Glu Arg Asn Arg Arg Val Met Asp Val Ile Ser Arg Ser 65 70 75 80 Gln Leu Tyr Leu Asp Asp Leu Phe Ser Asp Tyr Tyr Asp Lys Pro Leu 85 90 95 Ser Met Thr Asp Ile Ser Leu Lys Glu Gly Thr His Ile Arg Val Asn 100 105 110 Leu Leu Asn His Asn Ile Pro Lys Gly Pro Cys Ile Leu Cys Gly Met 115 120 125 Gly Asn Phe Lys Arg Glu Thr Val Tyr Gly Cys Phe Gln Cys Ser Val 130 135 140 Asp Gly Gln Lys Tyr Val Arg Leu His Ala Val Pro Cys Phe Asp Ile 145 150 155 160 Trp His Lys Arg Met Lys 165 <210> SEQ ID NO 95 <211> LENGTH: 978 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)...(978) <221> NAME/KEY: misc_feature <222> LOCATION: (1)...(978) <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 40, 50, 58, 59, 61, 62, 63, 68 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 95 atg gcg acg ccg ctg cct ccg ccc tcc ccg cgg cac ctg ngg ctg ctg 48 Met Ala Thr Pro Leu Pro Pro Pro Ser Pro Arg His Leu Xaa Leu Leu 1 5 10 15 cng ctg ctg nnc nnn ggc cnc gtc ctc ggc gcc gcc ctg cgt gga gcc 96 Xaa Leu Leu Xaa Xaa Gly Xaa Val Leu Gly Ala Ala Leu Arg Gly Ala 20 25 30 gcc gcc ggc cac cca gat gta gcc gcc tgt ccc ggg agc ctg gac tgt 144 Ala Ala Gly His Pro Asp Val Ala Ala Cys Pro Gly Ser Leu Asp Cys 35 40 45 gcc ctg aag agg cgg gca agg tgt cct cct ggt gca cat gcc tgt ggg 192 Ala Leu Lys Arg Arg Ala Arg Cys Pro Pro Gly Ala His Ala Cys Gly 50 55 60 ccc tgc ctt cag ccc ttc cag gag gac cag caa ggg ctc tgt gtg ccc 240 Pro Cys Leu Gln Pro Phe Gln Glu Asp Gln Gln Gly Leu Cys Val Pro 65 70 75 80 agg atg cgc cgg cct cca ggc ggg ggc cgg ccc cag ccc aga ctg gaa 288 Arg Met Arg Arg Pro Pro Gly Gly Gly Arg Pro Gln Pro Arg Leu Glu 85 90 95 gat gag att gac ttc ctg gcc cag gag ctt gcc cgg aag gag tct gga 336 Asp Glu Ile Asp Phe Leu Ala Gln Glu Leu Ala Arg Lys Glu Ser Gly 100 105 110 cac tca act ccg ccc cta ccc aag gac cga cag cgg ctc ccg gag cct 384 His Ser Thr Pro Pro Leu Pro Lys Asp Arg Gln Arg Leu Pro Glu Pro 115 120 125 gcc acc ctg ggc ttc tcg gca cgg ggg cag ggg ctg gag ctg ggc ctc 432 Ala Thr Leu Gly Phe Ser Ala Arg Gly Gln Gly Leu Glu Leu Gly Leu 130 135 140 ccc tcc act cca gga acc ccc acg ccc acg ccc cac acc tcc ctg ggc 480 Pro Ser Thr Pro Gly Thr Pro Thr Pro Thr Pro His Thr Ser Leu Gly 145 150 155 160 tcc cct gtg tca tcc gac ccg gtg cac atg tcg ccc ctg gag ccc cgg 528 Ser Pro Val Ser Ser Asp Pro Val His Met Ser Pro Leu Glu Pro Arg 165 170 175 gga ggg caa ggc gac ggc ctc gcc ctt gtg ctg atc ctg gcg ttc tgt 576 Gly Gly Gln Gly Asp Gly Leu Ala Leu Val Leu Ile Leu Ala Phe Cys 180 185 190 gtg gcc ggt gca gcc gcc ctc tcc gta gcc tcc ctc tgc tgg tgc agg 624 Val Ala Gly Ala Ala Ala Leu Ser Val Ala Ser Leu Cys Trp Cys Arg 195 200 205 ctg cag cgt gag atc cgc ctg act cag aag gcc gac tac gcc act gcg 672 Leu Gln Arg Glu Ile Arg Leu Thr Gln Lys Ala Asp Tyr Ala Thr Ala 210 215 220 aag gcc cct ggc tca cct gca gct ccc cgg atc tcg cct ggg gac cag 720 Lys Ala Pro Gly Ser Pro Ala Ala Pro Arg Ile Ser Pro Gly Asp Gln 225 230 235 240 cgg ctg gca cag agc gcg gag atg tac cac tac cag cac caa cgg caa 768 Arg Leu Ala Gln Ser Ala Glu Met Tyr His Tyr Gln His Gln Arg Gln 245 250 255 cag atg ctg tgc ctg gag cgg cat aaa gag cca ccc aag gag ctg gac 816 Gln Met Leu Cys Leu Glu Arg His Lys Glu Pro Pro Lys Glu Leu Asp 260 265 270 acg gcc tcc tcg gat gag gag aat gag gac gga gac ttc acg gtg tac 864 Thr Ala Ser Ser Asp Glu Glu Asn Glu Asp Gly Asp Phe Thr Val Tyr 275 280 285 gag tgc ccg ggc ctg gcc ccg acc ggg gaa atg gag gtg cgc aac cct 912 Glu Cys Pro Gly Leu Ala Pro Thr Gly Glu Met Glu Val Arg Asn Pro 290 295 300 ctg ttc gac cac gcc gca ctg tcc gcg ccc ctg ccg gcc ccc agc tca 960 Leu Phe Asp His Ala Ala Leu Ser Ala Pro Leu Pro Ala Pro Ser Ser 305 310 315 320 ccg cct gca ctg cca tga 978 Pro Pro Ala Leu Pro * 325 <210> SEQ ID NO 96 <211> LENGTH: 325 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: VARIANT <222> LOCATION: (1)...(325) <223> OTHER INFORMATION: Xaa = Any Amino Acid <221> NAME/KEY: VARIANT <222> LOCATION: 14, 17, 20, 21, 23 <223> OTHER INFORMATION: Xaa = Any Amino Acid <400> SEQUENCE: 96 Met Ala Thr Pro Leu Pro Pro Pro Ser Pro Arg His Leu Xaa Leu Leu 1 5 10 15 Xaa Leu Leu Xaa Xaa Gly Xaa Val Leu Gly Ala Ala Leu Arg Gly Ala 20 25 30 Ala Ala Gly His Pro Asp Val Ala Ala Cys Pro Gly Ser Leu Asp Cys 35 40 45 Ala Leu Lys Arg Arg Ala Arg Cys Pro Pro Gly Ala His Ala Cys Gly 50 55 60 Pro Cys Leu Gln Pro Phe Gln Glu Asp Gln Gln Gly Leu Cys Val Pro 65 70 75 80 Arg Met Arg Arg Pro Pro Gly Gly Gly Arg Pro Gln Pro Arg Leu Glu 85 90 95 Asp Glu Ile Asp Phe Leu Ala Gln Glu Leu Ala Arg Lys Glu Ser Gly 100 105 110 His Ser Thr Pro Pro Leu Pro Lys Asp Arg Gln Arg Leu Pro Glu Pro 115 120 125 Ala Thr Leu Gly Phe Ser Ala Arg Gly Gln Gly Leu Glu Leu Gly Leu 130 135 140 Pro Ser Thr Pro Gly Thr Pro Thr Pro Thr Pro His Thr Ser Leu Gly 145 150 155 160 Ser Pro Val Ser Ser Asp Pro Val His Met Ser Pro Leu Glu Pro Arg 165 170 175 Gly Gly Gln Gly Asp Gly Leu Ala Leu Val Leu Ile Leu Ala Phe Cys 180 185 190 Val Ala Gly Ala Ala Ala Leu Ser Val Ala Ser Leu Cys Trp Cys Arg 195 200 205 Leu Gln Arg Glu Ile Arg Leu Thr Gln Lys Ala Asp Tyr Ala Thr Ala 210 215 220 Lys Ala Pro Gly Ser Pro Ala Ala Pro Arg Ile Ser Pro Gly Asp Gln 225 230 235 240 Arg Leu Ala Gln Ser Ala Glu Met Tyr His Tyr Gln His Gln Arg Gln 245 250 255 Gln Met Leu Cys Leu Glu Arg His Lys Glu Pro Pro Lys Glu Leu Asp 260 265 270 Thr Ala Ser Ser Asp Glu Glu Asn Glu Asp Gly Asp Phe Thr Val Tyr 275 280 285 Glu Cys Pro Gly Leu Ala Pro Thr Gly Glu Met Glu Val Arg Asn Pro 290 295 300 Leu Phe Asp His Ala Ala Leu Ser Ala Pro Leu Pro Ala Pro Ser Ser 305 310 315 320 Pro Pro Ala Leu Pro 325 <210> SEQ ID NO 97 <211> LENGTH: 381 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)...(381) <400> SEQUENCE: 97 atg caa gta ctt tca tcc tcc tgc aca ctt gca agc cag act caa ggc 48 Met Gln Val Leu Ser Ser Ser Cys Thr Leu Ala Ser Gln Thr Gln Gly 1 5 10 15 agc tca tca tca gat gaa cat tca gct gcc tct gcc atg gcc ctg cag 96 Ser Ser Ser Ser Asp Glu His Ser Ala Ala Ser Ala Met Ala Leu Gln 20 25 30 cct ggt aca ctg caa ctg ata cca aag aga tca gca ctg gaa aag ccc 144 Pro Gly Thr Leu Gln Leu Ile Pro Lys Arg Ser Ala Leu Glu Lys Pro 35 40 45 aat ggt gcc acc ccg gtc ttt aat ccc act gtt ttc cac tgc caa cag 192 Asn Gly Ala Thr Pro Val Phe Asn Pro Thr Val Phe His Cys Gln Gln 50 55 60 gct ctg act aac ctg cag ctc cca cag ccg gca ttt atc cct gca ggg 240 Ala Leu Thr Asn Leu Gln Leu Pro Gln Pro Ala Phe Ile Pro Ala Gly 65 70 75 80 cca ata ctg tgc atg gca ccc gct tca aat att gtg ccc atg atg cac 288 Pro Ile Leu Cys Met Ala Pro Ala Ser Asn Ile Val Pro Met Met His 85 90 95 ggt gct aca cct acc act gtg tct gca gca aca aca cct gcc acc agc 336 Gly Ala Thr Pro Thr Thr Val Ser Ala Ala Thr Thr Pro Ala Thr Ser 100 105 110 gtt ccg ttc gct gca cca act aca ggc aat cag ctg aaa ttc tga 381 Val Pro Phe Ala Ala Pro Thr Thr Gly Asn Gln Leu Lys Phe * 115 120 125 <210> SEQ ID NO 98 <211> LENGTH: 126 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 98 Met Gln Val Leu Ser Ser Ser Cys Thr Leu Ala Ser Gln Thr Gln Gly 1 5 10 15 Ser Ser Ser Ser Asp Glu His Ser Ala Ala Ser Ala Met Ala Leu Gln 20 25 30 Pro Gly Thr Leu Gln Leu Ile Pro Lys Arg Ser Ala Leu Glu Lys Pro 35 40 45 Asn Gly Ala Thr Pro Val Phe Asn Pro Thr Val Phe His Cys Gln Gln 50 55 60 Ala Leu Thr Asn Leu Gln Leu Pro Gln Pro Ala Phe Ile Pro Ala Gly 65 70 75 80 Pro Ile Leu Cys Met Ala Pro Ala Ser Asn Ile Val Pro Met Met His 85 90 95 Gly Ala Thr Pro Thr Thr Val Ser Ala Ala Thr Thr Pro Ala Thr Ser 100 105 110 Val Pro Phe Ala Ala Pro Thr Thr Gly Asn Gln Leu Lys Phe 115 120 125 <210> SEQ ID NO 99 <211> LENGTH: 552 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)...(552) <400> SEQUENCE: 99 atg gag gcg gcg ctg ctg ggg ctg tgt aac tgg agc acg ctg ggc gtg 48 Met Glu Ala Ala Leu Leu Gly Leu Cys Asn Trp Ser Thr Leu Gly Val 1 5 10 15 tgc gcc gcg ctg aag ctg ccg cag atc tcc gct gtg cta gcg gcg cgc 96 Cys Ala Ala Leu Lys Leu Pro Gln Ile Ser Ala Val Leu Ala Ala Arg 20 25 30 agc gcg cgg ggc ctc agc ctt ccg agt tta ctt ctg gag ctg gca gga 144 Ser Ala Arg Gly Leu Ser Leu Pro Ser Leu Leu Leu Glu Leu Ala Gly 35 40 45 ttc ctg gtg ttt ctg cgg tac cag tgt tac tat ggg tat ccg ccg ctg 192 Phe Leu Val Phe Leu Arg Tyr Gln Cys Tyr Tyr Gly Tyr Pro Pro Leu 50 55 60 acc tac ctg gag tac ccc atc ctc atc gcg caa gat gtc atc ctc ctg 240 Thr Tyr Leu Glu Tyr Pro Ile Leu Ile Ala Gln Asp Val Ile Leu Leu 65 70 75 80 ctc tgt atc ttt cat ttt aac ggg aac gtg aag cag gcc act cct tac 288 Leu Cys Ile Phe His Phe Asn Gly Asn Val Lys Gln Ala Thr Pro Tyr 85 90 95 atc gct gta ttg gtg tct tct tgg ttc atc ctt gcc agt aag ttt gca 336 Ile Ala Val Leu Val Ser Ser Trp Phe Ile Leu Ala Ser Lys Phe Ala 100 105 110 cag ctc cag tgt ctg tgg aag acg aga gac tca gga act gtg agt gcg 384 Gln Leu Gln Cys Leu Trp Lys Thr Arg Asp Ser Gly Thr Val Ser Ala 115 120 125 ctg act tgg agc ctc tct tcc tat acc tgt gca aca aga ata atc aca 432 Leu Thr Trp Ser Leu Ser Ser Tyr Thr Cys Ala Thr Arg Ile Ile Thr 130 135 140 acc tta atg acc acc aat gat ttt aca att ctt cta cgt ttt gtg atc 480 Thr Leu Met Thr Thr Asn Asp Phe Thr Ile Leu Leu Arg Phe Val Ile 145 150 155 160 atg ctg gct tta aat ata tgg gta aca gtg aca gta ctt cgc tac cgg 528 Met Leu Ala Leu Asn Ile Trp Val Thr Val Thr Val Leu Arg Tyr Arg 165 170 175 aag acc gct ata aag gct gaa tga 552 Lys Thr Ala Ile Lys Ala Glu * 180 <210> SEQ ID NO 100 <211> LENGTH: 183 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 100 Met Glu Ala Ala Leu Leu Gly Leu Cys Asn Trp Ser Thr Leu Gly Val 1 5 10 15 Cys Ala Ala Leu Lys Leu Pro Gln Ile Ser Ala Val Leu Ala Ala Arg 20 25 30 Ser Ala Arg Gly Leu Ser Leu Pro Ser Leu Leu Leu Glu Leu Ala Gly 35 40 45 Phe Leu Val Phe Leu Arg Tyr Gln Cys Tyr Tyr Gly Tyr Pro Pro Leu 50 55 60 Thr Tyr Leu Glu Tyr Pro Ile Leu Ile Ala Gln Asp Val Ile Leu Leu 65 70 75 80 Leu Cys Ile Phe His Phe Asn Gly Asn Val Lys Gln Ala Thr Pro Tyr 85 90 95 Ile Ala Val Leu Val Ser Ser Trp Phe Ile Leu Ala Ser Lys Phe Ala 100 105 110 Gln Leu Gln Cys Leu Trp Lys Thr Arg Asp Ser Gly Thr Val Ser Ala 115 120 125 Leu Thr Trp Ser Leu Ser Ser Tyr Thr Cys Ala Thr Arg Ile Ile Thr 130 135 140 Thr Leu Met Thr Thr Asn Asp Phe Thr Ile Leu Leu Arg Phe Val Ile 145 150 155 160 Met Leu Ala Leu Asn Ile Trp Val Thr Val Thr Val Leu Arg Tyr Arg 165 170 175 Lys Thr Ala Ile Lys Ala Glu 180 <210> SEQ ID NO 101 <211> LENGTH: 1002 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)...(1002) <400> SEQUENCE: 101 atg cta cct ggc agg tgt aag cat ctc ttc ctg aat ctt ttt ctt tcc 48 Met Leu Pro Gly Arg Cys Lys His Leu Phe Leu Asn Leu Phe Leu Ser 1 5 10 15 ttt att ttt gtg gct aat tac ctc gag ggt gta aag cag gcc ctc tgg 96 Phe Ile Phe Val Ala Asn Tyr Leu Glu Gly Val Lys Gln Ala Leu Trp 20 25 30 ctc acc aag acc aag tta ata gaa ggc ctt ccc gag aaa gtg ctt agc 144 Leu Thr Lys Thr Lys Leu Ile Glu Gly Leu Pro Glu Lys Val Leu Ser 35 40 45 ctt gtt gat gat cca agg aac cac ata gag aac caa gac gag tgc gtt 192 Leu Val Asp Asp Pro Arg Asn His Ile Glu Asn Gln Asp Glu Cys Val 50 55 60 ctg aat gtg atc tct cac gcc cgt ctc tgg cag acc act gag gaa atc 240 Leu Asn Val Ile Ser His Ala Arg Leu Trp Gln Thr Thr Glu Glu Ile 65 70 75 80 ccc aag aga gag acc tac tgc ccg gtc atc gtg gac aac cta ata cag 288 Pro Lys Arg Glu Thr Tyr Cys Pro Val Ile Val Asp Asn Leu Ile Gln 85 90 95 ctg tgt aaa tct cag att ctc aag cat cct tct ctg gcc agg agg atc 336 Leu Cys Lys Ser Gln Ile Leu Lys His Pro Ser Leu Ala Arg Arg Ile 100 105 110 tgt gtc caa aac tcc acg ttt tct gct acc tgg aac cga gag tct ctt 384 Cys Val Gln Asn Ser Thr Phe Ser Ala Thr Trp Asn Arg Glu Ser Leu 115 120 125 ctc ctt caa gtc cgt ggt tct ggt gga gcc cga ctg agc act aag gat 432 Leu Leu Gln Val Arg Gly Ser Gly Gly Ala Arg Leu Ser Thr Lys Asp 130 135 140 cct ctg ccc acc atc gcc tcc aga gag gag att gaa gct act aag aat 480 Pro Leu Pro Thr Ile Ala Ser Arg Glu Glu Ile Glu Ala Thr Lys Asn 145 150 155 160 cat gtt cta gag acc ttc tac ccc ata tca ccc atc atc gat ctt cat 528 His Val Leu Glu Thr Phe Tyr Pro Ile Ser Pro Ile Ile Asp Leu His 165 170 175 gaa tgc aat att tat gat gtg aaa aat gac aca gga ttc cag gaa ggc 576 Glu Cys Asn Ile Tyr Asp Val Lys Asn Asp Thr Gly Phe Gln Glu Gly 180 185 190 tat cct tac ccc tat ccc cat acc ctg tac tta ctg gac aaa gcc aat 624 Tyr Pro Tyr Pro Tyr Pro His Thr Leu Tyr Leu Leu Asp Lys Ala Asn 195 200 205 tta cga cca cac cgc ctt caa cca gat cag ctg cgg gcc aag atg atc 672 Leu Arg Pro His Arg Leu Gln Pro Asp Gln Leu Arg Ala Lys Met Ile 210 215 220 ctg ttt gct ttt ggc agt gcc ctg gct cag gcc cgg ctc ctc tat ggg 720 Leu Phe Ala Phe Gly Ser Ala Leu Ala Gln Ala Arg Leu Leu Tyr Gly 225 230 235 240 aat gat gcc aag gtc ttg gag cag ccc gtg gtg gtg cag agc gtg ggc 768 Asn Asp Ala Lys Val Leu Glu Gln Pro Val Val Val Gln Ser Val Gly 245 250 255 acg gat gga cgt gtc ttc cat ttc cta gtg ttt caa ctg aat acc aca 816 Thr Asp Gly Arg Val Phe His Phe Leu Val Phe Gln Leu Asn Thr Thr 260 265 270 gac ctg gac tct aac gag ggt gtc aag aat ttg gcc tgg gtg gac tca 864 Asp Leu Asp Ser Asn Glu Gly Val Lys Asn Leu Ala Trp Val Asp Ser 275 280 285 gac cag ctc ctc tat cag cat ttt tgg tgt ctc cca gtg atc aaa aag 912 Asp Gln Leu Leu Tyr Gln His Phe Trp Cys Leu Pro Val Ile Lys Lys 290 295 300 aga gtg gtt gtg gaa cct gtt ggc cca gtt ggt ttc aag cca gag aca 960 Arg Val Val Val Glu Pro Val Gly Pro Val Gly Phe Lys Pro Glu Thr 305 310 315 320 ttc aga aag ttt tta gct cta tat ttg cat ggt gct gcg tga 1002 Phe Arg Lys Phe Leu Ala Leu Tyr Leu His Gly Ala Ala * 325 330 <210> SEQ ID NO 102 <211> LENGTH: 333 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 102 Met Leu Pro Gly Arg Cys Lys His Leu Phe Leu Asn Leu Phe Leu Ser 1 5 10 15 Phe Ile Phe Val Ala Asn Tyr Leu Glu Gly Val Lys Gln Ala Leu Trp 20 25 30 Leu Thr Lys Thr Lys Leu Ile Glu Gly Leu Pro Glu Lys Val Leu Ser 35 40 45 Leu Val Asp Asp Pro Arg Asn His Ile Glu Asn Gln Asp Glu Cys Val 50 55 60 Leu Asn Val Ile Ser His Ala Arg Leu Trp Gln Thr Thr Glu Glu Ile 65 70 75 80 Pro Lys Arg Glu Thr Tyr Cys Pro Val Ile Val Asp Asn Leu Ile Gln 85 90 95 Leu Cys Lys Ser Gln Ile Leu Lys His Pro Ser Leu Ala Arg Arg Ile 100 105 110 Cys Val Gln Asn Ser Thr Phe Ser Ala Thr Trp Asn Arg Glu Ser Leu 115 120 125 Leu Leu Gln Val Arg Gly Ser Gly Gly Ala Arg Leu Ser Thr Lys Asp 130 135 140 Pro Leu Pro Thr Ile Ala Ser Arg Glu Glu Ile Glu Ala Thr Lys Asn 145 150 155 160 His Val Leu Glu Thr Phe Tyr Pro Ile Ser Pro Ile Ile Asp Leu His 165 170 175 Glu Cys Asn Ile Tyr Asp Val Lys Asn Asp Thr Gly Phe Gln Glu Gly 180 185 190 Tyr Pro Tyr Pro Tyr Pro His Thr Leu Tyr Leu Leu Asp Lys Ala Asn 195 200 205 Leu Arg Pro His Arg Leu Gln Pro Asp Gln Leu Arg Ala Lys Met Ile 210 215 220 Leu Phe Ala Phe Gly Ser Ala Leu Ala Gln Ala Arg Leu Leu Tyr Gly 225 230 235 240 Asn Asp Ala Lys Val Leu Glu Gln Pro Val Val Val Gln Ser Val Gly 245 250 255 Thr Asp Gly Arg Val Phe His Phe Leu Val Phe Gln Leu Asn Thr Thr 260 265 270 Asp Leu Asp Ser Asn Glu Gly Val Lys Asn Leu Ala Trp Val Asp Ser 275 280 285 Asp Gln Leu Leu Tyr Gln His Phe Trp Cys Leu Pro Val Ile Lys Lys 290 295 300 Arg Val Val Val Glu Pro Val Gly Pro Val Gly Phe Lys Pro Glu Thr 305 310 315 320 Phe Arg Lys Phe Leu Ala Leu Tyr Leu His Gly Ala Ala 325 330 <210> SEQ ID NO 103 <211> LENGTH: 324 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)...(324) <400> SEQUENCE: 103 atg agt cct ccc cat ttc cat gca agc cag aac agt tgg ttg tgt ggg 48 Met Ser Pro Pro His Phe His Ala Ser Gln Asn Ser Trp Leu Cys Gly 1 5 10 15 agc ctc gtg gtg ccc agc gga gga cgg cca gga cca gct cca gca gct 96 Ser Leu Val Val Pro Ser Gly Gly Arg Pro Gly Pro Ala Pro Ala Ala 20 25 30 ggg gtg cag tgc ggg gcg cag ggc gtc cag gtc cag ctg gtg cag gat 144 Gly Val Gln Cys Gly Ala Gln Gly Val Gln Val Gln Leu Val Gln Asp 35 40 45 gac ccc tcc ggc gaa ggt gtc ctg ccc tcg gcc cgc ggc cca gcc acc 192 Asp Pro Ser Gly Glu Gly Val Leu Pro Ser Ala Arg Gly Pro Ala Thr 50 55 60 ttc ctc ccc ttc ctc act gtg gac ctg ccc gtc tac gtc ctc cag gag 240 Phe Leu Pro Phe Leu Thr Val Asp Leu Pro Val Tyr Val Leu Gln Glu 65 70 75 80 gtg ctc ccc tca tct gga ggc cct gct gga ccg gag gcc acc cag ttc 288 Val Leu Pro Ser Ser Gly Gly Pro Ala Gly Pro Glu Ala Thr Gln Phe 85 90 95 cca gga agc act atc aac ctg cag gat ctg cag tga 324 Pro Gly Ser Thr Ile Asn Leu Gln Asp Leu Gln * 100 105 <210> SEQ ID NO 104 <211> LENGTH: 107 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 104 Met Ser Pro Pro His Phe His Ala Ser Gln Asn Ser Trp Leu Cys Gly 1 5 10 15 Ser Leu Val Val Pro Ser Gly Gly Arg Pro Gly Pro Ala Pro Ala Ala 20 25 30 Gly Val Gln Cys Gly Ala Gln Gly Val Gln Val Gln Leu Val Gln Asp 35 40 45 Asp Pro Ser Gly Glu Gly Val Leu Pro Ser Ala Arg Gly Pro Ala Thr 50 55 60 Phe Leu Pro Phe Leu Thr Val Asp Leu Pro Val Tyr Val Leu Gln Glu 65 70 75 80 Val Leu Pro Ser Ser Gly Gly Pro Ala Gly Pro Glu Ala Thr Gln Phe 85 90 95 Pro Gly Ser Thr Ile Asn Leu Gln Asp Leu Gln 100 105 <210> SEQ ID NO 105 <211> LENGTH: 708 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)...(708) <400> SEQUENCE: 105 atg aaa tat gtc ttc tat ttg ggt gtc ctc gct ggg aca ttt ttc ttt 48 Met Lys Tyr Val Phe Tyr Leu Gly Val Leu Ala Gly Thr Phe Phe Phe 1 5 10 15 gct gac tca tct gtt cag aaa gaa gac cct gct ccc tat ttg gtg tac 96 Ala Asp Ser Ser Val Gln Lys Glu Asp Pro Ala Pro Tyr Leu Val Tyr 20 25 30 ctc aag tct cac ttc aac ccc tgt gtg ggc gtc ctc atc aaa ccc agc 144 Leu Lys Ser His Phe Asn Pro Cys Val Gly Val Leu Ile Lys Pro Ser 35 40 45 tgg gtg ctg gcc cca gct cac tgc tat tta cca aat ctg aaa gtg atg 192 Trp Val Leu Ala Pro Ala His Cys Tyr Leu Pro Asn Leu Lys Val Met 50 55 60 ctg gga aat ttc aag agc aga gtc aga gac ggt act gaa cag aca att 240 Leu Gly Asn Phe Lys Ser Arg Val Arg Asp Gly Thr Glu Gln Thr Ile 65 70 75 80 aac ccc att cag atc gtc cgc tac tgg aac tac agt cat agc gcc cca 288 Asn Pro Ile Gln Ile Val Arg Tyr Trp Asn Tyr Ser His Ser Ala Pro 85 90 95 cag gat gac ctc atg ctc atc aag ctg gct aag cct gcc atg ctc aat 336 Gln Asp Asp Leu Met Leu Ile Lys Leu Ala Lys Pro Ala Met Leu Asn 100 105 110 ccc aaa gtc cag ccc ctt acc ctc gcc acc acc aat gtc agg cca ggc 384 Pro Lys Val Gln Pro Leu Thr Leu Ala Thr Thr Asn Val Arg Pro Gly 115 120 125 act gtc tgt cta ctc tca ggt ttg gac tgg agc caa gaa aac agt ggc 432 Thr Val Cys Leu Leu Ser Gly Leu Asp Trp Ser Gln Glu Asn Ser Gly 130 135 140 cga cac cct gac ttg cgg cag aac ctg gag gcc ccc gtg atg tct gat 480 Arg His Pro Asp Leu Arg Gln Asn Leu Glu Ala Pro Val Met Ser Asp 145 150 155 160 cga gaa tgc caa aaa aca gaa caa gga aaa agc cac agg aat tcc tta 528 Arg Glu Cys Gln Lys Thr Glu Gln Gly Lys Ser His Arg Asn Ser Leu 165 170 175 tgt gtg aaa ttt gtg aaa gta ttc agc cga att ttt ggg gag gtg gcc 576 Cys Val Lys Phe Val Lys Val Phe Ser Arg Ile Phe Gly Glu Val Ala 180 185 190 gtt gct act gtc atc tgc aaa gac aag ctc cag gga atc gag gtg ggg 624 Val Ala Thr Val Ile Cys Lys Asp Lys Leu Gln Gly Ile Glu Val Gly 195 200 205 cac ttc atg gga ggg gac gtc ggc atc tac acc aat gtt tac aaa tat 672 His Phe Met Gly Gly Asp Val Gly Ile Tyr Thr Asn Val Tyr Lys Tyr 210 215 220 gta tcc tgg att gag aac act gct aag gac aag tga 708 Val Ser Trp Ile Glu Asn Thr Ala Lys Asp Lys * 225 230 235 <210> SEQ ID NO 106 <211> LENGTH: 235 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 106 Met Lys Tyr Val Phe Tyr Leu Gly Val Leu Ala Gly Thr Phe Phe Phe 1 5 10 15 Ala Asp Ser Ser Val Gln Lys Glu Asp Pro Ala Pro Tyr Leu Val Tyr 20 25 30 Leu Lys Ser His Phe Asn Pro Cys Val Gly Val Leu Ile Lys Pro Ser 35 40 45 Trp Val Leu Ala Pro Ala His Cys Tyr Leu Pro Asn Leu Lys Val Met 50 55 60 Leu Gly Asn Phe Lys Ser Arg Val Arg Asp Gly Thr Glu Gln Thr Ile 65 70 75 80 Asn Pro Ile Gln Ile Val Arg Tyr Trp Asn Tyr Ser His Ser Ala Pro 85 90 95 Gln Asp Asp Leu Met Leu Ile Lys Leu Ala Lys Pro Ala Met Leu Asn 100 105 110 Pro Lys Val Gln Pro Leu Thr Leu Ala Thr Thr Asn Val Arg Pro Gly 115 120 125 Thr Val Cys Leu Leu Ser Gly Leu Asp Trp Ser Gln Glu Asn Ser Gly 130 135 140 Arg His Pro Asp Leu Arg Gln Asn Leu Glu Ala Pro Val Met Ser Asp 145 150 155 160 Arg Glu Cys Gln Lys Thr Glu Gln Gly Lys Ser His Arg Asn Ser Leu 165 170 175 Cys Val Lys Phe Val Lys Val Phe Ser Arg Ile Phe Gly Glu Val Ala 180 185 190 Val Ala Thr Val Ile Cys Lys Asp Lys Leu Gln Gly Ile Glu Val Gly 195 200 205 His Phe Met Gly Gly Asp Val Gly Ile Tyr Thr Asn Val Tyr Lys Tyr 210 215 220 Val Ser Trp Ile Glu Asn Thr Ala Lys Asp Lys 225 230 235 <210> SEQ ID NO 107 <211> LENGTH: 1452 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)...(1452) <400> SEQUENCE: 107 atg gca ttg gcg tcc gga ccc gca agg cgg gcg cta gct ggc tcc ggg 48 Met Ala Leu Ala Ser Gly Pro Ala Arg Arg Ala Leu Ala Gly Ser Gly 1 5 10 15 cag ctc ggc ctt ggg ggc ttc ggg gcc ccg aga cgc ggg gcg tat gag 96 Gln Leu Gly Leu Gly Gly Phe Gly Ala Pro Arg Arg Gly Ala Tyr Glu 20 25 30 tgg ggc gtg cgc tcc acg cgg aag tcg gag cct cct ccc ctg gat agg 144 Trp Gly Val Arg Ser Thr Arg Lys Ser Glu Pro Pro Pro Leu Asp Arg 35 40 45 gtg tac gag atc cct gga ctg gag ccc atc acc ttt gcg ggg aag atg 192 Val Tyr Glu Ile Pro Gly Leu Glu Pro Ile Thr Phe Ala Gly Lys Met 50 55 60 cac ttc gtg ccc tgg ctg gcg cgg ccg atc ttt ccg ccc tgg gac cgc 240 His Phe Val Pro Trp Leu Ala Arg Pro Ile Phe Pro Pro Trp Asp Arg 65 70 75 80 ggc tac aag gac cca agg ttc tac cgc tcg ccc cct ctt cac gag cat 288 Gly Tyr Lys Asp Pro Arg Phe Tyr Arg Ser Pro Pro Leu His Glu His 85 90 95 ccg ctg tac aaa gac cag gcc tgc tat atc ttt cac cac cgt tgc cgc 336 Pro Leu Tyr Lys Asp Gln Ala Cys Tyr Ile Phe His His Arg Cys Arg 100 105 110 ctt ctc gag ggt gta aag cag gcc ctc tgg ctc acc aag acc aag tta 384 Leu Leu Glu Gly Val Lys Gln Ala Leu Trp Leu Thr Lys Thr Lys Leu 115 120 125 ata gaa ggc ctt ccc gag aaa gtg ctt agc ctt gtt gat gat cca agg 432 Ile Glu Gly Leu Pro Glu Lys Val Leu Ser Leu Val Asp Asp Pro Arg 130 135 140 aac cac ata gag aac caa gac gag tgc gtt ctg aat gtg atc tct cac 480 Asn His Ile Glu Asn Gln Asp Glu Cys Val Leu Asn Val Ile Ser His 145 150 155 160 gcc cgt ctc tgg cag acc act gag gaa atc ccc aag aga gag acc tac 528 Ala Arg Leu Trp Gln Thr Thr Glu Glu Ile Pro Lys Arg Glu Thr Tyr 165 170 175 tgc ccg gtc atc gtg gac aac cta ata cag ctg tgt aaa tct cag att 576 Cys Pro Val Ile Val Asp Asn Leu Ile Gln Leu Cys Lys Ser Gln Ile 180 185 190 ctc aag cat cct tct ctg gcc agg agg atc tgt gtc caa aac tcc acg 624 Leu Lys His Pro Ser Leu Ala Arg Arg Ile Cys Val Gln Asn Ser Thr 195 200 205 ttt tct gct acc tgg aac cga gag tct ctt ctc ctt caa gtc cgt ggt 672 Phe Ser Ala Thr Trp Asn Arg Glu Ser Leu Leu Leu Gln Val Arg Gly 210 215 220 tct ggt gga gcc cga ctg agc act aag gat cct ctg ccc acc atc gcc 720 Ser Gly Gly Ala Arg Leu Ser Thr Lys Asp Pro Leu Pro Thr Ile Ala 225 230 235 240 tcc aga gag gag att gaa gct act aag aat cat gtt cta gag acc ttc 768 Ser Arg Glu Glu Ile Glu Ala Thr Lys Asn His Val Leu Glu Thr Phe 245 250 255 tac ccc ata tca ccc atc atc gat ctt cat gaa tgc aat att tat gat 816 Tyr Pro Ile Ser Pro Ile Ile Asp Leu His Glu Cys Asn Ile Tyr Asp 260 265 270 gtg aaa aat gac aca gga ttc cag gaa ggc tat cct tac ccc tat ccc 864 Val Lys Asn Asp Thr Gly Phe Gln Glu Gly Tyr Pro Tyr Pro Tyr Pro 275 280 285 cat acc ctg tac tta ctg gac aaa gcc aat tta cga cca cac cgc ctt 912 His Thr Leu Tyr Leu Leu Asp Lys Ala Asn Leu Arg Pro His Arg Leu 290 295 300 caa cca gat cag ctg cgg gcc aag atg atc ctg ttt gct ttt ggc agt 960 Gln Pro Asp Gln Leu Arg Ala Lys Met Ile Leu Phe Ala Phe Gly Ser 305 310 315 320 gcc ctg gct cag gcc cgg ctc ctc tat ggg aat gat gcc aag gtc ttg 1008 Ala Leu Ala Gln Ala Arg Leu Leu Tyr Gly Asn Asp Ala Lys Val Leu 325 330 335 gag cag ccc gtg gtg gtg cag agc gtg ggc acg gat gga cgt gtc ttc 1056 Glu Gln Pro Val Val Val Gln Ser Val Gly Thr Asp Gly Arg Val Phe 340 345 350 cat ttc cta gtg ttt caa ctg aat acc aca gac ctg gac tct aac gag 1104 His Phe Leu Val Phe Gln Leu Asn Thr Thr Asp Leu Asp Ser Asn Glu 355 360 365 ggt gtc aag aat ttg gcc tgg gtg gac tca gac cag ctc ctc tat cag 1152 Gly Val Lys Asn Leu Ala Trp Val Asp Ser Asp Gln Leu Leu Tyr Gln 370 375 380 cat ttt tgg tgt ctc cca gtg atc aaa aag aga gtg gtt gtg gaa aat 1200 His Phe Trp Cys Leu Pro Val Ile Lys Lys Arg Val Val Val Glu Asn 385 390 395 400 aaa aga cat tcc agc gga cca aaa tgt gtt tgc aag aca aga aat gga 1248 Lys Arg His Ser Ser Gly Pro Lys Cys Val Cys Lys Thr Arg Asn Gly 405 410 415 aaa tgg ctt tta gac ggc ccc caa ata ttt aaa gtg aga tgg ata cct 1296 Lys Trp Leu Leu Asp Gly Pro Gln Ile Phe Lys Val Arg Trp Ile Pro 420 425 430 tcc ctc cca acc cac ctt ccg cca agg cca tcg cga ctc cac aag aac 1344 Ser Leu Pro Thr His Leu Pro Pro Arg Pro Ser Arg Leu His Lys Asn 435 440 445 aca gaa ctt gca ggc cca gga aaa gaa ggc aga cgc ctc aaa cac aaa 1392 Thr Glu Leu Ala Gly Pro Gly Lys Glu Gly Arg Arg Leu Lys His Lys 450 455 460 aca tct tgt tat gca cca gga aca aaa act gtg ccc aag aag tca cct 1440 Thr Ser Cys Tyr Ala Pro Gly Thr Lys Thr Val Pro Lys Lys Ser Pro 465 470 475 480 tgc att ttg taa 1452 Cys Ile Leu * <210> SEQ ID NO 108 <211> LENGTH: 483 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 108 Met Ala Leu Ala Ser Gly Pro Ala Arg Arg Ala Leu Ala Gly Ser Gly 1 5 10 15 Gln Leu Gly Leu Gly Gly Phe Gly Ala Pro Arg Arg Gly Ala Tyr Glu 20 25 30 Trp Gly Val Arg Ser Thr Arg Lys Ser Glu Pro Pro Pro Leu Asp Arg 35 40 45 Val Tyr Glu Ile Pro Gly Leu Glu Pro Ile Thr Phe Ala Gly Lys Met 50 55 60 His Phe Val Pro Trp Leu Ala Arg Pro Ile Phe Pro Pro Trp Asp Arg 65 70 75 80 Gly Tyr Lys Asp Pro Arg Phe Tyr Arg Ser Pro Pro Leu His Glu His 85 90 95 Pro Leu Tyr Lys Asp Gln Ala Cys Tyr Ile Phe His His Arg Cys Arg 100 105 110 Leu Leu Glu Gly Val Lys Gln Ala Leu Trp Leu Thr Lys Thr Lys Leu 115 120 125 Ile Glu Gly Leu Pro Glu Lys Val Leu Ser Leu Val Asp Asp Pro Arg 130 135 140 Asn His Ile Glu Asn Gln Asp Glu Cys Val Leu Asn Val Ile Ser His 145 150 155 160 Ala Arg Leu Trp Gln Thr Thr Glu Glu Ile Pro Lys Arg Glu Thr Tyr 165 170 175 Cys Pro Val Ile Val Asp Asn Leu Ile Gln Leu Cys Lys Ser Gln Ile 180 185 190 Leu Lys His Pro Ser Leu Ala Arg Arg Ile Cys Val Gln Asn Ser Thr 195 200 205 Phe Ser Ala Thr Trp Asn Arg Glu Ser Leu Leu Leu Gln Val Arg Gly 210 215 220 Ser Gly Gly Ala Arg Leu Ser Thr Lys Asp Pro Leu Pro Thr Ile Ala 225 230 235 240 Ser Arg Glu Glu Ile Glu Ala Thr Lys Asn His Val Leu Glu Thr Phe 245 250 255 Tyr Pro Ile Ser Pro Ile Ile Asp Leu His Glu Cys Asn Ile Tyr Asp 260 265 270 Val Lys Asn Asp Thr Gly Phe Gln Glu Gly Tyr Pro Tyr Pro Tyr Pro 275 280 285 His Thr Leu Tyr Leu Leu Asp Lys Ala Asn Leu Arg Pro His Arg Leu 290 295 300 Gln Pro Asp Gln Leu Arg Ala Lys Met Ile Leu Phe Ala Phe Gly Ser 305 310 315 320 Ala Leu Ala Gln Ala Arg Leu Leu Tyr Gly Asn Asp Ala Lys Val Leu 325 330 335 Glu Gln Pro Val Val Val Gln Ser Val Gly Thr Asp Gly Arg Val Phe 340 345 350 His Phe Leu Val Phe Gln Leu Asn Thr Thr Asp Leu Asp Ser Asn Glu 355 360 365 Gly Val Lys Asn Leu Ala Trp Val Asp Ser Asp Gln Leu Leu Tyr Gln 370 375 380 His Phe Trp Cys Leu Pro Val Ile Lys Lys Arg Val Val Val Glu Asn 385 390 395 400 Lys Arg His Ser Ser Gly Pro Lys Cys Val Cys Lys Thr Arg Asn Gly 405 410 415 Lys Trp Leu Leu Asp Gly Pro Gln Ile Phe Lys Val Arg Trp Ile Pro 420 425 430 Ser Leu Pro Thr His Leu Pro Pro Arg Pro Ser Arg Leu His Lys Asn 435 440 445 Thr Glu Leu Ala Gly Pro Gly Lys Glu Gly Arg Arg Leu Lys His Lys 450 455 460 Thr Ser Cys Tyr Ala Pro Gly Thr Lys Thr Val Pro Lys Lys Ser Pro 465 470 475 480 Cys Ile Leu <210> SEQ ID NO 109 <211> LENGTH: 537 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)...(537) <221> NAME/KEY: misc_feature <222> LOCATION: (1)...(537) <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 82 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 109 atg gcg gcc ctg ggc ggg gtg ctg ggt gcg ctg ctg ctg ctg gct ctc 48 Met Ala Ala Leu Gly Gly Val Leu Gly Ala Leu Leu Leu Leu Ala Leu 1 5 10 15 ctt ggc ctc gcc gtc ctt gtc cac aag cac tat ngc ccc cgg ctc aag 96 Leu Gly Leu Ala Val Leu Val His Lys His Tyr Xaa Pro Arg Leu Lys 20 25 30 tgc tgc tct ggc aaa gct ccg gag ccc cag ccc caa ggc ttt gac aac 144 Cys Cys Ser Gly Lys Ala Pro Glu Pro Gln Pro Gln Gly Phe Asp Asn 35 40 45 cag gcg ttc ctc cct gac cac aag gcc aac tgg gcg ccc gtc ccc agc 192 Gln Ala Phe Leu Pro Asp His Lys Ala Asn Trp Ala Pro Val Pro Ser 50 55 60 ccc acg cac gac ccc aag ccc gcg gag gca ccg atg ccc gca gag ccc 240 Pro Thr His Asp Pro Lys Pro Ala Glu Ala Pro Met Pro Ala Glu Pro 65 70 75 80 gca ccc ccc ggc cct gcc tcc cca ggc ggt gcc cct gag ccc ccc gca 288 Ala Pro Pro Gly Pro Ala Ser Pro Gly Gly Ala Pro Glu Pro Pro Ala 85 90 95 gcg gcc cga gct ggc gga agc ccc acg gcg gtg agg tcc atc ctg acc 336 Ala Ala Arg Ala Gly Gly Ser Pro Thr Ala Val Arg Ser Ile Leu Thr 100 105 110 aag gag cgg cgg cca gag ggc ggg tac aag gct gtc tgg ttt ggc gag 384 Lys Glu Arg Arg Pro Glu Gly Gly Tyr Lys Ala Val Trp Phe Gly Glu 115 120 125 gac atc ggg acg gag gca gac gtg gtc gtt ctc aac gcg ccc acc ctg 432 Asp Ile Gly Thr Glu Ala Asp Val Val Val Leu Asn Ala Pro Thr Leu 130 135 140 gac gtg gat ggc gcc agt gac tcc ggc agc ggc gat gag ggc gag ggc 480 Asp Val Asp Gly Ala Ser Asp Ser Gly Ser Gly Asp Glu Gly Glu Gly 145 150 155 160 gcg ggg agg ggt ggg ggt ccc tac gat gcg ccc ggt ggt gat gac tcc 528 Ala Gly Arg Gly Gly Gly Pro Tyr Asp Ala Pro Gly Gly Asp Asp Ser 165 170 175 tac atc taa 537 Tyr Ile * <210> SEQ ID NO 110 <211> LENGTH: 178 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: VARIANT <222> LOCATION: (1)...(178) <223> OTHER INFORMATION: Xaa = Any Amino Acid <221> NAME/KEY: VARIANT <222> LOCATION: 28 <223> OTHER INFORMATION: Xaa = Any Amino Acid <400> SEQUENCE: 110 Met Ala Ala Leu Gly Gly Val Leu Gly Ala Leu Leu Leu Leu Ala Leu 1 5 10 15 Leu Gly Leu Ala Val Leu Val His Lys His Tyr Xaa Pro Arg Leu Lys 20 25 30 Cys Cys Ser Gly Lys Ala Pro Glu Pro Gln Pro Gln Gly Phe Asp Asn 35 40 45 Gln Ala Phe Leu Pro Asp His Lys Ala Asn Trp Ala Pro Val Pro Ser 50 55 60 Pro Thr His Asp Pro Lys Pro Ala Glu Ala Pro Met Pro Ala Glu Pro 65 70 75 80 Ala Pro Pro Gly Pro Ala Ser Pro Gly Gly Ala Pro Glu Pro Pro Ala 85 90 95 Ala Ala Arg Ala Gly Gly Ser Pro Thr Ala Val Arg Ser Ile Leu Thr 100 105 110 Lys Glu Arg Arg Pro Glu Gly Gly Tyr Lys Ala Val Trp Phe Gly Glu 115 120 125 Asp Ile Gly Thr Glu Ala Asp Val Val Val Leu Asn Ala Pro Thr Leu 130 135 140 Asp Val Asp Gly Ala Ser Asp Ser Gly Ser Gly Asp Glu Gly Glu Gly 145 150 155 160 Ala Gly Arg Gly Gly Gly Pro Tyr Asp Ala Pro Gly Gly Asp Asp Ser 165 170 175 Tyr Ile <210> SEQ ID NO 111 <211> LENGTH: 1311 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)...(1311) <221> NAME/KEY: misc_feature <222> LOCATION: (1)...(1311) <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 1240 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 111 atg gtg ggt ttc ggg gcc aac cgg cgg gct ggc cgc ctg ccc tct ctc 48 Met Val Gly Phe Gly Ala Asn Arg Arg Ala Gly Arg Leu Pro Ser Leu 1 5 10 15 gtg ctg gtg gtg ctg ctg gtg gtg atc gtc gtc ctc gcc ttc aac tac 96 Val Leu Val Val Leu Leu Val Val Ile Val Val Leu Ala Phe Asn Tyr 20 25 30 tgg agc atc tcc tcc cgc cac gtc ctg ctt cag gag gag gtg gcc gag 144 Trp Ser Ile Ser Ser Arg His Val Leu Leu Gln Glu Glu Val Ala Glu 35 40 45 ctg cag ggc cag gtc cag cgc acc gaa gtg gcc cgc ggg cgg ctg gaa 192 Leu Gln Gly Gln Val Gln Arg Thr Glu Val Ala Arg Gly Arg Leu Glu 50 55 60 aag cgc aat tcg gac ctc ttg ctg ttg gtg gac acg cac aag aaa cag 240 Lys Arg Asn Ser Asp Leu Leu Leu Leu Val Asp Thr His Lys Lys Gln 65 70 75 80 atc gac cag aag gag gcc gac tac ggc cgc ctc agc agc cgg ctg cag 288 Ile Asp Gln Lys Glu Ala Asp Tyr Gly Arg Leu Ser Ser Arg Leu Gln 85 90 95 gcc aga gag ggc ctc ggg aag aga tgc gag gat gac aag gtt aaa cta 336 Ala Arg Glu Gly Leu Gly Lys Arg Cys Glu Asp Asp Lys Val Lys Leu 100 105 110 cag aac aac ata tcg tat cag atg gca gac ata cat cat tta aag gag 384 Gln Asn Asn Ile Ser Tyr Gln Met Ala Asp Ile His His Leu Lys Glu 115 120 125 caa ctt gct gag ctt cgt cag gaa ttt ctt cga caa gaa gac cag ctt 432 Gln Leu Ala Glu Leu Arg Gln Glu Phe Leu Arg Gln Glu Asp Gln Leu 130 135 140 cag gac tat agg aag aac aat act tac ctt gtg aag agg tta gaa tat 480 Gln Asp Tyr Arg Lys Asn Asn Thr Tyr Leu Val Lys Arg Leu Glu Tyr 145 150 155 160 gaa agt ttt cag tgt gga cag cag atg aag gaa ttg aga gca cag cat 528 Glu Ser Phe Gln Cys Gly Gln Gln Met Lys Glu Leu Arg Ala Gln His 165 170 175 gaa gaa aat att aaa aag tta gca gac cag ttt tta gag gaa caa aag 576 Glu Glu Asn Ile Lys Lys Leu Ala Asp Gln Phe Leu Glu Glu Gln Lys 180 185 190 caa gag acc caa aag att caa tca aat gat gga aag gaa ttg gat ata 624 Gln Glu Thr Gln Lys Ile Gln Ser Asn Asp Gly Lys Glu Leu Asp Ile 195 200 205 aac aat caa gta gta cct aaa aat att cca aaa gta gct gag aat gtt 672 Asn Asn Gln Val Val Pro Lys Asn Ile Pro Lys Val Ala Glu Asn Val 210 215 220 gca gat aag aat gaa gaa ccc tca agc aat cat att cca cat ggg aaa 720 Ala Asp Lys Asn Glu Glu Pro Ser Ser Asn His Ile Pro His Gly Lys 225 230 235 240 gaa caa atc aaa aga ggt ggt gat gca ggg atg cct gga ata gaa gag 768 Glu Gln Ile Lys Arg Gly Gly Asp Ala Gly Met Pro Gly Ile Glu Glu 245 250 255 aat gac cta gca aaa gtt gat gat ctt ccc cct gct tta agg aag cct 816 Asn Asp Leu Ala Lys Val Asp Asp Leu Pro Pro Ala Leu Arg Lys Pro 260 265 270 cct att tca gtt tct caa cat gaa agt cat caa gca atc tcc cat ctt 864 Pro Ile Ser Val Ser Gln His Glu Ser His Gln Ala Ile Ser His Leu 275 280 285 cca act gga caa cct ctc tcc cca aat atg cct cca gat tca cac ata 912 Pro Thr Gly Gln Pro Leu Ser Pro Asn Met Pro Pro Asp Ser His Ile 290 295 300 aac cac aat gga aac ccc ggt act tca aaa cag aat cct tcc agt cct 960 Asn His Asn Gly Asn Pro Gly Thr Ser Lys Gln Asn Pro Ser Ser Pro 305 310 315 320 ctt cag cgt tta att cca ggc tca aac ttg gac agt gaa ccc aga att 1008 Leu Gln Arg Leu Ile Pro Gly Ser Asn Leu Asp Ser Glu Pro Arg Ile 325 330 335 caa aca gat ata cta aag cag gct acc aag gac aga gtc agt gat ttc 1056 Gln Thr Asp Ile Leu Lys Gln Ala Thr Lys Asp Arg Val Ser Asp Phe 340 345 350 cat aaa ttg aag caa agc cga ttc ttt gat gaa aat gaa tcc cct gtt 1104 His Lys Leu Lys Gln Ser Arg Phe Phe Asp Glu Asn Glu Ser Pro Val 355 360 365 gat ccg cag cat ggc tct aaa ctg gcg gat tat aat ggg gat gat ggt 1152 Asp Pro Gln His Gly Ser Lys Leu Ala Asp Tyr Asn Gly Asp Asp Gly 370 375 380 aac gta ggt gag tat gag gca gac aag cag gct gag ctg gct tac aat 1200 Asn Val Gly Glu Tyr Glu Ala Asp Lys Gln Ala Glu Leu Ala Tyr Asn 385 390 395 400 gag gaa gaa gat ggt gat ggt gga gag gaa gac gtc caa nat gat gaa 1248 Glu Glu Glu Asp Gly Asp Gly Gly Glu Glu Asp Val Gln Xaa Asp Glu 405 410 415 gaa cga gag ctt caa atg gat cct gca gac tat gga aag caa cat ttc 1296 Glu Arg Glu Leu Gln Met Asp Pro Ala Asp Tyr Gly Lys Gln His Phe 420 425 430 aat gat gtc ctt taa 1311 Asn Asp Val Leu * 435 <210> SEQ ID NO 112 <211> LENGTH: 436 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: VARIANT <222> LOCATION: (1)...(436) <223> OTHER INFORMATION: Xaa = Any Amino Acid <221> NAME/KEY: VARIANT <222> LOCATION: 414 <223> OTHER INFORMATION: Xaa = Any Amino Acid <400> SEQUENCE: 112 Met Val Gly Phe Gly Ala Asn Arg Arg Ala Gly Arg Leu Pro Ser Leu 1 5 10 15 Val Leu Val Val Leu Leu Val Val Ile Val Val Leu Ala Phe Asn Tyr 20 25 30 Trp Ser Ile Ser Ser Arg His Val Leu Leu Gln Glu Glu Val Ala Glu 35 40 45 Leu Gln Gly Gln Val Gln Arg Thr Glu Val Ala Arg Gly Arg Leu Glu 50 55 60 Lys Arg Asn Ser Asp Leu Leu Leu Leu Val Asp Thr His Lys Lys Gln 65 70 75 80 Ile Asp Gln Lys Glu Ala Asp Tyr Gly Arg Leu Ser Ser Arg Leu Gln 85 90 95 Ala Arg Glu Gly Leu Gly Lys Arg Cys Glu Asp Asp Lys Val Lys Leu 100 105 110 Gln Asn Asn Ile Ser Tyr Gln Met Ala Asp Ile His His Leu Lys Glu 115 120 125 Gln Leu Ala Glu Leu Arg Gln Glu Phe Leu Arg Gln Glu Asp Gln Leu 130 135 140 Gln Asp Tyr Arg Lys Asn Asn Thr Tyr Leu Val Lys Arg Leu Glu Tyr 145 150 155 160 Glu Ser Phe Gln Cys Gly Gln Gln Met Lys Glu Leu Arg Ala Gln His 165 170 175 Glu Glu Asn Ile Lys Lys Leu Ala Asp Gln Phe Leu Glu Glu Gln Lys 180 185 190 Gln Glu Thr Gln Lys Ile Gln Ser Asn Asp Gly Lys Glu Leu Asp Ile 195 200 205 Asn Asn Gln Val Val Pro Lys Asn Ile Pro Lys Val Ala Glu Asn Val 210 215 220 Ala Asp Lys Asn Glu Glu Pro Ser Ser Asn His Ile Pro His Gly Lys 225 230 235 240 Glu Gln Ile Lys Arg Gly Gly Asp Ala Gly Met Pro Gly Ile Glu Glu 245 250 255 Asn Asp Leu Ala Lys Val Asp Asp Leu Pro Pro Ala Leu Arg Lys Pro 260 265 270 Pro Ile Ser Val Ser Gln His Glu Ser His Gln Ala Ile Ser His Leu 275 280 285 Pro Thr Gly Gln Pro Leu Ser Pro Asn Met Pro Pro Asp Ser His Ile 290 295 300 Asn His Asn Gly Asn Pro Gly Thr Ser Lys Gln Asn Pro Ser Ser Pro 305 310 315 320 Leu Gln Arg Leu Ile Pro Gly Ser Asn Leu Asp Ser Glu Pro Arg Ile 325 330 335 Gln Thr Asp Ile Leu Lys Gln Ala Thr Lys Asp Arg Val Ser Asp Phe 340 345 350 His Lys Leu Lys Gln Ser Arg Phe Phe Asp Glu Asn Glu Ser Pro Val 355 360 365 Asp Pro Gln His Gly Ser Lys Leu Ala Asp Tyr Asn Gly Asp Asp Gly 370 375 380 Asn Val Gly Glu Tyr Glu Ala Asp Lys Gln Ala Glu Leu Ala Tyr Asn 385 390 395 400 Glu Glu Glu Asp Gly Asp Gly Gly Glu Glu Asp Val Gln Xaa Asp Glu 405 410 415 Glu Arg Glu Leu Gln Met Asp Pro Ala Asp Tyr Gly Lys Gln His Phe 420 425 430 Asn Asp Val Leu 435 <210> SEQ ID NO 113 <211> LENGTH: 1014 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)...(1014) <221> NAME/KEY: misc_feature <222> LOCATION: (1)...(1014) <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 460 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 113 atg gat ctt gat gtg gtt aac atg ttt gtg att gcg ggc ggc acg ctg 48 Met Asp Leu Asp Val Val Asn Met Phe Val Ile Ala Gly Gly Thr Leu 1 5 10 15 gcc atc cca atc ctg gca ttt gtg gct tca ttt ctt ctg tgg cct tca 96 Ala Ile Pro Ile Leu Ala Phe Val Ala Ser Phe Leu Leu Trp Pro Ser 20 25 30 gca ctg ata aga atc tat tat tgg tac tgg cgg agg aca ttg ggc atg 144 Ala Leu Ile Arg Ile Tyr Tyr Trp Tyr Trp Arg Arg Thr Leu Gly Met 35 40 45 caa gtc cgc tat gtt cac cat gaa gac tat cag ttc tgt tat tcc ttc 192 Gln Val Arg Tyr Val His His Glu Asp Tyr Gln Phe Cys Tyr Ser Phe 50 55 60 cgg ggc agg cct ggg cac aaa ccc tcc atc ctc atg ctc cac gga ttc 240 Arg Gly Arg Pro Gly His Lys Pro Ser Ile Leu Met Leu His Gly Phe 65 70 75 80 tct gcc cac aag gat atg tgg ctc agt gtg gtc aag ttc ctt cca aag 288 Ser Ala His Lys Asp Met Trp Leu Ser Val Val Lys Phe Leu Pro Lys 85 90 95 aac ctg cac ttg gtc tgc gtg gac atg cca gga cat gag ggc acc acc 336 Asn Leu His Leu Val Cys Val Asp Met Pro Gly His Glu Gly Thr Thr 100 105 110 cgc tcc tcc ctg gat gac ctg tcc ata gat ggg caa gtt aag agg ata 384 Arg Ser Ser Leu Asp Asp Leu Ser Ile Asp Gly Gln Val Lys Arg Ile 115 120 125 cac cag ttt gta gaa tgc ctg aag ctg aac aaa aaa cct ttc cac ctg 432 His Gln Phe Val Glu Cys Leu Lys Leu Asn Lys Lys Pro Phe His Leu 130 135 140 gta ggc acc tcc atg ggt ggc cag gtg nct ggg gtg tat gct gct tac 480 Val Gly Thr Ser Met Gly Gly Gln Val Xaa Gly Val Tyr Ala Ala Tyr 145 150 155 160 tac cca tcg gat gtc tcc agc ctg tgt ctc gtg tgt cct gct ggc ctg 528 Tyr Pro Ser Asp Val Ser Ser Leu Cys Leu Val Cys Pro Ala Gly Leu 165 170 175 cag tac tca act gac aat caa ttt gta caa cgg ctc aaa gaa ctg cag 576 Gln Tyr Ser Thr Asp Asn Gln Phe Val Gln Arg Leu Lys Glu Leu Gln 180 185 190 ggc tct gcc gcc gtg gag aag att ccc ttg atc ccg tct acc cca gaa 624 Gly Ser Ala Ala Val Glu Lys Ile Pro Leu Ile Pro Ser Thr Pro Glu 195 200 205 gag atg agt gaa atg ctt cag ctc tgc tcc tat gtc cgc ttc aag gtg 672 Glu Met Ser Glu Met Leu Gln Leu Cys Ser Tyr Val Arg Phe Lys Val 210 215 220 ccc cag cag atc ctg caa ggc ctt gtc gat gtc cgc atc cct cat aac 720 Pro Gln Gln Ile Leu Gln Gly Leu Val Asp Val Arg Ile Pro His Asn 225 230 235 240 aac ttc tac cga aag ttg ttt ttg gaa atc gtc agt gag aag tcc aga 768 Asn Phe Tyr Arg Lys Leu Phe Leu Glu Ile Val Ser Glu Lys Ser Arg 245 250 255 tac tct ctc cat cag aac atg gac aag atc aag gtt ccg acg cag atc 816 Tyr Ser Leu His Gln Asn Met Asp Lys Ile Lys Val Pro Thr Gln Ile 260 265 270 atc tgg ggg aaa caa gac cag gtg ctg gat gtg tct ggg gca gac atg 864 Ile Trp Gly Lys Gln Asp Gln Val Leu Asp Val Ser Gly Ala Asp Met 275 280 285 ttg gcc aag tca att gcc aac tgc cag gtg gag ctt ctg gaa aac tgt 912 Leu Ala Lys Ser Ile Ala Asn Cys Gln Val Glu Leu Leu Glu Asn Cys 290 295 300 ggg cac tca gta gtg atg gaa aga ccc agg aag aca gcc aag ctc ata 960 Gly His Ser Val Val Met Glu Arg Pro Arg Lys Thr Ala Lys Leu Ile 305 310 315 320 atc gac ttt tta gct tct gtg cac aac aca gac aac aac aag aag ctg 1008 Ile Asp Phe Leu Ala Ser Val His Asn Thr Asp Asn Asn Lys Lys Leu 325 330 335 gac tga 1014 Asp * <210> SEQ ID NO 114 <211> LENGTH: 337 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: VARIANT <222> LOCATION: (1)...(337) <223> OTHER INFORMATION: Xaa = Any Amino Acid <221> NAME/KEY: VARIANT <222> LOCATION: 154 <223> OTHER INFORMATION: Xaa = Any Amino Acid <400> SEQUENCE: 114 Met Asp Leu Asp Val Val Asn Met Phe Val Ile Ala Gly Gly Thr Leu 1 5 10 15 Ala Ile Pro Ile Leu Ala Phe Val Ala Ser Phe Leu Leu Trp Pro Ser 20 25 30 Ala Leu Ile Arg Ile Tyr Tyr Trp Tyr Trp Arg Arg Thr Leu Gly Met 35 40 45 Gln Val Arg Tyr Val His His Glu Asp Tyr Gln Phe Cys Tyr Ser Phe 50 55 60 Arg Gly Arg Pro Gly His Lys Pro Ser Ile Leu Met Leu His Gly Phe 65 70 75 80 Ser Ala His Lys Asp Met Trp Leu Ser Val Val Lys Phe Leu Pro Lys 85 90 95 Asn Leu His Leu Val Cys Val Asp Met Pro Gly His Glu Gly Thr Thr 100 105 110 Arg Ser Ser Leu Asp Asp Leu Ser Ile Asp Gly Gln Val Lys Arg Ile 115 120 125 His Gln Phe Val Glu Cys Leu Lys Leu Asn Lys Lys Pro Phe His Leu 130 135 140 Val Gly Thr Ser Met Gly Gly Gln Val Xaa Gly Val Tyr Ala Ala Tyr 145 150 155 160 Tyr Pro Ser Asp Val Ser Ser Leu Cys Leu Val Cys Pro Ala Gly Leu 165 170 175 Gln Tyr Ser Thr Asp Asn Gln Phe Val Gln Arg Leu Lys Glu Leu Gln 180 185 190 Gly Ser Ala Ala Val Glu Lys Ile Pro Leu Ile Pro Ser Thr Pro Glu 195 200 205 Glu Met Ser Glu Met Leu Gln Leu Cys Ser Tyr Val Arg Phe Lys Val 210 215 220 Pro Gln Gln Ile Leu Gln Gly Leu Val Asp Val Arg Ile Pro His Asn 225 230 235 240 Asn Phe Tyr Arg Lys Leu Phe Leu Glu Ile Val Ser Glu Lys Ser Arg 245 250 255 Tyr Ser Leu His Gln Asn Met Asp Lys Ile Lys Val Pro Thr Gln Ile 260 265 270 Ile Trp Gly Lys Gln Asp Gln Val Leu Asp Val Ser Gly Ala Asp Met 275 280 285 Leu Ala Lys Ser Ile Ala Asn Cys Gln Val Glu Leu Leu Glu Asn Cys 290 295 300 Gly His Ser Val Val Met Glu Arg Pro Arg Lys Thr Ala Lys Leu Ile 305 310 315 320 Ile Asp Phe Leu Ala Ser Val His Asn Thr Asp Asn Asn Lys Lys Leu 325 330 335 Asp <210> SEQ ID NO 115 <211> LENGTH: 459 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)...(459) <400> SEQUENCE: 115 atg tgc ccc ccg gga tta ctg gta ttt gct ggc tcc tcg gaa caa gat 48 Met Cys Pro Pro Gly Leu Leu Val Phe Ala Gly Ser Ser Glu Gln Asp 1 5 10 15 gcc aac ttg gct aag cag ttc tgg atc tcg gcg tcg atg tat ccc cct 96 Ala Asn Leu Ala Lys Gln Phe Trp Ile Ser Ala Ser Met Tyr Pro Pro 20 25 30 agc gaa tct cag ctg gtg ctg cgc aga gac agc agt cag cgt ctg ccg 144 Ser Glu Ser Gln Leu Val Leu Arg Arg Asp Ser Ser Gln Arg Leu Pro 35 40 45 gtg gcg cgg ccc agg agg agc aga ggg tct gaa aac agc cac tcc tcg 192 Val Ala Arg Pro Arg Arg Ser Arg Gly Ser Glu Asn Ser His Ser Ser 50 55 60 cag tct ttt cac ctt gcg agt aac aaa aat aga gac atc ttt gcc gaa 240 Gln Ser Phe His Leu Ala Ser Asn Lys Asn Arg Asp Ile Phe Ala Glu 65 70 75 80 gcc cta aag ata cag gaa tct gag gag aaa gta aag tat ctc caa aag 288 Ala Leu Lys Ile Gln Glu Ser Glu Glu Lys Val Lys Tyr Leu Gln Lys 85 90 95 gct aaa aca aga gaa gag att ctc caa ctc tta aga aaa caa aga gaa 336 Ala Lys Thr Arg Glu Glu Ile Leu Gln Leu Leu Arg Lys Gln Arg Glu 100 105 110 gaa agg atc tcg aaa gaa ctg att tcc ctt ccg tat aaa cca aaa gcc 384 Glu Arg Ile Ser Lys Glu Leu Ile Ser Leu Pro Tyr Lys Pro Lys Ala 115 120 125 aaa gaa cac aaa gca aag aaa gtg gta tca gag tca gat aaa gag gac 432 Lys Glu His Lys Ala Lys Lys Val Val Ser Glu Ser Asp Lys Glu Asp 130 135 140 caa gaa gaa gtc aaa act ttg gac taa 459 Gln Glu Glu Val Lys Thr Leu Asp * 145 150 <210> SEQ ID NO 116 <211> LENGTH: 152 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 116 Met Cys Pro Pro Gly Leu Leu Val Phe Ala Gly Ser Ser Glu Gln Asp 1 5 10 15 Ala Asn Leu Ala Lys Gln Phe Trp Ile Ser Ala Ser Met Tyr Pro Pro 20 25 30 Ser Glu Ser Gln Leu Val Leu Arg Arg Asp Ser Ser Gln Arg Leu Pro 35 40 45 Val Ala Arg Pro Arg Arg Ser Arg Gly Ser Glu Asn Ser His Ser Ser 50 55 60 Gln Ser Phe His Leu Ala Ser Asn Lys Asn Arg Asp Ile Phe Ala Glu 65 70 75 80 Ala Leu Lys Ile Gln Glu Ser Glu Glu Lys Val Lys Tyr Leu Gln Lys 85 90 95 Ala Lys Thr Arg Glu Glu Ile Leu Gln Leu Leu Arg Lys Gln Arg Glu 100 105 110 Glu Arg Ile Ser Lys Glu Leu Ile Ser Leu Pro Tyr Lys Pro Lys Ala 115 120 125 Lys Glu His Lys Ala Lys Lys Val Val Ser Glu Ser Asp Lys Glu Asp 130 135 140 Gln Glu Glu Val Lys Thr Leu Asp 145 150 <210> SEQ ID NO 117 <211> LENGTH: 600 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)...(600) <400> SEQUENCE: 117 atg gag acc ttt cct ctg ctg ctg ctc agc ctg ggc ctg gtt ctt gca 48 Met Glu Thr Phe Pro Leu Leu Leu Leu Ser Leu Gly Leu Val Leu Ala 1 5 10 15 gaa gca tca gaa agc cca atg aag ata att aaa gaa gaa ttt aca gac 96 Glu Ala Ser Glu Ser Pro Met Lys Ile Ile Lys Glu Glu Phe Thr Asp 20 25 30 gaa gag atg caa tat gac atg gca aaa agt ggc caa gaa aaa cag acc 144 Glu Glu Met Gln Tyr Asp Met Ala Lys Ser Gly Gln Glu Lys Gln Thr 35 40 45 att gag ata tta atg aac ccg atc ctg tta gtt aaa aat acc agc ctc 192 Ile Glu Ile Leu Met Asn Pro Ile Leu Leu Val Lys Asn Thr Ser Leu 50 55 60 agc atg tcc aag gat gat atg tct tcc aca tta ctg aca ttc aga agt 240 Ser Met Ser Lys Asp Asp Met Ser Ser Thr Leu Leu Thr Phe Arg Ser 65 70 75 80 tta cat tat aat gac ccc aag gga aac agt tcg ggt aat gac aaa gag 288 Leu His Tyr Asn Asp Pro Lys Gly Asn Ser Ser Gly Asn Asp Lys Glu 85 90 95 tgt tgc aat gac atg aca gtc tgg aga aaa gtt tca gaa gca aac gga 336 Cys Cys Asn Asp Met Thr Val Trp Arg Lys Val Ser Glu Ala Asn Gly 100 105 110 tcg tgc aag tgg agc aat aac ttc atc cgc agc tcc aca gaa gtg atg 384 Ser Cys Lys Trp Ser Asn Asn Phe Ile Arg Ser Ser Thr Glu Val Met 115 120 125 cgc agg gtc cac agg gcc ccc agc tgc aag ttt gta cag aat cct ggc 432 Arg Arg Val His Arg Ala Pro Ser Cys Lys Phe Val Gln Asn Pro Gly 130 135 140 ata agc tgc tgt gag agc cta gaa ctg gaa aat aca gtg tgc cag ttc 480 Ile Ser Cys Cys Glu Ser Leu Glu Leu Glu Asn Thr Val Cys Gln Phe 145 150 155 160 act aca ggc aaa caa ttc ccc agg tgc caa tac cat agt gtt acc tca 528 Thr Thr Gly Lys Gln Phe Pro Arg Cys Gln Tyr His Ser Val Thr Ser 165 170 175 tta gag aag ata ttg aca gtg ctg aca ggt cat tct ctg atg agc tgg 576 Leu Glu Lys Ile Leu Thr Val Leu Thr Gly His Ser Leu Met Ser Trp 180 185 190 tta gtt tgt ggc tct aag ttg taa 600 Leu Val Cys Gly Ser Lys Leu * 195 <210> SEQ ID NO 118 <211> LENGTH: 199 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 118 Met Glu Thr Phe Pro Leu Leu Leu Leu Ser Leu Gly Leu Val Leu Ala 1 5 10 15 Glu Ala Ser Glu Ser Pro Met Lys Ile Ile Lys Glu Glu Phe Thr Asp 20 25 30 Glu Glu Met Gln Tyr Asp Met Ala Lys Ser Gly Gln Glu Lys Gln Thr 35 40 45 Ile Glu Ile Leu Met Asn Pro Ile Leu Leu Val Lys Asn Thr Ser Leu 50 55 60 Ser Met Ser Lys Asp Asp Met Ser Ser Thr Leu Leu Thr Phe Arg Ser 65 70 75 80 Leu His Tyr Asn Asp Pro Lys Gly Asn Ser Ser Gly Asn Asp Lys Glu 85 90 95 Cys Cys Asn Asp Met Thr Val Trp Arg Lys Val Ser Glu Ala Asn Gly 100 105 110 Ser Cys Lys Trp Ser Asn Asn Phe Ile Arg Ser Ser Thr Glu Val Met 115 120 125 Arg Arg Val His Arg Ala Pro Ser Cys Lys Phe Val Gln Asn Pro Gly 130 135 140 Ile Ser Cys Cys Glu Ser Leu Glu Leu Glu Asn Thr Val Cys Gln Phe 145 150 155 160 Thr Thr Gly Lys Gln Phe Pro Arg Cys Gln Tyr His Ser Val Thr Ser 165 170 175 Leu Glu Lys Ile Leu Thr Val Leu Thr Gly His Ser Leu Met Ser Trp 180 185 190 Leu Val Cys Gly Ser Lys Leu 195 <210> SEQ ID NO 119 <211> LENGTH: 729 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)...(729) <400> SEQUENCE: 119 atg ggg cag ccc tgg gcg gct ggg agc acg gac ggg gcg ccc gcg cag 48 Met Gly Gln Pro Trp Ala Ala Gly Ser Thr Asp Gly Ala Pro Ala Gln 1 5 10 15 ctg cct ctc gtg ctc acc gcg ctg tgg gcc gcg gcc gtg ggc ctg gag 96 Leu Pro Leu Val Leu Thr Ala Leu Trp Ala Ala Ala Val Gly Leu Glu 20 25 30 ctg gct tac gtg ctg gtg ctc ggt ccc ggg ccg ccg ccg ctg gga ccc 144 Leu Ala Tyr Val Leu Val Leu Gly Pro Gly Pro Pro Pro Leu Gly Pro 35 40 45 ctg gcc cgg gcc ttg cag ctg gcg ctg gcc tcc ttc cag ctg ctc aac 192 Leu Ala Arg Ala Leu Gln Leu Ala Leu Ala Ser Phe Gln Leu Leu Asn 50 55 60 ctg ctg ggc aac gtg ggg ctc ttc ctg cgc tcg gat ccc agc atc cgt 240 Leu Leu Gly Asn Val Gly Leu Phe Leu Arg Ser Asp Pro Ser Ile Arg 65 70 75 80 ggc gtg atg ctg gcc ggc cgc ggt ctg ggc cag ggc tgg gct tac tgc 288 Gly Val Met Leu Ala Gly Arg Gly Leu Gly Gln Gly Trp Ala Tyr Cys 85 90 95 tac caa tgc caa agc cag gtg ccg cca cgc agc gga cac tgc tct gcc 336 Tyr Gln Cys Gln Ser Gln Val Pro Pro Arg Ser Gly His Cys Ser Ala 100 105 110 tgc cgc gtc tgc atc ctg cgt cgg gac cac cac tgc cgc ctg ctg ggc 384 Cys Arg Val Cys Ile Leu Arg Arg Asp His His Cys Arg Leu Leu Gly 115 120 125 cgc tgc gtg ggc ttc ggc aac tac cgg ccc ttc ctg tgc ctg ctg ctt 432 Arg Cys Val Gly Phe Gly Asn Tyr Arg Pro Phe Leu Cys Leu Leu Leu 130 135 140 cat gcc gcc ggc gtc ctg ctc cac gtc tct gtg ctg ctg ggc cct gca 480 His Ala Ala Gly Val Leu Leu His Val Ser Val Leu Leu Gly Pro Ala 145 150 155 160 ctg tcg gcc ctg ctg cga gcc cac acg ccc ctc cac atg gct gcc ctc 528 Leu Ser Ala Leu Leu Arg Ala His Thr Pro Leu His Met Ala Ala Leu 165 170 175 ctc ctg ctt ccc tgg ctc atg ttg ctc aca gcc tta aag ccc act ctc 576 Leu Leu Leu Pro Trp Leu Met Leu Leu Thr Ala Leu Lys Pro Thr Leu 180 185 190 atc ttg caa gcc tct gaa gcc acc agt ttt ctg aga tgt tcc tcc cgg 624 Ile Leu Gln Ala Ser Glu Ala Thr Ser Phe Leu Arg Cys Ser Ser Arg 195 200 205 ccc cgg aga cca cgg atg tgg cta cct tct cag aat ata gat gtt tcc 672 Pro Arg Arg Pro Arg Met Trp Leu Pro Ser Gln Asn Ile Asp Val Ser 210 215 220 att gcg gca ggc cgc ggc aag ccg gaa ctc aac atc aaa ctg gcc aga 720 Ile Ala Ala Gly Arg Gly Lys Pro Glu Leu Asn Ile Lys Leu Ala Arg 225 230 235 240 aac ctc tag 729 Asn Leu * <210> SEQ ID NO 120 <211> LENGTH: 242 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 120 Met Gly Gln Pro Trp Ala Ala Gly Ser Thr Asp Gly Ala Pro Ala Gln 1 5 10 15 Leu Pro Leu Val Leu Thr Ala Leu Trp Ala Ala Ala Val Gly Leu Glu 20 25 30 Leu Ala Tyr Val Leu Val Leu Gly Pro Gly Pro Pro Pro Leu Gly Pro 35 40 45 Leu Ala Arg Ala Leu Gln Leu Ala Leu Ala Ser Phe Gln Leu Leu Asn 50 55 60 Leu Leu Gly Asn Val Gly Leu Phe Leu Arg Ser Asp Pro Ser Ile Arg 65 70 75 80 Gly Val Met Leu Ala Gly Arg Gly Leu Gly Gln Gly Trp Ala Tyr Cys 85 90 95 Tyr Gln Cys Gln Ser Gln Val Pro Pro Arg Ser Gly His Cys Ser Ala 100 105 110 Cys Arg Val Cys Ile Leu Arg Arg Asp His His Cys Arg Leu Leu Gly 115 120 125 Arg Cys Val Gly Phe Gly Asn Tyr Arg Pro Phe Leu Cys Leu Leu Leu 130 135 140 His Ala Ala Gly Val Leu Leu His Val Ser Val Leu Leu Gly Pro Ala 145 150 155 160 Leu Ser Ala Leu Leu Arg Ala His Thr Pro Leu His Met Ala Ala Leu 165 170 175 Leu Leu Leu Pro Trp Leu Met Leu Leu Thr Ala Leu Lys Pro Thr Leu 180 185 190 Ile Leu Gln Ala Ser Glu Ala Thr Ser Phe Leu Arg Cys Ser Ser Arg 195 200 205 Pro Arg Arg Pro Arg Met Trp Leu Pro Ser Gln Asn Ile Asp Val Ser 210 215 220 Ile Ala Ala Gly Arg Gly Lys Pro Glu Leu Asn Ile Lys Leu Ala Arg 225 230 235 240 Asn Leu <210> SEQ ID NO 121 <211> LENGTH: 774 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)...(774) <221> NAME/KEY: misc_feature <222> LOCATION: (1)...(774) <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 21, 295 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 121 atg ctg ctg acg ctg gcc ggn ggc gcg ctc ttc ttc ccg ggg ctc ttc 48 Met Leu Leu Thr Leu Ala Xaa Gly Ala Leu Phe Phe Pro Gly Leu Phe 1 5 10 15 gcg ctc tgc acc tgg gcg ctg cgc cgc tcc cag ccc gga tgg agc cgc 96 Ala Leu Cys Thr Trp Ala Leu Arg Arg Ser Gln Pro Gly Trp Ser Arg 20 25 30 acc gac tgc gtg atg atc agc acc agg ctg gtt tcc tcg gtg cac gcc 144 Thr Asp Cys Val Met Ile Ser Thr Arg Leu Val Ser Ser Val His Ala 35 40 45 gtg ctg gcc acc ggc tcg ggg atc gtc atc att cgc tcc tgc gac gac 192 Val Leu Ala Thr Gly Ser Gly Ile Val Ile Ile Arg Ser Cys Asp Asp 50 55 60 gtg atc acc ggc agg cac tgg ctt gcc cgg gaa tat gtg tgg ttt ctg 240 Val Ile Thr Gly Arg His Trp Leu Ala Arg Glu Tyr Val Trp Phe Leu 65 70 75 80 att cca tac atg atc tat gac tcg tac gcc atg tac ctc tgt gaa tgg 288 Ile Pro Tyr Met Ile Tyr Asp Ser Tyr Ala Met Tyr Leu Cys Glu Trp 85 90 95 tgc cga ncc aga gac cag aac cgt gcg ccc tcc ctc act ctt cga aac 336 Cys Arg Xaa Arg Asp Gln Asn Arg Ala Pro Ser Leu Thr Leu Arg Asn 100 105 110 ttc cta agt cga aac cgc ctc atg atc aca cat cat gcg gtc att ctc 384 Phe Leu Ser Arg Asn Arg Leu Met Ile Thr His His Ala Val Ile Leu 115 120 125 ttt gtc ctt gtg cca gtc gca cag agg ctc cgg gga gac ctt ggg gac 432 Phe Val Leu Val Pro Val Ala Gln Arg Leu Arg Gly Asp Leu Gly Asp 130 135 140 ttc ttt gtc ggc tgc atc ttc acg gca gaa ctg agc act ccg ttt gtg 480 Phe Phe Val Gly Cys Ile Phe Thr Ala Glu Leu Ser Thr Pro Phe Val 145 150 155 160 tcg ctg ggc agg gtt ctg att cag cta aag cag cag cac acc ctt ctg 528 Ser Leu Gly Arg Val Leu Ile Gln Leu Lys Gln Gln His Thr Leu Leu 165 170 175 tac aag gtg aat gga atc ctc acg ctg gcc acc ttc ctt tcc tgc cgg 576 Tyr Lys Val Asn Gly Ile Leu Thr Leu Ala Thr Phe Leu Ser Cys Arg 180 185 190 atc ctt ctc ttc ccc ttc atg tac tgg tcc tat ggc cgc cag cag gga 624 Ile Leu Leu Phe Pro Phe Met Tyr Trp Ser Tyr Gly Arg Gln Gln Gly 195 200 205 cta agc ctg ctc caa gta ccc ttc agc atc cca ttc tac tgc aac gtg 672 Leu Ser Leu Leu Gln Val Pro Phe Ser Ile Pro Phe Tyr Cys Asn Val 210 215 220 gcc aat gcc ttc ctc gta gct cct cag atc tac tgg ttc tgt ctg ctg 720 Ala Asn Ala Phe Leu Val Ala Pro Gln Ile Tyr Trp Phe Cys Leu Leu 225 230 235 240 tgc agg aag gca gtc cgg ctc ttt gac act ccc caa gcc aaa aag gat 768 Cys Arg Lys Ala Val Arg Leu Phe Asp Thr Pro Gln Ala Lys Lys Asp 245 250 255 ggc taa 774 Gly * <210> SEQ ID NO 122 <211> LENGTH: 257 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: VARIANT <222> LOCATION: (1)...(257) <223> OTHER INFORMATION: Xaa = Any Amino Acid <221> NAME/KEY: VARIANT <222> LOCATION: 7, 99 <223> OTHER INFORMATION: Xaa = Any Amino Acid <400> SEQUENCE: 122 Met Leu Leu Thr Leu Ala Xaa Gly Ala Leu Phe Phe Pro Gly Leu Phe 1 5 10 15 Ala Leu Cys Thr Trp Ala Leu Arg Arg Ser Gln Pro Gly Trp Ser Arg 20 25 30 Thr Asp Cys Val Met Ile Ser Thr Arg Leu Val Ser Ser Val His Ala 35 40 45 Val Leu Ala Thr Gly Ser Gly Ile Val Ile Ile Arg Ser Cys Asp Asp 50 55 60 Val Ile Thr Gly Arg His Trp Leu Ala Arg Glu Tyr Val Trp Phe Leu 65 70 75 80 Ile Pro Tyr Met Ile Tyr Asp Ser Tyr Ala Met Tyr Leu Cys Glu Trp 85 90 95 Cys Arg Xaa Arg Asp Gln Asn Arg Ala Pro Ser Leu Thr Leu Arg Asn 100 105 110 Phe Leu Ser Arg Asn Arg Leu Met Ile Thr His His Ala Val Ile Leu 115 120 125 Phe Val Leu Val Pro Val Ala Gln Arg Leu Arg Gly Asp Leu Gly Asp 130 135 140 Phe Phe Val Gly Cys Ile Phe Thr Ala Glu Leu Ser Thr Pro Phe Val 145 150 155 160 Ser Leu Gly Arg Val Leu Ile Gln Leu Lys Gln Gln His Thr Leu Leu 165 170 175 Tyr Lys Val Asn Gly Ile Leu Thr Leu Ala Thr Phe Leu Ser Cys Arg 180 185 190 Ile Leu Leu Phe Pro Phe Met Tyr Trp Ser Tyr Gly Arg Gln Gln Gly 195 200 205 Leu Ser Leu Leu Gln Val Pro Phe Ser Ile Pro Phe Tyr Cys Asn Val 210 215 220 Ala Asn Ala Phe Leu Val Ala Pro Gln Ile Tyr Trp Phe Cys Leu Leu 225 230 235 240 Cys Arg Lys Ala Val Arg Leu Phe Asp Thr Pro Gln Ala Lys Lys Asp 245 250 255 Gly <210> SEQ ID NO 123 <211> LENGTH: 6 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: peptide tag <400> SEQUENCE: 123 Glu Tyr Met Pro Met Glu 1 5 

We claim:
 1. An isolated polypeptide comprising fifteen contiguous amino acid residues of a polypeptide as shown in SEQ ID NO:M, wherein M is an even integer from 2 to
 122. 2. The isolated polypeptide according to claim 1 wherein M is 2, 4, 8, 10, 16, 18, 26, 32, 34, 36, 38, 40, 42, 44, 48, 50, 52, 56, 60, 62, 68, 70, 74, 78, 80, 82, 84, 86, 90, 94, 98, 100,102, 104, 106, 108, 110, 112, 114, 116, or
 118. 3. The isolated polypeptide of claim 1 which is from 15 to 514 amino acid residues in length.
 4. The isolated polypeptide of claim 3, wherein said at least fifteen contiguous amino acid residues of SEQ ID NO:M are operably linked via a peptide bond or polypeptide linker to a second polypeptide selected from the group consisting of maltose binding protein, an immunoglobulin constant region, a polyhistidine tag, and a peptide as shown in SEQ ID NO:
 123. 5. The isolated polypeptide of claim 1 comprising at least 30 contiguous residues of SEQ ID NO :M.
 6. The isolated polypeptide of claim 1 comprising at least 47 contiguous residues of SEQ ID NO:M.
 7. An isolated, mature protein encoded by a sequence selected from the group consisting of SEQ ID NO:N, wherein N is an odd integer from 1 to
 121. 8. The protein of claim 7 wherein N is 1, 3, 7, 9, 15, 17, 25, 31, 33, 35, 37, 39, 41, 43, 47, 49, 51, 55, 59, 61, 67, 69, 73, 77, 79, 81, 83, 85, 89, 93, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, or
 117. 9. An isolated polynucleotide comprising a sequence of nucleotides as shown in SEQ ID NO:N, wherein N is an odd integer from 1 to
 121. 10. The isolated polynucleotide according to claim 9 wherein N is is 1, 3, 7, 9, 15, 17, 25, 31, 33, 35, 37, 39, 41, 43, 47, 49, 51, 55, 59, 61, 67, 69, 73, 77, 79, 81, 83, 85, 89, 93, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, or
 117. 11. An expression vector comprising the following operably linked elements: a transcription promoter; a DNA segment encoding a polypeptide as shown in SEQ ID NO:M, wherein M is an even integer from 2 to 122; and a transcription terminator.
 12. The expression vector according to claim 11 wherein M is 2, 4, 8, 10, 16, 18, 26, 32, 34, 36, 38,40,42, 44, 48, 50, 52, 56, 60, 62, 68, 70, 74, 78, 80, 82, 84, 86, 90, 94, 98, 100,102, 104, 106, 108, 110, 112, 114, 116, or
 118. 13. A cultured cell comprising the expression vector of claim
 11. 14. A method of producing a polypeptide comprising culturing the cell of claim 13 under conditions whereby said sequence of nucleotides is expressed, and recovering said polypeptide.
 15. A polypeptide produced by the method of claim
 14. 16. An isolated polynucleotide encoding a fusion protein, said protein comprising a secretory peptide selected from the group consisting of secretory peptides shown in SEQ ID NO:M, wherein M is an even integer from 2 to 122, operably linked to a second polypeptide.
 17. An expression vector comprising the following operably linked elements: a transcription promoter; a DNA segment encoding a fusion protein, said protein comprising the secretory peptide according to claim 16, operably linked to a second polypeptide; and a transcription terminator.
 18. A cultured cell comprising the expression vector of claim 17, wherein the cell expresses the DNA segment and produces the encoded fusion protein.
 19. A method of producing a protein comprising culturing the cell of claim 18 under conditions whereby said DNA segment is expressed, and recovering said second polypeptide.
 20. An antibody that specifically binds to a protein selected from of the group consisting of SEQ ID NO:M, wherein M is an even integer from 2 to
 122. 21. An isolated immunogenic polypeptide comprising fourteen contiguous amino acid residues of a polypeptide as shown in SEQ ID NO:M, wherein M is an even integer from 2 to
 122. 